<SEC-DOCUMENT>0001437749-25-026207.txt : 20250812
<SEC-HEADER>0001437749-25-026207.hdr.sgml : 20250812
<ACCEPTANCE-DATETIME>20250812161713
ACCESSION NUMBER:		0001437749-25-026207
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250812
DATE AS OF CHANGE:		20250812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DiaMedica Therapeutics Inc.
		CENTRAL INDEX KEY:			0001401040
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36291
		FILM NUMBER:		251206961

	BUSINESS ADDRESS:	
		STREET 1:		301 CARLSON PARKWAY
		STREET 2:		SUITE 210
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55305
		BUSINESS PHONE:		(763) 496-5454

	MAIL ADDRESS:	
		STREET 1:		301 CARLSON PARKWAY
		STREET 2:		SUITE 210
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DiaMedica Inc.
		DATE OF NAME CHANGE:	20070525
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>dmtp20250630_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dmac="http://www.diamedica.com/20250630" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21"><head>
	<title>dmtp20250630_10q.htm</title>


	<!-- Generated by ThunderDome Portal - 8/12/2025 3:38:46 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:DocumentFiscalPeriodFocus" id="ixv-5285">Q2</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:DocumentFiscalYearFocus" id="ixv-5286">2025</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:CurrentFiscalYearEndDate" id="ixv-5287">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:AmendmentFlag" id="ixv-5288">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntityCentralIndexKey" id="ixv-5289">0001401040</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="ecd:NonRule10b51ArrTrmntdFlag" id="c837" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="ecd:Rule10b51ArrTrmntdFlag" id="c836" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="ecd:NonRule10b51ArrAdoptedFlag" id="c835" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="ecd:Rule10b51ArrAdoptedFlag" id="c834" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonFraction id="c735" contextRef="d_2025-01-01_2025-06-30" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-NonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c584" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-NonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c583" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c582" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c581" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c580" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonFraction id="c404" contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c402" contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c396" contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c394" contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c388" contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c386" contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c350" contextRef="d_2025-01-01_2025-06-30" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c81" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c80" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:CommonStockSharesAuthorizedUnlimited" id="c75">Unlimited</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:CommonStockSharesAuthorizedUnlimited" id="c74">Unlimited</ix:nonNumeric>
<ix:nonFraction id="c73" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockNoParValue" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c72" contextRef="i_2025-06-30" unitRef="USDPerShare" name="us-gaap:CommonStockNoParValue" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="dmac-20250630.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2025-01-01_2025-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2025-07-21_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-21</xbrli:startDate><xbrli:endDate>2025-07-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-07-21_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-21</xbrli:startDate><xbrli:endDate>2025-07-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="i_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-21</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-01-01_2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2025-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_PlanNameAxis-The2012DSUPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2012DSUPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_PlanNameAxis-StockOptionPriorPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:StockOptionPriorPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-12-03_2021-12-03_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_PlanNameAxis-The2019OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_AwardTypeAxis-DeferredShareUnitsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-06-30_PlanNameAxis-The2019OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-22_PlanNameAxis-The2019OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-05-18_2022-05-18_AwardTypeAxis-NonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:NonemployeeStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-18</xbrli:startDate><xbrli:endDate>2022-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-18</xbrli:startDate><xbrli:endDate>2022-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-18</xbrli:startDate><xbrli:endDate>2022-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-18</xbrli:startDate><xbrli:endDate>2022-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_AwardTypeAxis-The2021EmploymentInducementIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_AwardTypeAxis-The2019OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_AwardTypeAxis-DeferredShareUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_AwardTypeAxis-StockOptionsOutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:StockOptionsOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-25_2024-06-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-25</xbrli:startDate><xbrli:endDate>2024-06-25</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-25</xbrli:startDate><xbrli:endDate>2024-06-25</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-25</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-07-21_2025-07-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-21</xbrli:startDate><xbrli:endDate>2025-07-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-08-08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-08-08</xbrli:instant></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
<div>&#160;</div>

<div class="null">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#160;</p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNITED STATES</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; font-variant: normal; margin: 0pt; text-align: center;"><b>FORM <ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:DocumentType" id="c2">10-Q</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Mark one)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 108pt;text-indent:-108pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:DocumentQuarterlyReport" id="c3" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric> <b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 108pt; text-indent: -108pt;"><b>For the quarterly period ended <ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:DocumentPeriodEndDate" id="c4" format="ixt:date-monthname-day-year-en">June 30, 2025</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 108pt;text-indent:-108pt;"><b>or</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 108pt;text-indent:-108pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:DocumentTransitionReport" id="c5" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> <b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b>&#8208;&#8208;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 108pt;text-indent:-108pt;">For the transition period from ________________ to __________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Commission File Number: <ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntityFileNumber" id="c6">001-36291</ix:nonNumeric></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; font-variant: normal; margin: 0pt; text-align: center;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntityRegistrantName" id="c7">DIAMEDICA THERAPEUTICS INC</ix:nonNumeric>.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntityIncorporationStateCountryCode" id="c8" format="ixt-sec:edgarprovcountryen">British Columbia</ix:nonNumeric>, Canada</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p>
			</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not Applicable</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntityAddressAddressLine1" id="c9">301 Carlson Parkway, Suite 210</ix:nonNumeric></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntityAddressCityOrTown" id="c10">Minneapolis</ix:nonNumeric>, <ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntityAddressStateOrProvince" id="c11" format="ixt-sec:stateprovnameen">Minnesota</ix:nonNumeric> <ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntityAddressPostalZipCode" id="c12">55305</ix:nonNumeric></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices) (Zip Code)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:CityAreaCode" id="c13">763</ix:nonNumeric>) <ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:LocalPhoneNumber" id="c14">496-5454</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section&#160;12(b) of the Act<b>:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: top; width: 39%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 22%; border-top: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading Symbol</b></p>
			</td>
			<td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: top; width: 39%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 39%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:Security12bTitle" id="c15">Voting common shares, no par value per share</ix:nonNumeric></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 22%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:TradingSymbol" id="c16">DMAC</ix:nonNumeric></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 39%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:SecurityExchangeName" id="c17" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Stock Market LLC</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntityCurrentReportingStatus" id="c18">Yes</ix:nonNumeric>&#160;&#9746; No&#160;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntityInteractiveDataCurrent" id="c19">Yes</ix:nonNumeric>&#160;&#9746; No&#160;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 36pt; margin-right: auto;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Large accelerated filer &#9744;</p>
			</td>
			<td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accelerated filer &#9744;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntityFilerCategory" id="c20" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric> &#9746;</p>
			</td>
			<td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Smaller reporting company <ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntitySmallBusiness" id="c21" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Emerging growth company <ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntityEmergingGrowthCompany" id="c22" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dei:EntityShellCompany" id="c23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> No &#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of August 8, 2025, there were <ix:nonFraction id="c24" contextRef="i_2025-08-08" unitRef="Share" name="dei:EntityCommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">51,688,913</ix:nonFraction> voting common shares of the registrant outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&#160;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</div>

<div>&#160;</div>

<div>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM 10-Q</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>June 30, 2025</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TABLE OF CONTENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="2" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" style="vertical-align: top; width: 95%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><span style="text-decoration: underline; ">Description</span></b></td>
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b><span style="text-decoration: underline; ">Page</span></b></td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table cellpadding="2" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="2" style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: top; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">1</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>PART I.</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 83%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>FINANCIAL INFORMATION</b></td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 1.</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 83%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Financial Statements</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 2.</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 83%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">14</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 3.</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 83%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Quantitative and Qualitative Disclosures about Market Risk</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">20</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 4.</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 83%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Controls and Procedures</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">20</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>PART II.</b>&#160;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 83%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>OTHER INFORMATION</b></td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 1.</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 83%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Legal Proceedings</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">21</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 1A.</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 83%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Risk Factors</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">21</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 2.</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 83%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">22</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 3.</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 83%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Defaults Upon Senior Securities</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">22</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 4.</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 83%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Mine Safety Disclosures</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">22</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 5.</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 83%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Other Information</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">22</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 6.</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 83%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Exhibits</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">23</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>SIGNATURE PAGE</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">24</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 0pt auto 0pt auto;"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>This quarterly report on Form 10-Q contains certain forward-looking statements that are within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by those sections. For more information, see </i>&#8220;<i>Cautionary Note Regarding Forward-Looking Statements.</i>&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>As used in this report, references to </i>&#8220;<i>DiaMedica,</i>&#8221;<i> the </i>&#8220;<i>Company,</i>&#8221;<i> </i>&#8220;<i>we,</i>&#8221;<i> </i>&#8220;<i>our</i>&#8221;<i> or </i>&#8220;<i>us,</i>&#8221;<i> unless the context otherwise requires, refer to DiaMedica Therapeutics Inc. and its subsidiaries, all of which are consolidated in DiaMedica</i>&#8217;<i>s condensed consolidated financial statements. References in this report to </i>&#8220;<i>common shares</i>&#8221;<i> mean our voting common shares, no par value per share.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, the trademarks and trade names in this report are referred to without the </i>&#174;<i> and </i>&#8482;<i> symbols, but such references should not be construed as any indicator that the owner of such trademarks and trade names will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies</i>&#8217;<i> trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;&#160;</p>
</div>

<div>&#160;</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Statements in this report that are not descriptions of historical facts are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that are based on management&#8217;s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, prospects and share price. We have attempted to identify forward-looking statements by terminology including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; the negative of these terms or other comparable terminology and the use of future dates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The forward-looking statements in this report are subject to risks and uncertainties and include, among other things:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our plans to develop, obtain an investigational new drug (IND) application for the clinical study of DM199 for PE and ultimately to obtain regulatory approval for and commercialize our DM199 product candidate for the treatment of preeclampsia (PE) and acute ischemic stroke (AIS);</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our ability to conduct successful clinical testing of our DM199 product candidate for PE and AIS and meet certain anticipated or target milestones and dates thereof with respect to our clinical studies;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the ability of our physician collaborators to successfully complete the current Phase 2, proof-of-concept clinical trial of DM199 for the treatment of PE, our reliance on these physician collaborators to conduct the study, and our expectations related to the timing of Part 1a of this study and the ability of these physician collaborators to identify a suitable dose for use in Part 1b of this study;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our ability to meet anticipated site activations, enrollment and interim analysis timing with respect to our Phase 2/3 ReMEDy2 clinical trial of DM199 for the treatment of AIS, especially in the light of slower than expected site activations and enrollment which we believe are due, in part, to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the clinical hold which was lifted in June 2023; use of artificial intelligence and telemedicine which have enabled smaller hospitals to retain AIS patients not eligible for mechanical thrombectomy instead of sending these patients to the larger stroke centers which are more likely to be sites in our trial; and competition for research staff and trial subjects due to other pending stroke and neurological clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the success of the actions we are taking to mitigate the impact of the factors adversely affecting our ReMEDy2 trial site activations and enrollment rate, including significantly expanding our internal clinical team and bringing in-house certain trial activities, such as study site identification, qualification and activation, clinical site monitoring and overall program management; globally expanding the trial; and making additional changes to the study protocol; and risks associated with these mitigation actions;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">uncertainties relating to regulatory applications and related filing and approval timelines, especially in light of recent changes in funding and staffing levels for the U.S. Food and Drug Administration (FDA) and other government agencies;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the possible occurrence of future adverse events associated with or unfavorable results from the Phase 2 investigator-sponsored PE trial or our ReMEDy2 trial and their potential to adversely effect current or future trials;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the adaptive design of our ReMEDy2 trial, which is intended to enroll approximately 300 patients at up to 100 sites globally, and the possibility that the final sample size, which will be determined based upon the results of an interim analysis of 200 participants, may be up to 728 patients, according to a pre-determined statistical plan, other possible changes in the trial, including as a result of input from the FDA, and the results of the interim analysis as determined by our independent data safety monitoring board;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our expectations regarding the perceived benefits of our DM199 product candidate over existing treatment options for PE and AIS;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our ability to partner with and generate revenue from biopharmaceutical or pharmaceutical partners to develop, obtain regulatory approval for, and commercialize our DM199 product candidate for PE and AIS;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the potential size of the markets for our DM199 product candidate for PE and AIS and our or any future partner&#8217;s ability to serve those markets, the rate and degree of market acceptance of and ability to obtain coverage and adequate reimbursement for, our DM199 product candidate for PE and AIS both in the United States and internationally;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the success, cost and timing of our clinical trials, as well as our reliance on our key executives, clinical personnel, advisors and third parties in connection with our trials;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our or any future partner&#8217;s ability to commercialize, market and manufacture DM199;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">expectations regarding U.S. federal, state and foreign regulatory requirements and developments affecting our pending and future clinical trials and regulatory approvals of our DM199 product candidate for PE and AIS and future commercialization and manufacturing of such products if required regulatory approvals are obtained;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our expectations regarding our ability to obtain and maintain intellectual property protection for our DM199 product candidate;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">expectations regarding competition and our ability to obtain data exclusivity for our DM199 product candidate for PE and AIS; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our estimates regarding expenses, market opportunity for our product candidates, future revenue, and capital requirements; our anticipated use of the net proceeds from our prior private placements; how long our current cash resources will last; and our need for and ability to obtain additional financing to fund our operations, including funding necessary to complete our current clinical trials and obtain regulatory approvals for our DM199 product candidate for PE and/or AIS.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under &#8220;<i>Part I. Item 1A. Risk Factors</i>&#8221; in our annual report on Form 10-K for the fiscal year ended December&#160;31,&#160;2024 and those described above and elsewhere in this report, including under &#8220;<i>Part II. Item 1A. Risk Factors</i>.&#8221; Moreover, we operate in a very competitive and rapidly-changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, including the securities laws of the United States, we do not intend to update any forward-looking statements to conform these statements to actual results or to changes in our expectations.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PART I - FINANCIAL INFORMATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 1.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>FINANCIAL STATEMENTS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Condensed Consolidated Balance Sheets</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands, except share amounts)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(unaudited)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>ASSETS</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current assets:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c30" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,109</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c31" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,025</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c32" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:MarketableSecuritiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">25,929</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c33" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:MarketableSecuritiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,122</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Prepaid expenses and other assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c34" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">680</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c35" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">227</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Deposits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c36" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:DepositsAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-5">200</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c37" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DepositsAssetsCurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Amounts receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c38" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">161</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c39" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">236</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Total current assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c40" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">31,079</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c41" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">44,610</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-current assets:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating lease right-of-use asset, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c43" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">239</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c44" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">279</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c45" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">152</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c46" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">148</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Deposits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c47" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:DepositsAssetsNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c48" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DepositsAssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,308</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Total non-current assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c49" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">391</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c50" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,735</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c51" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-4">31,470</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c52" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,345</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>LIABILITIES AND EQUITY</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current liabilities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts payable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c54" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,261</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c55" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">940</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c56" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,747</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c57" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,347</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating lease obligation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c58" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">96</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c59" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">90</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Finance lease obligation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c60" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">12</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c61" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">13</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Total current liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c62" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,116</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">5,390</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-current liabilities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating lease obligation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c65" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">176</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c66" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">225</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Finance lease obligation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c67" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c68" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">12</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Total non-current liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c69" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:LiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">184</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c70" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">237</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Shareholders&#8217; equity:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Common shares, <span style="-sec-ix-hidden:c72"><span style="-sec-ix-hidden:c73">no</span></span> par value; <span style="-sec-ix-hidden:c74"><span style="-sec-ix-hidden:c75">unlimited</span></span> authorized; <ix:nonFraction id="c76" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF"><ix:nonFraction id="c77" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">43,072,488</ix:nonFraction></ix:nonFraction> and <ix:nonFraction id="c78" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF"><ix:nonFraction id="c79" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,818,660</ix:nonFraction></ix:nonFraction> shares issued and outstanding, as of June 30, 2025 and December 31, 2024, respectively</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c80">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c81">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Paid-in capital</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">182,592</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">180,697</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accumulated other comprehensive income (loss)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c84" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">14</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c85" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accumulated deficit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c86" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">155,408</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c87" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">140,002</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Total shareholders&#8217; equity</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c88" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">27,170</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c89" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,718</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total liabilities and shareholders&#8217; equity</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c90" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">31,470</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c91" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,345</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to the condensed consolidated financial statements.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Condensed Consolidated Statements of Operations and Comprehensive Loss</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands, except share and per share amounts)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c95" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,822</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,928</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c97" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,478</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c98" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,604</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c99" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,185</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c100" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,710</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,673</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c102" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,775</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">O<span style="text-transform:uppercase;"><span style="text-transform:lowercase;">perating loss</span></span></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c103" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">8,007</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c104" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,638</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c105" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">16,151</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c106" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">11,379</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">314</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c108" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">526</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c109" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">757</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c110" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,123</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c111" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">7,693</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c112" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,112</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c113" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,394</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c114" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">10,256</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">6</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c116" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">12</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c118" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">14</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c119" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">7,699</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c120" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,119</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c121" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,406</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c122" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">10,270</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other comprehensive loss</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Unrealized loss on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c124" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">19</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c125" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">12</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c126" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">37</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c127" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">57</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss and comprehensive loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c128" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">7,718</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c129" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,131</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c130" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,443</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c131" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">10,327</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic and diluted net loss per share</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c132" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.18</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c133" contextRef="d_2024-04-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.13</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c134" contextRef="d_2025-01-01_2025-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.36</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c135" contextRef="d_2024-01-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.27</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding &#8211; basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c136" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,957,619</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c137" contextRef="d_2024-04-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">38,068,378</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c138" contextRef="d_2025-01-01_2025-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,901,093</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c139" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">38,013,189</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to the condensed consolidated financial statements.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Condensed Consolidated Statements of Shareholders</b>&#8217;<b> Equity</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt;"><b>For the Three Months Ended June 30, 2025 and 2024</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands, except share amounts)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Paid-In</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Capital</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%; padding: 0px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated Other </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Comprehensive</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Income (Loss)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Deficit</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shareholders&#8217;</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Equity</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balances at December 31, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c142" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,818,660</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c143" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">180,697</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c144" contextRef="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c145" contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">140,002</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c146" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,718</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares upon the vesting and settlement of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c147" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,805</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c148" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c149" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c150" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c151" contextRef="d_2025-01-01_2025-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares upon the exercise of stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c152" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">37,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c153" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">94</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c154" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c155" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c156" contextRef="d_2025-01-01_2025-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">94</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Share-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c158" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">867</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c159" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c160" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c161" contextRef="d_2025-01-01_2025-03-31" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">867</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Unrealized loss on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c163" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c164" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">18</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c165" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c166" contextRef="d_2025-01-01_2025-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">18</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c168" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c169" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c170" contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">7,707</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c171" contextRef="d_2025-01-01_2025-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">7,707</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balances at March 31, 2025</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c172" contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,859,465</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c173" contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">181,658</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c174" contextRef="i_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">5</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c175" contextRef="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">147,709</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c176" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">33,954</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 18pt; text-indent: -9pt;">Issuance of common shares in settlement of deferred stock units</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c177" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="dmac:StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" scale="0" format="ixt:num-dot-decimal" decimals="INF">142,345</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares upon the vesting and settlement of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c182" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,803</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c183" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c184" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c185" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c186" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares upon the exercise of stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c187" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">66,875</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c188" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">163</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c189" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c190" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c191" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">163</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Share-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c193" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">771</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c194" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c195" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c196" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">771</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Unrealized loss on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c198" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c199" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">19</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c200" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c201" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">19</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c203" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c204" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c205" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">7,699</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c206" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">7,699</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balances at June 30, 2025</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c207" contextRef="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">43,072,488</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c208" contextRef="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">182,592</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c209" contextRef="i_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">14</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c210" contextRef="i_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">155,408</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c211" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">27,170</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Paid-In </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Capital</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%; padding: 0px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated Other</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Comprehensive</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Income (Loss)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Deficit</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shareholders&#8217; </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Equity</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balances at December 31, 2023</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c214" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">37,958,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c215" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">166,609</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c216" contextRef="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">6</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c217" contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">115,558</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c218" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">51,057</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares upon the vesting and settlement of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c219" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,916</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c220" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c221" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c222" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c223" contextRef="d_2024-01-01_2024-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Share-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c225" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">488</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c226" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c227" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c228" contextRef="d_2024-01-01_2024-03-31" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">488</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Unrealized loss on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c230" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c231" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">45</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c232" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c233" contextRef="d_2024-01-01_2024-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">45</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c235" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c236" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c237" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,151</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c238" contextRef="d_2024-01-01_2024-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,151</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balances at March 31, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c239" contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">37,963,916</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c240" contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">167,097</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c241" contextRef="i_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">39</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c242" contextRef="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">120,709</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c243" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,349</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares net of offering costs of $<ix:nonFraction id="c244" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c245" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,720,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c246" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,747</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c247" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c248" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c249" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,747</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares upon the vesting and settlement of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c250" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,916</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c251" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c252" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c253" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c254" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares upon the exercise of common stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c255" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,750</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c256" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c257" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c258" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c259" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Share-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c261" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">443</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c262" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c263" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c264" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">443</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Unrealized loss on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c266" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c267" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">12</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c268" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c269" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">12</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c271" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c272" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c273" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,119</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c274" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,119</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balances at June 30, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c275" contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,692,582</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c276" contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">179,294</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c277" contextRef="i_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">51</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c278" contextRef="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">125,828</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c279" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">53,415</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to the condensed consolidated financial statements.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Condensed Consolidated Statements of Cash Flows</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended June 30, </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from operating activities:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c283" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,406</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c284" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">10,270</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c286" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,638</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c287" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">931</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Amortization of discounts on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c288" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" format="ixt:num-dot-decimal" decimals="-3">441</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c289" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" format="ixt:num-dot-decimal" decimals="-3">648</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-cash lease expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c290" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="dmac:NoncashLeaseExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">40</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c291" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="dmac:NoncashLeaseExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">37</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Depreciation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c292" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">14</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c293" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">18</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Changes in operating assets and liabilities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Amounts receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c295" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">75</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c296" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" format="ixt:num-dot-decimal" decimals="-3">22</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Prepaid expenses and other assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c297" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">453</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c298" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">156</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Deposits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c299" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,108</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c300" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,308</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts payable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c301" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">321</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c302" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">167</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued liabilities and operating lease liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c303" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,643</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c304" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">413</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash used in operating activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c305" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">14,747</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c306" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">11,172</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from investing activities:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Purchase of marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c308" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-4">16,370</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c309" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">18,047</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Maturities of marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c310" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">31,967</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c311" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-6">27,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Purchases of property and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c312" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">18</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c313" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">9</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash provided by investing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c314" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,579</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c315" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,944</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from financing activities:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Proceeds from issuance of common shares, net of offering costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c317" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c318" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,747</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Proceed from the exercise of common stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c319" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">257</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c320" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Principal payments on finance lease obligation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c321" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" format="ixt:num-dot-decimal" decimals="-3">5</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c322" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash provided by financing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c323" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">252</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c324" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,751</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net increase in cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c325" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,084</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c326" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,523</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at beginning of period</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c327" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,025</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c328" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,543</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at end of period</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c329" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,109</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c330" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,066</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Supplemental disclosure of non-cash transactions:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Assets acquired under financing lease</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c332" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c333" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-4">30</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cash paid for income taxes</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c334" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:IncomeTaxesPaid" scale="3" format="ixt:num-dot-decimal" decimals="-3">12</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c335" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxesPaid" scale="3" format="ixt:num-dot-decimal" decimals="-3">14</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to the condensed consolidated financial statements.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">5</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Notes to the Condensed Consolidated Financial Statements</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="c336" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>1.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Business</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica Therapeutics Inc. and its wholly owned subsidiaries, DiaMedica USA Inc. and DiaMedica Australia Pty Ltd. (collectively, we, us, our, DiaMedica and the Company), is a clinical stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE) and acute ischemic stroke (AIS). DiaMedica&#8217;s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein, an established therapeutic modality in Asia for the treatment of preeclampsia, acute ischemic stroke and other vascular diseases. Our common shares are publicly traded on The Nasdaq Capital Market under the symbol &#8220;DMAC.&#8221;</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dmac:RisksAndUncertaintiesTextBlock" id="c338" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Risks and Uncertainties</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the United States Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in the European Union, and comparable agencies in other countries. We are in the clinical stage of development of our lead product candidate, DM199, for the treatment of PE and AIS. We have not completed the development of any product candidate and do not generate any revenues from the commercial sale of any product candidate. Our lead product candidate, DM199, requires significant additional clinical testing and investment prior to seeking marketing approval and is not expected to be commercially available for at least three to four years, if at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">With respect to our PE clinical program, a Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 for the treatment of PE is currently being conducted at the Tygerberg Hospital in Cape Town, South Africa. This Phase 2 study consists of three studies in PE (Part 1a, dose-escalation; Part 1b, dose-expansion; and Part 2, expectant management) and a fourth study in fetal growth restriction (FGR, Part 3, expectant management). Part 1a topline study results are intended to identify a suitable dose for Parts 1b, 2, and 3. Up to 90 women with PE and potentially an additional 30 subjects with fetal growth restriction may be evaluated. The first subject in Part 1a was enrolled in the fourth quarter of 2024 and interim results from Part 1a of the study were released in July 2025. The interim results (N=28 subjects) demonstrated that DM199 appears safe and well-tolerated with clinically-relevant pharmacodynamic activity with no evidence of placental transfer. Additionally, subjects exhibited rapid, statistically significant reductions in blood pressure with duration of effect that was sustained up to 24 hours post-infusion compared to pre-treatment baseline. Preparations are underway to initiate Part 1b where up to 30 subjects with PE and expected delivery within 72 hours will be treated with a dose regimen identified from Part 1a.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">With respect to our AIS clinical program, we are currently conducting a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial of DM199 for the treatment of AIS, known as the ReMEDy2 trial. Our ReMEDy2 trial is intended to enroll approximately 300 participants at up to 100 sites globally. The adaptive design component includes an interim analysis by our independent data safety monitoring board to be conducted after the first 200 participants have completed the trial. Based on the results of the interim analysis, the study may then be stopped for futility or the final sample size will be determined, ranging between 300 and 728 patients, according to a pre-determined statistical plan. We have experienced and continue to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the previous clinical hold; use of artificial intelligence and telemedicine which have enabled smaller hospitals to retain AIS patients not eligible for mechanical thrombectomy instead of sending these patients to the larger stroke centers which are more likely to be sites in our trial; and competition for research staff and trial subjects due to other pending stroke and neurological trials. We continue to reach out to current and potential study sites to understand the specific issues at each study site. In an effort to mitigate the impact of these factors, we have significantly expanded our internal clinical team and have brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring, and overall program management. We are currently conducting our ReMEDy2 trial in the United States and in the countries of Canada and Georgia. We are in the process of preparing regulatory filings and identifying and engaging study sites in an additional seven European countries and have submitted for approval of this study in the United Kingdom. We continue to work closely with our contract research organizations and other advisors to develop procedures to support both U.S. and global study sites and potential participants as needed. We intend to continue to monitor the results of these efforts and, if necessary, implement additional actions to enhance site activations and enrollment in our ReMEDy2 trial; however, no assurances can be provided as to the success of these actions and if or when these issues will resolve. Failure to resolve these issues may result in delays in our ReMEDy2 trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our future success is dependent upon the success of our development efforts, our ability to demonstrate clinical progress for our DM199 product candidate in the United States or other markets, our ability, or the ability of any future partner, to obtain required governmental approvals of our product candidate, our ability to license or market and sell our DM199 product candidate, and our ability to obtain additional financing to fund these efforts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of June 30,&#160;2025, we have incurred losses of $<ix:nonFraction id="c340" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">155.4</ix:nonFraction> million since our inception in 2000. For the six months ended June 30, 2025, we incurred a net loss of $<ix:nonFraction id="c341" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">15.4</ix:nonFraction> million and negative cash flows from operating activities of $<ix:nonFraction id="c342" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">14.7</ix:nonFraction> million. We expect to continue to incur operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments generate revenue sufficient to fund our continuing operations. For the foreseeable future, we expect to incur significant operating losses as we continue the development and clinical study of, and to seek regulatory approval for, our DM199 product candidate. As of June 30,&#160;2025, we had combined cash, cash equivalents and marketable securities of $<ix:nonFraction id="c343" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" format="ixt:num-dot-decimal" decimals="-7">30.0</ix:nonFraction> million, working capital of $<ix:nonFraction id="c344" contextRef="i_2025-06-30" unitRef="USD" name="dmac:WorkingCapital" scale="6" format="ixt:num-dot-decimal" decimals="-6">27.0</ix:nonFraction> million and shareholders&#8217; equity of $<ix:nonFraction id="c345" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="6" format="ixt:num-dot-decimal" decimals="-5">27.2</ix:nonFraction> million. Subsequent to quarter end, in July 2025, we completed a private placement of common shares in which we received net proceeds of $<ix:nonFraction id="c346" contextRef="d_2025-07-21_2025-07-21" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" format="ixt:num-dot-decimal" decimals="-5">29.9</ix:nonFraction> million, see Note 14, titled &#8220;<i>Subsequent Event</i>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our principal source of cash has been net proceeds from the issuance of equity securities. Although we have previously been successful in obtaining financing through equity securities offerings, there is no assurance that we will be able to do so in the future. This is particularly true if our clinical data are not positive or if economic and market conditions deteriorate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notwithstanding the completion of our July 2025 private placement, we expect that we will need substantial additional capital to further our research and development activities and complete the required clinical studies, regulatory activities and manufacturing development for our product candidate, DM199, or any future product candidates, to a point where they may be licensed or commercially sold. We expect our current cash, cash equivalents and marketable securities, including the $<ix:nonFraction id="c347" contextRef="d_2025-07-21_2025-07-21" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" format="ixt:num-dot-decimal" decimals="-5">29.9</ix:nonFraction> million net proceeds from our July 2025 private placement of common shares, to be sufficient to continue the Phase 2 PE trial, the ReMEDy2 trial, and otherwise fund our planned operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. The amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including our current ReMEDy2 trial and the rate of site activation and participant enrollment in the study; the Phase 2 PE trial; the potential expansion of our current development programs; the effects of ongoing site staffing shortages; and other factors on our clinical trials and our operating expenses. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising capital are favorable.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c348" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Summary of Significant Accounting Policies</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Interim financial statements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have prepared the accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. These condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly our condensed consolidated financial position, condensed consolidated results of operations, condensed consolidated statement of shareholders&#8217; equity and condensed consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on December&#160;31. The condensed consolidated balance sheet as of December&#160;31,&#160;2024 was derived from our audited consolidated financial statements. These condensed consolidated financial statements should be read in conjunction with our annual consolidated financial statements and the notes thereto. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year. Certain prior year amounts have been reclassified to conform to the current year presentation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c494700676267739" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Segments</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We operate in a <span style="-sec-ix-hidden:c350">single</span> segment focusing on researching and developing potentially transformative treatments for severe ischemic diseases. Consistent with our operational structure, our chief operating decision maker manages and allocates resources for the Company at a consolidated level. Therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting. All assets are held in the United States.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c1482347759684743" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Cash and cash equivalents</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of our cash equivalents approximates fair value due to the short maturity of the investments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:MarketableSecuritiesPolicy" id="c280681241393138" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Marketable securities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the condensed consolidated statements of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive income or loss, which is a separate component of shareholders&#8217; equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no other-than-temporary unrealized losses as of June 30, 2025.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="c778890428950662" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Fair value measurements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The hierarchy is broken down into three levels defined as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Level 1 Inputs</i> &#8212; quoted prices in active markets for identical assets and liabilities;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Level 2 Inputs</i> &#8212; observable inputs other than quoted prices in active markets for identical assets and liabilities; and</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Level 3 Inputs</i> &#8212; unobservable inputs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of June 30,&#160;2025, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled &#8220;<i>Marketable Securities</i>&#8221; for additional information.</p>
</ix:nonNumeric></ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="c355" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>4.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Marketable Securities</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" id="c383" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="30" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements Using Inputs Considered as of:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 1</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 2</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 1</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 2</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper and corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c385" contextRef="i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,419</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c386">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c387" contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,419</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c388">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c389" contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">28,291</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c390" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c391" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">28,291</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c392" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Government securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c393" contextRef="i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-4">13,510</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c394">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c395" contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-4">13,510</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c396">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c397" contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,831</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c398" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c399" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,831</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c400" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c401" contextRef="i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">25,929</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c402">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c403" contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">25,929</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c404">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c405" contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,122</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c406" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c407" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,122</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c408" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Maturities of individual securities are less than 12 months, and the amortized cost of all securities approximated fair value as of June 30,&#160;2025 and December&#160;31,&#160;2024. Accrued interest receivable on marketable securities is included in amounts receivable and was $<ix:nonFraction id="c381" contextRef="i_2025-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" unitRef="USD" name="us-gaap:InterestReceivable" scale="0" format="ixt:num-dot-decimal" decimals="0">142,000</ix:nonFraction> and $<ix:nonFraction id="c382" contextRef="i_2024-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" unitRef="USD" name="us-gaap:InterestReceivable" scale="0" format="ixt:num-dot-decimal" decimals="0">235,000</ix:nonFraction> as of June 30,&#160;2025 and December&#160;31,&#160;2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the six months ended June 30, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dmac:DepositAssetsTextBlock" id="c409" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>5.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Deposits</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica periodically advances funds to vendors engaged to support the performance of our clinical trials and related supporting activities. The funds advanced are held, interest free, for varying periods of time and may be recovered by the Company through partial reductions of ongoing invoices, application against final study/project invoices or refunded upon completion of services to be provided. Deposits are classified as current or non-current based upon their expected recovery time.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="c411" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>6.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Amounts Receivable&#160;</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amounts receivable consisted primarily of accrued interest receivable on marketable securities of $<ix:nonFraction id="c413" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">142,000</ix:nonFraction> and $<ix:nonFraction id="c414" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">235,000</ix:nonFraction> as of June 30,&#160;2025 and December&#160;31,&#160;2024, respectively.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c415" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>7.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Property and Equipment</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment, net, consisted of the following (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c429" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c431" contextRef="i_2025-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">136</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c432" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">118</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Furniture and equipment</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c433" contextRef="i_2025-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">128</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c434" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">128</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c435" contextRef="i_2025-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">16</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c436" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">16</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c437" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">280</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c438" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">262</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less accumulated depreciation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c439" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">128</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c440" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">114</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c441" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">152</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c442" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">148</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="c443" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>8.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Accrued Liabilities</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued liabilities consisted of the following (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="c457" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical trial costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c459" contextRef="i_2025-06-30" unitRef="USD" name="dmac:AccruedClinicalStudyCostsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,268</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c460" contextRef="i_2024-12-31" unitRef="USD" name="dmac:AccruedClinicalStudyCostsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,277</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development services</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c461" contextRef="i_2025-06-30" unitRef="USD" name="dmac:AccruedResearchAndProfessionalFeesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">790</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c462" contextRef="i_2024-12-31" unitRef="USD" name="dmac:AccruedResearchAndProfessionalFeesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">888</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c463" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">590</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c464" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,060</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional services fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c465" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">94</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c466" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">112</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c467" contextRef="i_2025-06-30" unitRef="USD" name="dmac:AccruedTaxesAndOtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">5</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c468" contextRef="i_2024-12-31" unitRef="USD" name="dmac:AccruedTaxesAndOtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">10</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total accrued liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c469" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,747</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c470" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,347</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:LesseeOperatingLeasesTextBlock" id="c471" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>9.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Operating Lease</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Office lease</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our operating lease costs were $<ix:nonFraction id="c473" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="0" format="ixt:num-dot-decimal" decimals="0"><ix:nonFraction id="c474" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="0" format="ixt:num-dot-decimal" decimals="0">52,000</ix:nonFraction></ix:nonFraction> for each of the six month periods ended June 30,&#160;2025 and&#160;2024. Our variable lease costs were $<ix:nonFraction id="c475" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:VariableLeaseCost" scale="0" format="ixt:num-dot-decimal" decimals="0">43,000</ix:nonFraction> and $<ix:nonFraction id="c476" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:VariableLeaseCost" scale="0" format="ixt:num-dot-decimal" decimals="0">38,000</ix:nonFraction> for the six months ended June 30,&#160;2025 and&#160;2024, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Maturities of our operating lease obligation are as follows as of June 30,&#160;2025 (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="c486" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c488" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" format="ixt:num-dot-decimal" decimals="-3">57</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c489" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" format="ixt:num-dot-decimal" decimals="-3">116</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c490" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" format="ixt:num-dot-decimal" decimals="-3">119</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c491" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" format="ixt:num-dot-decimal" decimals="-4">10</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c492" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" format="ixt:num-dot-decimal" decimals="-3">302</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Less interest portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c493" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" format="ixt:num-dot-decimal" decimals="-4">30</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Present value of operating lease obligation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c494" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">272</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Less current portion of operating lease</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c495" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">96</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease obligation, non-current</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c496" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">176</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c497" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>10.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Shareholders</b>&#8217;<b> Equity</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Authorized capital shares</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica has authorized share capital of an unlimited number of voting common shares, and the shares do not have a stated par value. Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company&#8217;s annual general meeting and any extraordinary or special general meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Equity issued during the six months ended June 30,</i>&#160;<i>2025</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the six months ended June 30,&#160;2025, <ix:nonFraction id="c499" contextRef="d_2025-01-01_2025-06-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,608</ix:nonFraction> common shares were issued upon the vesting and settlement of restricted stock units, <ix:nonFraction id="c500" contextRef="d_2025-01-01_2025-06-30" unitRef="Share" name="dmac:StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" scale="0" format="ixt:num-dot-decimal" decimals="INF">142,345</ix:nonFraction> shares were issued upon the settlement of deferred share units and <ix:nonFraction id="c501" contextRef="d_2025-01-01_2025-06-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">103,875</ix:nonFraction>&#160;common shares were issued upon the exercise of stock options for gross proceeds of $<ix:nonFraction id="c502" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="0">257,000</ix:nonFraction>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Equity issued during the six months ended June 30,</i>&#160;<i>2024</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On June 25, 2024, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate <ix:nonFraction id="c503" contextRef="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,720,000</ix:nonFraction> common shares at a purchase price of $<ix:nonFraction id="c504" contextRef="i_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.50</ix:nonFraction> per share in a private placement. As a result of the offering, which closed on June 28, 2024, we received gross proceeds of $<ix:nonFraction id="c505" contextRef="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">11.8</ix:nonFraction> million, which resulted in net proceeds to us of approximately $<ix:nonFraction id="c506" contextRef="d_2024-06-25_2024-06-25" unitRef="USD" name="dmac:ProceedsFromIssuanceOfCommonStockNet" scale="6" format="ixt:num-dot-decimal" decimals="-5">11.7</ix:nonFraction> million, after deducting the offering expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the June 2024 private placement, we entered into a registration rights agreement (Registration Rights Agreement) with the investors pursuant to which we agreed to file with the United States Securities and Exchange Commission (SEC) a registration statement registering the resale of the shares sold in the June 2024 private placement (Resale Registration Statement). The Resale Registration Statement was filed with the SEC on July 10, 2024 and declared effective by the SEC on July 18, 2024. Under the terms of the Registration Rights Agreement, we agreed to keep the Resale Registration Statement effective at all times until the shares are no longer considered &#8220;Registrable Securities&#8221; under the Registration Rights Agreement and if we fail to keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the six months ended June 30, 2024, <ix:nonFraction id="c507" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">11,832</ix:nonFraction> common shares were issued upon the vesting and settlement of restricted stock units and <ix:nonFraction id="c508" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,750</ix:nonFraction> common shares were issued upon the exercise of common stock options for gross proceeds of $<ix:nonFraction id="c509" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction> thousand.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Shares reserved</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common shares reserved for future issuance are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="dmac:CommonStockReservedForFutureIssuanceTableTextBlock" id="c516" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon exercise of employee and non-employee stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c518" contextRef="i_2025-06-30_AwardTypeAxis-StockOptionsOutstandingMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,685,604</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c519" contextRef="i_2025-06-30_AwardTypeAxis-DeferredShareUnitsMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">174,515</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon vesting and settlement of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c520" contextRef="i_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,607</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c521" contextRef="i_2025-06-30_AwardTypeAxis-The2019OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">754,919</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares available for grant under the 2021 Employment Inducement Incentive Plan</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c522" contextRef="i_2025-06-30_AwardTypeAxis-The2021EmploymentInducementIncentivePlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">357,500</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c523" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,980,145</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:EarningsPerShareTextBlock" id="c524" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>11.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Net Loss Per Share</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes our calculation of net loss per common share for the periods presented (in thousands, except share and per share data):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="c550" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c552" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">7,699</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c553" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,119</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c554" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,406</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c555" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">10,270</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding&#8212;basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c556" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,957,619</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c557" contextRef="d_2024-04-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">38,068,378</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c558" contextRef="d_2025-01-01_2025-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,901,093</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c559" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">38,013,189</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic and diluted net loss per share</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c560" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.18</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c561" contextRef="d_2024-04-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.13</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c562" contextRef="d_2025-01-01_2025-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.36</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c563" contextRef="d_2024-01-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.27</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="c564" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Common shares issuable upon exercise of employee and non-employee stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c566" contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,685,604</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c567" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,859,271</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c568" contextRef="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,685,604</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c569" contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,859,271</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Common shares issuable upon settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c570" contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">174,515</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c571" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">284,886</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c572" contextRef="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">174,515</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c573" contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">284,886</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Common shares issuable upon vesting and settlement of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c574" contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,607</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c575" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">11,828</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c576" contextRef="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,607</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c577" contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">11,828</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c578" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>12.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Share-Based Compensation</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Amended and Restated 2019 Omnibus Incentive Plan (2019 Plan)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The 2019 Plan permits the Board, or a committee or subcommittee thereof, to grant to the Company&#8217;s eligible employees, non-employee directors and certain consultants non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units (RSUs), deferred stock units (DSUs), performance awards, non-employee director awards and other share-based awards. We grant options to purchase common shares under the 2019 Plan at no less than the fair market value of the underlying common shares as of the date of grant. Options granted to employees and non-employee directors have a maximum term of <span style="-sec-ix-hidden:c580">ten</span> years and generally vest over <span style="-sec-ix-hidden:c581">one</span> to <span style="-sec-ix-hidden:c582">four</span> years. Options granted to non-employees have a maximum term of <span style="-sec-ix-hidden:c583">five</span> years and generally vest over <span style="-sec-ix-hidden:c584">one</span> year. Subject to adjustment as provided in the 2019 Plan, the maximum number of the Company&#8217;s common shares authorized for issuance under the 2019 Plan is <ix:nonFraction id="c585" contextRef="i_2024-05-22_PlanNameAxis-The2019OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,000,000</ix:nonFraction> shares. As of June 30,&#160;2025, options to purchase an aggregate of <ix:nonFraction id="c586" contextRef="d_2025-01-01_2025-06-30_PlanNameAxis-The2019OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,721,194</ix:nonFraction> common shares were outstanding, <ix:nonFraction id="c587" contextRef="i_2025-06-30_AwardTypeAxis-DeferredShareUnitsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">164,770</ix:nonFraction> common shares were reserved for issuance upon settlement of DSUs and <ix:nonFraction id="c588" contextRef="i_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2019OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,607</ix:nonFraction> shares were reserved for issuance upon the vesting and settlement of RSUs and <ix:nonFraction id="c589" contextRef="i_2025-06-30_PlanNameAxis-The2019OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">754,919</ix:nonFraction> shares remained available for issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>2021 Employment Inducement Incentive Plan (2021 Inducement Plan)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The 2021 Inducement Plan permits the Board, or a committee or subcommittee thereof, to grant of non-statutory options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other share-based awards, to new employees who satisfy the standards for inducement grants under Nasdaq Listing Rule 5635(c)(4) or 5635(c)(3), as applicable. The Inducement Plan has a term of <ix:nonNumeric contextRef="d_2021-12-03_2021-12-03_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c590" format="ixt-sec:duryear">10</ix:nonNumeric> years. The share reserve under the Inducement Plan may be increased at the discretion of and approval by the Board. As of June 30,&#160;2025, options to purchase an aggregate of <ix:nonFraction id="c591" contextRef="i_2025-06-30_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">590,000</ix:nonFraction> common shares were outstanding under the Inducement Plan and <ix:nonFraction id="c592" contextRef="i_2025-06-30_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">357,500</ix:nonFraction> shares remained available for issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Prior Stock Option Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s prior stock option plan was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the Prior Plan have terms similar to those used under the 2019 Plan. As of June 30,&#160;2025, options to purchase an aggregate of <ix:nonFraction id="c593" contextRef="i_2025-06-30_PlanNameAxis-StockOptionPriorPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">374,410</ix:nonFraction> common shares were outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Prior Deferred Stock Unit Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s prior deferred stock unit plan was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior DSU Plan remain outstanding in accordance with and pursuant to the terms thereof. As of June 30,&#160;2025, there were <ix:nonFraction id="c594" contextRef="i_2025-06-30_PlanNameAxis-The2012DSUPlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,745</ix:nonFraction> common shares reserved for issuance upon settlement of DSUs outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Share-based compensation expense for each of the periods presented is as follows (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c661" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c663" contextRef="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">538</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c664" contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">336</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c665" contextRef="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,216</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c666" contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">629</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c667" contextRef="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">233</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c668" contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">107</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c669" contextRef="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">422</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c670" contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">302</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c671" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">771</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c672" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">443</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c673" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,638</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c674" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">931</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize share-based compensation for options awards based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those options that actually vest.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A summary of option activity is as follows (in thousands except share and per share amounts):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c675" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Underlying</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average Exercise</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances at December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c677" contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,692,438</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c678" contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.33</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c679" contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,243</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c680" contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,333,416</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c681" contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.42</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeitures</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c682" contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">231,375</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c683" contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.35</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c684" contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">103,875</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c685" contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.51</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c686" contextRef="d_2025-01-01_2025-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c687" contextRef="d_2025-01-01_2025-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.91</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances at June 30, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c688" contextRef="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,685,604</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c689" contextRef="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.70</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c690" contextRef="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,767</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information about stock options outstanding, vested and expected to vest as of June 30,&#160;2025, is as follows:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="c691" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: bottom; width: 4%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="10" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Outstanding, Vested and Expected to Vest</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="6" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 18%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Options Vested and Exercisable</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Per Share </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exercise Price</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Shares</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted Average</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Remaining</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Contractual Life</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Years)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted Average</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exercise Price</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Options </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exercisable</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted Average</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Remaining</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Contractual Life</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Years)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$<ix:nonFraction id="c693" contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.00</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$<ix:nonFraction id="c694" contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.99</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c695" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">191,443</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c696" format="ixt-sec:duryear">7.7</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c697" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.59</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c698" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">105,457</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="c699" format="ixt-sec:duryear">7.7</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$<ix:nonFraction id="c700" contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.00</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$<ix:nonFraction id="c701" contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.99</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c702" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,769,645</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c703" format="ixt-sec:duryear">7.4</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c704" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.74</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c705" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,484,034</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="c706" format="ixt-sec:duryear">7.0</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$<ix:nonFraction id="c707" contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.00</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$<ix:nonFraction id="c708" contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.99</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c709" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">311,893</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c710" format="ixt-sec:duryear">5.2</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c711" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.56</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c712" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">229,393</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="c713" format="ixt-sec:duryear">3.9</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$<ix:nonFraction id="c714" contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.00</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$<ix:nonFraction id="c715" contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.99</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c716" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,652,069</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c717" format="ixt-sec:duryear">8.0</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c718" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.24</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c719" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">677,182</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="c720" format="ixt-sec:duryear">4.0</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$<ix:nonFraction id="c721" contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.00</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$<ix:nonFraction id="c722" contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">10.00</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c723" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">760,554</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c724" format="ixt-sec:duryear">7.3</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c725" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.93</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c726" contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">380,729</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="c727" format="ixt-sec:duryear">5.2</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: bottom; width: 4%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c728" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,685,604</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c729" format="ixt-sec:duryear">7.5</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c730" contextRef="i_2025-06-30" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.70</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c731" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,876,795</ix:nonFraction></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="c732" format="ixt-sec:duryear">5.8</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:SegmentReportingDisclosureTextBlock" id="c733" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>13.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Segment Information</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An operating segment is identified as a component of an enterprise that engages in business activities about which separate discrete financial information and operating results is regularly reviewed by the chief operating decision-maker (CODM) in making decisions regarding resource allocation and assessing performance. DiaMedica's CODM is the Chief Executive Officer. The Company operates in a <span style="-sec-ix-hidden:c735">single</span> operating segment focused on the development of its drug product candidate DM199 for the treatment of severe ischemic disease. The CODM manages and allocates resources to the operations of the Company on a total company basis. Further, the CODM reviews and utilizes functional expenses (i.e., research, development and general and administrative) at the consolidated level to manage the Company's operations. Other segment items included in consolidated net loss are revenues, share-based compensation, interest income, other expense, net, and income tax expense, which are reflected in the condensed consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table presents financial information, including significant segment expenses, which are regularly provided to the CODM and included within segment and consolidated net loss:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="c780" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses, excluding share-based compensation</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c782" contextRef="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,589</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c783" contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,821</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c784" contextRef="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,056</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c785" contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,302</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c786" contextRef="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,647</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c787" contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,374</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c788" contextRef="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,457</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c789" contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,146</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total operating expenses, excluding share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c790" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,236</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c791" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,195</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c792" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,513</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c793" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,448</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c794" contextRef="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">233</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c795" contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">107</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c796" contextRef="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">422</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c797" contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">302</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c798" contextRef="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">538</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c799" contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">336</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c800" contextRef="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,216</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c801" contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">629</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total share-based compensationd</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c802" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">771</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c803" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">443</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c804" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,638</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c805" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">931</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c806" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">8,007</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c807" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,638</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c808" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">16,151</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c809" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">11,379</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c810" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3">313</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c811" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3">524</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c812" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3">757</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c813" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,140</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other income (expense), net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c814" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c815" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c816" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c817" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">17</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c818" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">6</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c819" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c820" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">12</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c821" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">14</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Segment and consolidated net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c822" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">7,699</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c823" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,119</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c824" contextRef="d_2025-01-01_2025-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,406</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c825" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">10,270</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="us-gaap:SubsequentEventsTextBlock" id="c826" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>14.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Subsequent Event</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July 21, 2025, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate <ix:nonFraction id="c828" contextRef="d_2025-07-21_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,606,425</ix:nonFraction> common shares at a purchase price of $<ix:nonFraction id="c829" contextRef="i_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.50</ix:nonFraction> per share in a private placement. As a result of the offering, which closed on July 23, 2025, we received gross proceeds of $<ix:nonFraction id="c830" contextRef="d_2025-07-21_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">30.1</ix:nonFraction> million, which resulted in net proceeds to us of approximately $<ix:nonFraction id="c831" contextRef="d_2025-07-21_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" format="ixt:num-dot-decimal" decimals="-5">29.9</ix:nonFraction> million, after deducting the offering expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In connection with the July 2025 private placement, we entered into registration rights agreements (collectively the Registration Rights Agreement) with the investors pursuant to which we agreed to file with the United States Securities and Exchange Commission (SEC) a registration statement registering the resale of the shares sold in the July 2025 private placement (Resale Registration Statement). The Resale Registration Statement was filed with the SEC on August 1, 2025 and declared effective by the SEC on August 8, 2025. Under the terms of the Registration Rights Agreement, we agreed to keep the Resale Registration Statement effective at all times until the shares are no longer considered &#8220;Registrable Securities&#8221; under the Registration Rights Agreement and if we fail to keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>MANAGEMENT</b>&#8217;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based upon accounting principles generally accepted in the United States of America and discusses the financial condition and results of operations for DiaMedica Therapeutics Inc. and our subsidiaries for the three and six month periods ended June 30,&#160;2025 and&#160;2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This discussion should be read in conjunction with our condensed consolidated financial statements and related notes included elsewhere in this report and our annual report on Form 10-K for the year ended December&#160;31,&#160;2024. The following discussion contains forward-looking statements that involve numerous risks and uncertainties. Our actual results could differ materially from the forward-looking statements as a result of these risks and uncertainties. See &#8220;<i>Cautionary Note Regarding Forward-Looking Statements</i>&#8221; for additional cautionary information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Business Overview</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). Our lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein (serine protease enzyme) to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1 for the treatment of AIS and porcine KLK1 for the treatment of cardio renal disease, including hypertension. Our current focus is on the treatment of PE and AIS. We plan to advance DM199 through required clinical trials to create shareholder value by establishing its clinical and commercial potential as a therapy for PE and AIS. We have also produced a potential novel treatment for severe acute pancreatitis, DM300, which is currently in the early preclinical stage of development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DM199 is a recombinant form of KLK1 (rhKLK1), which is a synthetic version of the naturally occurring protease enzyme kallikrein-1, and the first and only rhKLK1 undergoing global clinical development studies in both PE and AIS. DM199 has been granted Fast Track designation from the FDA for the treatment of AIS. Naturally occurring KLK1 (extracted from human urine or porcine pancreas) has been an approved therapeutic agent in Asia for decades in the treatment of AIS and hypertension associated with cardiorenal disease. DM199 is produced using recombinant DNA technology without the need for extracted human or animal tissue sources and thereby eliminates risk of pathogen transmission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">KLK1 is a serine protease enzyme that plays an important role in the regulation of diverse physiological processes via a molecular mechanism that may enhance microcirculatory blood flow and tissue perfusion by increasing production of nitric oxide (NO), prostacyclin (PGI2) and endothelium-derived hyperpolarizing factor (EDHF). In preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta, potentially disease modifying outcomes improving both maternal and perinatal outcomes. In the case of AIS, DM199 is intended to enhance blood flow and boost neuronal survival in the ischemic penumbra by dilating arterioles surrounding the site of the vascular occlusion and inhibiting apoptosis (neuronal cell death) while also facilitating neuronal remodeling through the promotion of angiogenesis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our product development pipeline is as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>
<div style="text-align: center;"><img alt="divpipeimg.jpg" src="divpipeimg.jpg"/></div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are developing DM199 to address two major critical unmet needs. In PE, there are currently no approved agents in any global market to safely lower maternal blood pressure and/or reduce the risk of fetal growth restriction. Historically, the major issue with potential PE treatments has been that traditional vasodilators commonly used to reduce essential hypertension (e.g., beta-blockers, angiotensin converting enzyme inhibitors (ACEi)) can readily cross the placental barrier and enter into the fetal circulation and cause harm to the developing fetus. We believe that DM199 is uniquely suited to treat PE since its molecular size, ~26 kilodaltons (KD), is typically too large to cross the placental barrier and therefore may reduce blood pressure and enhance microcirculatory perfusion to the maternal organs and placenta without entering fetal circulation. Additionally, we believe DM199 has the potential to not only address hypertension of PE, but also to confer disease modifying outcomes for both maternal and perinatal outcomes, including fetal growth restriction. In AIS, up to 80% of AIS patients are not eligible for treatment with currently approved clot-busting (thrombolytic) drugs or catheter-based clot removal procedures (mechanical thrombectomy). DM199 is intended to enhance collateral blood flow and boost neuronal survival in the ischemic penumbra by inhibiting neuronal cell death (apoptosis) and promoting neuronal remodeling and neoangiogenesis, and accordingly, offer a potential treatment option for AIS patients who otherwise have no therapeutic options.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Preeclampsia Program and Phase 2 Investigator-Sponsored Study</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Our clinical development program in PE currently centers around an investigator-sponsored safety, tolerability and pharmacodynamic, proof-of-concept Phase 2 study in PE patients. This Phase 2 study consists of three studies in PE (Part 1a, dose-escalation; Part 1b, dose-expansion; and Part 2, expectant management) and a fourth study in fetal growth restriction (FGR, Part 3, expectant management). Part 1a topline study results are intended to identify a suitable dose for Parts 1b, 2, and 3. Up to 90 women with PE and potentially an additional 30 subjects with fetal growth restriction may be evaluated. The first subject in Part 1a was enrolled in the fourth quarter of 2024 and interim results from Part 1a of the study were released in July 2025. The interim results (N=28 subjects) demonstrate that DM199 appears safe and well-tolerated with clinically-relevant pharmacodynamic activity with no evidence of placental transfer.&#160; Additionally, subjects exhibited rapid, statistically significant reductions in blood pressure with duration of effect that was sustained up to 24 hours post-infusion compared to pre-treatment baseline, a durable effect extending up to 24 hours post-infusion. Preparations are underway to initiate Part 1b where up to 30 subjects with PE and expected delivery within 72 hours will be treated with a dose regimen identified from Part 1a.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Based in part upon these interim results, we believe DM199 has the potential to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta. We have completed studies on fertility, embryofetal development and pre- and post-natal development in animal models, which support the potential safety of DM199 in pregnant humans. Additionally, based on the strength of the interim results, DiaMedica plans to submit an Investigational New Drug (IND) application in the&#160;United States in the second half of 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>AIS Program and Phase 2/3 ReMEDy2 Trial</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Our clinical program in AIS centers on our ReMEDy2 clinical trial of DM199 for the treatment of AIS. Our ReMEDy2 clinical trial is a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial intended to enroll approximately 300 participants at up to 100 sites globally. The adaptive design component includes an interim analysis by our independent data safety monitoring board to be conducted after the first 200 participants have completed the trial. Based on the results of the interim analysis, the study may be stopped for futility or the final sample size will be determined, ranging between 300 and 728 patients, according to a pre-determined statistical plan. As previously disclosed, we have experienced and are continuing to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the previous clinical hold; use of artificial intelligence and telemedicine which have enabled smaller hospitals to retain AIS patients not eligible for mechanical thrombectomy instead of sending these patients to the larger stroke centers which are more likely to be sites in our trial; and competition for research staff and trial subjects due to other pending stroke and neurological trials. We continue to reach out to current and potential study sites to understand the specific issues at each study site. In an effort to mitigate the impact of these factors, we have significantly expanded our internal clinical team and have brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring and overall program management. We are currently conducting the trial in the United States and in the countries of Canada and Georgia. We are in the process of preparing regulatory filings and identifying and engaging study sites in an additional seven European countries and have submitted for approval of this study in the United Kingdom. We continue to work closely with our contract research organizations and other advisors to develop procedures to support both U.S. and global study sites and potential participants as needed. We intend to continue to monitor the results of these efforts and, if necessary, implement additional actions to enhance site activations and enrollment in our ReMEDy2 trial; however, no assurances can be provided as to the success of these actions and if or when these issues will resolve. Failure to resolve these issues may result in delays in our ReMEDy2 trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Financial Overview</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have not generated any revenues from product sales. Since our inception, we have financed our operations primarily from sales of equity securities, interest income on funds available for investment, and government grants. We have incurred a net loss in each year since our inception. Our net losses were $15.4 million and $10.3 million for the six months ended June 30,&#160;2025 and&#160;2024, respectively. As of June 30,&#160;2025, we had an accumulated deficit of $155.4 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development (R&amp;D) activities and general and administrative (G&amp;A) support costs associated with our operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect to continue to incur significant expenses and operating losses for at least the next few years. We anticipate that our quarterly expenses will increase moderately relative to recent prior quarterly periods as we continue to advance our DM199 clinical development program into PE and we continue our ReMEDy2 trial, including additional site activations in the U.S. and globally and enrollment of participants in the trial. Our efforts to expand our team to provide support for our clinical and administrative operations will likely also contribute to such increases.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">While we expect the level of future negative operating quarterly cash flows to generally increase moderately relative to recent prior quarterly periods as we expand our DM199 clinical development program into PE and we continue our ReMEDy2 trial, including our global expansion,&#160; we expect our current cash resources, including the $29.9 million net proceeds from our July 21, 2025 private placement of common shares, will be sufficient to allow us to continue our ReMEDy2 trial, support the Phase 2 PE trial, and otherwise fund our planned operations for at least the next 12 months from the date of issuance of the condensed consolidated financial statements included in this report. However, the amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including the current Phase 2 PE trial, our current ReMEDy2 trial and in particular the rate of site activation and participant enrollment in the study, the potential further expansion of our current development programs and other factors. We may require or otherwise seek significant additional funds earlier than we currently need or expect. We may elect to raise additional funds even before we need them if market conditions for raising additional capital are favorable.</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Components of Our Results of Operations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Research and Development Expenses</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">R&amp;D expenses consist primarily of fees paid to external service providers such as contract research organizations; clinical support services; clinical development including clinical site costs; outside nursing services; and laboratory testing. R&amp;D costs also include non-clinical testing; fees paid to our contract manufacturing and development organizations and outside laboratories for development of DM199 and related manufacturing processes; costs for production runs of DM199; consulting resources with specialized expertise related to the execution of our development plan for DM199; and personnel costs, including salaries, benefits, non-cash share-based compensation expense; and other personnel costs. Over the past approximately 10 years, our R&amp;D efforts have been primarily focused on developing DM199. At this time, due to the risks inherent in the clinical development process and the clinical stage of our product development programs, we are unable to estimate with any certainty the costs we will incur in completing the development of DM199 through marketing approval. The process of conducting clinical studies necessary to obtain regulatory approval and manufacturing scale-up to support expanded development and potential future commercialization is costly and time consuming. Any failure by us or delay in completing clinical studies, manufacturing scale-up, or in obtaining regulatory approvals could lead to increased R&amp;D expenses and, in turn, have a material adverse effect on our results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>General and Administrative Expenses</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">G&amp;A expenses consist primarily of salaries and benefits, including non-cash share-based compensation related to our executive, finance, business development and support functions. G&amp;A expenses also include insurance, including directors&#8217; and officers&#8217; liability coverage, rent and utilities, travel expenses, patent costs, and professional fees, including for auditing, tax and legal services.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Other Income, Net</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other income, net consists primarily of interest income earned on marketable securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results of Operations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 58pt;text-indent:-49pt;"><i>Comparison of the Three and Six Month Periods Ended June 30,</i>&#160;<i>2025 and</i>&#160;<i>2024</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes our unaudited results of operations for the three and six month periods ended June 30,&#160;2025 and&#160;2024 (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,822</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,928</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,478</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,185</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,710</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,673</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,775</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(314</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(526</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(757</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,123</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Research and Development Expenses</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">R&amp;D expenses increased to $5.8 million for the three months ended June 30,&#160;2025, up from $3.9 million for the three months ended June 30,&#160;2024. R&amp;D expenses increased to $11.5 million for the six months ended June 30,&#160;2025, up from $7.6 million for the six months ended June 30,&#160;2024. The increases are primarily due to cost increases driven by the continuation of our ReMEDy2 clinical trial, including our global expansion; the expansion of our clinical team in the prior and current year periods and increased manufacturing development activity. These increases were partially offset by cost reductions related to in-use study work performed and completed in the prior year period. We expect that our R&amp;D expenses will moderately increase in future periods relative to recent prior periods as we continue our ReMEDy2 trial, including our global expansion and continue the expansion of our DM199 clinical development program into PE.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>General and Administrative Expenses</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">G&amp;A expenses were $2.2 million and $1.7 million for the three months ended June 30,&#160;2025 and 2024, respectively. G&amp;A expenses were $4.7 million and $3.8 million for the six months ended June 30,&#160;2025 and 2024, respectively. These increases resulted primarily increased non-cash share-based compensation expense and increased personnel costs incurred in conjunction with expanding our team, partially offset by a reduction in legal fees incurred in connection with our lawsuit against PRA Netherlands. We expect G&amp;A expenses to remain steady in future periods as compared to recent prior periods.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Other Income, Net</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other income, net, was $313 thousand and $526 thousand for the three months ended June 30, 2025 and 2024, respectively, and $757 thousand and $1.1 million for the six months ended June 30,&#160;2025 and 2024, respectively. The decreases were driven by reduced interest income recognized during the current year period related to lower average marketable securities balances during the current year period as compared to the prior year period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liquidity and Capital Resources</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following tables summarize our liquidity and capital resources as of June 30,&#160;2025 and December&#160;31,&#160;2024, and our cash flows for each of the six month periods ended June 30,&#160;2025 and&#160;2024, and are intended to supplement the more detailed discussion that follows (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash, cash equivalents and marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,038</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,147</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31,470</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,345</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,116</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,390</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total shareholders&#8217; equity</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27,170</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,718</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Working capital</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,963</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,220</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash Flow Data</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cash flow provided by (used in):</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14,747</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11,172</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Investing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,579</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,944</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Financing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">252</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,751</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net increase in cash</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,084</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,523</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Working Capital</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We had aggregate cash, cash equivalents and marketable securities of $30.0 million, current liabilities of $4.1 million and working capital of $27.0 million as of June 30,&#160;2025, compared to aggregate cash, cash equivalents and marketable securities of $44.1 million, $5.4 million in current liabilities and $39.2 million in working capital as of December&#160;31,&#160;2024. The decreases in our combined cash, cash equivalents and marketable securities and in our working capital are due primarily to the net cash used to fund our current operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cash Flows</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Operating Activities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net cash used in operating activities for the six months ended June 30,&#160;2025 was $14.7 million compared to $11.2 million for the six months ended June 30,&#160;2024. The increase in cash used in operating activities resulted primarily from the increased net loss, partially offset by changes in operating assets and liabilities during the current year period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Investing Activities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Investing activities consist primarily of purchases and maturities of marketable securities. Net cash provided by investing activities was $15.6 million and $8.9 million for the six months ended June 30,&#160;2025 and&#160;2024, respectively. This change resulted primarily from the use of proceeds from the maturities of our marketable securities to fund our current operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Financing Activities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net cash provided by financing activities was $252 thousand for the six months ended June 30,&#160;2025 consisting primarily of proceeds from the exercise of stock options. Net cash provided by financing activities of $11.8 million for the six months ended June 30,&#160;2024 consisting primarily of net proceeds from the sale of common shares in our June 2024 private placement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Capital Requirements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Since our inception, we have incurred losses while advancing the development of our DM199 product candidate. We have not generated any revenues from product sales and do not expect to do so for at least three to four years. We do not know when or if we will generate any revenues from product sales or out-licensing of our DM199 product candidate or any future product candidate. We will not generate any revenue from product sales unless and until we obtain required regulatory approvals. We expect to continue to incur substantial operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments are sufficient to generate revenues to fund our continuing operations. We expect our operating losses to moderately increase as compared to recent prior periods as we continue the research, development and clinical studies of, and seek regulatory approval for, our DM199 product candidate, including, in particular, the expansion of our clinical development program into PE and the continuation and global expansion of our ReMEDy2 trial. In the long-term, subject to obtaining regulatory approval of our DM199 product candidate, or any other product candidate, and if we are unable to secure the assistance of, or out-license to, a strategic partner, we expect to incur significant commercialization expenses for product marketing, sales, manufacturing and distribution.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accordingly, we expect we will need substantial additional capital to complete our R&amp;D activities, including current and anticipated future clinical studies, regulatory activities, and otherwise develop our product candidate, DM199, or any future product candidate, to a point where the product candidate may be out-licensed or commercially sold. Although we are striving to achieve these plans, there is no assurance that these and other strategies will be achieved or that additional funding will be obtained on favorable terms or at all. We expect our rate of future negative quarterly cash flows to vary depending on our clinical activities and the timing of expenses Accordingly, and notwithstanding the completion of our July 2025 private placement in which we received net proceeds of $29.9 million, we expect we will need substantial additional capital to complete our R&amp;D activities, including current and anticipated future clinical studies, regulatory activities, and otherwise develop our product candidate, DM199, or any future product candidate, to a point where the product candidate may be out-licensed or commercially sold. Although we are striving to achieve these plans, there is no assurance that these and other strategies will be achieved or that additional funding will be obtained on favorable terms or at all. We expect our rate of future negative quarterly cash flows to vary depending on our clinical activities and the timing of expenses incurred and will increase moderately relative to recent prior quarterly periods as we expand our PE clinical development program and continue and globally expand our ReMEDy2 trial. We expect our current cash resources to be sufficient to support the expansion of our PE clinical development program, continue our ReMEDy2 trial and otherwise fund our planned operations for at least the next twelve months from the date of issuance of the condensed consolidated financial statements included in this report. The amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including our current ReMEDy2 trial and the Phase 2 PE trial, the potential further expansion of our current development programs, and other factors on our operating expenses. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising additional capital are favorable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Historically, we have financed our operations primarily from sales of equity securities and interest income received on funds available for investment and we expect to continue this practice for the foreseeable future. Our most recent equity financing was our July 2025 private placement in which we issued and sold an aggregate of 8,606,425 common shares pursuant to a securities purchase agreement at a purchase price of $3.50 per share to accredited investors. As a result of the offering, we received gross proceeds of $30.1 million, which resulted in net proceeds to us of approximately $29.9 million, after deducting offering expenses. We do not have any existing credit facilities under which we could borrow funds. We may seek to raise additional funds through various sources, such as equity or debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This is particularly true if our clinical data is not positive or economic and market conditions deteriorate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the extent we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted. Debt financing, if available, may involve agreements that include conversion discounts, pledging our intellectual property as collateral or covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, or strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. The availability of financing will be affected by the status of our clinical trials; our clinical data and other results of scientific and clinical research; the ability to obtain regulatory approvals and other regulatory actions; market acceptance of our product candidates; the state of the capital markets generally with particular reference to pharmaceutical, biotechnology and medical companies; the status of strategic alliance agreements; and other relevant commercial considerations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If adequate funding is not available to us when needed, we may be required to scale back our operations by taking actions that may include, among other things, implementing cost reduction strategies, such as reducing use of outside professional service providers, reducing the number of our employees or employee compensation, modifying or delaying the development of our DM199 product candidate; licensing to third parties the rights to commercialize our DM199 product candidate for PE, AIS or other indications that we would otherwise seek to pursue, or otherwise relinquishing significant rights to our technologies, future revenue streams, research programs or product candidates or granting licenses on terms that may not be favorable to us; and/or divesting assets or ceasing operations through a sale or liquidation of our Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Critical Accounting Policies and Estimates</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There have been no material changes to our critical accounting policies and estimates from the information provided in &#8220;<i>Part II. Item 7, Management</i>&#8217;<i>s Discussion and Analysis of Financial Condition and Results of Operations</i>&#8212;<i>Critical Accounting Policies</i>,&#8221; included in our annual report on Form 10-K for the fiscal year ended December&#160;31,&#160;2024.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 3. </b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a smaller reporting company, we are not required to provide disclosure pursuant to this item.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 4. </b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CONTROLS AND PROCEDURES</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Evaluation of Disclosure Controls and Procedures </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the United States Securities Exchange Act of 1934, as amended (Exchange Act)) that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered in this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of such period to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Changes in Internal Control over Financial Reporting</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There was no change in our internal control over financial reporting that occurred during the six months ended June 30,&#160;2025 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">20</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>PART II-</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>OTHER INFORMATION</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 1.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>LEGAL PROCEEDINGS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Litigation with Pharmaceutical Research Associates Group B.V., acquired by ICON plc as of July</i>&#160;<i>1,</i>&#160;<i>2021, (ICON/PRA Netherlands) </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On November&#160;23,&#160;2022, we filed a petition requesting leave for a prejudgment attachment of all relevant documents in possession of Pharmaceutical Research Associates Group B.V., acquired by ICON plc as of July&#160;1,&#160;2021, (ICON/PRA Netherlands), which was granted on November&#160;28,&#160;2022, by the District Court of Northern Netherlands. A representative of the District Court served ICON/PRA Netherlands with the prejudgment attachment on or about December&#160;7 and&#160;8,&#160;2022. The case was formally introduced to the Netherlands Commercial Court (NCC) on December&#160;28,&#160;2022 and a hearing by the NCC to determine whether we are entitled to take possession of the records seized was scheduled and held on March&#160;16,&#160;2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On April&#160;21,&#160;2023, the NCC issued a judgement affirming our ownership of the physical documents, including 51 hardcopy folders and certain digital files, related to the clinical studies performed by ICON/PRA Netherlands and seized by the Dutch courts in December&#160;2022. The NCC further ordered ICON/PRA Netherlands to allow and tolerate the surrender of the documents, including digital and source data. Additionally, the NCC found that we are not in breach of any obligation under the clinical study agreement and ICON/PRA Netherlands had no basis to suspend the fulfillment of its obligations under the clinical study agreement to provide us all clinical data and access to perform an audit of the study. On June&#160;15,&#160;2023, ICON/PRA Netherlands filed an appeal of this decision and requested a scheduling hearing with the NCC, which occurred on September&#160;23,&#160;2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The hearing addressing our claims for damages was conducted on December 7, 2023. On February 7, 2024, the NCC issued a judgment in which the NCC found that, although all data related to the study is the rightful property of DiaMedica, there was an insufficient causal link between PRA Netherlands withholding study data and the damages claimed by us. We notified the NCC and PRA Netherlands of our intent to appeal this decision and submitted our statement of grounds for appeal on October 15, 2024. The NCC issued a decision to consolidate both appeals and evaluate them concurrently at a single hearing, which occurred on March 20, 2025. The NCC ruling was issued on June 24, 2025, in which the court found that ICON/PRA Netherlands was not in default under the agreement. Additionally, the court ruled against all ICON/PRA Netherlands counter claims. We have decided to discontinue our pursuit of this matter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">From time to time, we may be subject to other various ongoing or threatened legal actions and proceedings, including those that arise in the ordinary course of business, which may include employment matters and breach of contract disputes. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. Other than the PRA Netherlands matter noted above, we are not currently engaged in or aware of any threatened legal actions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 1A.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>RISK FACTORS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Although this Item 1A is not applicable to us as a smaller reporting company, we hereby disclose the following new risk factor in addition to those disclosed in our annual report on Form 10-K for the fiscal year ended December 31, 2024, and we hereby update the risk factors in our annual report on Form 10-K for the fiscal year ended December 31, 2024 to reflect our current expectations regarding the timing of the results from Part 1a of the pending safety, tolerability and pharmacodynamic, proof-of-concept Phase 2 study in preeclampsia patients to between the second half of June and the first half of July 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Subsequent trials may fail to replicate promising data seen in earlier preclinical studies and clinical trials.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interim data from the ongoing Part 1a portion of the investigator-sponsored Phase 2 study of DM199 for the treatment of preeclampsia provided promising results. However, these results may not be replicated in ongoing and future studies or trials, and the final data analysis may differ from interim data analysis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Even if ongoing and future trials of DM199 are conducted and completed as planned, the results may not replicate the results seen in preclinical studies and early clinical studies or meet the primary or secondary endpoints, or otherwise not prove sufficient to obtain regulatory approval or result in a restricted product label that could negatively impact commercialization. Success in preclinical testing does not ensure success in clinical trials, and success in early stage clinical trials does not ensure success in later clinical trials. This can be due to a variety of reasons, including variations in patient populations, or the inability of certain patients to complete all assessments required by the clinical trial protocol, adjustments to clinical trial protocols or designs as compared to earlier testing or trials, variations in the data that could produce inconclusive or uninterpretable results, or the use of additional trial sites or investigators.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furthermore, if we fail to replicate the promising results from our preclinical studies or clinical trials in ongoing or future clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our current or future product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Changes in funding and staffing for the FDA, SEC and other government agencies could prevent our new products from being developed, approved or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions upon which the operation of our business substantially relies and which could negatively impact our business. </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The ability and propensity of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels; payment of user fees and reauthorization of user fee programs; staffing and other resource limitations; its ability to hire and retain key personnel; statutory, regulatory and policy changes; and other business disruptions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, the funding of government agencies that support research and development activities that pertain to FDA review, such as research to understand new technologies or establish new standards, is subject to the political process, which is inherently fluid and unpredictable. Such government agencies also have been subject to reductions in funding and downsizing of agency staffing levels, which could materially impact our business and operations. The current U.S. Presidential administration has implemented or proposed policies that may affect the FDA review process, including efforts to downsize the federal workforce, remove job elimination protections for federal workers, limit certain communications, and potentially impact user fee reauthorization. If political pressure, global health concerns, or other factors prevent the FDA or other regulatory authorities from conducting their regular reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We did not sell any unregistered equity securities of our Company during the quarterly period ended June 30,&#160;2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DEFAULTS UPON SENIOR SECURITIES</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 4.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>MINE SAFETY DISCLOSURES</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-06-30" name="ecd:MtrlTermsOfTrdArrTextBlock" id="c832" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 5.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>OTHER INFORMATION</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and Modifications</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the quarterly period ended June 30,&#160;2025, <span style="-sec-ix-hidden:c834"><span style="-sec-ix-hidden:c835"><span style="-sec-ix-hidden:c836"><span style="-sec-ix-hidden:c837">none</span></span></span></span> of our directors or &#8220;officers&#8221; (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) and 408(c), respectively, of SEC Regulation S-K.</p>
</ix:nonNumeric>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 6.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>EXHIBITS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following exhibits are being filed or furnished with this quarterly report on Form 10-Q:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 9%; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>No.</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: bottom; width: 48%; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: bottom; width: 39%; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Manner of Filing</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_849527.htm" style="-sec-extract:exhibit;">Notice of Articles of DiaMedica Therapeutics Inc. dated May 20, 2025</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.2</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774923015120/ex_523059.htm" style="-sec-extract:exhibit;">Amended and Restated Articles of DiaMedica Therapeutics Inc. Effective May 17, 2023</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 3.1 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on May 18, 2023 (File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774925024956/ex_848590.htm" style="-sec-extract:exhibit;">Letter Agreement dated as of August 4, 2025 between DiaMedica Therapeutics Inc. and Lorianne Masuoka, M.D.</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 10.1 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on August 6, 2025 (File No. 001-36291<span style="text-decoration: underline; ">)</span></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">31.1</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_846656.htm" style="-sec-extract:exhibit;">Certification of Chief Executive Officer Pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">31.2</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_846657.htm" style="-sec-extract:exhibit;">Certification of Chief Financial Officer Pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">32.1</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_846658.htm" style="-sec-extract:exhibit;">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furnished herewith</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">32.2</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_846659.htm" style="-sec-extract:exhibit;">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furnished herewith</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial statements from the quarterly report on Form&#160;10-Q of DiaMedica Therapeutics Inc. for the three months ended June 30, 2025, formatted in Inline XBRL: (i)&#160;the Condensed Consolidated Balance Sheets, (ii)&#160;Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) Condensed Consolidated Statements of Shareholders&#8217;&#160;Equity, (iv)&#160;Condensed Consolidated Statements of Cash Flows, and (v)&#160;Notes to the Condensed Consolidated Financial Statements.</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">104</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 39%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Embedded within the Inline XBRL document</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">23</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DIAMEDICA THERAPEUTICS INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: August 12, 2025</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;/s/ Rick Pauls</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Rick Pauls</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: August 12, 2025</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;/s/ Scott Kellen</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Scott Kellen</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial Officer and Principal Accounting Officer)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">24</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex_849527.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<html><head>
	<title>Image Exhibit</title>

	<!-- Created by RDG Filings Portal --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-right: 10px; margin-left: 10px; ">
<p style="text-align: right; margin: 0px 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Exhibit 3.1</b></font></p>

<p style="text-align: left; margin: 0px 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;">&nbsp;</p>

<p style="text-align: right; margin: 0px 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;">&nbsp;</p>

<p style="text-align: left; margin: 0px 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>

<div style="width:100%; text-align:center"><img src="noticeofarts_page1.jpg" alt="noticeofarts_page1.jpg"></div>

<p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; ">&nbsp;</p>

<div class="PGBK" style="width: 100 %; margin-right: 0pt; margin-left: 0pt; ">
<div class="PGNUM" style="width: 100 %; text-align: center; ">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100 %; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0); ">
<div class="PGHDR" style="width: 100 %; text-align: left; ">&nbsp;</div>
</div>

<div style="width:100%; text-align:center"><img src="noticeofarts_page2.jpg" alt="noticeofarts_page2.jpg"></div>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; ">&nbsp;</p>

<div class="PGBK" style="width: 100 %; margin-right: 0pt; margin-left: 0pt; ">
<div class="PGNUM" style="width: 100 %; text-align: center; ">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100 %; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0); ">
<div class="PGHDR" style="width: 100 %; text-align: left; ">&nbsp;</div>
</div>

<div style="width:100%; text-align:center"><img src="noticeofarts_page3.jpg" alt="noticeofarts_page3.jpg"></div>

<p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex_846656.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_846656.htm</title>

	<!-- Generated by ThunderDome Portal - 8/1/2025 2:25:56 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AS AMENDED, AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECTION</b>&nbsp;<b>302 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Rick Pauls, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q of DiaMedica Therapeutics Inc.(Registrant);</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: August 12, 2025</p>
			</td>
			<td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Rick Pauls</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td colspan="3" style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Rick Pauls</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td colspan="3" style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td colspan="3" style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex_846657.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_846657.htm</title>

	<!-- Generated by ThunderDome Portal - 8/1/2025 2:26:36 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AS AMENDED, AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECTION</b>&nbsp;<b>302 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Scott Kellen, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q of DiaMedica Therapeutics Inc.(Registrant);</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: August 12, 2025</p>
			</td>
			<td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Scott Kellen</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td colspan="3" style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Scott Kellen</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td colspan="3" style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td colspan="3" style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex_846658.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_846658.htm</title>

	<!-- Generated by ThunderDome Portal - 8/1/2025 2:27:20 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 32.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>18 U.S.C. SECTION</b>&nbsp;<b>1350, AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECTION</b>&nbsp;<b>906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Rick Pauls, hereby certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 9pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 of DiaMedica Therapeutics Inc. (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 9pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of DiaMedica Therapeutics Inc.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: August 12, 2025</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;/s/ Rick Pauls</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Rick Pauls</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex_846659.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title>ex_846659.htm</title>

	<!-- Generated by ThunderDome Portal - 8/1/2025 12:49:44 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 32.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>18 U.S.C. SECTION</b>&nbsp;<b>1350, AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECTION</b>&nbsp;<b>906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Scott Kellen, hereby certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 9pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the Quarterly Report on Form&nbsp;10-Q for the quarterly period ended June 30, 2025 of DiaMedica Therapeutics Inc. (the Report) fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 9pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of DiaMedica Therapeutics Inc.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: August 12, 2025</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;/s/ Scott Kellen</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Scott Kellen</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial Officer)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>dmac-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:39PM UTC 2025-08-12--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dmac="http://www.diamedica.com/20250630" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.diamedica.com/20250630">
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dmac-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dmac-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dmac-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dmac-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.diamedica.com/20250630/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" roleURI="http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flows-unaudited" roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-business" roleURI="http://www.diamedica.com/20250630/role/statement-note-1-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 1 - Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-risks-and-uncertainties" roleURI="http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 2 - Risks and Uncertainties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-" roleURI="http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 3 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-marketable-securities" roleURI="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 4 - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-deposits" roleURI="http://www.diamedica.com/20250630/role/statement-note-5-deposits">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 5 - Deposits</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-amounts-receivable" roleURI="http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 6 - Amounts Receivable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-property-and-equipment" roleURI="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 7 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-accrued-liabilities-" roleURI="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 8 - Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-operating-lease" roleURI="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 9 - Operating Lease</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-shareholders-equity" roleURI="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 10 - Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-net-loss-per-share" roleURI="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 11 - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation" roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 12 - Share-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-segment-information" roleURI="http://www.diamedica.com/20250630/role/statement-note-13-segment-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 13 - Segment Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-subsequent-events" roleURI="http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 14 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995445 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-marketable-securities-tables" roleURI="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995446 - Disclosure - Note 4 - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-property-and-equipment-tables" roleURI="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995447 - Disclosure - Note 7 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-accrued-liabilities-tables" roleURI="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995448 - Disclosure - Note 8 - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-operating-lease-tables" roleURI="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995449 - Disclosure - Note 9 - Operating Lease (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-shareholders-equity-tables" roleURI="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995450 - Disclosure - Note 10 - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-net-loss-per-share-tables" roleURI="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995451 - Disclosure - Note 11 - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation-tables" roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995452 - Disclosure - Note 12 - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-segment-information-tables" roleURI="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995453 - Disclosure - Note 13 - Segment Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-risks-and-uncertainties-details-textual" roleURI="http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995454 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995455 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-marketable-securities-details-textual" roleURI="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995456 - Disclosure - Note 4 - Marketable Securities (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" roleURI="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995457 - Disclosure - Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-amounts-receivable-details-textual" roleURI="http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995458 - Disclosure - Note 6 - Amounts Receivable (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-property-and-equipment-property-and-equipment-details" roleURI="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995459 - Disclosure - Note 7 - Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-accrued-liabilities-accrued-liabilities-details" roleURI="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995460 - Disclosure - Note 8 - Accrued Liabilities - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-operating-lease-details-textual" roleURI="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995461 - Disclosure - Note 9 - Operating Lease (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" roleURI="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995462 - Disclosure - Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-shareholders-equity-details-textual" roleURI="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995463 - Disclosure - Note 10 - Shareholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-shareholders-equity-shares-reserved-details" roleURI="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995464 - Disclosure - Note 10 - Shareholders' Equity - Shares Reserved (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" roleURI="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995465 - Disclosure - Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" roleURI="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995466 - Disclosure - Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation-details-textual" roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995467 - Disclosure - Note 12 - Share-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995468 - Disclosure - Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation-stock-option-activity-details" roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995469 - Disclosure - Note 12 - Share-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation-stock-options-outstanding-details" roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995470 - Disclosure - Note 12 - Share-based Compensation - Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-segment-information-details-textual" roleURI="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995471 - Disclosure - Note 13 - Segment Information (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-segment-information-segment-information-details" roleURI="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995472 - Disclosure - Note 13 - Segment Information - Segment Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-subsequent-events-details-textual" roleURI="http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995473 - Disclosure - Note 14 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="dmac_AccruedClinicalStudyCostsCurrent" name="AccruedClinicalStudyCostsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" name="AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_AccruedResearchAndProfessionalFeesCurrent" name="AccruedResearchAndProfessionalFeesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" name="AccruedTaxesAndOtherLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_CommercialPaperAndCorporateBondsMember" name="CommercialPaperAndCorporateBondsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" name="CommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_DeferredShareUnitsMember" name="DeferredShareUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_DepositAssetsTextBlock" name="DepositAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_EmployeeAndNonemployeeStockOptionsMember" name="EmployeeAndNonemployeeStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange1Member" name="ExercisePriceRange1Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange2Member" name="ExercisePriceRange2Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange3Member" name="ExercisePriceRange3Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange4Member" name="ExercisePriceRange4Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange5Member" name="ExercisePriceRange5Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" name="FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_NoncashLeaseExpense" name="NoncashLeaseExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NonemployeeStockOptionsMember" name="NonemployeeStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_OperatingExpensesExcludingSharebasedCompensation" name="OperatingExpensesExcludingSharebasedCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_RisksAndUncertaintiesTextBlock" name="RisksAndUncertaintiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" name="StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_StockOptionPriorPlanMember" name="StockOptionPriorPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_StockOptionsOutstandingMember" name="StockOptionsOutstandingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_The2012DSUPlanMember" name="The2012DSUPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_The2019OmnibusIncentivePlanMember" name="The2019OmnibusIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_The2021EmploymentInducementIncentivePlanMember" name="The2021EmploymentInducementIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_WorkingCapital" name="WorkingCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" name="statement-statement-note-10-shareholders-equity-shares-reserved-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-10-shareholders-equity-tables" name="statement-statement-note-10-shareholders-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" name="statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" name="statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-11-net-loss-per-share-tables" name="statement-statement-note-11-net-loss-per-share-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" name="statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" name="statement-statement-note-12-sharebased-compensation-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" name="statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-12-sharebased-compensation-tables" name="statement-statement-note-12-sharebased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-13-segment-information-segment-information-details" name="statement-statement-note-13-segment-information-segment-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-13-segment-information-tables" name="statement-statement-note-13-segment-information-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" name="statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-4-marketable-securities-tables" name="statement-statement-note-4-marketable-securities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-7-property-and-equipment-property-and-equipment-details" name="statement-statement-note-7-property-and-equipment-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-7-property-and-equipment-tables" name="statement-statement-note-7-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-8-accrued-liabilities-accrued-liabilities-details" name="statement-statement-note-8-accrued-liabilities-accrued-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-8-accrued-liabilities-tables" name="statement-statement-note-8-accrued-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" name="statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-9-operating-lease-tables" name="statement-statement-note-9-operating-lease-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>dmac-20250630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:39PM UTC 2025-08-12--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-5-deposits" xlink:href="dmac-20250630.xsd#statement-note-5-deposits" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-5-deposits" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DepositAssetsTextBlock" xlink:label="dmac_DepositAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dmac_DepositAssetsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-1-business" xlink:href="dmac-20250630.xsd#statement-note-1-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-1-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-document-and-entity-information" xlink:href="dmac-20250630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="dmac-20250630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="dmac-20250630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNoParValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:href="dmac-20250630.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" xlink:href="dmac-20250630.xsd#statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" xlink:href="dmac-20250630.xsd#statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="dmac-20250630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoncashLeaseExpense" xlink:label="dmac_NoncashLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dmac_NoncashLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties" xlink:href="dmac-20250630.xsd#statement-note-2-risks-and-uncertainties" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_RisksAndUncertaintiesTextBlock" xlink:label="dmac_RisksAndUncertaintiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dmac_RisksAndUncertaintiesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-" xlink:href="dmac-20250630.xsd#statement-note-3-summary-of-significant-accounting-policies-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities" xlink:href="dmac-20250630.xsd#statement-note-4-marketable-securities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_CommercialPaperAndCorporateBondsMember" xlink:label="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable" xlink:href="dmac-20250630.xsd#statement-note-6-amounts-receivable" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment" xlink:href="dmac-20250630.xsd#statement-note-7-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-" xlink:href="dmac-20250630.xsd#statement-note-8-accrued-liabilities-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease" xlink:href="dmac-20250630.xsd#statement-note-9-operating-lease" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity" xlink:href="dmac-20250630.xsd#statement-note-10-shareholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockOptionsOutstandingMember" xlink:label="dmac_StockOptionsOutstandingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_StockOptionsOutstandingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share" xlink:href="dmac-20250630.xsd#statement-note-11-net-loss-per-share" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation" xlink:href="dmac-20250630.xsd#statement-note-12-sharebased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange1Member" xlink:label="dmac_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange2Member" xlink:label="dmac_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange3Member" xlink:label="dmac_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange4Member" xlink:label="dmac_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange5Member" xlink:label="dmac_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockOptionPriorPlanMember" xlink:label="dmac_StockOptionPriorPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_NonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_StockOptionPriorPlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2012DSUPlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange3Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange4Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange5Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-13-segment-information" xlink:href="dmac-20250630.xsd#statement-note-13-segment-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-13-segment-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events" xlink:href="dmac-20250630.xsd#statement-note-14-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies" xlink:href="dmac-20250630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables" xlink:href="dmac-20250630.xsd#statement-note-4-marketable-securities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:label="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-tables" xlink:href="dmac-20250630.xsd#statement-note-7-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-tables" xlink:href="dmac-20250630.xsd#statement-note-8-accrued-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables" xlink:href="dmac-20250630.xsd#statement-note-9-operating-lease-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables" xlink:href="dmac-20250630.xsd#statement-note-10-shareholders-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables" xlink:href="dmac-20250630.xsd#statement-note-11-net-loss-per-share-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables" xlink:href="dmac-20250630.xsd#statement-note-12-sharebased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables" xlink:href="dmac-20250630.xsd#statement-note-13-segment-information-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual" xlink:href="dmac-20250630.xsd#statement-note-2-risks-and-uncertainties-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_WorkingCapital" xlink:label="dmac_WorkingCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WorkingCapital" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="dmac-20250630.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual" xlink:href="dmac-20250630.xsd#statement-note-4-marketable-securities-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivable" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:href="dmac-20250630.xsd#statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_CommercialPaperAndCorporateBondsMember" xlink:label="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable-details-textual" xlink:href="dmac-20250630.xsd#statement-note-6-amounts-receivable-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details" xlink:href="dmac-20250630.xsd#statement-note-7-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:href="dmac-20250630.xsd#statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedClinicalStudyCostsCurrent" xlink:label="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-details-textual" xlink:href="dmac-20250630.xsd#statement-note-9-operating-lease-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableLeaseCost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:href="dmac-20250630.xsd#statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual" xlink:href="dmac-20250630.xsd#statement-note-10-shareholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details" xlink:href="dmac-20250630.xsd#statement-note-10-shareholders-equity-shares-reserved-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockOptionsOutstandingMember" xlink:label="dmac_StockOptionsOutstandingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_StockOptionsOutstandingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:href="dmac-20250630.xsd#statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" xlink:href="dmac-20250630.xsd#statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual" xlink:href="dmac-20250630.xsd#statement-note-12-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockOptionPriorPlanMember" xlink:label="dmac_StockOptionPriorPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_NonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_StockOptionPriorPlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2012DSUPlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:href="dmac-20250630.xsd#statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:href="dmac-20250630.xsd#statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:href="dmac-20250630.xsd#statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange1Member" xlink:label="dmac_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange2Member" xlink:label="dmac_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange3Member" xlink:label="dmac_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange4Member" xlink:label="dmac_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange5Member" xlink:label="dmac_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange3Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange4Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange5Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-details-textual" xlink:href="dmac-20250630.xsd#statement-note-13-segment-information-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details" xlink:href="dmac-20250630.xsd#statement-note-13-segment-information-segment-information-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual" xlink:href="dmac-20250630.xsd#statement-note-14-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>dmac-20250630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:39PM UTC 2025-08-12--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DocumentAndEntityInformation" xlink:label="dmac_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="dmac_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DocumentAndEntityInformation" xlink:to="dmac_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="dmac_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="dmac_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-significant-accounting-policies-policies" xlink:label="dmac_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-significant-accounting-policies-policies" xlink:to="dmac_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-4-marketable-securities-tables" xlink:label="dmac_statement-statement-note-4-marketable-securities-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-4-marketable-securities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Marketable Securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-4-marketable-securities-tables" xlink:to="dmac_statement-statement-note-4-marketable-securities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-7-property-and-equipment-tables" xlink:label="dmac_statement-statement-note-7-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-7-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-7-property-and-equipment-tables" xlink:to="dmac_statement-statement-note-7-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_AccruedTaxesAndOtherLiabilitiesCurrent</link:label>
    <link:label xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of accrued taxes and other liabilities classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:to="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee and Non-employee Stock Options [Member]</link:label>
    <link:label xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to employee and non-employee stock option awards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-8-accrued-liabilities-tables" xlink:label="dmac_statement-statement-note-8-accrued-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-8-accrued-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Accrued Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-8-accrued-liabilities-tables" xlink:to="dmac_statement-statement-note-8-accrued-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedClinicalStudyCostsCurrent" xlink:label="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="dmac_AccruedClinicalStudyCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label xlink:label="dmac_AccruedClinicalStudyCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of accrued clinical study costs classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AccruedClinicalStudyCostsCurrent" xlink:to="dmac_AccruedClinicalStudyCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-9-operating-lease-tables" xlink:label="dmac_statement-statement-note-9-operating-lease-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-9-operating-lease-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Operating Lease</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-9-operating-lease-tables" xlink:to="dmac_statement-statement-note-9-operating-lease-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-10-shareholders-equity-tables" xlink:label="dmac_statement-statement-note-10-shareholders-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-10-shareholders-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Shareholders' Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-10-shareholders-equity-tables" xlink:to="dmac_statement-statement-note-10-shareholders-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-11-net-loss-per-share-tables" xlink:label="dmac_statement-statement-note-11-net-loss-per-share-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-11-net-loss-per-share-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Net Loss Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-11-net-loss-per-share-tables" xlink:to="dmac_statement-statement-note-11-net-loss-per-share-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-12-sharebased-compensation-tables" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-12-sharebased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Share-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-tables" xlink:to="dmac_statement-statement-note-12-sharebased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DepositAssetsTextBlock" xlink:label="dmac_DepositAssetsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_DepositAssetsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposit Assets [Text Block]</link:label>
    <link:label xlink:label="dmac_DepositAssetsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description of the companies deposits labeled as assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DepositAssetsTextBlock" xlink:to="dmac_DepositAssetsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoncashLeaseExpense" xlink:label="dmac_NoncashLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="dmac_NoncashLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label xlink:label="dmac_NoncashLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of expense recognized over the period for lease expense, non-cash.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NoncashLeaseExpense" xlink:to="dmac_NoncashLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-13-segment-information-tables" xlink:label="dmac_statement-statement-note-13-segment-information-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-13-segment-information-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Segment Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-13-segment-information-tables" xlink:to="dmac_statement-statement-note-13-segment-information-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_DeferredShareUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Share Units [Member]</link:label>
    <link:label xlink:label="dmac_DeferredShareUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The deferred share units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DeferredShareUnitsMember" xlink:to="dmac_DeferredShareUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:label="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:to="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-7-property-and-equipment-property-and-equipment-details" xlink:label="dmac_statement-statement-note-7-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-7-property-and-equipment-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Property and Equipment - Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-7-property-and-equipment-property-and-equipment-details" xlink:to="dmac_statement-statement-note-7-property-and-equipment-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:label="dmac_statement-statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-8-accrued-liabilities-accrued-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Accrued Liabilities - Accrued Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:to="dmac_statement-statement-note-8-accrued-liabilities-accrued-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:label="dmac_statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:to="dmac_statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:label xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees and accrued research. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:to="dmac_AccruedResearchAndProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" xlink:label="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Shareholders' Equity - Shares Reserved (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" xlink:to="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:label="dmac_statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:to="dmac_statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" xlink:label="dmac_statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" xlink:to="dmac_statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:to="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Share-based Compensation - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:to="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Share-based Compensation - Stock Options Outstanding (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:to="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_CommercialPaperAndCorporateBondsMember" xlink:label="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_CommercialPaperAndCorporateBondsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper and Corporate Bonds [Member]</link:label>
    <link:label xlink:label="dmac_CommercialPaperAndCorporateBondsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Papers are unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents and commercial bonds are debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_CommercialPaperAndCorporateBondsMember" xlink:to="dmac_CommercialPaperAndCorporateBondsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-13-segment-information-segment-information-details" xlink:label="dmac_statement-statement-note-13-segment-information-segment-information-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-13-segment-information-segment-information-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Segment Information - Segment Information (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-13-segment-information-segment-information-details" xlink:to="dmac_statement-statement-note-13-segment-information-segment-information-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatements" xlink:label="dmac_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="dmac_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NotesToFinancialStatements" xlink:to="dmac_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="dmac_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="dmac_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestReceivableCurrent</link:label>
    <link:label xlink:label="us-gaap_InterestReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:label="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Marketable Securities Measured on a Recurring Basis [Table Text Block]</link:label>
    <link:label xlink:label="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of marketable securities measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:to="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockOptionsOutstandingMember" xlink:label="dmac_StockOptionsOutstandingMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_StockOptionsOutstandingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options Outstanding [Member]</link:label>
    <link:label xlink:label="dmac_StockOptionsOutstandingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to stock options outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_StockOptionsOutstandingMember" xlink:to="dmac_StockOptionsOutstandingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Reserved for Future Issuance [Table Text Block]</link:label>
    <link:label xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A tabular disclosure of common stock reserved for future issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="dmac_CommonStockReservedForFutureIssuanceTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator"/>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_ProceedsFromIssuanceOfCommonStockNet</link:label>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock, Net</link:label>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from the issuance of common stock, net of offering costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:to="dmac_ProceedsFromIssuanceOfCommonStockNet-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_The2012DSUPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2012 DSU Plan [Member]</link:label>
    <link:label xlink:label="dmac_The2012DSUPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the 2012 DSU plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_The2012DSUPlanMember" xlink:to="dmac_The2012DSUPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange1Member" xlink:label="dmac_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 1 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange1Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the first exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange1Member" xlink:to="dmac_ExercisePriceRange1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_NonemployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonemployee Stock Options [Member]</link:label>
    <link:label xlink:label="dmac_NonemployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the nonemployee stock options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NonemployeeStockOptionsMember" xlink:to="dmac_NonemployeeStockOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange5Member" xlink:label="dmac_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange5Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 5 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange5Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the fifth exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange5Member" xlink:to="dmac_ExercisePriceRange5Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange4Member" xlink:label="dmac_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange4Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 4 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange4Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the fourth exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange4Member" xlink:to="dmac_ExercisePriceRange4Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange3Member" xlink:label="dmac_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 3 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange3Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the third exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange3Member" xlink:to="dmac_ExercisePriceRange3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange2Member" xlink:label="dmac_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 2 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange2Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the second exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange2Member" xlink:to="dmac_ExercisePriceRange2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositsAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:label xlink:label="us-gaap_DepositsAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DepositsAssetsCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares, no par value; unlimited authorized; 43,072,488 and 42,818,660 shares issued and outstanding, as of June 30, 2025 and December 31, 2024, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireMarketableSecurities</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized, Unlimited [Fixed List]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeitures, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockNoParValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, No Par Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares reserved for future issuance (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxesPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional services fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfOperatingSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsAndShortTermInvestments</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label xlink:label="us-gaap_MarketableSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_MarketableSecuritiesCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' Equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</link:label>
    <link:label xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of discounts on marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">operating loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_The2019OmnibusIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2019 Omnibus Incentive Plan [Member]</link:label>
    <link:label xlink:label="dmac_The2019OmnibusIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to the 2019 Omnibus Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_The2019OmnibusIncentivePlanMember" xlink:to="dmac_The2019OmnibusIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockOptionPriorPlanMember" xlink:label="dmac_StockOptionPriorPlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_StockOptionPriorPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Prior Plan [Member]</link:label>
    <link:label xlink:label="dmac_StockOptionPriorPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the company's stock option plan known as the Prior Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_StockOptionPriorPlanMember" xlink:to="dmac_StockOptionPriorPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest Receivable On Available For Sale Securities [Member]</link:label>
    <link:label xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to accrued interest receivable on available for sale securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:to="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common shares, net of offering costs</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities and operating lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses, excluding share-based compensation</link:label>
    <link:label xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_OperatingExpensesExcludingSharebasedCompensation</link:label>
    <link:label xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Generally recurring costs associated with normal operations, excluding share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:to="dmac_OperatingExpensesExcludingSharebasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentQuarterlyReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentQuarterlyReport</link:label>
    <link:label xlink:label="dei_DocumentQuarterlyReport-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="locator"/>
    <link:label xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares in settlement of deferred stock units (in shares)</link:label>
    <link:label xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares Settlement of Deferred Stock Units</link:label>
    <link:label xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares issued during the period due to the settlement of deferred stock units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:to="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2021 Employment Inducement Incentive Plan [Member]</link:label>
    <link:label xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the company's 2021 Employment Inducement Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentTransitionReport</link:label>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_CityAreaCode</link:label>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityInteractiveDataCurrent</link:label>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balances (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_VariableLeaseCost</link:label>
    <link:label xlink:label="us-gaap_VariableLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivableTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestReceivable</link:label>
    <link:label xlink:label="us-gaap_InterestReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDepositOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseCost</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets acquired under financing lease</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentPeriodEndDate</link:label>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidExpense</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityFileNumber</link:label>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentType</link:label>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityShellCompany</link:label>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityCurrentReportingStatus</link:label>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityRegistrantName</link:label>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressAddressLine1</link:label>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding&#8212;basic and diluted (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding &#8211; basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressCityOrTown</link:label>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressPostalZipCode</link:label>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressStateOrProvince</link:label>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityCommonStockSharesOutstanding</link:label>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" xlink:type="locator"/>
    <link:label xlink:label="ecd_TradingArrByIndTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_LocalPhoneNumber</link:label>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares upon the exercise of stock options (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares upon the exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares upon the vesting and settlement of restricted stock units</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesNoncurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, options (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeitures, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</link:label>
    <link:label xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares net of offering costs of $0.1 million (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares net of offering costs of $0.1 million</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Ending Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balances</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease obligation, non-current</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Present value of lease obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease obligation</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less current portion of operating lease</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeaseLiabilityNoncurrent</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositsAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeasePrincipalPayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeasePrincipalPayments</link:label>
    <link:label xlink:label="us-gaap_FinanceLeasePrincipalPayments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments on finance lease obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less interest portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_WorkingCapital" xlink:label="dmac_WorkingCapital" xlink:type="locator"/>
    <link:label xlink:label="dmac_WorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_WorkingCapital</link:label>
    <link:label xlink:label="dmac_WorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:label xlink:label="dmac_WorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of working capital.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_WorkingCapital" xlink:to="dmac_WorkingCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_RisksAndUncertaintiesTextBlock" xlink:label="dmac_RisksAndUncertaintiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_RisksAndUncertaintiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Text Block]</link:label>
    <link:label xlink:label="dmac_RisksAndUncertaintiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A complete disclosure of the risks and uncertainties the company may face.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_RisksAndUncertaintiesTextBlock" xlink:to="dmac_RisksAndUncertaintiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>dmac-20250630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:39PM UTC 2025-08-12--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-5-deposits" xlink:href="dmac-20250630.xsd#statement-note-5-deposits" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-5-deposits" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DepositAssetsTextBlock" xlink:label="dmac_DepositAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dmac_DepositAssetsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-1-business" xlink:href="dmac-20250630.xsd#statement-note-1-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-1-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-document-and-entity-information" xlink:href="dmac-20250630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="dmac-20250630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="dmac-20250630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNoParValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:href="dmac-20250630.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" xlink:href="dmac-20250630.xsd#statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" xlink:href="dmac-20250630.xsd#statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="dmac-20250630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoncashLeaseExpense" xlink:label="dmac_NoncashLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dmac_NoncashLeaseExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties" xlink:href="dmac-20250630.xsd#statement-note-2-risks-and-uncertainties" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_RisksAndUncertaintiesTextBlock" xlink:label="dmac_RisksAndUncertaintiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dmac_RisksAndUncertaintiesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-" xlink:href="dmac-20250630.xsd#statement-note-3-summary-of-significant-accounting-policies-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities" xlink:href="dmac-20250630.xsd#statement-note-4-marketable-securities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_CommercialPaperAndCorporateBondsMember" xlink:label="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable" xlink:href="dmac-20250630.xsd#statement-note-6-amounts-receivable" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment" xlink:href="dmac-20250630.xsd#statement-note-7-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-" xlink:href="dmac-20250630.xsd#statement-note-8-accrued-liabilities-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease" xlink:href="dmac-20250630.xsd#statement-note-9-operating-lease" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity" xlink:href="dmac-20250630.xsd#statement-note-10-shareholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockOptionsOutstandingMember" xlink:label="dmac_StockOptionsOutstandingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_StockOptionsOutstandingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share" xlink:href="dmac-20250630.xsd#statement-note-11-net-loss-per-share" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation" xlink:href="dmac-20250630.xsd#statement-note-12-sharebased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange1Member" xlink:label="dmac_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange2Member" xlink:label="dmac_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange3Member" xlink:label="dmac_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange4Member" xlink:label="dmac_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange5Member" xlink:label="dmac_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockOptionPriorPlanMember" xlink:label="dmac_StockOptionPriorPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_NonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_StockOptionPriorPlanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2012DSUPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange3Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange4Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange5Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-13-segment-information" xlink:href="dmac-20250630.xsd#statement-note-13-segment-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-13-segment-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events" xlink:href="dmac-20250630.xsd#statement-note-14-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_TradingArrByIndTable" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies" xlink:href="dmac-20250630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-significant-accounting-policies-policies" xlink:label="dmac_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables" xlink:href="dmac-20250630.xsd#statement-note-4-marketable-securities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:label="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-4-marketable-securities-tables" xlink:label="dmac_statement-statement-note-4-marketable-securities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-4-marketable-securities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-tables" xlink:href="dmac-20250630.xsd#statement-note-7-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-7-property-and-equipment-tables" xlink:label="dmac_statement-statement-note-7-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-7-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-tables" xlink:href="dmac-20250630.xsd#statement-note-8-accrued-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-8-accrued-liabilities-tables" xlink:label="dmac_statement-statement-note-8-accrued-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-8-accrued-liabilities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables" xlink:href="dmac-20250630.xsd#statement-note-9-operating-lease-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-9-operating-lease-tables" xlink:label="dmac_statement-statement-note-9-operating-lease-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-9-operating-lease-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables" xlink:href="dmac-20250630.xsd#statement-note-10-shareholders-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-10-shareholders-equity-tables" xlink:label="dmac_statement-statement-note-10-shareholders-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-10-shareholders-equity-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables" xlink:href="dmac-20250630.xsd#statement-note-11-net-loss-per-share-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-11-net-loss-per-share-tables" xlink:label="dmac_statement-statement-note-11-net-loss-per-share-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-11-net-loss-per-share-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables" xlink:href="dmac-20250630.xsd#statement-note-12-sharebased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-12-sharebased-compensation-tables" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables" xlink:href="dmac-20250630.xsd#statement-note-13-segment-information-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-13-segment-information-tables" xlink:label="dmac_statement-statement-note-13-segment-information-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-13-segment-information-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual" xlink:href="dmac-20250630.xsd#statement-note-2-risks-and-uncertainties-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_WorkingCapital" xlink:label="dmac_WorkingCapital-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-n2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WorkingCapital-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="dmac-20250630.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual" xlink:href="dmac-20250630.xsd#statement-note-4-marketable-securities-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivable-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:href="dmac-20250630.xsd#statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_CommercialPaperAndCorporateBondsMember" xlink:label="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:label="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable-details-textual" xlink:href="dmac-20250630.xsd#statement-note-6-amounts-receivable-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivableCurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details" xlink:href="dmac-20250630.xsd#statement-note-7-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-7-property-and-equipment-property-and-equipment-details" xlink:label="dmac_statement-statement-note-7-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-7-property-and-equipment-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:href="dmac-20250630.xsd#statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedClinicalStudyCostsCurrent" xlink:label="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:label="dmac_statement-statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-details-textual" xlink:href="dmac-20250630.xsd#statement-note-9-operating-lease-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableLeaseCost-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:href="dmac-20250630.xsd#statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:label="dmac_statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual" xlink:href="dmac-20250630.xsd#statement-note-10-shareholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ProceedsFromIssuanceOfCommonStockNet-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details" xlink:href="dmac-20250630.xsd#statement-note-10-shareholders-equity-shares-reserved-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockOptionsOutstandingMember" xlink:label="dmac_StockOptionsOutstandingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" xlink:label="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_StockOptionsOutstandingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:href="dmac-20250630.xsd#statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:label="dmac_statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-1" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" xlink:href="dmac-20250630.xsd#statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" xlink:label="dmac_statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual" xlink:href="dmac-20250630.xsd#statement-note-12-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_StockOptionPriorPlanMember" xlink:label="dmac_StockOptionPriorPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_NonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_StockOptionPriorPlanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2012DSUPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:href="dmac-20250630.xsd#statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:href="dmac-20250630.xsd#statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n0" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n0" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:href="dmac-20250630.xsd#statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange1Member" xlink:label="dmac_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange2Member" xlink:label="dmac_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange3Member" xlink:label="dmac_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange4Member" xlink:label="dmac_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_ExercisePriceRange5Member" xlink:label="dmac_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange3Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange4Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange5Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-details-textual" xlink:href="dmac-20250630.xsd#statement-note-13-segment-information-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details" xlink:href="dmac-20250630.xsd#statement-note-13-segment-information-segment-information-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_statement-statement-note-13-segment-information-segment-information-details" xlink:label="dmac_statement-statement-note-13-segment-information-segment-information-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-13-segment-information-segment-information-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_OperatingExpensesExcludingSharebasedCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual" xlink:href="dmac-20250630.xsd#statement-note-14-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>dmac-20250630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:39PM UTC 2025-08-12--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="dmac-20250630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:href="dmac-20250630.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="dmac-20250630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="dmac-20250630.xsd#dmac_NoncashLeaseExpense" xlink:label="dmac_NoncashLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dmac_NoncashLeaseExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details" xlink:href="dmac-20250630.xsd#statement-note-7-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:href="dmac-20250630.xsd#statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedClinicalStudyCostsCurrent" xlink:label="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20250630.xsd#dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:href="dmac-20250630.xsd#statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details" xlink:href="dmac-20250630.xsd#statement-note-13-segment-information-segment-information-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details" xlink:type="extended">
    <link:loc xlink:href="dmac-20250630.xsd#dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>divpipeimg.jpg
<TEXT>
begin 644 divpipeimg.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M'E:662XBVLF-C0D!PWI]X$>H-0OX+A?6S>?;[@6C7JZ@]B%78UPH #[L;L<
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M07,EI]K&4^79Z9_O8R<>@K-U?X?:/JYD#PQQ1'36T^&)8$*VX8YWH".&%*/
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MSF06\FT8Z\[L4_JN*?VOQ#ZSAOY?P/2?^$/T+_GQ_P#(S_\ Q5'_  A^A?\
M/C_Y&?\ ^*KSM?BCXD;1WU(VVF+"LX@ */EF*EN/F[ <_454_P"%Q:__ ,^F
MG_\ ?M__ (JFL)BGL_Q$\5AET_ ]/_X0_0O^?'_R,_\ \51_PA^A?\^/_D9_
M_BJ\P_X7%K__ #Z:?_W[?_XJC_A<6O\ _/II_P#W[?\ ^*I_4\7W_$7UO"]O
MP/3_ /A#]"_Y\?\ R,__ ,51_P (?H7_ #X_^1G_ /BJ\P_X7%K_ /SZ:?\
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MM)]P#P2.]:=><VG@[5['P[#/(]S=:A"TL45H)41;>&6X#2%&0H6)55X9_;-
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ML5%>=Z-\1KC4/B';^'TCMI+23S82XR)HY(HD<DY;)!+$9V@>A/->B4 %%%%
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MR1G!/.,UZ7126+J+M]R&\+3??[V>9GX?>*VF,K>(K5F,KS'=!D%V 5B01@Y
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M PP&!UK;@\96EX;C^U+)8TCTV6S@1)7^="4VQDXX/!^;WJQ_PJ#Q%_SWT_\
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M0<<8 X-<L<9X&!V%=Y_PJ#Q%_P ]]/\ ^_K_ /Q-'_"H/$7_ #WT_P#[^O\
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M+T.:&+4KAHY)PQC58G<L!U^Z#ZUJ5QWB>[73?'6@W]Q'.UM##<!WBA:3:2H
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M-)L9+I8F"N4(X)Z#D\DX->S/"TYR<Y.VK_,\F&)J1BH15]%^1]"?\+1\&_\
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M4YIT]=KDVD276II:W-RA2.#=M)ZR/RNX?[(!.#WSGIUUY?\ 4O\ [IIX 4
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M:/%+&D2::JFV5HMJ@MU?YOK]><5SW_"$>)O^@)=_]\C_ !H_X0CQ-_T!+O\
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M*:Z[[6/^>$__ '[KHQ'Q_)?DC"A\'S?YLL457^UC_GA/_P!^Z/M@_P">$_\
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M1]K'_/"?_OW18+EBBJXNP3_J)_\ OW1]L''[B?G_ *9T6"Y8HJO]L'_/"?\
M[]T?:Q_SPG_[]T6"Y8HJO]K'_/"?_OW1]L'_ #PG_P"_=%@N6**K_;!_SPG_
M ._='VP?\\)_^_=%@N6**KF\ _Y83_\ ?N@W8'_+"?\ []T6"Y8HJO\ :Q_S
MPG_[]T?:Q_SPG_[]T6"Y8HJN+L'_ )83_P#?NC[6,_ZB?_OW18+EBBJ_VP<?
MN)^?^F='VP?\\)_^_=%@N6**K_:Q_P \)_\ OW1]L'_/"?\ []T6"Y8HJO\
M;!_SPG_[]T?;!_SPG_[]T6"Y8HJO]K'_ #PG_P"_=!O /^6$_P#W[HL%RQ15
M<W8'_+"?_OW1]K'_ #PG_P"_=%@N6**K_:Q_SPG_ ._= NP?^6$__?NBP7+%
M%5Q=@_\ +"?_ +]T?;!Q^XGY_P"F=%@N6**K_;!_SPG_ ._='VL?\\)_^_=%
M@N6**K_;!_SPG_[]T?;!C_43_P#?NBP7+%%5_M@Y_<3_ /?NC[8/^>$__?NB
MP7+%%5S> ?\ +"?_ +]T&[ _Y83_ /?NBP7+%%5_M8_YX3_]^Z/M8_YX3_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,[BQP.M $EQ\5?#/]F75QI]V;B6"!YQ%-#+ &".$<;F3[RLP!7!(SR*V]/\
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M?$8TTK<3PM'Y-H)&S8A9TBD#<Y.XL<9SQ47H_P OX%VJ=SF1\:?'9_YC$?\
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M+(94N$\R0*74-\DB-D 8P1UYH?L5O#\$->U>TOQ9F?\ "W/&G_053_P%B_\
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M .)H_P"%N>-/^@JG_@+%_P#$UQ5%'L:7\J^X/;5/YG]YVO\ PMSQI_T%4_\
M 6+_ .)H_P"%N>-/^@JG_@+%_P#$UQ5%'L:7\J^X/;5/YG]YVO\ PMSQI_T%
M4_\  6+_ .)H_P"%N>-/^@JG_@+%_P#$UQ5%'L:7\J^X/;5/YG]YVO\ PMSQ
MI_T%4_\  6+_ .)H_P"%N>-/^@JG_@+%_P#$UQ5%'L:7\J^X/;5/YG]YVO\
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M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:(3%"DZF6(QR^6!(FXM\P^;.T =.>#7H%1QV\,4KR10QH[XW,J@%L=,GO4E
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M:-M_>?\ []-_A1_:-M_>?_OVW^%%F%T6:*K?VC;?WG_[]M_A1_:-MS\S\?\
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MDD6/^)VA_P"W4_\ Q5>7[&<HII=$</LY2BFD<A:=JUT^Z*Z>'X7O%_S%E/\
MV[G_ .*JX/AZP&/[27_OS_\ 95B\+6[?D9.A4?0XVBNS_P"%?-_T$E_[\_\
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MAS)'\NY-Q7:&&.O?.U>:I17OB74I=4733>RW(=MA290L6UIMF5+ *2=@*\8
M4D$$BB["R/1_[/M_23_OZW^-']GV_I)_W];_ !KC8]-\3VM\ZVYO2C7;R(S7
M*M&-TP8E@3G9Y1P%'1@>!P:O7%KX@@TS0O*EO)[F(*;Y3*@#,=NXNV1P/GP
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>noticeofarts_page1.jpg
<TEXT>
begin 644 noticeofarts_page1.jpg
M_]C_X  02D9)1@ ! 0$"SP+-  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_X@I(24-#7U!23T9)3$4  0$   HX041"10(0  !M;G1R
M4D="(%A96B 'Y@ ! !< #  Y "QA8W-P35-&5     !$14Q,
M            ]M8  0    #3+41%3$P
M                                  ID97-C    _    'EC<')T   !
M>    #=W='!T   !L    !1R6%E:   !Q    !1G6%E:   !V    !1B6%E:
M   ![    !1R5%)#   "    " QG5%)#   "    " QB5%)#   "    " QC
M:&%D   *#    "QD97-C         "5$14Q,(% R-#(R2" @0V]L;W(@4')O
M9FEL92Q$-C4P,
M
M=&5X=     !#;W!Y<FEG:'0@*&,I(#(P,C(@1&5L;"!);F,N
M              !865H@        ]M8  0    #3+5A96B        !XC0
M.I,   $36%E:(        %O:  "V.0  %CE865H@        (G4   \U  "[
M[F-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!*
M $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +<
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MCPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N
M"Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-
MPPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F
M$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2
MXQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]
M%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BABO&-48
M^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2
M''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@
M%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P
M)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<* TH
M/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB
M+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ
M@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R
M-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[
MZ#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J
M0:Q![D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'
M>T? 2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV3
M3=Q.)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_94
M0E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU
M6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B
M26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH/VB6:.QI0VF:
M:?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQ
ME7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV^'=6=[-X$7AN>,QY*GF)
M>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K@<V"
M,(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*
MBS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6D3^1J)(1DGJ2XY--D[:4
M()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUD
MG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG
M;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[  L'6PZK%@
ML=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\
M(;R;O16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#
MQT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2
M/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6
MWAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;I
MT.I;ZN7K<.O[[(;M$>V<[BCNM.] [\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>
M]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?__<V8S,@
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M 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGQ:%XFTUH+(!KAH8&O1',T+I)";F/>JLK)L<AO ?&/["7QT\<?M7ZYXF\-^
M)/AOXRO?%7C.&/X@6-OHD,":7>Z/K]II%W/J)O;C7+\BYN='F-NR0V]J8A''
M:A+:W,7ZKT4 ?G)\,/V(9->\5?"F'0_V55^#?@_2/$VG2^.-/U#6=)N8?$$(
M\,^*-/O))[*UN9K>Y03:E9PO=N6N[WS_ -[&8K6-SP7PY_X)C^/?A)\&?AGI
M=U\(+/6/"'A_X=_"^P\>> =-N=*C7QI>:<?%#ZW9,C3I:W#PWVJZ?J$OG2+#
M>&!U$DK,RG]6** /*_V+O!O_  @'[/.EZ7'\.?\ A4MC#>:A+8>$CJL>HMHM
MK+>SRPQEHG>"',;J_P!EMW>WM0X@A9HHD-?-_@_]DKXE:1^RY\"O#LOAF:+6
M?"/Q9U;Q'K5J-1M/]#TV>?7WBG+"79(&6\M3L0LX\T94%7V_<E% 'Y/:5_P1
MQUK3?V;-4AA^#7ARU^(!_9FTW3+*:.73EE'Q+@M+Q?MWF"79_:L4LD6S5&.Y
M=YV7(!>N\^''["GQ.\/_ /!2E/&VK>&?%5UJG_"QM5UZ;Q];/X=M[&?P[-'=
MFST^2[)?6;B&.VEMK$Z>T*P++;+.LBB.*5OTEHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&;3XO%>MZO8V^GZEXCOW>ZAC+0Q!FEA6&W5XIY)2SI,,(JX9@#[$HKX9OO\
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M:V53&;6Z'G-YRB.:W1%296\U/<J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y#_ /@ZBUN[
MU7_@N3\8(+AV:'3;;0K:U!Z)&=$L92![>9)(?J37YYU_9Q^U1_P05_9=_;;_
M &B]9^*7Q3^']YXL\5:Y;6UK<.WB#4+" +!&L4;!+6:+YMBJI+$Y"BN/U7_@
MV,_8;U>S6&3X%VD03[KP>)]:A<'&,EEO 3^.10!_-[_P2Z_X+E_'3_@DZ=8T
M_P !:CI?B#PAK2/)-X6\1QRW6E0W>TA+N%8Y(Y(9 <!_+=5E4 .&*1M'XO\
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M4'XD4 ?.-?OW_P &,UU-]H_:=APS6^WPNY.?E1O^)P/U'_H-?'O[,G_!I/\
MM>?'36+?_A*?#_AGX3Z*Q1Y+WQ%K4-Q,T9(W>7;V9FD\P#)"2^4"1@LN<U^_
M?_!&_P#X(O> _P#@CE\*/$&D^&M>UKQ?XJ\;26LWB37K]!;I>-;+*L$<%LI9
M8(4\^9@"\DA,K;I& 14 /LBL'XI_\DQ\2?\ 8+N?_135O5@_%/\ Y)CXD_[!
M=S_Z*:@"QX!_Y$31?^O"#_T6M?+_ /P6F/\ QA=(O\3:W:@#U.V6OJ#P#_R(
MFB_]>$'_ *+6N-^.7[)W@?\ :2FMSXTL-6UBWM IALUUV_M;-'7?B3R(9DC,
MF)''F%2VTXSCB@#N)3IWB3PHWVI;2\TF_M#YJSJKP3P.GS!@WRE"I.0>"#7P
M7^P1\!)OC?\ LE_'/PCI]PT?@WQ#K,]OX6N9RQA,T7*3]RR I:;B.I1Q]X''
MU+:?L+_#JU\.1Z*UMXKNO#\*"%-'N_&&L7&FB,=(S;/=&)HQQ\C*5XZ5ZGX>
M\.Z?X1T2UTW2;&STS3;&,16]I:0K#!;H.BHB@*H'H!B@#Y=_X)9?&;ROAA<?
M"/Q-&VB^/OAW/-;3Z9=L%N)K5I#(DB#HZIYFPE<C:(VSB12?JZN!^+_[,7@?
MXZ:C8ZAXCT*.?6-+P;+5;2XEL=2L\$D>7<P,DJ@$DX#8R3Q6)>?LA:7K6E-I
MNJ>,OB=JFDR*8Y+*;Q3<QK,A&"CRQ%)G4C@AI#D9SF@#K?A7\9-)^,<GB-]$
M,EQ8^'=7DT5KS@P7LT<43RM"0?F1'D:(DX^>)\9 !/YF_P#!2!K>3_@YX_8<
MCF\EPOA_6VVN P!-M?[#@]]PX/J*_4#X9?#'0?@WX'L/#?AC2[?1]#TM66VM
M(<[8]S%V.2222S,Q)))))-?-?Q)_X(B?LZ_&+XVV/Q*\4^'_ !]KGQ"TE]^F
M^(KGXG>*/[1TD"629$M)5U &VC2261D2'8J%SM R: /BK_@M=^SKXD_X)8_M
MD^$?V_O@;H(DL=/E31?C!X:L'-O%KFG3.JF[95&T;\)&[G(2>.RF\MRLS5K_
M /!P;^UCX-_:&_X)8_L]_&OPR;GQU\$;KXL^&_$/B>/3WD4W>CQK>">VN/+8
M&,B<+ Z,RM'<!%RKKQ^J5C\-M'@^&4/@^\MYM<T&/2UT>:'6[B359-0MA%Y+
M+=27+.]R73(D:9G:0LQ<L6)/S7\)?^"*'[/_ ,"['Q=HGA7P[K6F_#_Q[YS>
M(/ 4NN75[X5U.65 K3&QN'D2.4;8RKQ%"ABBVX$:  &%?_\ !+[]BSXN?!*#
MQYJ/@_P9XB^';Z:?$":WJ/B&[N=)2S$1E-X99;@Q)&L>YC(2 J[B2!FOGCP[
MX&\9_L??\'!/Q4\<?"OPNWQZ\(_%KP1IUUXP\/\ A;4;"TUCX<R016T.GM*]
M]/!9O'=+!(T$/VB.5HS,X0):J9_=O@9_P;O_ ++O[/WB>6ZT;PKXGOM!^W)J
M4'A35O%6H7_AR"X1U=)&L9)3%<%652/M(F *@]0"/F2T_9 ^&7_!4?\ X*^?
MM#:U\&?BK\;/@3>?#(67AOXGZEX!\3R:+<>-]<)FA39%AO(AM%LI(GE9"MS,
MS,B)Y3SW0!]4_P#!/O\ 8@\7^'?V[?V@/VHOB-HMMX-\2?&PZ9I6C>$4O8K^
M[\/Z5I]M%;*][<0$P-=7)@BD:*%I8X0@43S;CL\'_P""=7Q"TCX2_P#!9+_@
MIEXI\0736.A^&5\+ZMJ-P(9)FM[:#3+R65Q'&K.^U%)VHK,<8 )(%<U\<OV/
M_C5_P3$_:\_9OU'X>?M/?'[XO>&_BU\0K+P'XF\%_$'Q'+K\\NFSQ33WNH6S
MJ8S"+:VMYI&DC17C/EMYFW<C?:7PB_X(]? 3X&?%G7/''AW0/&4?BCQ7&\7B
M*\O_ (@^(=37Q.C120E-1BNKZ2*\7;(^!.CA201@@&@#\YOBKX"^*?\ P;GZ
M"?CM\ ?&-I\5/V)/%.KVFK:QX OW$MQX8M=1>(1W6FW1/SQ,TB)&X8$_:(!+
M%.5:X7V;]MF51_P=5_L7D\;_  +XB R,9_XE^L&OISP7_P $6/@MX0T30_#<
M\OQ%\2?#KPK?0ZCH?@37_&6H:GX9TJ:%U>';:RR$S1QLH*PW#RQ Y.S/-=5^
MW%_P2X^$W_!0+Q/X)\1>.+/Q'IOC#X<W#W'ASQ)X;URXT;5M*+LCL$FA8?Q1
M(RE@6C()0H6?< ?'/_!WRBR?\$O_  JL@5HV^)NC!@W0CR+W.:_5"OECXU?\
M$8OV?_VD_ACH7@WXA:!XV\:>&_#\KW=O9:K\0_$,R7-X[S.U[<D7P-S=$SRJ
M)YB\BQMY:LL85![K\.OA_P"'_P!FWX:MIT.LZ]_8FGO)</?>*/$][K5Q$';)
MWWNH3RS% 3@!Y"%' P* /QQ_9F\4^(OV"/CI^U1^P'X/N)M'\1_$[QG!??"&
MXMH9BNC:-KL#/J5W$Q90J:3I\+3+A@)+F!U'S/@_L_\ "3X5Z'\#/A7X;\%>
M%[%=-\-^$=+MM&TJT5BXMK6WB6*)-S$EL(BC)))ZDDU\M?LB^$O#/[77_!0G
MXE?M1:;#;ZAH^@Z+%\'O!.K1,S0ZO;6-Y/=:MJ$)("O$VH3&SC=<@_V9.RL4
MG&?L:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /#_ /@HI^T?
MJG[)_P"RKJ'C71]6\'^'[R#7_#ND/J_BJ%Y=&T:WU'7+#3KB]NE6>W)C@ANY
M)C^_C \L%F"YKYI\*?\ !6/QI<P>(O#>AZI\%/CIXDOM5\.>'_!OBWP/=RV7
MA&\U75YKY9K&\;[1?,DNGVM@]],(9G:2&:)-D+R1E_M#X_\ P1L_V@O EAH-
M]>75A!8>)-!\2K+ JEFETG6+/58HSNXVR26:(QZA7;'.*C_:(_9_T?\ :1^'
ML>@ZK=ZEI-Q8ZC::SI.KZ8T2ZAH>H6LRS6]W;M+')'YB.HRLD;QR(SQR(\;N
MC 'G?PA^-/Q*\$_M-V?PG^*TW@OQ%?>)O#=]XI\.>)/"VE7&BVUQ%87-C;7M
MG<6-Q=W;QRQMJ-F\<J7#K*LDH*1&$>;\T_%G_@KAXM^&?[67C;PJWBSX,+:^
M%_B1I'@;3O EWI5_#XF\00WT>D_Z1'J/VPVL3[]2E*B2U$9%L%>1 S2)]3_
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M  *;M=%\0:0EO<?Z/=K&MU8W5M<1R0W%I,8+9W0A7#VT+QR1L@:@#R'X'?\
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M>W=K?AK>*)89=VI7X>.)%A83)M2/RP" >Z4444 %%%% !1110 4444 %%%%
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M/''AWXF0>.?!_P 2O$=]X_N-:>:S.G6LDZ)]H-M/ JQM9A(4*EV<@*Q,K@\
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M?X3\)Z7X"\*Z;H6A:9I^BZ)HMI%8:?I]A;I;6MA;Q($BABB0!(XT15544 *
M   *T* "BBB@ HHHH **** "BBB@!LL8FC96W88$':Q4_@1R/J*^"_A1\<O'
MGBE?AC\ ;GQ3KTWC[X;>,-4B\?ZRTWDZAJOA[PX+:YL[B6;<29M434O##SJ,
M^9%?WR]%:OO:N3TGX%>#]"^*GB/QQ9^'=+MO%WBZPM=,UG58XL7&HVUKYOD1
MR-W">=( >I! )(5< 'R+^Q3^WK\0OV@?@QX)U3PSH/A"#PMX?TCP7IGB*X\9
M>+)QK%]>ZSH^E7Y>&X\DK*88M4M0&E_>7UP9H@+<JKR<G^RI_P %#_CMXO\
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M%[<2"18-6FM0HM9;VW5A!>20!$$4EQ'(T0C0(5V+@ ]BC<2(K+]UAD4ZBB@
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M6^'M&N[>2>^TK5M$T6*S>5\DQBTUNWMRTARL,$VJ,1\K@>+^)[[0/AQ\'_\
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MCS_@T]UVZ^$/[$VJ?"GQEX9\=>"_'G_"5ZIKL>FZ]X6U'3EFL7CM LRSRPK
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MTST4 ?S,?\(S_P %GO\ GI\:?_ _3/\ XNC_ (1G_@L]_P ]/C3_ .!^F?\
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MS,?\(S_P6>_YZ?&G_P #],_^+H_X1G_@L]_ST^-/_@?IG_Q=?TST4 ?S,?\
M",_\%GO^>GQI_P# _3/_ (NC_A&?^"SW_/3XT_\ @?IG_P 77],]% '\S'_"
M,_\ !9[_ )Z?&G_P/TS_ .+H_P"$9_X+/?\ /3XT_P#@?IG_ ,77],]% '\S
M'_",_P#!9[_GI\:?_ _3/_BZ/^$9_P""SW_/3XT_^!^F?_%U_3/10!_,Q_PC
M/_!9[_GI\:?_  /TS_XNC_A&?^"SW_/3XT_^!^F?_%U_3/10!_,Q_P (S_P6
M>_YZ?&G_ ,#],_\ BZ/^$9_X+/?\]/C3_P"!^F?_ !=?TST4 ?S,?\(S_P %
MGO\ GI\:?_ _3/\ XNC_ (1G_@L]_P ]/C3_ .!^F?\ Q=?TST4 ?S,?\(S_
M ,%GO^>GQI_\#],_^+H_X1G_ (+/?\]/C3_X'Z9_\77],]% '\S'_",_\%GO
M^>GQI_\  _3/_BZ/^$9_X+/?\]/C3_X'Z9_\77],]% '\S'_  C/_!9[_GI\
M:?\ P/TS_P"+H_X1G_@L]_ST^-/_ ('Z9_\ %U_3/10!_,Q_PC/_  6>_P">
MGQI_\#],_P#BZ/\ A&?^"SW_ #T^-/\ X'Z9_P#%U_3/10!_,Q_PC/\ P6>_
MYZ?&G_P/TS_XNC_A&?\ @L]_ST^-/_@?IG_Q=?TST4 ?S,?\(S_P6>_YZ?&G
M_P #],_^+H_X1G_@L]_ST^-/_@?IG_Q=?TST4 ?S,?\ ",_\%GO^>GQI_P#
M_3/_ (NC_A&?^"SW_/3XT_\ @?IG_P 77],]% '\S'_",_\ !9[_ )Z?&G_P
M/TS_ .+H_P"$9_X+/?\ /3XT_P#@?IG_ ,77],]% '\S'_",_P#!9[_GI\:?
M_ _3/_BZ/^$9_P""SW_/3XT_^!^F?_%U_3/10!_,Q_PC/_!9[_GI\:?_  /T
MS_XNC_A&?^"SW_/3XT_^!^F?_%U_3/10!_,Q_P (S_P6>_YZ?&G_ ,#],_\
MBZ/^$9_X+/?\]/C3_P"!^F?_ !=?TST4 ?S,?\(S_P %GO\ GI\:?_ _3/\
MXNO4?V'_  __ ,%9X/VSOA+)\3)/BZ?ARGC#23XH%W>Z<UO_ &9]LB^U>:%;
M<8_)W[@O.,XYQ7]"U% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !17\M/_!&/_@Y$^+GP8_;LT*T
M^/WQ1\2>-/A5XO/]A:K)K=RLR>'I)'7R-15FV[%B? EYQY,DK;69(P/U@_X.
MN?VK/B1^Q]_P3F\)^*/A?XSU[P-X@N_B'8Z;/?Z3<>3-+;/I^I2-"6_NEXHV
M(]4% 'Z;45X=_P $R/'FM?%+_@G%\!/$WB+4KS6O$'B'X>Z#J6I:A=R>9/>W
M,VGP22RNW\3,[,Q/<FM7Q7^W_P# ?P)\19O!^N?&SX1Z-XMMYQ:RZ)?>,-.M
M]1CF)P(VMWF$@?/&TKF@#URBL[Q3XPTGP-X=N-8UO5-.T?2;-0\][?7*6]O
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M07GQ'L=,GO\ 2;DP336SZ9JDC0L1U0O%&V/5%/:@#]/:*\1_X)H>.M8^)_\
MP3F^ ?B7Q%J5YK.O^(?AUX?U/4K^ZD,D][<S:;;R2RR,>69W9F)[DFM;PE^W
MK\"_'_Q(7P;H/QH^$^M>,&G:V70[#Q=I]SJ1E4X:,6Z2F3<#P5VY!H ]8HHK
MQF\_X*-?L]Z?XT?PW<?'CX,P>(HYOLSZ7)XUTU;U9<X\LPF;>&SQMQG- 'LU
M% .:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXATGPUI,^I3Z+K(PT\[10QEEANLF7<=V)A."5#Q*0#Z'_P""H'[>OB[]B?\
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M-?AC\2/ 2Z[JVH^"/$VI^,Y]#/AZSU"[EO1::K:?9;B2<VUQ<3J);5SYT*Q
MI"^XU)\*/^"8OB[X2?&?]GVZFURR\36/A?Q3XM^*'Q-UN6-;9O$OBS4[)[2W
MEBM1D1Q1K>W:Q@8\J*U@7)8DD OZY_P48U;]H3P!^QW?_#+4+?PSJWQ^\9Q1
MZYIU[;+/<6&G:;I]_>:[IQ\U1MGAGLOL;N%#*Q8K@X-></\ M,?&S]H[]KCX
MK^"=+_: \,? 7XA^!]=NK#P3\*M8\*V5ROC33(0S6VJSSW1%S=P7H1R3ISQ"
MV0;7WNI)[KX6_P#!-#Q1\._^"M&N_$=9]+7X.)IGB#Q%X:BBN'_M+0_$^OG2
MHM4V(^Y?)<:;/= X"B74IAM/->?_ +0W[*7[4'[7?[-%K\!/B9\,?@WXJUG3
MH([6Q^.5SXFD#Z;(A"KKEKI:6JW5OJRQ@-Y44Z0&?.9O))0@'Z"?"'6/$GB'
MX3^%[_QCH]KX>\77VDVL^MZ7:W0NH--OFA1KBWCE'$B1REU#C[P4'O7PW\+_
M /@I)\0OC!_P5&\%V^DW&GM^S7\0+[Q/\/\ PR8[2.237M9T.VCN[C6$N0I/
MV=Y(M2LXE5RCC3WEY\Q=OTW^W7X&^*'Q%_9EO/!/PGU./2/%'C":VT"[\3W%
MSY4_AG39F"7VIPJFPR74=OYGDJA3$TD;9"H:^?OB)_P2)L_@?K7[/&J? F;Q
ME$?A'X_TN[N-+\0_$77-3TRT\/&UNK"^2TL[RZFM8I5M[HLHCB1L(T:E5=E(
M!TFM_%7XQ?MV_M&_$CP?\(_B%8_![X;_  =U>+PUK'BNUT*TUS6_$6N_98KJ
MYL[6.[WV]M;6R75LLDDD$CR2EU3:JECU7@CX=_M-_$'X":UX/\5?$?2/ /CS
MPSXF^S:;\0-#\.V5_%XST98(WCN6TZ=W2SG=Y7BE0Y >U9H_W<BXX?PW\(OC
MY^PI\<OBI'\*?ASX*^+7P]^,'BZ;QO;/J7C$^'=0\*:G=PP1WT5SFTG6XLWD
MA$T;PCS4WR(R.-CUZ=H'PB^-G@O_ ()^^-M'U3QE8^-_CUK^BZU?6U]"IL]'
ML=8NXYGM;.T$F7CL;:1XHHVE)=DCWMAF*@ \1_X)':C^T!^U3\)_!/QL\8?M
M$:EX@\%Z[?ZO)!X6;P'I.G_VMIT5W>6EC,]S$GFQM(D<%T=F!\VSH2:^]J\U
M_8S^ _\ PRY^R)\+_AL7@FD\!^%-,T"::%0J7$MM:QPR2\ <NZ,Q.!DL3U->
ME4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 45^%?C7_@J'^WY^T#_ ,%%OVB/A?\  O6/
MAC_8/P?\2W%C'%K>G6\,D5H;B6* >8^3(W[LY/7OWKHO^%S?\%<_^@K\!_\
MOBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_
M ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,*
M/VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRH
MK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?
M^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?
M\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_
M^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\
M!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\
MOBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_
M ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/
M^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?
M\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_
M^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\
M!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\
MOBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_
M ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,*
M/VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRH
MK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?
M^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?
M\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_
M^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\
M!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\
MOBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_
M ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/
M^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?
M\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_
M^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\
M!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\
MOBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_
M ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,*
M/VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRH
MK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?
M^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?
M\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_
M^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\
M!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\
MOBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_
M ,*/^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/
M^%S?\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?
M\%<_^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_
M^@K\!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\
M!_\ OBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\
MOBS_ ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_
M ,* /VRHK\3?^%S?\%<_^@K\!_\ OBS_ ,*/^%S?\%<_^@K\!_\ OBS_ ,*
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M#IL6IC3F;S[Z?Y_-,4OW=GW=G.>HH [C_AOW_@HM_P!&>>#?_ Z7_P"3Z/\
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M\<__  *O?_E30 __ (;]_P""BW_1GG@W_P #I?\ Y/H_X;]_X*+?]&>>#?\
MP.E_^3Z9_P /]OB[_P!&&_'/_P "KW_Y4T?\/]OB[_T8;\<__ J]_P#E30 _
M_AOW_@HM_P!&>>#?_ Z7_P"3Z/\ AOW_ (*+?]&>>#?_  .E_P#D^F?\/]OB
M[_T8;\<__ J]_P#E31_P_P!OB[_T8;\<_P#P*O?_ )4T /\ ^&_?^"BW_1GG
M@W_P.E_^3Z/^&_?^"BW_ $9YX-_\#I?_ )/IG_#_ &^+O_1AOQS_ / J]_\
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MM_T9YX-_\#I?_D^F?\/]OB[_ -&&_'/_ ,"KW_Y4T?\ #_;XN_\ 1AOQS_\
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M4T /_P"&_?\ @HM_T9YX-_\  Z7_ .3Z/^&_?^"BW_1GG@W_ ,#I?_D^F?\
M#_;XN_\ 1AOQS_\  J]_^5-'_#_;XN_]&&_'/_P*O?\ Y4T /_X;]_X*+?\
M1GG@W_P.E_\ D^C_ (;]_P""BW_1GG@W_P #I?\ Y/IG_#_;XN_]&&_'/_P*
MO?\ Y4T?\/\ ;XN_]&&_'/\ \"KW_P"5- #_ /AOW_@HM_T9YX-_\#I?_D^C
M_AOW_@HM_P!&>>#?_ Z7_P"3Z9_P_P!OB[_T8;\<_P#P*O?_ )4T?\/]OB[_
M -&&_'/_ ,"KW_Y4T /_ .&_?^"BW_1GG@W_ ,#I?_D^C_AOW_@HM_T9YX-_
M\#I?_D^F?\/]OB[_ -&&_'/_ ,"KW_Y4T?\ #_;XN_\ 1AOQS_\  J]_^5-
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M_?\ @HM_T9YX-_\  Z7_ .3Z/^&_?^"BW_1GG@W_ ,#I?_D^F?\ #_;XN_\
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M &^+O_1AOQS_ / J]_\ E30 _P#X;]_X*+?]&>>#?_ Z7_Y/H_X;]_X*+?\
M1GG@W_P.E_\ D^F?\/\ ;XN_]&&_'/\ \"KW_P"5-'_#_;XN_P#1AOQS_P#
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MT9YX-_\  Z7_ .3Z/^&_?^"BW_1GG@W_ ,#I?_D^F?\ #_;XN_\ 1AOQS_\
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MI?S7LEUY%[)Y:1+/;Q6L3(TX"%Q'(U=%\*OV"= \"Z#X'TWQ!XBU[QY8^ ?
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M2^3Q-KGA?4OA]XDC\2Z?/I\%I<+-*+:XM)(Y8KF*6-E:WNIU#A0\;.'4@@4
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M%</,F&>!R1$KX6O7?A_^PGX3^'?PN^"O@^WU#6KS1O@?JQU[2UNVBDDU6_\
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M7_E%=^S5_P!DL\,_^FJVKZ#KY\_X)*_\HKOV:O\ LEGAG_TU6U?0= !1110
M4444 ?S^_LG_ /*2;_@J1_NZK_Z%J5?+_BO_ )5-?#/_ &4%O_2Z[KZ@_9/.
M/^"DW_!4C_=U7_T+4J^7_%?_ "J:^&?^R@M_Z77= '[B? ;_ )(-X#_[%K3/
M_2.*NJKE?@-_R0;P'_V+6F?^D<5=50 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML](\&V]E;6VNQSZ;(\.I+=BXGCMK5;25?+EDEG";I(@AD,B!@#W"BO O%/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G#^Q__
M ,K57[3'_9,M,_\ 1?A6OBO]DK_E4\_:8_[*-#_Z5>$Z^U/V/_\ E:J_:8_[
M)EIG_HOPK7Q7^R5_RJ>?M,?]E&A_]*O"= ']$?\ P25_Y17?LU?]DL\,_P#I
MJMJ^@Z^?/^"2O_**[]FK_LEGAG_TU6U?0= !1110 4444 ?S^_LGG_C9-_P5
M(_W=5_\ 0M2KY?\ %?\ RJ:^&?\ LH+?^EUW7U!^R>?^-DW_  5(_P!W5?\
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MXIZ?\9;/XK^(&N-2N;#3O%(LXDMX+?[3]FDD@DVVUE/DP2()86&"&W5]P44
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MY=:OXQ\5:7>Z[?\ CCQ-J#K*\,UQ<W06"0++)@KL4!7E< RR2._M/PL_9/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7_9+/#/_ *:K:OH.OGS_ ()*_P#**[]FK_LEGAG_ --5M7T'0 4444 %%%%
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MI9T9IIH58;2R*X8K@C/!^#OV4]6^"TW['/PJ\-:!'!X7^%5IJ?B?7K]-/?\
MLR'6[;1#8VTLTJ#8)KF^U2YN"N2T@@E(!"Y'C_PO^'VJ_$K]FW]E/X+S?"/X
MF6.K>#_B#I7BCXD:GXD\+74-CI>I:>MY>WUR]],OEWCZA<HZK<P/,ABNE1Y$
M>:&-P#] /B;-XFT3P?J3>$]-T#6O$]OL6SM-5U.73M/G;S$63?<1P3R(HC\Q
MEQ"Q9E52%#%E^>OV=?VN/C!\</%/BXWW@'X1:#X3^'/C2Y\(>*-7'CV_F> V
M26\E_<6L;Z5&DRPI.RCS9(0TL,BED4;Z^GUNH[:3S[@3/#%^\E$4;2R,HY.U
M%!9F(SA0"2>!S7PWX8\ _$KPC_P0^\86K>$->D^,7Q0TC7+_ %+1H;&X_M.'
M4_$FI3AFDA"^:CVT-^C2$J#&MJ[,%"M@ ]XTW]N7P'X(^$7AG7OBIXV^&/P_
MU;Q!HUIKOV(>*X;JU:UNVE^RRVT[+&;F*5(7972/#>5*1E8V:NQ\*?M/?#7Q
M[\49_!.@_$+P5KGC"WM%OY-'T_6K>ZO! 55A($C<DC:R-QDA75CA6!/RM\0_
M@AK7PRT/]L'QIX7\#^)-2U?3?!5E\(?A?!!H$LFJ3Z=:Z''$6LD"%Y;634+\
MEGC!C<6!).(VV['Q&_91\0>"_B!X"^'_ ,+]#NM)M?@7\"_%4'@K7X+=K33/
M^$IU**VTRT N2!&+DBVN;F1MWF?Z0)'_ -8&(!](^$OVGOAKX^^*&I>"-"^(
M/@O6O&6CM-'>Z)8ZS;W%];O"<3HT2N6WQ'B1 "T9(#A<BNA\(?$+0?B"VL+H
M.M:7K1\.ZI-HFJ?8;E)_[.OX0C36DNTG9-&)$W(<,N\9 S7PW^QA\%_$&KW'
M[/WA%+SX]6OA'X+VT.N7=CXD\$Z?X2TWPMJ$6G3V8L8Y1ID5SJTLQNKE9C;S
M/&ZN9I)I'= WVS\)?%%KX[^'NG>(+3PWKGA-?$"MJ$FEZWI7]EZI;R.QW?:K
M?DQS'&2&);D9YH Z.O$_BI^U!XEN/CE>?"[X3^$-'\:>,]#TZWU7Q)?ZYK;Z
M3H/A*"Z\S[(ES+#!<3RW,XB=DMXHL^6/,9PO!]LKY7TSX@:A^Q[^UK\:KKQ-
MX!^)7B#P[\4]2T[Q-X?\1>$O"UYXE64P:3::?-I=U'9QO);31R6NZ'S%\N2.
M8G>I4B@#TSX3_M/75WX8\<2?%;0;+X3:E\-;N.WUR[O=6\WPW<6\T:26]_9Z
MG-%!'+;R!]I5U22&4&*10V-V_P"%_P!JCX9>-_A7JWCC1_B%X-U3P=H+/'JF
MLVVKPR6>ENFTLEPX;$+@.A*R;6PZG&&&?G?XH:O\3/B??_!#X@?$KX;ZA9>
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MJ?#G5?"UNOA?PW>>(+K3]4DU*RNR'MK2.25/M4-NL:2E1&'@V.Z!U->.ZO\
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MEC+'I_B7Q5KVIO?:K-8RLBI)!:V^G:;9HL?,,$5NC $XK9^-_P"S+JO[4?\
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M_P#D"C_A[O\ M8_]& ?$C_P9W?\ \@4 ?H[17YQ?\/=_VL?^C /B1_X,[O\
M^0*/^'N_[6/_ $8!\2/_  9W?_R!0!^CM&:_.+_A[O\ M8_]& ?$C_P9W?\
M\@4?\/=_VL?^C /B1_X,[O\ ^0* /T=!Q1GBOSB_X>[_ +6/_1@'Q(_\&=W_
M /(%'_#W?]K'_HP#XD?^#.[_ /D"@#]':,U^<7_#W?\ :Q_Z, ^)'_@SN_\
MY H_X>[_ +6/_1@'Q(_\&=W_ /(% 'Z.T9S7YQ?\/=_VL?\ HP#XD?\ @SN_
M_D"C_A[O^UC_ -& ?$C_ ,&=W_\ (% 'Z.T5^<7_  ]W_:Q_Z, ^)'_@SN__
M ) H_P"'N_[6/_1@'Q(_\&=W_P#(% 'Z.T5^<7_#W?\ :Q_Z, ^)'_@SN_\
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M.* <&OSB_P"'N_[6/_1@'Q(_\&=W_P#(%'_#W?\ :Q_Z, ^)'_@SN_\ Y H
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MO_H;/'W_ (3T_P#\70!YS_Q%!?#S_HB/QL_\ [;_ ..4?\107P\_Z(C\;/\
MP#MO_CE>C?\ $3U^RW_T-GC[_P )Z?\ ^+H_XB>OV6_^AL\??^$]/_\ %T >
M<_\ $4%\//\ HB/QL_\  .V_^.4?\107P\_Z(C\;/_ .V_\ CE>C?\1/7[+?
M_0V>/O\ PGI__BZ/^(GK]EO_ *&SQ]_X3T__ ,70!YS_ ,107P\_Z(C\;/\
MP#MO_CE'_$4%\//^B(_&S_P#MO\ XY7HW_$3U^RW_P!#9X^_\)Z?_P"+H_XB
M>OV6_P#H;/'W_A/3_P#Q= 'G/_$4%\//^B(_&S_P#MO_ (Y1_P 107P\_P"B
M(_&S_P  [;_XY7HW_$3U^RW_ -#9X^_\)Z?_ .+H_P"(GK]EO_H;/'W_ (3T
M_P#\70!YS_Q%!?#S_HB/QL_\ [;_ ..4?\107P\_Z(C\;/\ P#MO_CE>C?\
M$3U^RW_T-GC[_P )Z?\ ^+H_XB>OV6_^AL\??^$]/_\ %T ><_\ $4%\//\
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M?^$]/_\ %T ><_\ $4%\//\ HB/QL_\  .V_^.4?\107P\_Z(C\;/_ .V_\
MCE>C?\1/7[+?_0V>/O\ PGI__BZ/^(GK]EO_ *&SQ]_X3T__ ,70!YS_ ,10
M7P\_Z(C\;/\ P#MO_CE'_$4%\//^B(_&S_P#MO\ XY7HW_$3U^RW_P!#9X^_
M\)Z?_P"+H_XB>OV6_P#H;/'W_A/3_P#Q= 'G/_$4%\//^B(_&S_P#MO_ (Y1
M_P 107P\_P"B(_&S_P  [;_XY7HW_$3U^RW_ -#9X^_\)Z?_ .+H_P"(GK]E
MO_H;/'W_ (3T_P#\70!YS_Q%!?#S_HB/QL_\ [;_ ..4?\107P\_Z(C\;/\
MP#MO_CE>C?\ $3U^RW_T-GC[_P )Z?\ ^+H_XB>OV6_^AL\??^$]/_\ %T >
M<_\ $4%\//\ HB/QL_\  .V_^.4?\107P\_Z(C\;/_ .V_\ CE>C?\1/7[+?
M_0V>/O\ PGI__BZ/^(GK]EO_ *&SQ]_X3T__ ,70!YS_ ,107P\_Z(C\;/\
MP#MO_CE'_$4%\//^B(_&S_P#MO\ XY7HW_$3U^RW_P!#9X^_\)Z?_P"+H_XB
M>OV6_P#H;/'W_A/3_P#Q= 'G/_$4%\//^B(_&S_P#MO_ (Y1_P 107P\_P"B
M(_&S_P  [;_XY7HW_$3U^RW_ -#9X^_\)Z?_ .+H_P"(GK]EO_H;/'W_ (3T
M_P#\70!YS_Q%!?#S_HB/QL_\ [;_ ..4?\107P\_Z(C\;/\ P#MO_CE>C?\
M$3U^RW_T-GC[_P )Z?\ ^+H_XB>OV6_^AL\??^$]/_\ %T ><_\ $4%\//\
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M?^$]/_\ %T ><_\ $4%\//\ HB/QL_\  .V_^.4?\107P\_Z(C\;/_ .V_\
MCE>C?\1/7[+?_0V>/O\ PGI__BZ/^(GK]EO_ *&SQ]_X3T__ ,70!YS_ ,10
M7P\_Z(C\;/\ P#MO_CE'_$4%\//^B(_&S_P#MO\ XY7HW_$3U^RW_P!#9X^_
M\)Z?_P"+H_XB>OV6_P#H;/'W_A/3_P#Q= 'G/_$4%\//^B(_&S_P#MO_ (Y1
M_P 107P\_P"B(_&S_P  [;_XY7HW_$3U^RW_ -#9X^_\)Z?_ .+H_P"(GK]E
MO_H;/'W_ (3T_P#\70!YS_Q%!?#S_HB/QL_\ [;_ ..4?\107P\_Z(C\;/\
MP#MO_CE>C?\ $3U^RW_T-GC[_P )Z?\ ^+H_XB>OV6_^AL\??^$]/_\ %T >
M<_\ $4%\//\ HB/QL_\  .V_^.4?\107P\_Z(C\;/_ .V_\ CE>C?\1/7[+?
M_0V>/O\ PGI__BZ/^(GK]EO_ *&SQ]_X3T__ ,70!YS_ ,107P\_Z(C\;/\
MP#MO_CE'_$4%\//^B(_&S_P#MO\ XY7HW_$3U^RW_P!#9X^_\)Z?_P"+H_XB
M>OV6_P#H;/'W_A/3_P#Q= 'G/_$4%\//^B(_&S_P#MO_ (Y1_P 107P\_P"B
M(_&S_P  [;_XY7HW_$3U^RW_ -#9X^_\)Z?_ .+H_P"(GK]EO_H;/'W_ (3T
M_P#\70!YS_Q%!?#S_HB/QL_\ [;_ ..4?\107P\_Z(C\;/\ P#MO_CE>C?\
M$3U^RW_T-GC[_P )Z?\ ^+H_XB>OV6_^AL\??^$]/_\ %T ><_\ $4%\//\
MHB/QL_\  .V_^.4?\107P\_Z(C\;/_ .V_\ CE>C?\1/7[+?_0V>/O\ PGI_
M_BZ/^(GK]EO_ *&SQ]_X3T__ ,70!YS_ ,107P\_Z(C\;/\ P#MO_CE'_$4%
M\//^B(_&S_P#MO\ XY7HW_$3U^RW_P!#9X^_\)Z?_P"+H_XB>OV6_P#H;/'W
M_A/3_P#Q= 'G]A_P=%?#NTOH96^!_P ;B(W#$"SMN<'/_/2ODC]F'1;S0/\
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MXD_Y\=#_ ._4O_QR@#T+_ACGX0_]$K^&_P#X3-E_\;H_X8Y^$/\ T2OX;_\
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MA#_T2OX;_P#A,V7_ ,;H_P"&.?A#_P!$K^&__A,V7_QNO/?^&N?$G_/CH?\
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M_#7/B3_GQT/_ +]2_P#QR@#T+_ACGX0_]$K^&_\ X3-E_P#&Z/\ ACGX0_\
M1*_AO_X3-E_\;KSW_AKGQ)_SXZ'_ -^I?_CE'_#7/B3_ )\=#_[]2_\ QR@#
MT+_ACGX0_P#1*_AO_P"$S9?_ !NC_ACGX0_]$K^&_P#X3-E_\;KSW_AKGQ)_
MSXZ'_P!^I?\ XY1_PUSXD_Y\=#_[]2__ !R@#T+_ (8Y^$/_ $2OX;_^$S9?
M_&Z/^&.?A#_T2OX;_P#A,V7_ ,;KSW_AKGQ)_P ^.A_]^I?_ (Y1_P -<^)/
M^?'0_P#OU+_\<H ]"_X8Y^$/_1*_AO\ ^$S9?_&Z/^&.?A#_ -$K^&__ (3-
ME_\ &Z\]_P"&N?$G_/CH?_?J7_XY1_PUSXD_Y\=#_P"_4O\ \<H ]"_X8Y^$
M/_1*_AO_ .$S9?\ QNC_ (8Y^$/_ $2OX;_^$S9?_&Z\]_X:Y\2?\^.A_P#?
MJ7_XY1_PUSXD_P"?'0_^_4O_ ,<H ]"_X8Y^$/\ T2OX;_\ A,V7_P ;H_X8
MY^$/_1*_AO\ ^$S9?_&Z\]_X:Y\2?\^.A_\ ?J7_ ..4?\-<^)/^?'0_^_4O
M_P <H ]"_P"&.?A#_P!$K^&__A,V7_QNC_ACGX0_]$K^&_\ X3-E_P#&Z\]_
MX:Y\2?\ /CH?_?J7_P".4?\ #7/B3_GQT/\ []2__'* /0O^&.?A#_T2OX;_
M /A,V7_QNC_ACGX0_P#1*_AO_P"$S9?_ !NO/?\ AKGQ)_SXZ'_WZE_^.4?\
M-<^)/^?'0_\ OU+_ /'* /0O^&.?A#_T2OX;_P#A,V7_ ,;H_P"&.?A#_P!$
MK^&__A,V7_QNO/?^&N?$G_/CH?\ WZE_^.4?\-<^)/\ GQT/_OU+_P#'* /0
MO^&.?A#_ -$K^&__ (3-E_\ &Z/^&.?A#_T2OX;_ /A,V7_QNO/?^&N?$G_/
MCH?_ 'ZE_P#CE'_#7/B3_GQT/_OU+_\ '* /0O\ ACGX0_\ 1*_AO_X3-E_\
M;H_X8Y^$/_1*_AO_ .$S9?\ QNO/?^&N?$G_ #XZ'_WZE_\ CE'_  USXD_Y
M\=#_ ._4O_QR@#T+_ACGX0_]$K^&_P#X3-E_\;H_X8Y^$/\ T2OX;_\ A,V7
M_P ;KSW_ (:Y\2?\^.A_]^I?_CE'_#7/B3_GQT/_ +]2_P#QR@#T+_ACGX0_
M]$K^&_\ X3-E_P#&Z/\ ACGX0_\ 1*_AO_X3-E_\;KSW_AKGQ)_SXZ'_ -^I
M?_CE'_#7/B3_ )\=#_[]2_\ QR@#T+_ACGX0_P#1*_AO_P"$S9?_ !NC_ACG
MX0_]$K^&_P#X3-E_\;KSW_AKGQ)_SXZ'_P!^I?\ XY1_PUSXD_Y\=#_[]2__
M !R@#T+_ (8Y^$/_ $2OX;_^$S9?_&Z/^&.?A#_T2OX;_P#A,V7_ ,;KSW_A
MKGQ)_P ^.A_]^I?_ (Y1_P -<^)/^?'0_P#OU+_\<H ]"_X8Y^$/_1*_AO\
M^$S9?_&Z/^&.?A#_ -$K^&__ (3-E_\ &Z\]_P"&N?$G_/CH?_?J7_XY1_PU
MSXD_Y\=#_P"_4O\ \<H ]"_X8Y^$/_1*_AO_ .$S9?\ QNC_ (8Y^$/_ $2O
MX;_^$S9?_&Z\]_X:Y\2?\^.A_P#?J7_XY1_PUSXD_P"?'0_^_4O_ ,<H ]"_
MX8Y^$/\ T2OX;_\ A,V7_P ;H_X8Y^$/_1*_AO\ ^$S9?_&Z\]_X:Y\2?\^.
MA_\ ?J7_ ..4?\-<^)/^?'0_^_4O_P <H ]"_P"&.?A#_P!$K^&__A,V7_QN
MC_ACGX0_]$K^&_\ X3-E_P#&Z\]_X:Y\2?\ /CH?_?J7_P".4?\ #7/B3_GQ
MT/\ []2__'* /0O^&.?A#_T2OX;_ /A,V7_QNC_ACGX0_P#1*_AO_P"$S9?_
M !NO/?\ AKGQ)_SXZ'_WZE_^.4?\-<^)/^?'0_\ OU+_ /'* /0O^&.?A#_T
M2OX;_P#A,V7_ ,;H_P"&.?A#_P!$K^&__A,V7_QNO/?^&N?$G_/CH?\ WZE_
M^.4?\-<^)/\ GQT/_OU+_P#'* /0O^&.?A#_ -$K^&__ (3-E_\ &Z/^&.?A
M#_T2OX;_ /A,V7_QNO/?^&N?$G_/CH?_ 'ZE_P#CE'_#7/B3_GQT/_OU+_\
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M_P#OU+_\<H ]"_X8Y^$/_1*_AO\ ^$S9?_&Z/^&.?A#_ -$K^&__ (3-E_\
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M$M>/5]7?$GX,:5\4KRUGU":_B>S1HT^SR*H(8@G.5/I7-_\ #(_AG_G\UO\
M[_Q__&Z /G6BOHK_ (9'\,_\_FM_]_X__C='_#(_AG_G\UO_ +_Q_P#QN@#Y
MUHKZ*_X9'\,_\_FM_P#?^/\ ^-T?\,C^&?\ G\UO_O\ Q_\ QN@#YUHKZ*_X
M9'\,_P#/YK?_ '_C_P#C='_#(_AG_G\UO_O_ !__ !N@#YUHKZ*_X9'\,_\
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M_#(_AG_G\UO_ +_Q_P#QN@#YUHKZ*_X9'\,_\_FM_P#?^/\ ^-T?\,C^&?\
MG\UO_O\ Q_\ QN@#YUHKZ*_X9'\,_P#/YK?_ '_C_P#C='_#(_AG_G\UO_O_
M !__ !N@#YUHKZ*_X9'\,_\ /YK?_?\ C_\ C='_  R/X9_Y_-;_ ._\?_QN
M@#YUHKZ*_P"&1_#/_/YK?_?^/_XW1_PR/X9_Y_-;_P"_\?\ \;H ^=:*^BO^
M&1_#/_/YK?\ W_C_ /C='_#(_AG_ )_-;_[_ ,?_ ,;H ^=:*^BO^&1_#/\
MS^:W_P!_X_\ XW1_PR/X9_Y_-;_[_P ?_P ;H ^=:*^BO^&1_#/_ #^:W_W_
M (__ (W1_P ,C^&?^?S6_P#O_'_\;H ^=:*^BO\ AD?PS_S^:W_W_C_^-T?\
M,C^&?^?S6_\ O_'_ /&Z /G6BOHK_AD?PS_S^:W_ -_X_P#XW1_PR/X9_P"?
MS6_^_P#'_P#&Z /G6BOHK_AD?PS_ ,_FM_\ ?^/_ .-T?\,C^&?^?S6_^_\
M'_\ &Z /G6BOHK_AD?PS_P _FM_]_P"/_P"-T?\ #(_AG_G\UO\ [_Q__&Z
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MX'^'6@?#WQWHR:S':P>)M-MK:U<P23,XMY6M+ZV21,D!U).YC%"M?27[5W[
MGQZ^"_[;'P]_:F_9UT_P?XF\9:?X$@\!>.O NNWPT]?$EBDB2!K>\P4CG#+&
M-S,J@6L1'F O&P!S/P\\6_'+_@GU_P %.O!/[,?C3XU>+/B]\+?VC/"FK_\
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MK!.* "BH=.U*WU>RCN;2XANK>8;HY87#HX]01P?PJ:@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<[)+>ZU,QJ(+C2[R0RM')</>/&(Q"J;8CEMVX,/3_%?_  11^%OB_P#9D_:
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MVN+FUBABG:*[L4GAE\E9 MRRLS^6I'KGCS4O'G[:'[5O_"F]+^(GBSX;^!/
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M/%GAOQUX_D^)?AFUU")_!FLZH4/B);$VZ>;;ZDT4$4,LD<XDV3*"[HP+_,*
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M+F+S?)#2J2?*W8!PI/%?85% 'S?^W[^QKXB_:U_X)ZW_ ,(M$U31].\07AT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9_Y^-8_\"$_^(H_X9+\,_P#/QK'_ ($)_P#$4 ?.=%?1G_#)?AG_ )^-8_\
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M^(H_X9+\,_\ /QK'_@0G_P 10!\YT5]&?\,E^&?^?C6/_ A/_B*/^&2_#/\
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M_/QK'_@0G_Q% 'SG17T9_P ,E^&?^?C6/_ A/_B*/^&2_#/_ #\:Q_X$)_\
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M ?.=%?1G_#)?AG_GXUC_ ,"$_P#B*/\ ADOPS_S\:Q_X$)_\10!\YT5]&?\
M#)?AG_GXUC_P(3_XBC_ADOPS_P _&L?^!"?_ !% 'SG17T9_PR7X9_Y^-8_\
M"$_^(H_X9+\,_P#/QK'_ ($)_P#$4 ?.=%?1G_#)?AG_ )^-8_\  A/_ (BC
M_ADOPS_S\:Q_X$)_\10!\YT5]&?\,E^&?^?C6/\ P(3_ .(H_P"&2_#/_/QK
M'_@0G_Q% 'SG17T9_P ,E^&?^?C6/_ A/_B*/^&2_#/_ #\:Q_X$)_\ $4 ?
M.=%?1G_#)?AG_GXUC_P(3_XBC_ADOPS_ ,_&L?\ @0G_ ,10!\YT5]&?\,E^
M&?\ GXUC_P "$_\ B*/^&2_#/_/QK'_@0G_Q% 'SG17T9_PR7X9_Y^-8_P#
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M/@JUL#;F\M=->RDC.]W@"*;AW+1M)\PE*,\GZI_%?X8Z+\;?A;XE\%^)+/\
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M$* 0!PUG_P $3/'7P:TW]K+X;_"_Q=X.TGX _M%>'+]]#\*WD-Q#)X'\074
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M[4WQ@U/6-&OM%^/,_AF72;*U\S[5IPTNQGMI1/N4+\[2@KL+< YP>* /SG\
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M]8^*/B%XEU7Q9XD?Q3KEF]_J+AYS%#>R)&A( X50 !C@5SL?_!#BS^*?A?\
M;$\,?$O5M'U+P_\ M)>+1XGT*?3HY3>>&)HT)MK@[M@\Z*;8VU&VNH9&)5V4
M^L?\$7/V!?%'_!-3]A+1_A9XP\0:1XGUZQU74-1GU#33*8)OM,[2CF55<MSR
M2.OK0!]74444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***^3OVE_P#@N1^RO^QY\<-9^&_Q(^+5CX9\:>'_ +/_
M &AILFC:E<-;>?!'<19DAMWC.Z*6-N&. W.""  ?6-%<I\$?CIX-_:4^%^D^
M-? /B;1O%WA/7(S+8ZII=RMQ;S@,59=R]'1E9&0X9&5E8!@0*G[1?[17@W]D
MSX*Z]\1/B%K2>'?!OAF))]3U%K::X%LCR)$I\N%'D;+NBX52>: .VHKRWP)^
MVE\,?B9\?[CX6Z'XJ@O_ !Y:^&K?QA)I0M+A&72KAD6*Y\QHQ&0S2(-@;>-P
MRHS7J5 !1110 445R?QS^.7A/]FGX0^(/'OCK6K?P[X1\*V;W^J:C.KNEM"O
M4[4#.[$D *BEF8@ $D"@#K**XW]GW]H+P;^U3\&M!^(/P_UZU\3>#O$\!N=,
MU*W1T2Y0.R-\KJKJRNC*RNH964@@$$5G_%?]JOP!\#_BO\/? _BKQ!'I/BKX
MJ7=S8^%K%K2>5M5FMXUEF4/&C)'M1E.9&0'( )/% 'H5%<#^T_\ M0>!?V,_
M@9KGQ*^)6NKX9\$^&_L_]HZD;2>[%MY]Q%;1?NX$>5MTTT:_*AQNR< $CO5;
M>H8=",B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K^<#XZ?&AO\ @G__ ,%0?C[^U98VEQ>7'PV^,NH^$=2L[="?
M[2M]8\.7AMA,1QY45Y8PL,D -*.I(K^C^O'?&?\ P3Y^"/Q$T;QMI^N?"_P;
MJEE\2-2@UCQ1#<:<CKKEY"<Q3S_WI$).&ZC)]30!^$__  3AO;/_ ()F_#S]
MKW4-6\6^+?AS=:/\'?AYJFIZ]H^E1:IKEAJ>LVT5Q*(H9G5))S=:@80TDBA,
MAMZ!-P]>_9\^.'QN_9S_ &E/VGOAGJ'C[XY6^D6/[,&N?$'3M/\ 'WQ,LO&N
MO:1JL,B16M\EW9KLL':&0R"VCD?[\<I8AHEC_8KQ%^Q)\(?%VL>.=0U7X;^#
MM2N_B98VVF>*GN=,BE_MZVMD6.WBN P(=8E50F1\NQ<8P,<G\,/^"5_[.7P5
MM+N'PG\%_A[X?74=#N_#5\]EI,<4FHZ;=?\ 'Q:W#@;IXY. PD+$@ = , 'Y
MJ_LJ^/M<^*7[='_!*OQ%XFUC5/$/B#6?A-XFNK_4M2NGNKN]F;26+22RN2SN
M3U9B2:\F_9I_::^.'Q\_8K_X)UZ>WQV^*N@ZU\7/B!XKT/Q/XBM=:>XU34;-
M;J:(([W'F)(\<)986E200ML=5RBU^VGA?]C+X4^"M?\  6JZ3X!\,Z?J7PMT
M^;2O"5S#9*LGAZUFC,<L-L?^6:.A*D#J"?6L[PC^P'\%O 6B^!-.T;X9>#]-
ML?AA?W&J>$X(+!53P_=3L7FFMQ_RS9V))(ZF@#\??B5^VM\</V*OV*_VZO N
MB?%OXA>)4^#OQ%T/PUH/C?Q/>'6-?\,Z7JDJI<S27+*7D*C$:-PR--NCV,%Q
M[M^R/XEU+X&?\%X/ _P6\*?M-_%+XY?#5?A%>>([FW\3^,H_$+07\]U\K33P
MJBRDPK#+&)0SQK.2A6.1%K[<_:L_8!M?B+\!OBYI'PCN/"?PL^('Q=,4^M^(
M+GPG8Z]:ZY(APT>H6=VCQ7,<L)EA.Y25$I8!L;6^?_\ @G#_ ,$<_%7[-/[8
MT/QE\=GX'^';C0?"$WA#0_"OPI\+W&BZ.//NEN)M2N6GE9Y+IPOE$8*E G(V
M $ XC_@YT^/]U?\ PD^%/[-N@Z-XP\5:I\>O$\4OB#1_".G#4M>G\-:6\=Y?
MBT@W*?/8K$R;BJ,L$X9@H8CY\_X)M_MMZQ^Q%#^W)\+?#7P]^('PO%CX9USX
MZ?![PIX\\-?V5?6<!MI1<6HM1*Z&UANHH%ACB=MZ17#</O _9+4/V;_ >J_'
MVQ^*=UX1T*X^(VF:2="L_$4MJKZA:V)>20V\<AY5"TLAP,?ZQNQ-,\3_ +,W
MP_\ &?QR\._$S5?!^@WWQ \)6LUCH_B"6T5M0T^"5)$DB27[P1EFE!7I^\;U
M- 'X5?\ "/7,GBW_ ()G^/M4_:6\??&+Q)\8O'ND>*]=\/\ B/7K?5K72KYU
MA:=K!%7S+**WFFEM)( QC+*ORQM&17(_MY^.?%7[4O\ P2W_ &OOC-\2OV@_
MB#I_C73_ (H3> K?X3RZW;0^&[*TMM6L?(T[^RVC):\CCCDG^T1%96%H2Q;;
M<,_[>_#_ /X)4_LV?"CQ';ZQX9^!WPST#5++7(?$EK=6&@P6\MI?PAA#-$RJ
M#&(][[$7"(6)"@G-/^)?_!+/]G'XQ_$G7O&'BGX)_#;7O%'B>W^S:IJ=WH<$
MEQ>J<99VV_ZP@!3(,.R_*6*\4 ?"OP:\(_$#]K7_ (+<?$KP/??'+XQ>#_AG
M\+_"/@KQ1:^%_"_B%M/M=0N_LENWDRG:Q6TD!N!/#%Y9G,B%GS&M?)O[,O[<
MG[4/QE\0^$OVA(_%WQ&M/%&M?%S_ (1W5_#&M?%'POI'P]6P^T-'+X<@T:]O
M(KJ/4EMU7RY#%Y[\N [,)C^\7@[]G#P'\/OBKK7CC0_">AZ7XO\ $5E;:;J>
MKVULJ75];6R!((I''++&JJJCL /2N(M_^";/P!M/VC6^+D?P?^'J?$I[DWI\
M0#1H?M?VHMO-UG;C[06R3/CS"2?FYH _(3]M;]HOXW? K]J;XT?%CQ5\3/C/
MK_PJ^'OQ"6&+Q=\'/BCI-WHO@6R%S##;Z'J?A2= DMXAD$4[W#*&E9<[]K[^
ML_X*A_&+XV6?[:GQD\<:;\0_BMXH^#7@#3-'U&-O@W\5=/T;4/A-;K:F6X.L
M^'9DWWTLTL<L@%P5'E KO7(CA_4CXA?\$Q_V>?BS\<X_B7XF^"_PXUSQW'(L
M[:Q>:'!)<7$J !)9LKMFD4!0KR!F7:N"-HP_X\?\$S_V??VH/B=:^-/B'\&_
MAYXQ\56FP?VEJFBPW$]PJ !$G)'[]%  "R[U X Q0!Q?P(U[PS\=_P!H#X2?
M%33?CUXHN+CQ5\)K2_T_X<7FJVUG%KUE=%;A=>FTM"&%Q^\6-I$7RTV[ 1@@
M_4M<6W[.?@1OC5I_Q&_X1/0QXZTK1CX=L]<%JHO+;3O,,GV1''(BWLS;1P"Q
M]:[2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K\LOV5?B;X5^&G_!R!^W/-XL\1>'O#]C=>
M&O!Z!M7OX;2*8#2+0L!YK -A3SZ \U^IM>!_&C_@EC^SG^T9\4M1\;>//@O\
M/?%OBS5S";W5=4TB.XN;ORHDACWLP^;;'&B#/\*@4 ?BCHO[3WB_]F?]C_\
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M\4OVE/V[_BG\$?"WQ0\=>$X+O]EK1=1\+1Z;XANM/MM$UWS+8V]Y&(F'EL9
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M$K_A&M)_X3Z+0_\ A&4UWR!]M73//-Q]D#]?*\XE]O\ >YH ZZBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OC.Q^-/QV_;K^,GQ1L
M?@YX[\"?"7X>_"7Q2W@O^UM4\)3>)M5\4ZM:PI)J!$;75K#;6<,D\<"[3+))
M)!.=T0"J?LROB/0/!?QL_P"">?QN^+4?PZ^#+?&SX:_%?Q1=>/-/_LKQ3I^C
MZKX;U:[AA%]:W*7\D44EK+<1-.DL+M)'YTBM&^%:@#IOB%^U)\;_ (:?L-M=
M^,O"_A;PA\==7\66?P_T3[+*+_0]6N[W58K"VUBVB69YEM3!*UX;>=EFC2"5
M7^[N.1HWQ>_: _;M^*7Q&D^$OC7P1\&_AI\-?%5SX,M+_6?!\OB76/%^I:>[
M1:G,8S=VT-K8QW/^CQA?,EE-M-(7B5D6F_";X _M!?$KXU?!O6/C=<Z3J-EX
M;U_Q-\1[NWTXV4UAX4NY;<:9H?A^&58H9[L066HZE.]T\)S/"/WA'E5#X9\+
M_'+_ ()\?$KXD:;X%^$MS\=?AO\ $+Q5J?C?1WTWQ3IND:KX8OM0D%Q>V-S'
M?-#'):M=O/-%-%(\B+,4:-MJL0#UO]A+]J'Q/\=[+Q_X2^(NE:+HOQ4^$/B+
M_A&_$T.C.S:9?^9:P7MIJ%HKN\D<%S:W,3B.5B\;B1"6VAF\GB\<?M%?M#?M
MD_'KP[X'^+GP]^'OA'X2:]I.D6EEJWPZDUZ:[6XT'3M1DD>X74[7 \RZD7:$
MX4#YO3T[]@;]G3QA\+9/B;\0OB9%X?M?B9\:O$X\1ZOI^B3O=6>@6D%G;V&G
MZ:MPRQFY>&TM8S)/Y48>:6;:NP*3YCX1_P""5W@#XO\ [;?[1WQ ^,GP7^'O
MC*W\7^)-%N?">I^(-)L=6FGLK?P]IEK,%#AWB1;J"==CA=Q4M@JRL0#COV>/
M^"HGQ"^-7Q%_93TNZ7P/):_%+Q3X^\+^*;_08I+C2=;_ .$?BO4@O](G>5F%
MK/+:B0%S(=K,FXXWGZ%^)7[2GB;P;^W]X=^'=C91:IX=U#X6^(?&$ME!"/MU
MY?V.HZ1;P1QR,P4!DO9EVG@L5)( KB?VV?V3?$GA_P 3?L^_$3X)^"?#VL7W
M[.NJ7WV/P+!>PZ!:ZAI-]I4^G2V]F_EF"&:'?!)$C^7$5C=2Z9&<3X=?"?XY
M?M/?M8>(OBYXG\-_\,\QZ/\ #?5/A]X-M+J^T_Q'KB7NH7-I=2ZS.MO))9+'
M ]E;+%;&24R$2F0HI52 >1?LJ?M^?'?]IOP=X=^(7@OXK?L__$SQ#J9TZ?Q)
M\"--TM-+\0>%+:6XCCO8?MMQJ?FI?6B><SFYMEBE,#B.-<IGV7PE_P %1O#'
M@/\ X*!_M#_#/XM?$CX7^ O#_P /SX;/A./7-8M='N[Q;W33<79+7$R^<%E*
M %%&T, <YS7SU^TK^R9\</VWOA=8^"O'G[*_@/2/CE EE9?\- 6'BG3(X=&N
M[4Q,-=T^2W6+64D\R+S8[3R8E!VQO)L!)^DO@Q^PI]J_X**?M.?$#XA> _"^
MM^%_'S>%O^$5OM3MK/4))Q9Z6UO=X1@SP[9=HPP7=U&1S0!YMI7_  5VUK7?
M@_\ %S6?"$W@;XA:Y=?'&'X0?"=K2\)T74I;O3],F@FNKFW\TR0P&XO9YGBY
M:.V9!M;!'4_%WXQ_M$_\$\]'T_XD_%;XA?#7XJ?"VXU[3M.\66NF>"Y_#=]X
M0MKZZ2S2]LY?MUT+F&&>XA,L4R>88E9UD!!4\9:?\$O/&E[X$^,R^'M-\-^!
M?%6C?M!P_%_X5?:O+.BWGV72M+MT2YCM27AM[A8]0M7 598_,,H1L*'W_CAX
M9_: _P""FW@O2?A+XX^!=O\ !'X>:AJNFZEX\UK5_&%CKDVHVEC>PWATW28;
M"0LS7,MO'&US=^0(X&D/D22%44 S]2_:8^+WQ4_:9^.&B:;^TE\%?@YHGPW\
M8)X;TW1_$?@R/4[ZY@_LC3;XW33/JUJ2#)>2H!Y6!Y7WCR%]S_X)=_M<>(/V
MT/V8;CQ5XD7P[>7VE>*=;\-1Z[X<5ET'Q9#I]_-:QZIIVZ64FVF6/@^:XWK)
MAB,5Y=X=_P""2WP]_:!^)'[3UU\;_@_X*U^/XE>-FN/#VMWUA97.K?V4V@:3
M:>9;7:[KFT*7,%UL&Z-T=2Z@!PS>P?\ !.;PS\6OAC\ I/ 7Q?@&H:Q\/-3G
M\/Z+XJ6Y@<>-]&BV_8=2>&-BUM.866&:*3GS8'<,RR T >'_ /!._P#X*-_$
M#X_?\%!?V@/A7X^M]%C\/^'=>U:U^'MWI]B\+W,&D7D5MJ<%S(797FB&H:3(
M,!<K<N>Q"^;:3_P5R^*7C;P5^W=XNTVW\-6OAGX,^%4\0?"US:F9[R"-]=LW
MN[D[AYL=Q<:,9X@-H\B:,Y.ZLSQQ_P $YOCYX.\)_$[QY\-]#TFQ^,]G\=O%
M?BCP3+<ZK"B7.@>(--CTN69W63:@B9H;\PR?.S:5&H7<R@]7\4?^"9GC+P7\
M(OVM/ ?P_P##,MYX=\5? ;PO\.?A\)=3MEDU6YTRQUNV:!VDD4QLHN;3,DVQ
M&,N0QP^T [__ (*#_$#]I#X)S^&?%G@CXN_#_2?"_COQEX6\'V.@ZC\.7U"X
MTEM5N[2PEN&O!J47G!))9)Q'Y*9!$>X8\RM;XJ_&_P"/'[/M_P###X-KXQ^'
MOQ!^-7QHU[4&TWQ-<^$;C1M#\+:%I]K%/?W4]A%>SR7<\99(XD%Q LDM[%N>
M-8F,G>?M[? ;Q7\:O@]\*M+\,Z6-2O\ PS\3O!7B+48OM,4/V>QT_6;2YO)L
MR,H;RX8G?:I+-MPH9B <_P#;]_9\\>>(?B=\(OC1\*M+TWQ-X^^"]YJ:_P#"
M-:AJ8TV#Q/I.I6H@O;-+AD98;@/#:31.^$W6^UB%8D %[]GNP_:6^$WQRL_#
M/Q,UCP?\7_A_K6DW%VOC/1=#3PS?^'-1BD3;9W=D]Y,+BWGC<F*:W^>-X765
M=K))7S[\+O\ @M[X)U[_ ()%1?$K6?C)\$;;XYM\-;K7CH3^(K&.3^VDL998
MK<V)N/-W&947R>&).W@FO<O@CXQ_:0^/O[36C>(/%7@V3X#_  E\+Z;>1W?A
MJ_U?2=<UCQMJ$XA6!Y6M1.EG:VH69E\JY$DKNN]=@P/'?@O_ ,$PCH/_  0\
MM_ACK'PI\%P_&K_A4UYX?:*2STZ2Y76)-.FBC4WB[H]_G,H\T2%0>=V.: ./
M\5?\%$?BMXU^/OPH\'I\;/@]\#=/\4_ O1OB3J.K>*O#27\6H:I=7+0S6\ D
MU&T$:[<.%W.0%/7.1Z;XL_:S^(OP6^ ?@/7(?C1\+/C?=>+OC-X6\%W&M>&?
M#R6-C9Z?J%_:VUU:[([^[4W 25G$AD!7S%^3@$^,>)_V+?B=\-?VC?A!XMU+
M]F'2OC_H?A[]G[1/A]J&FW6L:"BZ-K5M=&68A=0E"L GR^9$"#NX)&:[;XW_
M  E^*?Q3_94\/6_@O]DJ'X5:MX!^+?A7QO%X/T_Q#X=A7Q%;V%_#=74T<EM,
MMM')LA6/]ZP9L+C(% 'T5_P5A_:=\4?L;?L!^._B1X+_ +,'B7PZ^FK9_P!H
M6QN+;_2-3M+:3<@92?W<SX^88.#SC%?15?GS^W<O[1/_  4&_8$^+?PZ;]FG
M7/ /B"]M-+NM#34?&^A7B:U-!JUI/);JT%P1"PAA=M\I53C )/%?1G[.'[2?
MQD^*WQ)?2?'7[.'B+X5Z"MG+<+KE]XQT758VF5D"0>39SR2[G#.V[&T>603D
MC(!GZE^T_P")[3_@K1HWP77^S?\ A#+_ .$=_P"-9,VY^V?VA#K-E9IB3=CR
M_*N'RNW.[!SVH_:#_:>\4?#3_@HK^SG\+],_LW_A%_BAI?BV\UOSK<O<[],M
M["2V\I]P"#=<R;LJVX8Z8KRW]JWP5\9OA7_P5/\ #'QL^'OP;U+XN>'8?A3?
M>"+N"P\2Z7I$UI=SZO:WJL?MLT>Y?+MB/E!Y<>AKEOVB$_:(^(G[2W[-/QTT
MW]FO7)M0^'%MXRTS7?"!\;:$M[:+J$6GQ6DXN6N!;R*_V>5BJ,64 ;@"0" >
MU_\ !3+XY?$;X1V'P5T/X8Z_H/A?7OBE\2[3P=<:KJ^AG6H+*VETO5+MG%L)
MX"S>99Q#_6K@%NM<[\'OC_\ &'X/?M[^&/@;\3?&GPZ^*J>,_!VJ>*H=1\->
M&)O#^J^'#97-G"/MULU]=H;2X^U%89AL)EAD3#8R.-_:B^"OQ$_X*7^#/@C:
M?$C]GE/#.D>$/C-::QXD\->(]<T?7+>[T.+1-2B:\<0RO%(GVF[BB\CYI<KN
MV;/F'U)\ /V-?A'^RB^H/\,?ACX!^'\NK*B7TOA[0;73I;U4+%%E>)%:0*68
MJ&) W'&,T >E4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTR71]/MM=\.K#XIN%O8Y)5+64OEQ-%% /GG*AA( I."* /L[]NWXQ:Q^SO\
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MRPPO<6NG3,MU>6$$MS DMS&!DF4PI.L;-7U]7YC?\%1/C_H'[17A'QUX!O\
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M^HKZXH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1W@GQ'^SE:?%RUU^V_X5S?>'$\71ZW-');PC2FMA="Z=)%61%$!WE74,HR"
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M&(+ 'W'1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^'?B+QKXROO!FO:7X4T^WT:W\1Z))H6I7LS75O;HBS_99[&TF1V!*$8SA\4
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M_P"R_P##23X'GX8M\// _P#PK=HO(/A3^PK7^Q/+\WSMOV/9Y./-_>8V??\
MFZ\U:^!_[/?@/]F;P0/#7PZ\%^%_ OA_SFN3IV@Z7#I]L\S*JM*R1*H:1E1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZY_X'2__ !5 'V#17Q]_PLOQ)_T,.N?^!TO_ ,51_P ++\2?]##KG_@=+_\
M%4 ?8-%?'W_"R_$G_0PZY_X'2_\ Q5'_  LOQ)_T,.N?^!TO_P 50!]@T5\?
M?\++\2?]##KG_@=+_P#%4?\ "R_$G_0PZY_X'2__ !5 'V#17Q]_PLOQ)_T,
M.N?^!TO_ ,51_P ++\2?]##KG_@=+_\ %4 ?8-%?'W_"R_$G_0PZY_X'2_\
MQ5'_  LOQ)_T,.N?^!TO_P 50!]@T5\??\++\2?]##KG_@=+_P#%4?\ "R_$
MG_0PZY_X'2__ !5 'V#17Q]_PLOQ)_T,.N?^!TO_ ,51_P ++\2?]##KG_@=
M+_\ %4 ?8-%?'W_"R_$G_0PZY_X'2_\ Q5'_  LOQ)_T,.N?^!TO_P 50!]@
MT5\??\++\2?]##KG_@=+_P#%4?\ "R_$G_0PZY_X'2__ !5 'V#17Q]_PLOQ
M)_T,.N?^!TO_ ,51_P ++\2?]##KG_@=+_\ %4 ?8-%?'W_"R_$G_0PZY_X'
M2_\ Q5'_  LOQ)_T,.N?^!TO_P 50!]@T5\??\++\2?]##KG_@=+_P#%4?\
M"R_$G_0PZY_X'2__ !5 'V#17Q]_PLOQ)_T,.N?^!TO_ ,51_P ++\2?]##K
MG_@=+_\ %4 ?8-%?'W_"R_$G_0PZY_X'2_\ Q5'_  LOQ)_T,.N?^!TO_P 5
M0!]@T5\??\++\2?]##KG_@=+_P#%4?\ "R_$G_0PZY_X'2__ !5 'V#17Q]_
MPLOQ)_T,.N?^!TO_ ,51_P ++\2?]##KG_@=+_\ %4 ?8-%?'W_"R_$G_0PZ
MY_X'2_\ Q5'_  LOQ)_T,.N?^!TO_P 50!]@T5\??\++\2?]##KG_@=+_P#%
M4?\ "R_$G_0PZY_X'2__ !5 'V#17Q]_PLOQ)_T,.N?^!TO_ ,51_P ++\2?
M]##KG_@=+_\ %4 ?8-%?'W_"R_$G_0PZY_X'2_\ Q5'_  LOQ)_T,.N?^!TO
M_P 50!]@T5\??\++\2?]##KG_@=+_P#%4?\ "R_$G_0PZY_X'2__ !5 'V#1
M7Q]_PLOQ)_T,.N?^!TO_ ,51_P ++\2?]##KG_@=+_\ %4 ?8-%?'W_"R_$G
M_0PZY_X'2_\ Q5'_  LOQ)_T,.N?^!TO_P 50!]@T5\??\++\2?]##KG_@=+
M_P#%4?\ "R_$G_0PZY_X'2__ !5 'V#17Q]_PLOQ)_T,.N?^!TO_ ,51_P +
M+\2?]##KG_@=+_\ %4 ?8-%?'W_"R_$G_0PZY_X'2_\ Q5'_  LOQ)_T,.N?
M^!TO_P 50!]@T5\??\++\2?]##KG_@=+_P#%4?\ "R_$G_0PZY_X'2__ !5
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MCS_X]0!\Y;QZBC>/45]:^(_#G@OP?HL^I:M8>%]+TZU ::ZO((((802 "SL
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M $ =%_\  &+_ .)H ^/-X]11O'J*^P_^%;^'?^@#HO\ X Q?_$T?\*W\._\
M0!T7_P  8O\ XF@#X\WCU%&\>HK[#_X5OX=_Z .B_P#@#%_\31_PK?P[_P!
M'1?_  !B_P#B: /CS>/44;QZBOL/_A6_AW_H Z+_ . ,7_Q-'_"M_#O_ $ =
M%_\  &+_ .)H ^/-X]11O'J*^P_^%;^'?^@#HO\ X Q?_$T?\*W\._\ 0!T7
M_P  8O\ XF@#X\WCU%&\>HK[#_X5OX=_Z .B_P#@#%_\31_PK?P[_P! '1?_
M  !B_P#B: /CS>/44;QZBOL/_A6_AW_H Z+_ . ,7_Q-'_"M_#O_ $ =%_\
M &+_ .)H ^/-X]11O'J*^P_^%;^'?^@#HO\ X Q?_$T?\*W\._\ 0!T7_P
M8O\ XF@#X\WCU%&\>HK[#_X5OX=_Z .B_P#@#%_\31_PK?P[_P! '1?_  !B
M_P#B: /CS>/44;QZBOL/_A6_AW_H Z+_ . ,7_Q-'_"M_#O_ $ =%_\  &+_
M .)H ^/-X]11O'J*^P_^%;^'?^@#HO\ X Q?_$T?\*W\._\ 0!T7_P  8O\
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MKXR>)OACX>U#^T](^%^N>.+J^\%:7.&=U:.R;YV 9V)$DKAMS!]P9@0#\_\
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MFY>[\:^&O!'C.;2= \8R2;A*;VTVNK"0.X8(4!WMQEB2 ?CYXL^(GBKX\?\
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ML<U[Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%?#'[._P#P6]T/XZ?\%9/'G[*]UX%O?#FH
M>$_[0AT[Q%-JJS0:_<V8MWD@C@\I2C>3,\I_>-M6+D?," #[GHKX2_X)8?\
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MF@#WJBN1\!?'[P'\5?AM-XS\+^-O"/B3P?;K,\NNZ7K%O>:;&L()E+7$;M&
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M$?XBZ[X/\.^.O!NO>+?"Y(UG1-.UJVNM1T@A@I%Q;QN9(<,0/G4<D"N:U/\
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MS8W,Q/[15P_[1_P.B_:1^#&M>"YO%/C?P5'K0A']M^$-9?1]:L3'-'*#;W2
MM&6\O8V =R.ZGAC0!^7W_!O?XC\7_P#!0S]IOQ/^T=\2=*U"UU;X0^!-%^!N
MEG4MC7,^J6L276NW<JXS'.URZ88<^7<LAZ$5U_\ P6U\,_&?]MO]O7]G_P"!
M7P9T/PO=)\-YQ\8=>O\ QG:W?_"*R75G*(=.M;F6V4R,0S3EX%.7%S$3A037
MWQ^QI^QOX _8(_9ZT/X8_#31VT?POH7F.@FG:XN;R>5S)-<3RM\TDKNQ))P%
M&U5"HJHOJ5 'X6_#GX'?M/?LWZK^VY^SEXHT;P^OBC]I+P3JWQ0\)7/@&&_E
M\,G6;@3PZCIMM)=)YD-U=Q)A8Y' C%NFTA72N9_9O\)_#GQ?^V/_ ,$Z;CX1
M_ 'Q5X#U7X=I<Z+\3M;?X?W.AQIJRZ5'$UI=W3P1_;+F.6&XD>4E]HN4)?=*
MRK^_%% '\RG[3OP.\.^&/^"8G[0WPS\:_ /QOXD_;,A^)EUK=[XNC\"7=Y=7
M%I-JT,AUA=5\LC^SYX/,@6)9#OEG\P1$,\R_I'^SG^Q?H/Q8_P"#A;]L?QYX
MN^'^G:IJ'A_3?!=QX&US7M$^U6NGWHTFV9KJT:5=GGQ36L'[R,AT*,H9=S _
MJ110!_.+_P $[OV7_$UC\2/@#X#\4:7XL\)_M%?#OXLGQ!XI?2O@;<3>)?*2
M^N))KK5_%LNJPP76CW5O<A7:-79U$:I%.-K3Z7QM^&%Y\&_VTO'US\,_A[KW
MQ$\;:W\7+CQ'%\'?BC\%'.M7EU-=Q2RZKIOBVQ:0?85=Y9(I)[N.-(X6>1)0
MQ:7^BBB@#^?O_@K7\)H/"'[?GQW\0:#X=\3:UXP\7SZ9,GP[^)'P-?Q?I?Q-
MGAMUCB_L'7M/::YMX1''$OE>9:LCOL+ H8X?U=^"7C7P=JO[:/@>Q\3_  ?U
M?PK^T%=?!:RU'4M;CM!>:7HFG->*)M!&HA\22Q7F]]@3YD ?=SBOJ>B@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX'^ WP9T__
M (*F?&#X[^*OBIKWQ#N/#WP_^)5_X \)^%=%\9ZIX=TW1X=(2&.2]=-.FMGF
MN[BYDGD\R=Y-L1@6/8 <_?%?*_CO]@SXC^#OCKXW\;? OXSV/PNA^)DHU'Q-
MH&M>#$\2Z7-JJV\5L-3M46ZM7M[AH8(ED!>2.4QJS)NR2 <?\?/AAX^^ _[&
MGA3X&WGQ1\6^/M?^*GQ"L_!.B>)766T\06OA^6Y>_O(KJ\25GGN[?1+/4D^W
M#RFD:.-RBON9L/X!?LYVO_!33Q_\7OB!\7O$WQ!OM+\._$?6/!7@_P *Z!XV
MU3P]I'AVRT.\DL1<F/3IK9YKZYN([B>2:X>0JLD,<>Q(_F]&_9J_X)9Z7^SK
M\3_ OB23Q=J7BV\\-S^)O$NMWFJ6D:WOB?Q5KCVJSZU(8=D,/E6L5S:Q01Q;
M5AN@NXE"7F\5_L$?$+X=?&#QIXJ^ OQBTWX66/Q(O)-9\2>'M9\%1^)-+DU=
MXHHGU.T5;JTEMYY%B0RAI)8I'&\H&+%@ _X)K>./%&@^,_CE\%?%'B?6O'3?
M OQ9::5HWB36"9=2U#2K[2;/4[6&\G))N;JW^U20M.<-*L<3,-Y9F^6_'GC/
MX,ZO_P %*/VF]/\ C)JW[0=U?Z'XGT&#P];>"KGQ^]EI]L_AG2960+H!^S1N
MUP\KX<"0EBW0@U]Y?L<?LDV'[(7PZU;35\1:_P"-?%'B[6[GQ/XK\3ZVZ?;O
M$.JW 19)VCB588(TCBAAB@A18XH8(D )!9IO@?\ LS?\*:^/GQI\<?VY_:7_
M  M_7=.UK[#]C\G^R/LFCV6F>7YF]O.W_8_-W;4QYFW!V[B ?!G[/GC'XL:#
M\;/V"=)\;:O\3K"/7O$OQ'$-AXNO98_$.HZ#'87LFBKKL8;;+>I:?9F82 LK
M@%L2AS7U%\5O$?B0_P#!67P7H.C:Q-9QWOP4\5W<%K/+(^GF^35] 2"XE@5@
MKLGFN,_>VNX!&XUVG[:G[&]S^U(O@;7O#/C*[^'/Q*^%NLR:YX4\2PZ9!JD5
MI)-:S6=S;W-I-@3VT]O/(CHKQ2 A&612O/&?#7_@G-J?B/XI>-/''QV^($?Q
M<\1^+O"%S\/HK73=#;PSHFCZ!=,DEY:PVJ74\IEN)$1I+AYV?$4:IY84Y /A
M/POJ-O\ L]>'_"MQ\9M:_:F_9R_:"TV]T5?$7Q<\4ZGJ_B?X=>(KTW<0GMY3
M;W[Z3'I]T&>-(YTM%M1)&>#$=WNOAK]NG7OV>_\ @J_^UIHEQX!^._Q6TE#X
M/;3K3PAIO]L67A_=HQ:5?+EN(UMS,QWD1K\Y4EN:[>\_X)4?%CQ3\"X_@EXF
M_:8OO$7P(6V319],F\#VL7BS4=$C18TTV?64G$39C58WN$L4F==QWAR7KW[X
M(?LB+\&?VN?C?\5%\0'4?^%S-H3'2_L/DC1_[,L6M.)?,;SO-W;_ +B;,8^;
MK0!^??A7]M/X@>//A)\4]+T6^^(WP]UCXU_M66OPSLKG6\0:]X#TRZT32KFZ
M\B.0SQV\P@@NEA RJ2W22##5[%^V_P#L[:7_ ,$J_@?_ ,+^^%OBKXIP:QX-
MU_2)O$^EZWX]UCQ#9>/+&ZU&VL;J"YAU"YGC6Y,=P\D,\2*ZRA0,JQ6O9+S_
M ()<>'O%?@#XU^'_ !#XDU2X7XL?$A?B9I>IZ5"-/U3P7J4-MIL=I+:3%I,S
MP3::DRRE5#"0QM&4W!\NU_X)[_%/XP^)/",/QY^/B_$WP1X,U"UUJ+PUH?@N
M+PO#XCU&TF2:SGU>5+J<W4<,R),+:%;>!Y8XV='5!'0!\@_%OXP_!_PM^U+^
MU/K'QRT7]JC7-/\ !_CE5@UGP9?^,X_#>@Z6OA_1YC#++I=U%90,LLD\K!PK
M!9U9CM9<?;G_  21L?B);?L;V=Q\0KSQ!>+JFN:KJ/A+_A(M6CU?7H?#4]Y)
M)I*:C=QS3)/=?96C+,LTF%9%9BRL!Z%\!_V6;?X->,_C/JEUJD.OVOQ@\6_\
M)/-92V CCL$.DZ?IS6K9=Q,I%B7+$(,3;=OR[FR_V$OV0)OV'/A1JGP_LO%E
MQXB\#V>MW=YX-TZYLS'-X2TJ=_-32?/,CM=102-*(I'"NL3)&<B-30!\._\
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MZ5X(_L6&[MHM,N[$:<8?MLVUB]Y)*;C>W ">7_$/J*@ HHHH **** "BBB@
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MD7Q38:"-"CN@)W A>R#,8)8<>2Z/AP\;!U5LJ/@+P#^W=XJ^*OQ/^,\7B_\
M;]^%_P !;CP?\4?$OA72O">KZ7X86ZMM-L;^2"UD8WDB3MNC7[[#YMN<GK7V
M[_P3B_99\0?LR_#?QY?>+ET>S\7?%CQ[K'Q"UC2](NFNM.T.:_D0)9PS-%$9
MMD,,1DE,2>9.TS[0&KYH^!/P8_:._9)\5_&'3=/_ &9_A?\ %'1_&GQ2\3>-
M=,UO4/B-!I=P]IJ5^\\,;P-ILY5ECVY_>'DX[4 >P_"+]I7QA+_P45^&GPKD
M\?:;\0/!>K? 6;QG<:W:6-K''XEU*/5-.M8]3C>#*+%-#<2.(XF,6) 1G"FN
MH_:._:-\6_#O_@I1^S/\.=)OK>#PE\2-+\87.OVK6J2274FGVMA):E9"-T>U
MIY20I&[(SG KQ[XE?#K]I#0?VW/AW\>O"GP1\%ZU>Q?":[\#ZWX3E^(::?%H
MEU/JEK>#RKO[$XN(T2U"C$* ^9VVX,7[0'@G]IWXF?'_ /9S^-VG_ WP7_PE
M'POA\7:?K/A"3XE(L(CU**PAMIH]0^P8?(MY69/(&WY1DYS0![-_P48_:-\6
M_L]:[^SK#X5OH+&/XA?&/1_"&N"6U2?[3IMQ::A++$NX'8Q>"([UPPVD \FO
MF7XH_MS>//&?[:'Q4\$:Y^U!X!_93U;P/K46G>"O!GB7PY831^-+!H(6AU:>
M]OI$-U'=7#SQK!8/"\(MPKL\F[/K'QM^%'QW_;5T;X%ZEXL^&7A?X;ZQ\,?C
M9I7BS4-.M_&BZY'/HMM87:27*3"U@_?>==!!#LZ)NW<X!\8?!?[1EGK_ (T\
M&^(_@U\)/VI_AGXFU^YU+P_<>)/$-OHKZ'8SE773;^RFT^XBFCMF,L:3Q&21
MXUBWQ[RQH ^I_@!K?C+Q)\$/"=_\0]'TSP_X[N])MY/$&G:=<_:+.SOC&OGI
M#)EMT8DW;?F8[< DGD_FG\$_^"@'QJ_:$6]US2?VB/A7X;^.UKJD]NW[-'B7
M1K+26A>*1U_L@W4[IJ,EVT2!A>QDVY=P1"(SQ]R_\$YOV4]>_8W_ &#?A_\
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MV,_ W[+&H:G=>$6\;&;5XHX;C^W?'&M^(D"H6*^6FHW<ZQ'YCDQA2> 20!@
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M3VMW!=/#+$]K+'<^5/$0LBF"&1!+S& #Q/XP?\%2?%D<'P;\ ZO\6/AI\/\
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MMALK6"-I9I7/94168^P-?(T7_!2+XW7?P//QBM?V7;RY^$9M?[<BB3QQ;_\
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MK?$#P#XRT'7/">L_";Q%OFBT.QUBVT"P(U)+=T-O?8E@-I/O64"%YXP$=RU
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MNG>$_ >J^(+#QQ%IUM'#;WVEZA#!]C:.X@6*0BYF@:"1W241["Q /7/V>/\
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M'\P[0<@?6?[6/[07P^_:$_;N_97\+_#WQ=X7\4>-O!OB[4_&FM76BWL&H_\
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MIL*6J>,M(BN[NS4LW]FWJYBO+0E@#N@N8YH3D#F(T >L4444 %%%% !1110
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MJVJ^'K2\.IS6T;16\DYDC;S7BC=TC9\E%=E7 )%6OAW^S/\ #?X0>$=2\/\
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MP 9))&9W<_,S,2222:UZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M L6(DD!#D ]QHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>noticeofarts_page2.jpg
<TEXT>
begin 644 noticeofarts_page2.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_X  2 !!*1DE&  $"  9U")8  /_; $,  @$! @$! @("
M @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'
M"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$(!&H#4@,!
M(@ "$0$#$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U
M$  " 0,# @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!
M%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:
M8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.T
MM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_
MQ  ? 0 # 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$
M!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*
M%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ
M<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"
MP\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#
M$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **\]^+OQO\ ^%5:C8V[:9)J
M'VV-Y0PN?)\L @ ?=;.<YKD?^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79
M/_!C_P#:Z/\ AL-?^A=D_P#!C_\ :Z /<**\/_X;#7_H79/_  8__:Z/^&PU
M_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79/_!C_P#:Z/\ AL-?^A=D_P#!C_\
M:Z /<**\/_X;#7_H79/_  8__:Z/^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7
M_H79/_!C_P#:Z/\ AL-?^A=D_P#!C_\ :Z /<**\/_X;#7_H79/_  8__:Z/
M^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79/_!C_P#:Z/\ AL-?^A=D_P#!
MC_\ :Z /<**\/_X;#7_H79/_  8__:Z/^&PU_P"A=D_\&/\ ]KH ]PHKP_\
MX;#7_H79/_!C_P#:Z/\ AL-?^A=D_P#!C_\ :Z /<**\/_X;#7_H79/_  8_
M_:Z/^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79/_!C_P#:Z/\ AL-?^A=D
M_P#!C_\ :Z /<**\/_X;#7_H79/_  8__:Z/^&PU_P"A=D_\&/\ ]KH ]PHK
MP_\ X;#7_H79/_!C_P#:Z/\ AL-?^A=D_P#!C_\ :Z /<**\/_X;#7_H79/_
M  8__:Z/^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79/_!C_P#:Z/\ AL-?
M^A=D_P#!C_\ :Z /<**\/_X;#7_H79/_  8__:Z/^&PU_P"A=D_\&/\ ]KH
M]PHKP_\ X;#7_H79/_!C_P#:Z/\ AL-?^A=D_P#!C_\ :Z /<**\/_X;#7_H
M79/_  8__:Z/^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79/_!C_P#:Z/\
MAL-?^A=D_P#!C_\ :Z /<**\/_X;#7_H79/_  8__:Z/^&PU_P"A=D_\&/\
M]KH ]PHKP_\ X;#7_H79/_!C_P#:Z/\ AL-?^A=D_P#!C_\ :Z /<**\/_X;
M#7_H79/_  8__:Z/^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79/_!C_P#:
MZ/\ AL-?^A=D_P#!C_\ :Z /<**\/_X;#7_H79/_  8__:Z/^&PU_P"A=D_\
M&/\ ]KH ]PHKP_\ X;#7_H79/_!C_P#:Z/\ AL-?^A=D_P#!C_\ :Z /<**\
M/_X;#7_H79/_  8__:Z/^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79/_!C
M_P#:Z/\ AL-?^A=D_P#!C_\ :Z /<**\/_X;#7_H79/_  8__:Z/^&PU_P"A
M=D_\&/\ ]KH ]PHKP_\ X;#7_H79/_!C_P#:Z/\ AL-?^A=D_P#!C_\ :Z /
M<**\/_X;#7_H79/_  8__:Z/^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79
M/_!C_P#:Z/\ AL-?^A=D_P#!C_\ :Z /<**\/_X;#7_H79/_  8__:Z/^&PU
M_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79/_!C_P#:Z/\ AL-?^A=D_P#!C_\
M:Z /<**\/_X;#7_H79/_  8__:Z/^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7
M_H79/_!C_P#:Z/\ AL-?^A=D_P#!C_\ :Z /<**\/_X;#7_H79/_  8__:Z/
M^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79/_!C_P#:Z/\ AL-?^A=D_P#!
MC_\ :Z /<**\/_X;#7_H79/_  8__:Z/^&PU_P"A=D_\&/\ ]KH ]PHKP_\
MX;#7_H79/_!C_P#:Z/\ AL-?^A=D_P#!C_\ :Z /<**\/_X;#7_H79/_  8_
M_:Z/^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79/_!C_P#:Z/\ AL-?^A=D
M_P#!C_\ :Z /<**\/_X;#7_H79/_  8__:Z/^&PU_P"A=D_\&/\ ]KH ]PHK
MP_\ X;#7_H79/_!C_P#:Z/\ AL-?^A=D_P#!C_\ :Z /<**\/_X;#7_H79/_
M  8__:Z/^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79/_!C_P#:Z/\ AL-?
M^A=D_P#!C_\ :Z /<**\/_X;#7_H79/_  8__:Z/^&PU_P"A=D_\&/\ ]KH
M]PHKP_\ X;#7_H79/_!C_P#:Z/\ AL-?^A=D_P#!C_\ :Z /<**\/_X;#7_H
M79/_  8__:Z/^&PU_P"A=D_\&/\ ]KH ]PHKP_\ X;#7_H79/_!C_P#:Z/\
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MF_Z&9?\ P6__ &V@#Q>BO:/^&-IO^AF7_P %O_VVC_AC:;_H9E_\%O\ ]MH
M\7HKVC_AC:;_ *&9?_!;_P#;:/\ AC:;_H9E_P#!;_\ ;: /%Z*]H_X8VF_Z
M&9?_  6__;:/^&-IO^AF7_P6_P#VV@#Q>BO:/^&-IO\ H9E_\%O_ -MH_P"&
M-IO^AF7_ ,%O_P!MH \7HKVC_AC:;_H9E_\ !;_]MH_X8VF_Z&9?_!;_ /;:
M /%Z*]H_X8VF_P"AF7_P6_\ VVC_ (8VF_Z&9?\ P6__ &V@#Q>BO:/^&-IO
M^AF7_P %O_VVC_AC:;_H9E_\%O\ ]MH \7HKVC_AC:;_ *&9?_!;_P#;:/\
MAC:;_H9E_P#!;_\ ;: /%Z*]H_X8VF_Z&9?_  6__;:/^&-IO^AF7_P6_P#V
MV@#Q>BO:/^&-IO\ H9E_\%O_ -MH_P"&-IO^AF7_ ,%O_P!MH \7HKVC_AC:
M;_H9E_\ !;_]MH_X8VF_Z&9?_!;_ /;: /%Z*]H_X8VF_P"AF7_P6_\ VVC_
M (8VF_Z&9?\ P6__ &V@#Q>BO:/^&-IO^AF7_P %O_VVC_AC:;_H9E_\%O\
M]MH \7HKVC_AC:;_ *&9?_!;_P#;:/\ AC:;_H9E_P#!;_\ ;: /%Z*]H_X8
MVF_Z&9?_  6__;:/^&-IO^AF7_P6_P#VV@#Q>BO:/^&-IO\ H9E_\%O_ -MH
M_P"&-IO^AF7_ ,%O_P!MH \7HKVC_AC:;_H9E_\ !;_]MH_X8VF_Z&9?_!;_
M /;: /%Z*]H_X8VF_P"AF7_P6_\ VVC_ (8VF_Z&9?\ P6__ &V@#Q>BO:/^
M&-IO^AF7_P %O_VVC_AC:;_H9E_\%O\ ]MH \7HKVC_AC:;_ *&9?_!;_P#;
M:/\ AC:;_H9E_P#!;_\ ;: /%Z*]H_X8VF_Z&9?_  6__;:/^&-IO^AF7_P6
M_P#VV@#Q>BO:/^&-IO\ H9E_\%O_ -MH_P"&-IO^AF7_ ,%O_P!MH \7HKVC
M_AC:;_H9E_\ !;_]MH_X8VF_Z&9?_!;_ /;: /%Z*]H_X8VF_P"AF7_P6_\
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MOC70/"/BC0? ,?C+QY\1]3\-)J,T ,R6UO#I^GM*D!FGE5GD,A>*.*7"GS%
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M'X?Z[&6_X]UDVF6PE0[0JEY%)7A1&3-Z/\9?V1/''C'_ (+/_!OXT6-A9R>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-IKV/E^;]J%P&\LP>7\_F;MFWYLXYK\I?B+^V&W[7'[0'PSM_$=C;>&?BQX
M^$_Q7\.?$+PN)E:;0M6BM=&61E 9LVEQ@S6TH)62)Q@DJP'E_P */$M]_P $
MZ_\ @CU:^ ?$FJR2?!7]HK]GNXU3P3J>H7*K'X8\7WGAFXO=0T21VP/)OW>6
MZM06SY_VB%0Q=* /V>\4_';P7X%^%L?C;7/%_A?1?!\D$5TNO7^JP6VF/#(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;3-2^"5EJ.G>$[+3&%GINGVU]:PVLL7V=!LV+#!&L:C"H!P*]8HH \'^*_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5^1_[$?_!9?XG^+O\ @LA\;_A3\7-8\.6?
MP=T'4?&6E>$[B.S@MIEN-#N+>XE21U;S'\O3I6=BP ;DC)1@/UPK\*/VY/\
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M&EVKW,D4NYX;>*-#*\[E2 "^!P/[!?\ P3H^+_P0_:@_8_\ $GB3PO!8Z/\
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MGPZ?HGQ5\"_$S4OA_K6D".S: _V[9YN(KZ .("ILEBD=;>-&VJ?D /T@T_\
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M59_#^@^))/#U_;^%M?U:%W1].L]6DA6TN)R8SL,<C1REXUC=V=5)XJ_X+)_
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MUR\T_P"&_P 4?AO\0M0T^ 7%W;^&/$ECJ\UK$6VAY$MY795+$#<1C)QFNO\
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M:I+#^S_\>KJ^T_QI->R$VO@3Q2-5N+2QU9I&;$-C>10Q6LY8".*:*VD+*'8
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M)ZGK<UOX_O\ [->Z?=74UM;S+";:"PLIB2<N-3<#[CY[OXU_M<Z]^UG\._V
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MB;2_#FBW&H:A/:V.G6Z&::YN)$BMXD[NTC$(%YSDGO7P:_P_^)G@+]J3X_\
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M$J'*L,L".596((/&/-M1_P""7O@"X\>^,/$6C^*OC3X1OO'>M2^(=;MO#7Q
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M/".O?'6UO-#^"?BW1M,EBB\"6$$GB*UN-+LM2F21Q(3"3]I>$-'R%4-C<<
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MP9\6/'E[X]T:]TKQ+8:?>:/>:A%!]L@U*.^>$+;K<QLT<EJ;A_*<AHMR /\
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M0_!:]GT2RU7PY<QW*^1<6<IWZ==(ML[Q2VDEW'"B6\+0N6+H_P!?44 ?'O\
MP36_8[U;X#_%KXL>.O\ A7.A_ WPK\2)=-_LSX:Z3<6T\.ER62SQ2:I.+0_8
MX+N[26)7AM#)&%M8V:61V.S["HHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **\I^/7Q\\3_"+6=-M]%^'NL>,H;V!Y99K$3XMF
M5P K>7!(.0<\D=#7!_\ #;/C_P#Z(9XM_P#)O_Y#H ^DJ*^;?^&V?'__ $0S
MQ;_Y-_\ R'1_PVSX_P#^B&>+?_)O_P"0Z /I*BOFW_AMGQ__ -$,\6_^3?\
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MW_R;_P#D.@#Z2HKYM_X;9\?_ /1#/%O_ )-__(='_#;/C_\ Z(9XM_\ )O\
M^0Z /I*BOFW_ (;9\?\ _1#/%O\ Y-__ "'1_P -L^/_ /HAGBW_ ,F__D.@
M#Z2HKYM_X;9\?_\ 1#/%O_DW_P#(='_#;/C_ /Z(9XM_\F__ )#H ^DJ*^;?
M^&V?'_\ T0SQ;_Y-_P#R'1_PVSX__P"B&>+?_)O_ .0Z /I*BOFW_AMGQ_\
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M\?\ _1#/%O\ Y-__ "'1_P -L^/_ /HAGBW_ ,F__D.@#Z2HKYM_X;9\?_\
M1#/%O_DW_P#(='_#;/C_ /Z(9XM_\F__ )#H ^DJ*^;?^&V?'_\ T0SQ;_Y-
M_P#R'1_PVSX__P"B&>+?_)O_ .0Z /I*BOFW_AMGQ_\ ]$,\6_\ DW_\AT?\
M-L^/_P#HAGBW_P F_P#Y#H ^DJ*^;?\ AMGQ_P#]$,\6_P#DW_\ (='_  VS
MX_\ ^B&>+?\ R;_^0Z /I*BOFW_AMGQ__P!$,\6_^3?_ ,AT?\-L^/\ _HAG
MBW_R;_\ D.@#Z2HKYM_X;9\?_P#1#/%O_DW_ /(='_#;/C__ *(9XM_\F_\
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M23$Q0&418 /VZ^%_Q]\(_&36_$NG^&/$VB:_>^#M5?1=<@L9Q))I%Z@RUM,
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ME*_9],5(682B *?WSG>^\Y    !Z91110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DO[8G[#WPO_ &]_A[H_
MA;XK>'9O$FB:#K4/B'3H8=7O=+DM;^&.6**=9;.:*7<J3R@#=C+9QD*1Y_\
M#3_@C[^S[\)K7Q3;Z3X/UJ[L_&VAW'AS6[/7/&.MZ[:7]C.R/)&8;V\FC5BT
M:$2(JR+@A6 9LL_X*4?M$>+/@!X@_9MM?"NH0V$/Q$^,VD>#M>62UBN/MFF7
M%CJ,LT(WJ=A9[>([TPXVD X)!]L^.7QV\,_LV?"Z\\8>,M0DT[0M.:"&:6*T
MFNYI99Y4@@AA@A5Y9II9I(XTBC5G=Y% !)H \3_9Y_X(X?LY?LI_$3PWXM\
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M_P"*O'6K_"CP1I_@N\^).H)JGB);.YN7@NYT:9D\N&21HK=%-Q-MC@6.-0^
MH 4#H_ G[*'@/X8?'OXA?$_0=$.G^.OBJNG)XIU/[;<3?VH-/@-O9CR9)&AB
M\N(E?W2)NSEMQYKP'0O^"C&C?#SXA_%JX\3:IXTUJZM?%OAWPWX>\#+X9M(-
M6L+_ %/0;*^CTFU>.=OMDK[YKF66=HT@VSKN\F'S#[S^S'^U)HO[4_A'4]2T
MG1_%GA^ZT'5[C0=7TKQ%H\NFWVFWL&TR1$-F.5<.I$T$DL+9(60D,  >0?\
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M?WDJO)Z.,#'M\$WG*>,%3@\U)0!\W?'O_@D7^SK^T[\4+CQEXX^%^BZUXBU
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M%/BOX2Z+J.K>.8W&O>5?7MG:ZG*P8-=26T$Z0?:_G8BZ$8G#,6$@8YKZHHH
M^9_'W_!'G]G#XG>(?"NK:Y\+])OM0\&Z';^&=/E-[>QBXTJ!(TBL;Y8YE74(
M%6)!Y=X)E(&"#DYUOA)_P2V^!GP*/PA_X17P3_9?_"A3K7_"!YUG4+C^P?[8
MW_VEGS9V^T>=YC_\?'F;,_)LP*^@J* /G$_\$D?V=?\ AI&3XM#X5^'?^$ZF
MU3^W6N6,[6(U/(;^T5L#)]B6]W /]J$/G%LL7+$FO1?VE?V2/ /[8'P^@\*_
M$;19/$7A^UU.VUF*T&H75GLN[:3S()-]O+&_RN<[2Q4\9!  KTFB@#Q?X]_\
M$]_A'^T[\;_A[\2/''A&WUKQQ\*;P7_A;6%O;JSN--E$L<R[O(E19T62)6$<
MZR("7PH#N&\M\1_\$(_V4_%7B?Q%K5Y\)=/_ +2\4:D=9O)8-9U2W6UOFN(+
MA[NR2.Z5;"X>2VAW36@B=D4QL2C,I^NJ* /#[_\ X)R_![4=.^,EI+X39K?]
MH AO'R'5[_\ XGY$30]?/S;CRV*XM_*_E5K_ (=_?"=O%7P@UM_"JRZI\!M)
MN="\#32:A=R#1K&YLTL9X61I2MR'M46,M<B5N-P(8EC[-10!\Y?L]?\ !)3]
MG?\ 95^+G_"=^ ?A=H/A_P 50_:!8WBRW-RFB+<,[3)I\,TKQ6"/YL@9;5(E
M*R.N-K$'T3]FK]DCP#^R'H_B;3_A[H(\/V/C'Q#=^*]7B%[<W7VO5+O9]HN,
MSR2%-_EI\B%47;\JC)SZ310 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!\I_\%5_@+X^^-&E_ ;6/A[X=
MM?%6I?"WXMZ5XWU#3)M4ATUKFRMK+4(9!'++\F_?<Q8!ZC/I7'_M8_!'XH_\
M%(?@E;^'?$WP]O/A+JO@/Q7H7C30\_$%8X/$4]C=&26RFO--1KNQ5HMP6YA'
MF12M%*H8Q%&^W** /SK\%_\ !+W6/CCKOQ4D\?>$5\$Z'XV^&-_\.+9M6^*?
MB/X@^)XI+V59+B=;G4;J2RM;1&@MY(HT@DG9T$CM"-T#>7ZI_P $D?C1\8O#
M/PKU+QK-X9B\5?$#7];_ .%\QP7Y:.\TB^UO3=52VM2S.KHD&C6U@J1[0([D
ML1DRLWZR8HQ0!^?WQM_8 \7?$;QS^TM?ZGX#^'OC_P -?$;QWX=\26&B:_?R
MVUQJMA8^'[.QN387D$B/IFII<1-]GN&X^0J3&LOGQZ/[->G_ !C_ &"/A1XO
MU_Q%8:QXF\/^*_'GAW2O!/P[U3QQ-X@U/P1IE[/9Z=<,^L7$<DMTPEF>X%H&
MDCAB@"K.2SE?O#%% $3S%K5F5<GL,^]?)W[&G[,GQ&^!7P/_ &@M&^WZ5X5\
M7>//B9XV\4>%=38)J4-A'J=U++IUW+"" VUF1V@9@2 5)&:^ML<48H _+/X<
M_P#!.GXQ7WQL_9\\:>*? OF^*/A7XGL+CQ?XJUGXNZEXKU7Q&J6-[:7-UI]I
M=XM;&P>:[%TT4?DRG&Q;9!$BOVWPW_X)\_$WP[_P3.^"_P -KK3=+'BKP9\:
M;3QMJD*:E&\":9'XUN=7:1)1P[?8Y$?8/F).W&X8K]%L4V2/S(V7CYACI0!^
M:7@?X00_$[_@MYXHT'P[KVDZ]\)?!=U9?&OQ'9:?=Q7*Z+XSN;";0[>PG"O\
MCO#!)J(!Y#QJ60"2-FX3]JS_ ()K?M"?M"_"[QCX?\4>';/Q]XXM?$IUFR\>
MZC\4=0ATN^L(=9M]1M8=+\-/NL=/N_L<$=E)O\E4V2.+B?S6+?JIX1\"Z/X%
MBU!-'TG2=)75+Z74KP6-HEO]KNI2#+/+M WRN1EG;+,>I-:V* (;*3S5D;&W
MYSQ4U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %?,?[-W_!7'X/_M5_MG_$+X">$[O7G^(?PR-\-:@O
M--:WM1]CNX[.?RI22),2RIC &5)/:OIROYG/CG\4?$'[ WQ__:&_:D\%!;35
MM(^/?Q*^'&J7,5JLTDG]I:2DVE^9C:YBBO[8R%FE C8Y5'+LI /W+_X)\?\
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M/>'-,\77NGZ*U^_AZRN%EGMHI%27#6[)L8^65N[C<I9U=?G3]D;]I_XS>/\
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M4?""QGB\ :UJ@M;BTT"XO8[E;^YTL9V7:W#BWDFR0I#1>] 'TU1110 4444
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MQ/!/-8O%-IUM;6UU:SM;-;F%[=9DEFB=9F7='7BG_!#_ /X*A_$;]I32=/\
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MZ-8VL]C)##*UR+N5WMX_LY62-A(N/IK]@WXY>*_C)\4?VDM/\2:NVIV7P_\
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M S' )Q3=4^!G@G7/B39>,KWP?X5O/&&FQ&"TUV?28)-2M8SC*1W!0R(O X#
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MG@A_'?C3Q?%86MSJ5II]E;Z<)8K&WGMY+(7-W=:@BEY(F2&*.4B,L8P/2_\
M@GG\=_&GC*7XK?#?XF:UI_B;QW\%/%P\-7.O6=H+7_A(K&XL+34+&^FA1%BA
MN&@NQ'+'$/+$D#LH564  ^DJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *^&_VN/V9?VGOVB_AG\8/@OJ4GPA\6?#W
MXN:C<VFD^+]3EEMKWP-H5RL7F02:2EL4OKRV_>_99A=IOD6.61H2@4_<E?%/
M_!/3_@J?JW[7?[;'[0?PD\1^%].\-CX6:]?6/AF[M;MKAO$=G9:A+8W<SACE
M)(I/LFY5  ^U+U!4D P?'G['?[07P(UOX\>&/@G9^ -8\(?'Y5U6VUSQ)KT]
MOJ'@K7)=-M],O[NXA^RSC44FCMH+I,,A$XF1D\MPPZ[]OW_@G5JOQ*_X(V:M
M^S;\*OL,FHZ?X9T7PSH+ZQ=F"-X;"XLR#-*%8AC%;$YVG+'WS7&^&_\ @L#K
MGC&?]N"^T_P?IPT']EWP_-K/AFYENW+>*VMX=92Y\X#_ %<0OM&GC1E&6C.X
M9!5B_P"&'_!:'SOVUO OPO\ &W@\Z'X;^(/@/PQKECXJM9)Y[2QU_6O.-MI%
MP3'M07'DRK!(S+EX"A#&0; #[QNHVDB^7&X$$$C.,>U?$/P)^ W[2W[!?PRU
M+X3_  Y\)_"#XA>"-.U*^?P#KFJ^)+K09?#UA<SFYCM-3L8K.99Q;23RQH]K
M*GG0PH"D#$FLG]M#_@KQXM_9HO/VHH=!\ :;XHNO@'!X!ET>R:]E@F\1R>([
MXVLD+D*?+:/ \LJ#EC\P(XKTKX@?\%.=-N/V)? ?Q@\#:5)?0^,/&&A>$KG2
M];BFLKS1+B\UF'2[ZVN(R \=U:2O,C(PP7AZLI!(!P&B?\$KO%WQ6^/_ (+G
M^-WC[Q-\2O"OPG^'_P#8>BZQ'K=UX<U;6]?O;PRZEJ+_ -FRQ211+:P6EK&C
MS.Q7S?,,K'S6Y'Q9_P $F?&7@'4?&_@KX?PZ;-\)_$7Q2\%?%73+?5M;N;Z\
MLK^UU&WD\1+/-=--/-]H2S@N8PSOF66X!9=RK7H/P/\ VPOVB/VK_B!\8X?
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MJOP8DL+7X?:#J7QS;XIS?!FST"S\2/+X>U'5[>,3W6HQWRV[2KI]O:":>8&
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M2\)_%S1/AMIVCV.NQZWJ7A.:WM]5M;V>W@M6M/F/G,YN86"@#Y"6[8(!\D?
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MXIFO? -LEMJ&J?#+P9?K(;:W_LNW,D=["\BS2S65I))+%'J'E0Q3M'Y0\O\
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MXA\2_"GXT^'/&GAO3[/06FO/&6CR^%K#1=:MM/9ES(#:W-TV8=_[ZQC7#,H
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M$CQ1I_PWO)=.\7:OX9\%ZAJNC^&)HH8YY8KBYBA*R/%%(K2);><\0XD56PI
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_!U;?_%T =E17&_\-&?#W_H?/!O_ (.K;_XNC_AHSX>_]#YX-_\ !U;?_%T
M=E17&_\ #1GP]_Z'SP;_ .#JV_\ BZ/^&C/A[_T/G@W_ ,'5M_\ %T =E17&
M_P##1GP]_P"A\\&_^#JV_P#BZ/\ AHSX>_\ 0^>#?_!U;?\ Q= '945QO_#1
MGP]_Z'SP;_X.K;_XNC_AHSX>_P#0^>#?_!U;?_%T =E17&_\-&?#W_H?/!O_
M (.K;_XNC_AHSX>_]#YX-_\ !U;?_%T =E17&_\ #1GP]_Z'SP;_ .#JV_\
MBZ/^&C/A[_T/G@W_ ,'5M_\ %T =E17&_P##1GP]_P"A\\&_^#JV_P#BZ/\
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M_P#0^>#?_!U;?_%T =E17&_\-&?#W_H?/!O_ (.K;_XNC_AHSX>_]#YX-_\
M!U;?_%T =E17&_\ #1GP]_Z'SP;_ .#JV_\ BZ/^&C/A[_T/G@W_ ,'5M_\
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MM_\ %T =E17&_P##1GP]_P"A\\&_^#JV_P#BZ/\ AHSX>_\ 0^>#?_!U;?\
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MBSFUCF +!,^8&C4 ^O?^&#?A3_T+,W_@WOO_ (]1_P ,&_"G_H69O_!O??\
MQZO#-/\ ^"XWPQTC1/BS)XX\+_$KX9Z]\'X=/NM3\->(=!!UK4X-1,<>GO91
M6LLR3-<3RQPA-X:-VQ)Y8#,/0/V3/^"E_AO]J'XWZY\,]2\$?$CX4?$31](B
M\1P^'?'&D1V%YJNDRLJ+?VQBEEC>)9'$4BEP\<F490RL  =D?V#OA2HY\,S?
M^#B^_P#CU-_X84^$^<?\(W)G_L,WO_QZNO\ VB?$-YX4^ /C;5M-N&M=1TO0
M+^\M+A &:"6.VD=' (()# 'D$<5^('[%?_!:OX]7?_!*/X^+X\\92>(/CW;R
M^''^'6I/'!#=7D?B-8;>T6WBCM1'-]FDCGE;Y7R^Z-BNU20#]D&_85^$JCGP
MXX^NLWO_ ,>IS?L(?"A5W'PU*%'4G6+[C_R-7YU_\$V/^"B_CCX@? #]D>;X
MN_$?XD:EX^^)WC_Q-X=FDT.PTC^S=>-C.ZK#J6^))$MT1/D:U"N3NW9R*]*_
MX*"_\%M+71_V7?VB%^$/AOXLW+?#&UU'0!\3],\.13^&])\0P@K]G#2.99!'
M,5C:9;9H%9E)?RV$A /LK_AA#X48S_PC4N/7^V+[_P"/4T?L*?"=NGAN0\X_
MY#-[U_[_ %?-OP5_X+':1!X2\%^#9/!?Q<^+WC?0_AYX?\4?$75?"'A^.^M?
M"QOM.@N5>\_>0L\\RN\ZV]I%+(T88I&2I0?,G_!-?_@I)\;/C6O_  3/;Q5X
M\O\ 6/\ A>'_  M(^.=]E:H?$']D_:?[/W[(AL\G8N/*V;L?-NH _3#_ (8-
M^%/_ $+,W_@WOO\ X]2']A'X3JV#X;D!]/[8OO\ X]7A\O\ P7#^&L?BA;@>
M#OBJ_P +&\2'PBWQ67P\/^$+34OM)M-IN?-\XVWVK_1_M@A-OYI"^9U(P_\
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M_P#!O??_ !ZO7Z* /(/^&#?A3_T+,W_@WOO_ (]1_P ,&_"G_H69O_!O??\
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M7Z* /(/^&#?A3_T+,W_@WOO_ (]1_P ,&_"G_H69O_!O??\ QZO7Z* /(/\
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M_P#!O??_ !ZO7Z* /(/^&#?A3_T+,W_@WOO_ (]1_P ,&_"G_H69O_!O??\
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MA2ZU4>'?%7AC[+JE]I?V3Q!IQL+J7[+<R6_VA(R23;S>7YL4G_+2)T; W8K
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"R;P<NIS>))-8C;4;?73=[/[,^RJ3NB%N=_GKE"V5!KUQ?NT %%%% !1110
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M]^*WQ/T/X?ZC=Z3XKUOPOH]N]EH5U:-MNH0MU<03W[Q$.'33HKM@R%,;RJ,
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M=)Y@G #["J^7R-S]:X#X ?\ !%#4/V<O%.BZ)X=^/OQ$TWX'^$?$$GB/P_\
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MDVE^&]2\4QZ/<:5JFH10M/\ 8?M.FZA>+!<21)(T27'EB;RI%C+NI6JVH_\
M!57X6:!^R+JGQFU0^(=+\/V?B#4O"EEI4MFDFM:_J]G?W&GBPL;:*1_M$]Q/
M;OY**V2IW/Y:JY0 ^DZ*\-^ /[>GAOXX>./B%X7O_#?B[X>>)OA?9:5J/B'3
M?%"V4;V=MJ-K+<V\OFVMS<0X"P7"N/,#(T#9&TJS<1X)_P""OGPR\9?\$\-:
M_:2DT7Q]HOA/P^LB7V@:CI,<?B.&X\V.*WM3:I,R"6Y\^U>'=*%:.ZA=F16)
M !]4T5X7^UC_ ,%"O ?[%M[\.;7QQ!X@M[CXE:[!H=HMK;1S+I/F20PO>7K^
M8$BM8I[FUADD5G(>YCPK+N9=CXX_MF>&/V>/CA\+?!/B?3]?LU^+>I7&B:1X
M@$,(T2TU*. SQ6%S.TJM'<7*K(+= C>:\;J"&&* /7**\EC_ &P] U/]K_\
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MV1[8Q+C;'Y9&W:,# Q@8%3:KH%CKMK'#?6=K?0PS)<(EQ$LJI*C!T<!@<,K
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MXC^+'QXU:V\!MIO@2Y2^:.VG:2?56LIKY+<;UT>"\VO*L>)7CQCAJ]F^(/\
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M2QN_!EM<>+HM!>$VYTF'5S.(%B\@^4)9-/DG52V)%;8R '*_\%H/V9/!%[\
M)?B=!;:K'XQUCQAX-TN?5+#Q)J-NLUG<ZYIME-&L<-P(@LEK(\9*KDJY.=QW
M5T7_  4,U'PI_P $TO\ @GAXNT#X=ZMI?PYU+XGZU:>#]"U/7O$5T;?3M4UB
M2*P?4&N;AY7C6SM4EO3@A +)R0,L:]G_ &F?V(-.^.?[*&B?"?0]07P9H?AO
M4_#EWIQCM&OQ:V^C:C9W<5L%>5&8,EFL6]G)7=N(<C!O?&C]D:/XZ_M3?"?X
M@:UJC2:)\*H]8N+3PXUB'BO]1O[=+-;R:4R8VP6K7B+%Y9RUT7+ HHH ^<O^
M"77Q \ ?M/? [XQ?LZZEXRL_B=H_P@\52Z)97]CXLEU.75/#5XRZAHLC7]O(
M'9HH6-FQ64L&TYPQ&2M9/["?[$/PWNOV^OVE+>;3-?GM_A+XY\.GPG#-XJU:
M6+2!_8&F7Q 1KDK(INI))2L@8$N005PH^GI/V+['PQ^VGH_QA\)ZA;>&?^*4
MN/"GB70[;3C]G\2P_:$N+&9BDBI%-:2?:0KF*1GCNY4RHP:T_@!^RXWP4^/W
MQM\>'6VU(_&+7-.UK[ ;(0_V1]DTFTT[RO,\QO.W?9?,W;4QOVX;&X@'YJ?L
M-Q_!/Q[^SS+JWQ,^%?[2'COQE)XJ\4Q7NMZ+H'B_4K*\CB\0:C' D4UDWD,(
MX$BBPGW3$5/*FO>OV]/A9K_@?X[>#]:UCX6_&OXQ?LXZ1X$@T:T\)_#W7KB.
M_P!!UB.[51=7FG?:[>?43);/;Q1RF60VWV>X9T^?S!Z5^SM^PY\?_P!E#X9M
MX)\#_'#X5KX7M=8U;5;&/6OA+?7M]#_:&I76H21O-%K\*2;9+IU#")/E5<C/
M)Z3QE^P_\0+;XU)\4OA_\5K'P7\0=<T&PT3QI!=^$?[5\+^+6M(Y5BNVL!=P
MW-M.AGDV-%?'"!(W\T+E@"Y_P2Z\=>%_&7P1\26_@[X@>,/'F@:'XIO;*T@\
M7:=?6>O^$8V$5PNC79O@+R;[.)\Q2W WF"6%2S[-[?2U>(_L=_L@?\,VZEXX
M\4:]XCN_''Q,^*%_;:GXO\2S646G1ZC+;6L=I;Q6]G$3';V\,$:HB;I)",M)
M-*Y+5[=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 V10\;!N5(P17RC^PSXEO=5_;;_;*L[S
M4+VZM=,\=Z+#9PS7#R1V<;>&-*D98U)(12[.Q"X&22:^KI,^6V.N.*^;/%O[
M%OC/PI^T?XP^)WPA^)%EX(UCXC16*^)]%\1^&#XC\/W\]G$((KZ*&*[LKB"\
M\A8H&=;DQ/''\T+.(Y(P#\[/VR=1^('Q#MO%'A?PA\2?%'@/Q%K?[<]EX<TK
M7K2XEF;1TD\*6[HOE>8@EMUF^=K<L$;)XYS7T'XC_;:U[]I;_AE>'7X+CP7\
M4?"/Q\B\'?$KPW:2R0Q6.I0^'M9D=$^8F6QN (KFW8LZR1.AW,RMCUF7_@D;
M8GP=\-['_A/O$6H:]X2^-$/QL\0^(M7L+>XOO&.IK%<0O%*D'DPVR^5+#$AB
M3;'':QJL9Y(W_P!I?_@E7X5^.?[=7PB^/VEZI=>%?%WPYU,7>LP6EMYEMXSA
MCMIX+9+H>8@6>V^T2B*XP[+'-+&592AC /./V,/@#X9_:_\ $O[4VF?$:+6/
M$=CX8_:!U<:5&=<OK7[$G]B:-B-#!,A\L;W(C)V L2 #S7S'^Q7\'='TS_@V
MO\9?&V.X\2O\5-2^$'C(7'B&?Q)J-Q<,4.H*CA9)VC5U$$0#JH8;!@CFOTL_
M9'_93/[,/B#XQ7_]NMK7_"V/B#=^.MC6/V7^R_/LK&U^RY\Q_-V_8MWF83/F
M8V#;N;ROX1_\$P_^%3?\$B]1_92C\:37T6H>$-:\*_\ "4MHXC9#J)NB9_LG
MG$'RS=$;/.&[8/F&25 /&?V2? W[/>JZQ\,YK+X-_M&6/BM3IM[!J^J>'O&-
MOI<%[&L<JSS3SO\ 9A$)%W%I,QL.N0<')_X)U_L;> /VP;K]IG7_ (C6GB;Q
M%K%C\??&VB6MR/%VKV3V=G#>JL,,/V>YC$8C#$)L"E>-I'%?4GPJ^!G[1_P^
M_P"$5TW4/C)\(=7\-:";2UN[6T^$U]9WM[9PA4>-+A]?D2*5XU($GDN%9@WE
ML!M/GGPJ_P"">7QN_9YU#XJ6?P[^/'@WP_X=^*'C[6_'<@O/A@^HZQH\VJ3B
M62."Z?5EMF,04>6\MHZ[N6C<?( #9_X)#_%/Q!XA^%_Q4\#^)_$6O>+KKX'_
M !/USX>6?B#7+O[7JNMV-N+:[M9;J3&7FCAO4@:0Y,GV<.WS,0/FOX]^$;[X
M9_M"_%J;]HCP+^T]XLL?$_B>\O\ P)\3/AOJ>J7VE>"=%:TMUMHH;#3KL3Z;
M<6T@"O(+20W,V^9F9,B/[N_8K_9!T?\ 8L^"</@O2=8\0^)'DU*^UW5=<UV=
M)M3UW4KVZDN;J[N&1$0L\CG 51A54<D%F\JTK]@CXI?!/5?%6F_!SXZ+X*\#
M^+-8O=:&B:[X*A\1/X6N+R=[BY.CS_:;=8%>:6641745W$CN-L>T,K@'SO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **:)58\,IXSP:7<* %HI-PHW"@!:*3<*-PH 6BD
MW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<
M* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %H
MI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PH
MW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!
M:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<
M*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH
M 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BD
MW"C<* %HI-PHW"@!:*3<*-PH 6BBB@ HHHH **** /*/COX4^*GB+5M/;X>^
M(]'T*SAA<7:7T:LTLA;(*[K:7@#W'T/6N$_X5?\ M+?]%"\)?]^8O_D"NI_;
M1_;?\._L16WPOD\1:7K6J#XK?$'2OASIHTY(F^R7NH>=Y4TWF.O[E?);<5W-
MR,*>:]HW8 W<9H ^;O\ A5_[2W_10O"7_?F+_P"0*/\ A5_[2W_10O"7_?F+
M_P"0*^CX[B.4-MD1MK%3@YP1U'U%,ENP2RQ,LDBL%91\Q3/J* /G/_A5_P"T
MM_T4+PE_WYB_^0*/^%7_ +2W_10O"7_?F+_Y KT+]E3]KGP7^V=\/[OQ9\/]
M3;6_#-OJMWHR7WV5[=9Y[63RI2BOA_+$@=0S*N[:2 05+>4^$_\ @KA\,O%/
M_!3?QI^RC*NI:-\2?"5A;:A;RZ@88[#Q );*"]>&T82%VFC@G5RC("5BF896
M,F@#4_X5?^TM_P!%"\)?]^8O_D"C_A5_[2W_ $4+PE_WYB_^0*Z+]DO]NC0/
MVOOB!\7?#^AZ/K6EW'P;\8W'@O59;\1!+VZA0.98-CL?*((QO"MSR!@U[4;^
M 6_G>=#Y/]_>-O7'7Z\4 ?.?_"K_ -I;_HH7A+_OS%_\@4?\*O\ VEO^BA>$
MO^_,7_R!7T>;F,%_WB?N^7^;[O&>?3BC[1'Y>[S$V[=V<\8]?I0!\X?\*O\
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M%'_"K_VEO^BA>$O^_,7_ ,@5])44 ?-O_"K_ -I;_HH7A+_OS%_\@4?\*O\
MVEO^BA>$O^_,7_R!7TE10!\V_P#"K_VEO^BA>$O^_,7_ ,@4?\*O_:6_Z*%X
M2_[\Q?\ R!7TE10!\V_\*O\ VEO^BA>$O^_,7_R!1_PJ_P#:6_Z*%X2_[\Q?
M_(%?25% 'S;_ ,*O_:6_Z*%X2_[\Q?\ R!1_PJ_]I;_HH7A+_OS%_P#(%?25
M% 'S;_PJ_P#:6_Z*%X2_[\Q?_(%'_"K_ -I;_HH7A+_OS%_\@5])44 ?-O\
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M%'_"K_VEO^BA>$O^_,7_ ,@5])44 ?-O_"K_ -I;_HH7A+_OS%_\@4?\*O\
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M0\,K+#<1HT,R&_Y5T;*LI7((88(!R,$BOT3>+?(&W$8["F75G]I[J/JN<>M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME%-EE\K'RLV?[HIL,XF_A9>^"* )**** "BBB@ HHHH **** "BBB@ HHHH
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M/![>'_A=XIN/%YL8$FU?QO)I-M>VULLM[)\UO%/+9^=<B-#),LC1>8JL[/\
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M4* 2\5NP5LN:_0_2_ >C^'KV:\TW1M+L;Z1#&9[>UCAD=20=K,HR5W<X/'%
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MG6- MO"^B67B73M)A-M<>'["YG=4N+:1WS<22,6W8!;'%?1'Q2_:9MOV9_\
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MM^-WBSXA^%/&VJSZA/=:)X<6UT&^AFM=*M%2.\FMHEAB?YV65GGN9I#@,$4
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MOX?(^OZQJBWU^=.E1/M++!;-&F]74[03@YKK_C#^V+\5/ ?Q?^%OP?T?PO\
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MWZ?2GT4 1+9QA<=>,>G\J0V*';RWRG/;DXQSQZ5-10!'! MNN%YZ=AS4E%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !4<UJL[AFSPI7'8@]:DHH A%C&/4Y.3GO_G_ #U-
M/D@65E)ZKTI]% #8X5B+$=6/-1_84VXR_3 .[D5-10!#)91R(R_,-PP2#SBD
M?3HW$G+?O!AL'\S]34]%  .!4;6BM)N^;/7KW]?TJ2B@"-[=7A\L_='2A;=5
MDW#=USC/!-244 12V:RON.<Y!XQ2?V?'GH>%*@=0 >O%344 1"S0>O7-(+",
M>OZ<\YJ:B@!L47DIM'KFG444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >5_'G]K?P]^SKJ^GV>NV>KW4FI0O-$;*.%E4*VTAO,E
M0Y^@(]ZX/_AZ#X!_Z!7BS_OQ:?\ R17T-<36^FB-I[B.'S&$2>8P7<S'@#U)
M]/:K'ET ?./_  ]!\ _] KQ9_P!^+3_Y(H_X>@^ ?^@5XL_[\6G_ ,D5]&*5
M9RH92R]0#R*-R[]N]=WIGF@#YS_X>@^ ?^@5XL_[\6G_ ,D4?\/0? /_ $"O
M%G_?BT_^2*^C?EW[=PW8SCOBHTNH9+B2%9HFEAQO0,-R9Y&1VSVH ^=O^'H/
M@'_H%>+/^_%I_P#)%'_#T'P#_P! KQ9_WXM/_DBOHB&^M[EI!'<0R&%MD@5P
M?+;T/H?8U)E=F[<NWUSQ0!\Y_P##T'P#_P! KQ9_WXM/_DBC_AZ#X!_Z!7BS
M_OQ:?_)%?1@=#G]XOR]>>E.VC&=U 'SC_P /0? /_0*\6?\ ?BT_^2*/^'H/
M@'_H%>+/^_%I_P#)%?1P7<.#4-[>V^FQ>9<7$-O'D#=(X49/3DT ?.__  ]!
M\ _] KQ9_P!^+3_Y(H_X>@^ ?^@5XL_[\6G_ ,D5]!6NOZ??9\G4+.;:AD.R
M96PHZG@]/>K$5S#/"DD<T;QR#<C*P*L/4'O0!\Z_\/0? /\ T"O%G_?BT_\
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M  ]!\ _] KQ9_P!^+3_Y(H_X>@^ ?^@5XL_[\6G_ ,D5]&2;8D+,RJJC))X
MJO#K%E<6KS1WEK)#'G?(LJE4QC.3G ZC\Z /GO\ X>@^ ?\ H%>+/^_%I_\
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M?_)%'_#T'P#_ - KQ9_WXM/_ )(KZ(N+RWM'C66XAC:9_+C#N%,C>@]3["I
M5)^\OIUH ^<_^'H/@'_H%>+/^_%I_P#)%'_#T'P#_P! KQ9_WXM/_DBOHSY<
M?>6C>F[;YB[L9QF@#YS_ .'H/@'_ *!7BS_OQ:?_ "11_P /0? /_0*\6?\
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M%I_\D4?\/0? /_0*\6?]^+3_ .2*^CO+H\N@#YQ_X>@^ ?\ H%>+/^_%I_\
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M^ ?^@5XL_P"_%I_\D4?\/0? /_0*\6?]^+3_ .2*^CO+H\N@#YQ_X>@^ ?\
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MPA?6/A>S\)7?A73-:QX9UFSLK1[.S-U;2(\DCP0L@CQ*JJT*/M+&0R 'Q/\
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M;M\LQOB>0%C\FSR?6_\ @W1^$>J^&+[P[#\1/C=I_@V/Q,WC'PYX7M_$5O\
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MQ\WB7Q%>>(1<>+]7_M*?2A<;,6%JVQ?*LXMG[N+G9O?DYX /2**** "BBB@
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MH\,S?%S7M!M_ LW@J_T3X?>)[#1M;TR1K\7JW<"Z@\5M/%/A8YU\Z)Q]EMV
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1M&,8HKR;X7?MS_"7XW?&[Q/\ #7PAX^\,
M^(O'W@S[0-;T*RNP]YIA@G6WF\U,?+LF94/7#,!0!ZSCBC%>6?LY?MM_"?\
M:[U;Q+8_#/Q[X=\;77@Z2*'6X]+N?.;3'E:58UE&/E+&"8#_ *YM7?\ C;QI
MI?PY\'ZIX@UR^MM+T70[.;4-0O;A]D-G;PQM)+*Y[*J*S$]@#0!J8Q1BO+?
M?[:WPJ^*'BCPAHOA[QUX=UC5O'VBOXC\/6MM<[I=7TY"0UU",?-&""">.AK>
M^ _[0G@[]ISX9:9XS\ Z_IWBKPGK+3+8ZMI\OF6MUY4KPR;&XSMDC=#QU4T
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M$TK>5&46,5N?\%'_ -N/]HCP!^UA\5]:T/QI\1;#X'^!=$MG\.ZU\'M*\/\
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M/##::$ES]J2QCM%<6RJLO(81AP %#!0%KU0# H **** "BBB@ HHHH ****
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M$E\!PZE!=3QQP:&ET+M+)+4/]F51, P<1AP!M#!?E !Z?1110 4444 %%%%
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M>GP-I%W?2SV.B?:49UN#;0N%+J[(K,T:,\<:.P!S7Q8_X*.>*/"G_!3SX1_
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M<A@^&7@37]?:34M*\06JW-T=7M8A>.NEVTMXUB8K=KA/FM&=XX$*JP!]!_\
M#>GBZW_X*IQ_")M#T_\ X57-;?\ ",1ZS]EN9-1'C(:7_;IMFF#_ &=;3^Q@
MS[&43&89SL*FO0_V#OVD_$G[4_A[X@>)-8L=#L?#^G^/]>\,^$6TVX-PVI:5
MI5V=/-Y.^]@TDUW;W;C8J 1F(8;'F/\ )>G_ +,7Q.7_ ()MVOQ*F\%WEO\
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M2.#XL7KQ++<V2,UZTUAI*MM66$.\\YD>+SD2(O<==XOG\7? 7]L?2_CUX?\
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MAY)>Q74G@C2I(X8DMW$+R06S3R12W?V.W=H;;[7Y:G(90 8W[87_  4B\4?
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M (1YO!/PU\8Q^#-"GL@[WEW<V]A;3ZB]Q)YA0[+BZ\A42-"AMY S.3\OQO\
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M/;Z3<7(W:?I$41<2W&H7*[76)0$5)H2\@,BBO$?V7OV?_P#A;7_!"[Q%\/\
MQUHFK67A>/2]>A\*&ZTF/0=:&B6E[<SZ#?SP10Q);7ZQPVMRI6,?.J2,N]FS
MUO[!OBZS_9!_X(S^#?B[#X2\9?$#7O%7AFT^)OBZ#P_:PWOB'Q1J^KQPWFHW
M:H3$LKAIF8)D%8;=8U#;$4@'K7[,G[=\OQF^/6I?"_QA\-_&GPG\>6OAV+Q=
M8:7X@N;&\76-)DF^SM/#-9SS()()]L<\,FUXVFA(+J^ZOHBOSM_8_P!=\'^/
M_P#@KE?^,O@9XN\0?$KPCXD\#7X^(^JZM<3ZK9^&[[[=;7.E:;:7MQ&9[2X
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MMX>MK?[-#HET;6,RVJ1?\LEC?<@C_@"A>U>)?\%X6V_\$=_VA\_]"==?^RT
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MOBF73C_;UA 8#+'MM[F5H+Z.*Y@E>UE&Y(WR22K*/J8=*_-7X0_%?P;\>?\
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M %F.)85VJ*&B5GW<Y'N:=10 UX@[9^;\&(H\H9_B_P"^C3J* &0P+ N$7:,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P .P_ FW/\ ;GBO'KYMI_\ (] 'TE17S;_P["\"X_Y#?BS_ +^VG_R/0/\
M@F)X#./^)YXJYX'[ZTY_\EZ /I*BOF[_ (=@>!?^@UXL_P"_MI_\CTV3_@F-
MX#B'S:YXJ7ZS6@_]MZ /I.BOFW_AV)X#_P"@YXJ]/]=:?_(]+_P[ \"_]!KQ
M9_W]M/\ Y'H ^D:*^;O^'8'@7_H->+/^_MI_\CT?\.P/ O\ T&O%G_?VT_\
MD>@#Z1HKYN_X=@>!?^@UXL_[^VG_ ,CT?\.P/ O_ $&O%G_?VT_^1Z /I&BO
MF[_AV!X%_P"@UXL_[^VG_P CT?\ #L#P+_T&O%G_ ']M/_D>@#Z1HKYN_P"'
M8'@7_H->+/\ O[:?_(]'_#L#P+_T&O%G_?VT_P#D>@#Z1HKYN_X=@>!?^@UX
ML_[^VG_R/1_P[ \"_P#0:\6?]_;3_P"1Z /I&BOF[_AV!X%_Z#7BS_O[:?\
MR/1_P[ \"_\ 0:\6?]_;3_Y'H ^D:*^;O^'8'@7_ *#7BS_O[:?_ "/1_P .
MP/ O_0:\6?\ ?VT_^1Z /I&BOF[_ (=@>!?^@UXL_P"_MI_\CT?\.P/ O_0:
M\6?]_;3_ .1Z /I&BOF[_AV!X%_Z#7BS_O[:?_(]'_#L#P+_ -!KQ9_W]M/_
M )'H ^D:*^;O^'8'@7_H->+/^_MI_P#(]'_#L#P+_P!!KQ9_W]M/_D>@#Z1H
MKYN_X=@>!?\ H->+/^_MI_\ (]'_  [ \"_]!KQ9_P!_;3_Y'H ^D:*^;O\
MAV!X%_Z#7BS_ +^VG_R/1_P[ \"_]!KQ9_W]M/\ Y'H ^D:*^;O^'8'@7_H-
M>+/^_MI_\CT?\.P/ O\ T&O%G_?VT_\ D>@#Z1HKYN_X=@>!?^@UXL_[^VG_
M ,CT?\.P/ O_ $&O%G_?VT_^1Z /I&BOF[_AV!X%_P"@UXL_[^VG_P CT?\
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M_P .P/ O_0:\6?\ ?VT_^1Z /I&BOF[_ (=@>!?^@UXL_P"_MI_\CT?\.P/
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MO@'P?X[^#O@'P_XF-UXQTC6/BC9^+_A^-+_?AX]"LY8WU**YFCF9/.D,1C.
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MOV,_$?BKP*UAI/PG^!UWX1U^\DO[*?\ L369&8"%525G9BA8>9$&3#D;^2*
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MV=/!M_JO@Z+28,QK+NF(N<J3;[Q\F2P7#$ ^T_@'_P %9?V?_P!J#XR0^ ?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU#66N/)_M.!(RKW\KQVF3-'Y:]0#]1J;-+Y,>[KR!^9Q7YM?L/?&#QU\,_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDVMM"L,*9/7"(HSWQ70T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI\1+*+4K?3%U"XT>%&C^TVKQW%Q#'>I)NQ!<* CQX<'!6O/)O^"+GQ&\&O\
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MW["OQTUCX(^%?BY;Z7X-EDT#3_BWINFVTGA^/5X+J-95A+2M/);Y#P_:Q;F
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M0KK>E_%?3-'O_#_Q$\-1>=!*8/+TUX+'49E$"HEW<D2*&D*JA93& ?37Q?\
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MB#3(8[G5;'1M#U#7)M @D7?'/J L8)A80L@+B2Z\I"BLP.U21V?BS]I3X?\
M@3X)K\2M9\:>&--^'LEG;:A'XEN-2A729;>Y,8MI4N-WENLQEB$94G>9$"Y+
M+GXZT'P'X\U?]J;X[>,OV5/B]X%76)]?AL/B#\//B#X/OA:6WB"ULH(5N8;R
M-H+RWAN+2&T5'$5S;.IDFB+Y"#RWX6?%70OB7\5OV*[[5/!OA?X:_#CP?XY\
M>>$KG1-.N#<>%;;QI:O)8Z9+97!BBCD69EU8VA=5S+<B- TP0T ?>GP#_;C^
M&/[3'B6_T'PCXAN)/$NEVPOKK0-7TF]T+6H;8OY8N38W\4%SY!?Y!,(_++?+
MNSQ6I^S3^UK\.OVQ/ARWBWX9^*=/\7>'X]0N-)FN;4/&UK=V[[)8)8I LD3J
M2K;74$HZ.,HZ,W@O_!1T-J7[47[(\/AA=)_X6/;_ !,:ZMS<Q3/=0>'%TR\3
M7''E?.L#1O:1EF_<_:)+/?\ PU\'_P#!)^+4/^"?/[&?PW_:;T6WU2^^&'C#
M4?$.D_&C2K*&6Y_LV*'Q)J45GXKC@0,V;.)!!=^6"3:[7VDP$T ?KY^SU^T)
MX/\ VJO@UH/Q \ ZPOB#P?XHMOM>F:@+::V^U1;V3=Y<RI(OS(PPZJ>*\*TC
M_@M1^SIKGAQ-=M_%?BX^%VE:)O$<GP\\1Q:!$%F,#R2:DU@+2.%)597E>41H
M4;<P"DCFO^#>EMW_  1D_9_]?^$</;_IZN*^8_\ @DCX<_:%^+O_  1=\,^!
M/!'A;X+VO@_Q3:^)-%A\2:[XOU*34+6"YUG48IYWTJ/2_*D>/?+LB^W*LFQ"
MTB!BJ@'Z/?M"?MC_  Q_93^&^G^,/B'XQTGPOX7U;4;32K+4KEF>WNKBZ/[A
M4,8;*E0SE_N)&CR.RHC,)_VF?VK_  '^Q]X(TWQ%\0-7N])TS6-7MM!L/LFD
MWFJ7-]?W)806T5O:12S222%2%54.3@=2 ?SN^/'P9M?&WQF\!_LPZ'X#^)GQ
MK^&O[,WPD_L'Q)#X>U'1+&9-7UC2#HNFS72ZA?6:221Z/'J<@$#'RWU"%LCC
M;P_Q?_:"\=?'S_@FG^RWI?B%8])^.GPQ_:,\&> ?%5MKTGVW[)X@TZ^:%;BZ
M\AP)8YT^S71,3[72X^21AB0@'Z,_";_@I+\'_C/\5M*\#:7KVOZ7XN\017$V
MD:7XF\):QX9GUH6Z"2X%H-2M;<7+Q1D2.D)=D0AF 4YK?7]N#X5C]GCQ!\6)
MO&.GV?P[\*W&HVFJZW>12VD-G+874EG=(5E179EN(GB4*I\QMHCW[UW?&?Q&
MU7XH^._^"FWP'^'/[2FM?#_0_#.E:M+X]^'%[X0TVZAM?'&N65E/;2Z==37%
MXTMC/:K>M.D0BDBO(R1YJ-&T)^4O@OX7\>>#_ ?A?XV_%BWT?Q=^RO\ "OXS
M>+_.\(Z=:RRW&D--X@U(+XNU!&D5+G[%?2"/R-CK#;;KA5WAR #]??V?/VS_
M (=?M2:GX@L/!>LWUYJ?A2.QFUC3]1T6^T>^TZ*]@^T6DLEO>PPR^7-$&97"
ME24<9W(P&#X2_P""D7P3\<_L<7O[06F>.K*;X/:=;75U<>(Y+2Y@CC2VF>"4
M>1)&MPS^:A146,M(Q4(&WKGXT_X*;_$N[^!'QT\0Z]\/;[2;BX_:_P#A1;>
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M%?$GCW1/#\VL^+/"^J^)]0CT;2F\6>!->\+VNI7TF[R;**YU*RMX'N9-K>7
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M^UNA*T<9@GN$D#S0IMW2QAO2O#?QY\*>+OC/XF^'NGZI]H\8>#;"PU36=/\
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M'C?1[^SN[6P:6+X?^(+^PFN+H1FWAAO+:RDMII)#(B*D4C,9"8\;U91^;O\
MP4EMVUKP]_P5B\06;07>BS>&_ FBI=P3)+']MM+25KJW.TDK)$+B'<K $%P.
MH./NK_@LB-GP"^%^WC_B]7@$\>O_  D5E0!U&L_\%8_@IX?BT 7FH?$2&^\4
M&^_LO3/^%8^)VU2Z2R^S_:9?L0T\W*PI]K@'FM&(V+D*S%7"^B_L^?M:^#OV
MGGU9?"D?C2,Z)Y/VK^W_  7K/AS/G>9L\K^T;6W\[_5/N\K?L^7=MWKN^8OV
MY+?Q_>?\%;?V=8_AK?>#[#Q)_P (!XV)E\36-U>V(@^TZ#N 2WFB<.3MP2V
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MX0?#WX^?#>*V\>:;I.K>'[&]M=<MKBYG^S_V?=6[B2WO(+A&5X)4;!66-U8
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M#_A+=)AU:ZT5;;4[NSBT> 31YMHK2.%8?*C6/,BR.RB1W->(7?B34[GP_P#
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M>^''@+PS^S%'X)\*V_ANS^'MGH+Z/96__'SI,%@(FB*,?, >%4R&'F E0PW
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M?:Q>:X--\&6>M_"/Q'J"!;GQ1X;AOK*-].F=46.34-,/EH^W#2V\D$NQ<2$
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MK?[0-[>ZAXHAN/VC_"-IX,\31VUU;A+"RMK*^M$>RS ?+E,=_.2TOFJ71,*
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M-(A\/3^*?%=U:S7RZ;%(TT=K#':06]M!&9&#N(H4:5T5Y#(PWGW"B@ HHHH
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M'_!0OXZ?#34/VCOCY-X:^%VD>$=4TI5OM'6XGDU)=2:Y2=_[.P\?^AQ;0 I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ;*"T;8ZX.*^69/V>/B]^S[^U-\2_B%\*;7X<^+]"^+KZ??ZUX;\4:K>
M^'IM.U2UM([,W=O?V]I?;XI+>W@1K=[=<.N]95Y23ZHHH _/_4?^"47Q"O\
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MY4)=RD,4*0VZ!F)*0+P@PB\&GP<_:<^%MOXW\*Z3-\(_C%X*U[5;R]\.WGQ
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MWA[^Q/%GPQUGQ!?2>&+N07)FCO;#5([,3V]XBO(C2O8.LT9C0QH8UD7Z:HH
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M[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4
M?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_
M  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_
M *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[
M^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\
M+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)
MSX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_
M\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%
M?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC
M]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)S
MX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\
MF4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:
M0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_
M[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4
M?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_
M  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_
M *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[
M^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\
M+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)
MSX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_
M\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%
M?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC
M]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)S
MX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\
MF4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:
M0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_
M[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4
M?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_
M  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_
M *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[
M^I_\F4?\+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\
M+8_:0_Z)SX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)
MSX9_[^I_\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F4?\+8_:0_Z)SX9_[^I_
M\F4 ?25%?-O_  MC]I#_ *)SX9_[^I_\F5H^$?B=^T!?>+M)@U?P#X>M-)FO
M8([Z>.1-\%N9%$KK_I;<JA8CY3R.AZ4 ?0-%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 44C@E#MX;L?2OC3P]\9?VF/VGO@A<?&
M#X0ZI\++/0;[[5=^#O!?B#0;F:X\3Z?%-)';S76II>QBTENXD$R1BV(@,L:2
M[B)  #[,HKY4_;"_;+^)7P7\=?"?2?#7PYU"/0_%OBKP[I_B?Q+K%S9_8M&A
MU+4ELWTV&**<S3WX)Y=5^SQ(ROYDC%8S2_;9^,WQZ^#ND?$SQUI.L_"_X>_#
M?X6:)'J]D_B6TDU*?QO+';M<7,4DT=S"-,@W>7:H_ESRM*SR!=HCCD /KBBO
MDK]IO]MKXF?#/Q;\%;'0/AKJ%CHOCC7_  W;>*-?UF>W%KHD>I77D/I<4(D%
MQ+J"GEF,20Q1E6+L[".J?[2G[4WQ:T[Q=\9M4^&^K> X/#?[.NC0WVN:3K6B
MW5U=^*M0.GR:G/8K<K/$ME&+%[$QSI%<_O;E]RD0F-P#[!HKXE^)/[9/Q4\7
MZW\9O&7P[\4?#+1/AS\"=.MKV33?$NDW,EUXP630[?6Y;B:[%Q#_ &7:FWNH
M88I?)F*S0W3R(ZH(JWOB9^WSXTN?B[^S=:^#?!-]#\./C%J=C)J7BO6'MT58
M+W2;^^@T^VMDE:7[4/LR/+*RB*-0$!E:3,8!]>45\K_MY_MVZY\!/B-\._!/
M@/2[?6?$&K^*O"P\77%S&YM?#/A_4_$-GH_FLP&W[7<S7#QVT;$;DM[R49%L
M5;MO^"B/QN\3_ +]D_4O$O@N^TG2_$DNLZ!H]G>ZG9&^M+(:CK5AI\DSPK+$
M9-D=T[A?,4$J,D"@#W*BOC'Q#^T5\5?V1/CW\/K#XG?%KX4^.O _C1=:;69+
M/PS)X>U+PM::;I5SJ,FK<7UTDMBA@CM[AG5!')?6F'!?8WJ/PK_X*!^%O''C
M2\TC7]!\>?#:3^P;OQ1IL_C325TF#6](M&A%S?PYD9XEB%S;-)#=+!<1B=2\
M*_,% /?:*^0]-_X+*_"]O$WA>VUS1_B1X+T/QU:7>L^&O$GB+P\;/1M9TFUT
MN]U6XU))O,)B@CM+,L8[A(K@?:+<^1M9V3TCX,?MPZ5\7/B=;>$;[PC\1OA_
MK&L6D^I: /&&@G34\2V<)C$DUMAW:.15FB=K6Z$%VJ,2T"^7+L /=**XG0/B
MGJ'C3]GVU\9:1X4\10ZKJ6BC5;+PWKD8TG5//:'S([*Y#DBWE+8C;<2$))/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>noticeofarts_page3.jpg
<TEXT>
begin 644 noticeofarts_page3.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X0 B17AI9@  34T *@    @  0$2  ,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **Y7XJ_'+P?\#8_#[^,/$FC
M^&U\5ZU;>'-'.H7*P_VEJ5QN\BTBS]Z:38^U1R=IKJ@<B@ HHILLHA7)SUQP
M* '451TCQ-I^ORW4=C>6MXUE,UM<"&59#!*H!:-\'Y7 9<J<$;AD<BN8\/\
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M%% !1110 4444 %%%% !1110 4444 %%%% 'Y\_\'!*EM*_8U&"W_&4G@G(
MSGB_KZP_;@^,\?[/7[(_Q"\9-XNT'P!_PC^B7%Q'XBUNUDNK#1Y"NR.=X(P9
M+@J[+M@C!>9]D:@EQ4?[8G[$_P +_P!NOX?:/X;^*WA^X\1:+X=UN#Q'IL=O
MJ]]I<UGJ$,<L<5PDUG-%*&5)Y0!NQE@<9"D>?_"__@D/^SW\*K7Q39Z5X/UN
M^L?&>A3^'-:LM<\8ZYKEG?6$[1O)&8;Z\FC5BT2$2(HD7!VL QR ?$O[&O\
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M_M#QM\)6U%O"FH_;;B'^RCJ$"V]W^ZCD6*7S(D5?WJ/MQE=I)-<CXE_X)N?
M_P 8?M)>(/B]J7P\TFZ^(7BSPW+X1US5#-.JZSIDL8BD@N;=9!!,6B58S))&
MTGEHB;]J*  ?G;^Q/_P4-^/5S_P4&_9=\-:Y\0/B/X\^'/[0VF:[<W%]XO\
M ^B>'+#518Z0;^"]T.*T?[=':L98AF]C3S%VE#)E_+\C^%/[?W[8,G_!-'X!
M?M#O^T)9ZKK'CSXIQ> QX>U+P5IS:5=VL^H7EKYUZ\*1W#R*\ (^SR0@1!%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 445\??LN?\%J?A;^UO\
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M]NKJ.*UBN+LI]JG6)5DGVJ53>P +8!P-V>#CO56+X>:':VUO&FE:5'':I)%
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M'B/Q)IO[<$>OZWI)L'US4H-6ATT7 DL[&RM$D\N70C:Y<_+);^4Q<O@1,O\
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MX6/X?TW4O$$2>&?BKHNI7$UG9>-=%5#]GNR(H91)J=D^%A>5%WP/+ TL<9&
M#@_V3_!WQ8_;^_9KT/XX:U\<O'7PPOOB-;'Q%X3\.>#H-*DTCPCIMP@^QPW
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MC4K:WB\2Z'+IL!M;BSN9((4M[L13R6EQ#<NB3'S)$E$Q02GTKQ]\:/%FG_\
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MO((Y/,C0B98Y5#JH90W1F'->[T %%%&: "BBB@ HHHH **** "BBB@ HHHH
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M8[C5-.M;VX$65CC:2)7?;DG"C<>&)X'>OCK_ ()O_MS^._VV;'PAK&K?%O\
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MN8P3"T94_0G[&K?%>]^%$VH_&6/PW8^,-9U.\U&'1]&?SX_#>G2S,]GILUR
MJW=Q!"522=$1';.T. )9 #YK\2_MU_&[X4?&WP#_ ,)]X9^'>AZ'\4/B&/!V
MB_#RWD>Z\=66ERS/%!KL]Q#=2VDB 0M<7%O%!LAMWS]K:16CJU^RI\>?VC?V
MTM2^,5]H?C/X*^#=#^'_ ,4O$?@#3[+4/ASJVM75S;Z9=F&*XFN$UZV1I'0K
MN"PJN5)'& /.?V@OA)\8?VQ]2\)>'_%7[/\ I?@OXW^'?&FG7MG\:=';3GT;
MP_H6G:PUVES:SO.^HRRSVAFMQI\D(4R74TDOE1,6&1\%O^"'7P^_:2^&W[3%
MG\:OA?I^B^+OB#\8O%^K>'O%T5M OB"#3+F]$]A=VUVNY@G\8BD.UEWJZ%68
M$ [OX6?\%1/B%^TEX'^#7A?PCX=\!V'Q.^*6M^*]+N]>>>XUCP;I]EX;O!:Z
MAJMCY;VUQJ4-P[P"VC62+)F;?*/)9G^C/V+OVF=8^,_B7XE^"?&5KX<L_B)\
M']>BT'7ET.X=[*_CN-/M+^UOX8I/WMO'/%<X,,C2&.2"5?,D"[S\JK\,/BAX
MX_9:^%.@_$[X$:O=:U\%_$-[I.L7/PWUH>%]:V0V<UO:^(?#;VEQ9QBUO$D=
M+BS\R%U6Y<+"?+16]L_X)8?LBW7[/FI_&3QSJWA6\\$ZQ\8_%JZO#HM]KDFL
M:E8Z;:V5O9VIO[@S3(]_.T=S=S%)9<->[3*Y0$ 'UQ1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5X/X^_;VT;1OC)KWP[\$^!_'WQ<\<>$4@F\2:9X4@L(8_#JW$:RP"
MYO-2NK.S\V5&5E@CG>?8=YC"?-7O%?GY^QW^TUX#_83_ &E?VG_A_P#&KX@Z
M+X+\4>(/B7?_ !#T>]\77T>CV^OZ#?VEF+:2TN+F01W"6GV:6S94<F,6B@J@
MPH /H_P/_P %$_AC\0_V3?%WQFT_4-4C\(^ 8-5D\36]YILUIJWA^;3$D:^L
M[JRE59H;J+RR#"RACN0C(=29OAS^W?X3^)O[&6H?&ZQT?Q59^'=)TK5M2OM(
MO[&.VUJRDTM[B*^LY(&D\M;F*:UFB*^9L+J,/M.ZOC3]L']IZX_X*'_#'X:?
M"'X?_#];.S^-7Q O=3MXO%*2:;H?C?PGH,D.K7.I&2."2=++4IFL(%+0;YEN
M9F&^(B5\"2_\=?LN:K^V9\,?B9H_@OP[;_'#X>^(/BWX3A\+ZC/?Z;%>)IIL
MM>@,L\%NZRM-]CO"OD@$WDQWNV[: ?9/PG_X*C_"OX[?\$]=5_:6\*3:MK7P
M_P!#\-ZCXCU&SCMXUU>S%A;R3W=B\#.$6Z3RF7:9!&Q*,LC1NDC2_M.?\%-/
MAW^R/^RMX7^+WBS3_%;>'?& M9+*RTW3EO-2"S64NH2/)&K[ MO96]S<3,)"
M EM)MWML5_S%^-/P^\0_L5_\$:[+XP>"]+O-:^'/QN_9LTWPM\3M$LI$,FF:
MM/X72RTOQ+!$S*&#23PVEYL.[RC%/M?R6->U>$=/\7?MG_'SX?Z)X-\*_#OQ
MIX?_ &=/@YI6BZSI_C76+S3[&35?$^DQ&<Q"WLKD3-'I$*QDR#:$U:0 9W9
M/O3]J[]M+2?V5-#\!W3>$_%GCR^^)7B:W\*:#IWAEM/^T75Y-:7=W&2][=6T
M"1&*SE^8R]2HQR<8'@;_ (*%Z/J7[07AOX6^.OAU\2/A#XR\<6]Q/X7M?%4.
MF7%MXE^S1M+=1V]SI=[>VZRPQ)O:*:2-RC*5#"OST\'?&J[^#?[//[*OPO\
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M3P.ROAE9HY$)5N03@T =,(U5<!5 ],4I4'L*6B@!-BC^$=<]*38O]U?RIU%
M#?+7'W5_*G%=PY&:** $"A1P .,=*4#%%%  %"]!B@C-%% !BDV+_='Y4M%
M#=BX^ZOY4XC(QVZ8HHH :T:MU53]13B,BBB@!ODIC&U<9!Z>G2G444 %%%%
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M*AW ST#MCJ:?I7@+0]!T.ZTNQT72;/3;W=]HM(+..."?<H1MZ* K94!3D<@
M=*UJ* ([6UCL;6.&&..&&%0D<:*%5% P  .  .PJ+1]&L_#VF0V6GVMM8V=N
MNV*"WB6**(>BJH  ^E6:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOGP?_P!!^Q_,_P"%?*./]W_OD48_W?\ OD4 ?5W_  OGP?\ ]!^Q_,_X4?\
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M /0?L?S/^%?*./\ =_[Y%&/]W_OD4 ?5W_"^?!__ $'['\S_ (4?\+Y\'_\
M0?L?S/\ A7RCC_=_[Y%&/]W_ +Y% 'U=_P +Y\'_ /0?L?S/^%'_  OGP?\
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M^%?*./\ =_[Y%&/]W_OD4 ?5W_"^?!__ $'['\S_ (4?\+Y\'_\ 0?L?S/\
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M?^^11C_=_P"^10!]7?\ "^?!_P#T'['\S_A1_P +Y\'_ /0?L?S/^%?*./\
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MN)O"R?$+PQ!IMIXB>!"\T%O<07%PGFHBEBK[/OQ@99T#-\(?\%@= ^*/[/\
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MC*T@EWNK*Z@1%2&!+#I0!QW_  I'Q=_T+]]^:?\ Q5'_  I'Q=_T+]]^:?\
MQ5>B>%_VVO"_BW]N3Q5\ [73_$">+_!_ABT\5WMW+:P?V9+:W$HBC2.02^:9
M<G)4Q*H[.>A\\^ 7_!7_ .$G[2/_  4!^(O[-GAV37C\0/AI!-+J%S-:VXTJ
M_:!X8KF*UE25Y'EADF".DD<9!23&0AH 3_A2/B[_ *%^^_-/_BJ/^%(^+O\
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M]FFPMXQ(PN"[I-%,0V/+\IBK*5<J0: ,+_A2/B[_ *%^^_-/_BJ/^%(^+O\
MH7[[\T_^*KT4_MP>$I?V\-2_9[^QZU;^,-*\#+\09]0FMX%TE=/-X+/8)?-\
MSSA(=Q4Q!-N3YF>*^>KK_@X-^!FGVMCXDO-&^+VG_!_5+PV&G_%:Z\$7">"[
MZX$@B\M;C_CX"^9O7S&MUC)B<!SM.0#T#_A2/B[_ *%^^_-/_BJ/^%(^+O\
MH7[[\T_^*KFOVN?^"TN@_L8?%RR\'^)/@/\ M&:U_;FO6OAC0-=T3PUITVD>
M)=0N8Q)#!92RW\;2LWS  HO*,.V:[SP[_P %,/#M[\5?@%X)U[P#\4/!/BO]
MHAO$/]AZ3XATJSM;K1/[%A\^Y&HJERYB\V+:\/E>;O61-WEYH R/^%(^+O\
MH7[[\T_^*H_X4CXN_P"A?OOS3_XJND^/?_!2KP+^S[^TSKOPLU?1_%MSX@\.
M_"Z^^+5U/96EJ]E)I5I/)#+"CO.KFZ+1$JA01D$9D7G'@$?_  <1> K/X/Z/
M\3->^ _[4'A#X3ZPEK<'QOJG@NSET2RMKA@L5U+);7TTHB9G0!EC<DLH"DL
M0#UO_A2/B[_H7[[\T_\ BJ/^%(^+O^A?OOS3_P"*K,^-_P#P6+\+_"+]I^[^
M$OA_X3_&SXQ>)[/PY:>*Y)_A_HNG:G8C3[IBL,H>2^B8@G'(7!W @D&O=/V3
M?VBKC]J'X=WGB&\^&_Q*^%\EO?O8+H_CK2K?3M3E")&_VA8X9YE,+%RJL6!+
M12?*  2 >/?\*1\7?]"_??FG_P 51_PI'Q=_T+]]^:?_ !5?6/E+_=7\J/*7
M^ZOY4 ?)W_"D?%W_ $+]]^:?_%4?\*1\7?\ 0OWWYI_\57UCY2_W5_*CRE_N
MK^5 'R=_PI'Q=_T+]]^:?_%4?\*1\7?]"_??FG_Q5?6/E+_=7\J/*7^ZOY4
M?)W_  I'Q=_T+]]^:?\ Q5'_  I'Q=_T+]]^:?\ Q5?6/E+_ '5_*CRE_NK^
M5 'R=_PI'Q=_T+]]^:?_ !5'_"D?%W_0OWWYI_\ %5]8^4O]U?RH\I?[J_E0
M!\G?\*1\7?\ 0OWWYI_\51_PI'Q=_P!"_??FG_Q5?6/E+_=7\J/*7^ZOY4 ?
M)W_"D?%W_0OWWYI_\51_PI'Q=_T+]]^:?_%5]8^4O]U?RH\I?[J_E0!\G?\
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M4?\ "D?%W_0OWWYI_P#%5]8^4O\ =7\J/*7^ZOY4 ?)W_"D?%W_0OWWYI_\
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MM=1\4K:I=7]W+?I%963_ &*"%!&]U)#&&$>5$V22!D?*6@?#KX_?\$[/@/\
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MGRA6MW3(D64#TG_@@?M-Y^VIGJ/VJ?&V,?6SKXVTC_@]2^#_ (>TZ&ST_P"
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M?'W_ (.+3_"@#]P**_#_ /XC>OA=_P!$-\??^#BT_P */^(WKX7?]$-\??\
M@XM/\* /W HK\/\ _B-Z^%W_ $0WQ]_X.+3_  H_XC>OA=_T0WQ]_P"#BT_P
MH _<"BOP_P#^(WKX7?\ 1#?'W_@XM/\ "C_B-Z^%W_1#?'W_ (.+3_"@#]P*
M*_#_ /XC>OA=_P!$-\??^#BT_P */^(WKX7?]$-\??\ @XM/\* /W HK\/\
M_B-Z^%W_ $0WQ]_X.+3_  H_XC>OA=_T0WQ]_P"#BT_PH _<"BOP_P#^(WKX
M7?\ 1#?'W_@XM/\ "C_B-Z^%W_1#?'W_ (.+3_"@#]P**_#_ /XC>OA=_P!$
M-\??^#BT_P */^(WKX7?]$-\??\ @XM/\* /W HK\/\ _B-Z^%W_ $0WQ]_X
M.+3_  H_XC>OA=_T0WQ]_P"#BT_PH _<"BOP_P#^(WKX7?\ 1#?'W_@XM/\
M"NW_ &9O^#POX<_M-?M)?#WX;Z?\&_&VF7WQ"\3:;X:M[RXU6U:*TDO;J*V6
M5U49*J9 Q Y(&* /V)HHHH **** "BBB@#P?]K7_ ()C_ G]NWQ#H^K?%SX<
MZ3XYU'P_;/::?/?3W"-:Q.P=E CD0'+ 'D$UY)_Q#L_L5_\ 1 /"?_@5>_\
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M^OVJ]_\ C].7_@W;_8K<9'P!\)_^!5[_ /'ZQ)O^"B?CX_L->-'UZST/P?\
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M ,?H_P"(=G]BO_H@'A/_ ,"KW_X_75>"O^"J&E^+[F*2X^$_QA\/Z+;>+(?
MFMZSJMAI<=EX<UV?4$TZ&QF$>H/-<;[F>T3[18Q75L/M*9F&R;RM.P_X*:>&
M]3\1QR6W@WXAW'P_F\6CP/%\1(["S;PW)JQO_P"S1"%%T;\Q'4/]%^U?9/LW
MF<^;L_>4 <%_Q#L_L5_]$ \)_P#@5>__ !^FR_\ !N]^Q3"NYO@#X25<XR;N
M]_\ C]=AX1_X*G:#XM\?Z?IG_"M?BSIGAO4_'FH_#:W\7WNF6"Z+-K=G<7EL
MT*A+UKLPR364B)<BV,&]U1Y(W$BI8_X*9_M1>(_V9?A?X5U#3]3D\&^&-9UL
MV/BWQRGABX\1CP)IXL[F<7CVD6=H>:&. 7,RO;V[S*\L;K\M '#'_@WB_8G!
MQ_PH/PCGGC[7>_\ Q^G+_P &[?[%;KD? 'PGC_KZO?\ X_7'ZC^W?XKTC]@/
MXL_$;P=\5O _QPT7PB-+G\-^,_#=K:W&H7<EQ<Q?:],OM.@)C6]ACDC*!4B9
MTO85,(EC:27W:T_X*)Z;IFF^,H?$'PX^*7A#Q-X-M=*OO^$6O--LM2UC6(=5
MN;BTTYK1=.O+J%O.N;6YCVR2QM%Y#/*(HAYE 'G7_$.S^Q7_ -$ \)_^!5[_
M /'Z/^(=G]BO_H@'A/\ \"KW_P"/UW7BS_@IIHOPU^%?Q&\0^+OAW\3_  MK
M7POM],O=6\(7%EIU[KMQ:ZC</;64]J+.^GM;A99HIT4).7W6TJ[=P56GU'_@
MHA>6TTUA9_ SXUZUXET73SJ?B?0--M]#N;[PG"TLZ0"Y8:IY$\TZ6\D\=M8R
MW4YA>%FC4RQAP#S[_B'9_8K_ .B >$__  *O?_C]'_$.S^Q7_P!$ \)_^!5[
M_P#'ZZG3/^"LG@_Q[K5\OP[\%_$SXM:'H6G:1JNNZQX1TJUG31+;4[2*]M9'
ML[BZAU"Y+6DT<QCLK2Y< E #*&B7ZBTR[:^LHY67:7&<%64CZAL$'V(!'<9H
M ^-/^(=G]BO_ *(!X3_\"KW_ ./T?\0[/[%?_1 /"?\ X%7O_P ?K[3HH ^+
M/^(=G]BO_H@'A/\ \"KW_P"/T?\ $.S^Q7_T0#PG_P"!5[_\?K[3HH ^+/\
MB'9_8K_Z(!X3_P# J]_^/T?\0[/[%?\ T0#PG_X%7O\ \?K[3HH ^+/^(=G]
MBO\ Z(!X3_\  J]_^/T?\0[/[%?_ $0#PG_X%7O_ ,?K[3HH ^+/^(=G]BO_
M *(!X3_\"KW_ ./T?\0[/[%?_1 /"?\ X%7O_P ?K[3HH ^+/^(=G]BO_H@'
MA/\ \"KW_P"/T?\ $.S^Q7_T0#PG_P"!5[_\?K[3HH ^+/\ B'9_8K_Z(!X3
M_P# J]_^/T?\0[/[%?\ T0#PG_X%7O\ \?K[3HH ^+/^(=G]BO\ Z(!X3_\
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MW@::ZN[F'2YD>W#3 /$$U:WRTC(V4EPIPI< \E_XAV?V*_\ H@'A/_P*O?\
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M0WBGPFOQ>;5_[!FT];>Z;0A\/]X'_"/(Y.\72R@:F+X0AFN]T.Q;9L+]GT4
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MWQ1/AA?A,_BSP/\ \*33QL/&7VW^R[L^)C:C7O[<&C;-_P!FQ]H C^W;]YA
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M%WB:W^W6.FZU=B\M6.F;[>6*\@T^33[2+3"T+!XX"[H@^6*OMVB@#\Y_#_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?:%C@;[4'M7ECRT2ZBMD)0CA&)P" =Y\#?V<O$7PU_X)R>"/A)/XE7P]XO\
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M?2OASX1\$ZKX,TW5%FN;C5/&MK)I-QI^E07\#VNS3?(,D$L]Q:S7+3O;$I%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAK&^MHS?^&DMH=,M7:XO1>/(DUQ(LD 2-U5R4_0*B@#Y+_8P_8R^(GP=U/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7._%?PIK'CCX?ZEI.@^*-4
M\%ZM?($M];TZVM;FZTXA@2\<=U%+ Q(!7$D;##$XR 1OK.K'K[]*7S%]: /G
M'3OV/?C'9ZC;33?M9?%J[BAE222WE\+>$52=002C%=)# ,."5(.#P0:]D^,_
M@C7_ (C_  ZNM)\.^,]:^'NL7#Q-'K>DV=C>75J%=695CO89H&#J"A+1D@,2
MN&P1U7F+ZT>8OK0!\^>$?V3OBWX>\7:3J&H?M2?%37]/L+V"YNM*NO#/A6&W
MU*%)%:2WD>'2TE5)%!0M&Z. Q*LK8(](^./PU\5_%+P=#IOAGXA>(OAEJ"72
M7#ZMHMCIU]</&%<-;E+^VGBV,65BP0/F,88 D'N_,7UH\Q?6@#P7X<_LM_%7
MP7XYTS5M7_:7^)GC#3+&;S;C1-0\.>&+:UU)<$>7));:9'.BY(.8Y%.0.<9%
M=M\>OA1XP^*^AZ?:>%OB?XH^%MU:3^;<7VAZ=I5_+>IL(\IUU"UN$5<D-N15
M;*X)QP?1/,7UH\Q?6@#Q'X/?LU_$SX>?$33]6\0?M$_$;Q]I%J)1<:)JOA_P
MW:6EYNC95WR6>G0SKL8JXV2+DJ <J2#T7[1'P9\;?%V;1_\ A$?B]XP^%*Z<
M)OM?]A:5H]__ &KO\O9YG]H6=QL\K8^WRMF[S6W;L+M],\Q?6CS%]: /&_@;
M^SS\1OA?X[_M3Q-\?/'WQ*TLVSP?V/K.A^'[*V$C,I$WF6-A!-N4*0!YFT[S
ME20"-#]H+X&^//BQKVGW/A/XT^-OA=:VMNT4]IHFCZ)?1WKELB5VU"RN'5@/
ME 1E4@\C/->J>8OK1YB^M 'D?P%^ WQ ^%'B>\O/%/QN\<_%&QN;;R(K#6]&
MT*PALY-ZGSE;3[&WD9MH9=KN4PQ.W.")_P!H+X$^//BQX@T^[\)_&WQO\+K2
MUMS#/9:)HVAWT5ZY;(E=M0LKAU8#Y<(RKCMGFO5?,7UH\Q?6@#R7X"_ ?X@?
M"CQ%>7GBGXW>./BC9W5N(8;'6]&T*PALGWAC,K6%E;R,Q4%<.S+ALX!P:K_'
M']GWXC?%+QG%J7AGX\>/OAGIL=HENVDZ+H>@7UO+*KR,;@R7UC<3;V5E4J'"
M 1J0H)8GV+S%]:/,7UH \U_9V^#'C3X1R:P?%WQ@\8?%5=0$ M%UW2='L/[*
MV>9O\O\ L^TM]_F;TW>;OQY2[=N6W<[\8OV;?B9\1O']WJWA[]H;XB?#[2;A
M(UBT32= \.7=K;%4"LRR7FGS3DNP+'=(0"Q P, >V>8OK1YB^M 'GO[/?PG\
M7_"?3=2M_%OQ2\5?%&:\E22VN=<TS2K&2P4+AHT73[6W5E8_,3(&.>A XKB_
MB?\ LP_%+QQX^U35=%_:2^)7@O2KZ4/;:+IOAWPS<VNGJ$5=B276FRSL"06S
M)(QRQ&0  /=O,7UH\Q?6@#A_@!\,_%'PJ\)W6G^+/B-XD^)]_->/<QZKK6GZ
M;8SV\12-5MU2PM[>(HK([AF0N3*P+$!0OFWC7]D[XM>)/&6K:CIO[4GQ2\/:
M=?WDUQ:Z5:>&?"LUOIL3N62WC>;2WE9$4A0TCNY"@LS')/T#YB^M'F+ZT <;
M\&? 7B3X;> X=)\1^-M=^(FJ0RR2/K6K6=A975PK/N6,QV4$, "+\H(C4D 9
M).37DVL_LA?&#4]9O+FW_:O^+&G6]Q/)+%:0^%O"3QVB,Q*Q*SZ4SE5!"@LS
M,0!DDY-?1?F+ZT>8OK0!SGPH\(:UX!^'.FZ3KWBS5O'6L6887&N:G:V=K=W^
M9&8%X[2*&!=JD(/+C7(0$Y8DGPV+]C7XSHJ[OVN_B\Y& <^$_!XS[_\ ()KZ
M5\Q?6CS%]: .;T'PEK>E_"2#0[KQ5JVI^((=-^Q/XCGM;2.]GG\O9]L:*.);
M82;OGV+$(\\;-ORUX>?V-?C.5_Y.[^+^<8S_ ,(GX/Y]_P#D$5]*>8OK1YB^
MM '.ZKX1UK4OA-<:##XJU;3]?ETLV,?B2*UM'OH;CRM@O1"\36QE#?O-C1&+
M=QLV_+7A<O[&?QH:-@O[7GQ@5B#@_P#")^#N#_X**^EO,7UH\Q?6@#!\=^']
M8\5>"M4TW2]<O_"^I:A:RV]MJ]E%;SW.ER,"%GCCGCDA=D."%D1D/=2.*\(?
M]C/XSLC!?VO?C K$8!_X1/P=Q_Y2*^E?,7UH\Q?6@#EOBMX0U[Q]X U+2=#\
M5:MX&U:^""WUO3+>SNKK3BLBL2D=W#+ VY05/F1M@.2,, 1X[HW[(?Q@TO6+
M.YN/VKOBQJ5O;SQRRVDWA?PDD=TBL"T3,FE*X5P"I*,& )P0<$?1?F+ZT>8O
MK0!R/QP\!^(?B5X"FTGPSXXUSX=ZI++'(NMZ196-Y=0JK LBQWL$\!#C*DM&
M2 >"#S7E?@S]D_XM>&O&&DZEJ'[47Q2\1:?I]Y%<76DWGAKPK#;ZG$C!GMY'
M@TM)D20 J6C=7 .58'!'T%YB^M'F+ZT </\ 'WX:>*/BIX/M-/\ "OQ%\2?#
M'4(;U;F75-$T_3;ZXN(A'(IMV2_MKB((S,K%E0.#&H#!2P/ _#/]E_XI>!_'
MNFZMK7[2?Q*\:Z792,UQH>I>'O#-K::@I1E"R2VNFQ3J Q#9CD4Y4#)!(/NW
MF+ZT>8OK0!YS\?/A)XR^+.F:?;^%?BIXJ^%DUG,TL]UH>FZ3?R:@A7 C==0M
M+A552-P,85B3R2.*Y?X0?LV?$WX<^/;75O$'[0_Q$^(6EVZ2+)H>K:!X<L[6
MZ+(55FEL].AG!0D. L@!*X((R*]N\Q?6CS%]: /+_P!H#X+^./BW+I/_  BG
MQ?\ &'PJ73Q.+H:%I6C7_P#:N_R]AE_M"SN-GE['V^5LSYK;MV%VT/@/^S]\
M0OA;XWDU+Q1\=_'GQ,TR2S>W72=:T/0+*WCE+(RW >PL+>;>H5E"ERA$C$J2
M%(]?\Q?6CS%]: /)OC_\"/'WQ8\3V=YX4^-WCCX76-K;>1+8:)HVA7T5Y)N+
M><[:A8W$BM@A=J,JX4'&<DN_9_\ @7X^^$_B*^NO%GQL\;?%*SNX!##9:YHV
MAV,=DX;)E1M/LK=V8CY<.S+@Y S7J_F+ZT>8OK0!X[\=?V>_B)\4/'2ZEX7^
M/7C[X:Z6MJD!TC1M#\/WMLTBERTY>^L)YM[!E4J'V (,*"6)U/V>_@QXV^$<
M^K?\);\7O&'Q674/(^R_V[I6CV']E;/-\SR_[/M+;?YF^/=YN_'E+MVY;=Z=
MYB^M'F+ZT >._'7]GCXB?$_QR-4\+_'WQ_\ #;2Q:QP?V/HVA>'[VV,BEBTW
MF7UA/-N8,H(\S:-@PH).=3]G[X,^-_A'+JW_  EGQ>\8?%9=0\G[+_;FE:-I
M_P#9>SS-_E_V?:6^_P S>F?-WX\I=NW+;O3O,7UH\Q?6@#P[XL_LT?$_XA>/
M[[5]!_:+^(_@'2KH1"'0M+\/^&[NULRL:HQ26\TZ:=M[*SG?(<%R%PH '9_L
M^?"GQ9\)] U"U\6?%#Q1\4KJZN1-!>ZYIFEV,ME'L"^4BZ?:VZ,I(+9=6;+$
M9Q@#OO,7UH\Q?6@#P7XC_LN?%3QIXZU/5M'_ &EOB9X/TN^E\VVT73_#GABX
MM=.7 'EI)<Z;+,PR"<R2,>>N,"O1?@+\./$WPN\'3Z;XJ^(7B+XE:A)=M<)J
MVM6&G65Q%&RH! $L+>"(JI5F#%"Y,ARQ  ':^8OK1YB^M 'SYXO_ &3_ (M^
M)/%FJ:AI_P"U'\4_#UC?WDUS;:7:>&?"LUOID3R,R6T;S:6\K)&I"*TCLY"@
MLS,23ZS\%? ^O?#GP!:Z1XD\::U\0-5MVD:37-6L[&SNKH-(S*K1V4,, "*5
M0%8P2%!.6R3U7F+ZT>8OK0!\XZE^Q[\8KS4;B:']K3XMVD,TKR1P1^%?"+)
MI8D(I;22Q"@@ L22!R2>:]F^&WA'7O!?P]L-(UCQ5JWC#5K.(QSZ[J%M9VUW
M?L68^8\5M%% I (&$C484'&2<]1YB^M'F+ZT ?-,?[&?QH6-0W[7GQ@9@.3_
M ,(GX.Y_\I%>Z6OA'6K7X1PZ#)XJU:Z\01Z0NGOXF>UM%OI;D0^6;\PB(6OF
ME_WNP1"+=P(]GRUT7F+ZT>8OK0!\U']C7XS[3_QEW\7\D8S_ ,(GX/X]_P#D
M$5[CXI\):WKGPGN=#L?%6K:+KT]@+2/Q%;6MI)>VTVT*;I8I8FMC)G+;6B,>
M3C9CBND\Q?6CS%]: /FM_P!C;XS-G;^UU\7E]!_PB?@_C_RDU[S\1?#FJ>+_
M  #JNEZ/X@U'PGJU];O#:ZQ8P6UQ=::YZ2QI<1R0LR]0)(V4]P:V_,7UH\Q?
M6@#YK_X8W^,P.[_AKCXO-CG;_P (IX/Y]O\ D$5[3\7/!?B#X@_#_4='\/\
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M6@#KO^%^>._^AV\6?^#>X_\ BZ/^%^>._P#H=O%G_@WN/_BZY'>OHM&]?1:
M.N_X7YX[_P"AV\6?^#>X_P#BZ/\ A?GCO_H=O%G_ (-[C_XNN1WKZ+1O7T6@
M#KO^%^>._P#H=O%G_@WN/_BZ/^%^>._^AV\6?^#>X_\ BZY'>OHM&]?1: .N
M_P"%^>._^AV\6?\ @WN/_BZ/^%^>._\ H=O%G_@WN/\ XNN1WKZ+1O7T6@#K
MO^%^>._^AV\6?^#>X_\ BZ/^%^>._P#H=O%G_@WN/_BZY'>OHM&]?1: .N_X
M7YX[_P"AV\6?^#>X_P#BZ/\ A?GCO_H=O%G_ (-[C_XNN1WKZ+1O7T6@#KO^
M%^>._P#H=O%G_@WN/_BZ/^%^>._^AV\6?^#>X_\ BZY'>OHM&]?1: .N_P"%
M^>._^AV\6?\ @WN/_BZ/^%^>._\ H=O%G_@WN/\ XNN1WKZ+1O7T6@#KO^%^
M>._^AV\6?^#>X_\ BZ/^%^>._P#H=O%G_@WN/_BZY'>OHM&]?1: .N_X7YX[
M_P"AV\6?^#>X_P#BZ/\ A?GCO_H=O%G_ (-[C_XNN1WKZ+1O7T6@#KO^%^>.
M_P#H=O%G_@WN/_BZ/^%^>._^AV\6?^#>X_\ BZY'>OHM&]?1: .N_P"%^>._
M^AV\6?\ @WN/_BZ/^%^>._\ H=O%G_@WN/\ XNN1WKZ+1O7T6@#KO^%^>._^
MAV\6?^#>X_\ BZ/^%^>._P#H=O%G_@WN/_BZY'>OHM&]?1: .N_X7YX[_P"A
MV\6?^#>X_P#BZ/\ A?GCO_H=O%G_ (-[C_XNN1WKZ+1O7T6@#KO^%^>._P#H
M=O%G_@WN/_BZ/^%^>._^AV\6?^#>X_\ BZY'>OHM&]?1: .N_P"%^>._^AV\
M6?\ @WN/_BZ/^%^>._\ H=O%G_@WN/\ XNN1WKZ+1O7T6@#KO^%^>._^AV\6
M?^#>X_\ BZ/^%^>._P#H=O%G_@WN/_BZY'>OHM&]?1: .N_X7YX[_P"AV\6?
M^#>X_P#BZ/\ A?GCO_H=O%G_ (-[C_XNN1WKZ+1O7T6@#KO^%^>._P#H=O%G
M_@WN/_BZ/^%^>._^AV\6?^#>X_\ BZY'>OHM&]?1: .N_P"%^>._^AV\6?\
M@WN/_BZ/^%^>._\ H=O%G_@WN/\ XNN1WKZ+1O7T6@#KO^%^>._^AV\6?^#>
MX_\ BZ/^%^>._P#H=O%G_@WN/_BZY'>OHM&]?1: .N_X7YX[_P"AV\6?^#>X
M_P#BZ/\ A?GCO_H=O%G_ (-[C_XNN1WKZ+1O7T6@#KO^%^>._P#H=O%G_@WN
M/_BZ/^%^>._^AV\6?^#>X_\ BZY'>OHM&]?1: .N_P"%^>._^AV\6?\ @WN/
M_BZ/^%^>._\ H=O%G_@WN/\ XNN1WKZ+1O7T6@#KO^%^>._^AV\6?^#>X_\
MBZ/^%^>._P#H=O%G_@WN/_BZY'>OHM&]?1: .N_X7YX[_P"AV\6?^#>X_P#B
MZ/\ A?GCO_H=O%G_ (-[C_XNN1WKZ+1O7T6@#KO^%^>._P#H=O%G_@WN/_BZ
M/^%^>._^AV\6?^#>X_\ BZY'>OHM&]?1: .N_P"%^>._^AV\6?\ @WN/_BZ/
M^%^>._\ H=O%G_@WN/\ XNN1WKZ+1O7T6@#KO^%^>._^AV\6?^#>X_\ BZ/^
M%^>._P#H=O%G_@WN/_BZY'>OHM&]?1: .N_X7YX[_P"AV\6?^#>X_P#BZ/\
MA?GCO_H=O%G_ (-[C_XNN1WKZ+1O7T6@#KO^%^>._P#H=O%G_@WN/_BZ/^%^
M>._^AV\6?^#>X_\ BZY'>OHM&]?1: .N_P"%^>._^AV\6?\ @WN/_BZ/^%^>
M._\ H=O%G_@WN/\ XNN1WKZ+1O7T6@#KO^%^>._^AV\6?^#>X_\ BZ/^%^>.
M_P#H=O%G_@WN/_BZY'>OHM&]?1: .N_X7YX[_P"AV\6?^#>X_P#BZ/\ A?GC
MO_H=O%G_ (-[C_XNN1WKZ+1O7T6@#KO^%^>._P#H=O%G_@WN/_BZ/^%^>._^
MAV\6?^#>X_\ BZY'>OHM&]?1: .N_P"%^>._^AV\6?\ @WN/_BZ/^%^>._\
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MPSO\/_\ H1?!W_@EMO\ XBC_ (9W^'__ $(O@[_P2VW_ ,178T4 <=_PSO\
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M+;?_ !%=C10!QW_#._P__P"A%\'?^"6V_P#B*/\ AG?X?_\ 0B^#O_!+;?\
MQ%=C10!QW_#._P /_P#H1?!W_@EMO_B*/^&=_A__ -"+X._\$MM_\178T4 <
M=_PSO\/_ /H1?!W_ ();;_XBC_AG?X?_ /0B^#O_  2VW_Q%=C10!QW_  SO
M\/\ _H1?!W_@EMO_ (BC_AG?X?\ _0B^#O\ P2VW_P 178T4 <=_PSO\/_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DIAMEDICA THERAPEUTICS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">301 Carlson Parkway, Suite 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Minneapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">496-5454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Voting common shares, no par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DMAC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,688,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001401040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,109<span></span>
</td>
<td class="nump">$ 3,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">25,929<span></span>
</td>
<td class="nump">41,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Amounts receivable</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">31,079<span></span>
</td>
<td class="nump">44,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">31,470<span></span>
</td>
<td class="nump">46,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,747<span></span>
</td>
<td class="nump">4,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligation</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,116<span></span>
</td>
<td class="nump">5,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Liabilities, Noncurrent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligation</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value; unlimited authorized; 43,072,488 and 42,818,660 shares issued and outstanding, as of June 30, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Paid-in capital</a></td>
<td class="nump">182,592<span></span>
</td>
<td class="nump">180,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(155,408)<span></span>
</td>
<td class="num">(140,002)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">27,170<span></span>
</td>
<td class="nump">40,718<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 31,470<span></span>
</td>
<td class="nump">$ 46,345<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares<br> $ / shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common Stock, No Par Value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common Stock, Shares Authorized, Unlimited [Fixed List]</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in shares)</a></td>
<td class="nump">43,072,488<span></span>
</td>
<td class="nump">42,818,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding (in shares)</a></td>
<td class="nump">43,072,488<span></span>
</td>
<td class="nump">42,818,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 5,822<span></span>
</td>
<td class="nump">$ 3,928<span></span>
</td>
<td class="nump">$ 11,478<span></span>
</td>
<td class="nump">$ 7,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,185<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
<td class="nump">3,775<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">operating loss</a></td>
<td class="num">(8,007)<span></span>
</td>
<td class="num">(5,638)<span></span>
</td>
<td class="num">(16,151)<span></span>
</td>
<td class="num">(11,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">757<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(7,693)<span></span>
</td>
<td class="num">(5,112)<span></span>
</td>
<td class="num">(15,394)<span></span>
</td>
<td class="num">(10,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,699)<span></span>
</td>
<td class="num">(5,119)<span></span>
</td>
<td class="num">(15,406)<span></span>
</td>
<td class="num">(10,270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (7,718)<span></span>
</td>
<td class="num">$ (5,131)<span></span>
</td>
<td class="num">$ (15,443)<span></span>
</td>
<td class="num">$ (10,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; basic and diluted (in shares)</a></td>
<td class="nump">42,957,619<span></span>
</td>
<td class="nump">38,068,378<span></span>
</td>
<td class="nump">42,901,093<span></span>
</td>
<td class="nump">38,013,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2023</a></td>
<td class="nump">37,958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2023</a></td>
<td class="nump">$ 166,609<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (115,558)<span></span>
</td>
<td class="nump">$ 51,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)</a></td>
<td class="nump">5,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,151)<span></span>
</td>
<td class="num">(5,151)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">37,963,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 167,097<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(120,709)<span></span>
</td>
<td class="nump">46,349<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2023</a></td>
<td class="nump">37,958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2023</a></td>
<td class="nump">$ 166,609<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(115,558)<span></span>
</td>
<td class="nump">$ 51,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,270)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">42,692,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 179,294<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(125,828)<span></span>
</td>
<td class="nump">53,415<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Mar. 31, 2024</a></td>
<td class="nump">37,963,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2024</a></td>
<td class="nump">$ 167,097<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(120,709)<span></span>
</td>
<td class="nump">46,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)</a></td>
<td class="nump">5,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options (in shares)</a></td>
<td class="nump">2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,119)<span></span>
</td>
<td class="num">(5,119)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">42,692,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 179,294<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(125,828)<span></span>
</td>
<td class="nump">53,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares net of offering costs of $0.1 million (in shares)</a></td>
<td class="nump">4,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares net of offering costs of $0.1 million</a></td>
<td class="nump">$ 11,747<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,747<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2024</a></td>
<td class="nump">42,818,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2024</a></td>
<td class="nump">$ 180,697<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(140,002)<span></span>
</td>
<td class="nump">40,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)</a></td>
<td class="nump">3,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options (in shares)</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">867<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,707)<span></span>
</td>
<td class="num">(7,707)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2025</a></td>
<td class="nump">42,859,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 181,658<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(147,709)<span></span>
</td>
<td class="nump">33,954<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2024</a></td>
<td class="nump">42,818,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2024</a></td>
<td class="nump">$ 180,697<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(140,002)<span></span>
</td>
<td class="nump">$ 40,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,406)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits', window );">Issuance of common shares in settlement of deferred stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,345<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2025</a></td>
<td class="nump">43,072,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 182,592<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(155,408)<span></span>
</td>
<td class="nump">$ 27,170<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Mar. 31, 2025</a></td>
<td class="nump">42,859,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2025</a></td>
<td class="nump">$ 181,658<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(147,709)<span></span>
</td>
<td class="nump">33,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)</a></td>
<td class="nump">3,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options (in shares)</a></td>
<td class="nump">66,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">771<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,699)<span></span>
</td>
<td class="num">(7,699)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits', window );">Issuance of common shares in settlement of deferred stock units (in shares)</a></td>
<td class="nump">142,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2025</a></td>
<td class="nump">43,072,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 182,592<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (155,408)<span></span>
</td>
<td class="nump">$ 27,170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period due to the settlement of deferred stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480513/718-10-30-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,406,000)<span></span>
</td>
<td class="num">$ (10,270,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,638,000<span></span>
</td>
<td class="nump">931,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of discounts on marketable securities</a></td>
<td class="num">(441,000)<span></span>
</td>
<td class="num">(648,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Amounts receivable</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="num">(22,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other assets</a></td>
<td class="num">(453,000)<span></span>
</td>
<td class="num">(156,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits</a></td>
<td class="nump">1,108,000<span></span>
</td>
<td class="num">(1,308,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">321,000<span></span>
</td>
<td class="num">(167,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities and operating lease liabilities</a></td>
<td class="num">(1,643,000)<span></span>
</td>
<td class="nump">413,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,747,000)<span></span>
</td>
<td class="num">(11,172,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(16,370,000)<span></span>
</td>
<td class="num">(18,047,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">31,967,000<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(18,000)<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">15,579,000<span></span>
</td>
<td class="nump">8,944,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,747,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">257,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance lease obligations</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">252,000<span></span>
</td>
<td class="nump">11,751,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="nump">1,084,000<span></span>
</td>
<td class="nump">9,523,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">3,025,000<span></span>
</td>
<td class="nump">4,543,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">4,109,000<span></span>
</td>
<td class="nump">14,066,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Assets acquired under financing lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized over the period for lease expense, non-cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>1.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Business</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica Therapeutics Inc. and its wholly owned subsidiaries, DiaMedica USA Inc. and DiaMedica Australia Pty Ltd. (collectively, we, us, our, DiaMedica and the Company), is a clinical stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE) and acute ischemic stroke (AIS). DiaMedica&#8217;s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein, an established therapeutic modality in Asia for the treatment of preeclampsia, acute ischemic stroke and other vascular diseases. Our common shares are publicly traded on The Nasdaq Capital Market under the symbol &#8220;DMAC.&#8221;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_RisksAndUncertaintiesTextBlock', window );">Risks and Uncertainties [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Risks and Uncertainties</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the United States Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in the European Union, and comparable agencies in other countries. We are in the clinical stage of development of our lead product candidate, DM199, for the treatment of PE and AIS. We have not completed the development of any product candidate and do not generate any revenues from the commercial sale of any product candidate. Our lead product candidate, DM199, requires significant additional clinical testing and investment prior to seeking marketing approval and is not expected to be commercially available for at least three to four years, if at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">With respect to our PE clinical program, a Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 for the treatment of PE is currently being conducted at the Tygerberg Hospital in Cape Town, South Africa. This Phase 2 study consists of three studies in PE (Part 1a, dose-escalation; Part 1b, dose-expansion; and Part 2, expectant management) and a fourth study in fetal growth restriction (FGR, Part 3, expectant management). Part 1a topline study results are intended to identify a suitable dose for Parts 1b, 2, and 3. Up to 90 women with PE and potentially an additional 30 subjects with fetal growth restriction may be evaluated. The first subject in Part 1a was enrolled in the fourth quarter of 2024 and interim results from Part 1a of the study were released in July 2025. The interim results (N=28 subjects) demonstrated that DM199 appears safe and well-tolerated with clinically-relevant pharmacodynamic activity with no evidence of placental transfer. Additionally, subjects exhibited rapid, statistically significant reductions in blood pressure with duration of effect that was sustained up to 24 hours post-infusion compared to pre-treatment baseline. Preparations are underway to initiate Part 1b where up to 30 subjects with PE and expected delivery within 72 hours will be treated with a dose regimen identified from Part 1a.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">With respect to our AIS clinical program, we are currently conducting a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial of DM199 for the treatment of AIS, known as the ReMEDy2 trial. Our ReMEDy2 trial is intended to enroll approximately 300 participants at up to 100 sites globally. The adaptive design component includes an interim analysis by our independent data safety monitoring board to be conducted after the first 200 participants have completed the trial. Based on the results of the interim analysis, the study may then be stopped for futility or the final sample size will be determined, ranging between 300 and 728 patients, according to a pre-determined statistical plan. We have experienced and continue to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the previous clinical hold; use of artificial intelligence and telemedicine which have enabled smaller hospitals to retain AIS patients not eligible for mechanical thrombectomy instead of sending these patients to the larger stroke centers which are more likely to be sites in our trial; and competition for research staff and trial subjects due to other pending stroke and neurological trials. We continue to reach out to current and potential study sites to understand the specific issues at each study site. In an effort to mitigate the impact of these factors, we have significantly expanded our internal clinical team and have brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring, and overall program management. We are currently conducting our ReMEDy2 trial in the United States and in the countries of Canada and Georgia. We are in the process of preparing regulatory filings and identifying and engaging study sites in an additional seven European countries and have submitted for approval of this study in the United Kingdom. We continue to work closely with our contract research organizations and other advisors to develop procedures to support both U.S. and global study sites and potential participants as needed. We intend to continue to monitor the results of these efforts and, if necessary, implement additional actions to enhance site activations and enrollment in our ReMEDy2 trial; however, no assurances can be provided as to the success of these actions and if or when these issues will resolve. Failure to resolve these issues may result in delays in our ReMEDy2 trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our future success is dependent upon the success of our development efforts, our ability to demonstrate clinical progress for our DM199 product candidate in the United States or other markets, our ability, or the ability of any future partner, to obtain required governmental approvals of our product candidate, our ability to license or market and sell our DM199 product candidate, and our ability to obtain additional financing to fund these efforts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of June 30,&#160;2025, we have incurred losses of $155.4 million since our inception in 2000. For the six months ended June 30, 2025, we incurred a net loss of $15.4 million and negative cash flows from operating activities of $14.7 million. We expect to continue to incur operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments generate revenue sufficient to fund our continuing operations. For the foreseeable future, we expect to incur significant operating losses as we continue the development and clinical study of, and to seek regulatory approval for, our DM199 product candidate. As of June 30,&#160;2025, we had combined cash, cash equivalents and marketable securities of $30.0 million, working capital of $27.0 million and shareholders&#8217; equity of $27.2 million. Subsequent to quarter end, in July 2025, we completed a private placement of common shares in which we received net proceeds of $29.9 million, see Note 14, titled &#8220;<i>Subsequent Event</i>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our principal source of cash has been net proceeds from the issuance of equity securities. Although we have previously been successful in obtaining financing through equity securities offerings, there is no assurance that we will be able to do so in the future. This is particularly true if our clinical data are not positive or if economic and market conditions deteriorate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notwithstanding the completion of our July 2025 private placement, we expect that we will need substantial additional capital to further our research and development activities and complete the required clinical studies, regulatory activities and manufacturing development for our product candidate, DM199, or any future product candidates, to a point where they may be licensed or commercially sold. We expect our current cash, cash equivalents and marketable securities, including the $29.9 million net proceeds from our July 2025 private placement of common shares, to be sufficient to continue the Phase 2 PE trial, the ReMEDy2 trial, and otherwise fund our planned operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. The amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including our current ReMEDy2 trial and the rate of site activation and participant enrollment in the study; the Phase 2 PE trial; the potential expansion of our current development programs; the effects of ongoing site staffing shortages; and other factors on our clinical trials and our operating expenses. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising capital are favorable.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_RisksAndUncertaintiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A complete disclosure of the risks and uncertainties the company may face.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_RisksAndUncertaintiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Summary of Significant Accounting Policies</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Interim financial statements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have prepared the accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. These condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly our condensed consolidated financial position, condensed consolidated results of operations, condensed consolidated statement of shareholders&#8217; equity and condensed consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on December&#160;31. The condensed consolidated balance sheet as of December&#160;31,&#160;2024 was derived from our audited consolidated financial statements. These condensed consolidated financial statements should be read in conjunction with our annual consolidated financial statements and the notes thereto. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year. Certain prior year amounts have been reclassified to conform to the current year presentation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Segments</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We operate in a <span style="-sec-ix-hidden:c350">single</span> segment focusing on researching and developing potentially transformative treatments for severe ischemic diseases. Consistent with our operational structure, our chief operating decision maker manages and allocates resources for the Company at a consolidated level. Therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting. All assets are held in the United States.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Cash and cash equivalents</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of our cash equivalents approximates fair value due to the short maturity of the investments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>




<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Marketable securities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the condensed consolidated statements of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive income or loss, which is a separate component of shareholders&#8217; equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no other-than-temporary unrealized losses as of June 30, 2025.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Fair value measurements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The hierarchy is broken down into three levels defined as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Level 1 Inputs</i> &#8212; quoted prices in active markets for identical assets and liabilities;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Level 2 Inputs</i> &#8212; observable inputs other than quoted prices in active markets for identical assets and liabilities; and</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Level 3 Inputs</i> &#8212; unobservable inputs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of June 30,&#160;2025, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled &#8220;<i>Marketable Securities</i>&#8221; for additional information.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>4.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Marketable Securities</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="30" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements Using Inputs Considered as of:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 1</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 2</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 1</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 2</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper and corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,419</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c386">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,419</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c388">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Government securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,510</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c394">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,510</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c396">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,831</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,831</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,929</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c402">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,929</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c404">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,122</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,122</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Maturities of individual securities are less than 12 months, and the amortized cost of all securities approximated fair value as of June 30,&#160;2025 and December&#160;31,&#160;2024. Accrued interest receivable on marketable securities is included in amounts receivable and was $142,000 and $235,000 as of June 30,&#160;2025 and December&#160;31,&#160;2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the six months ended June 30, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Deposits<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_DepositAssetsTextBlock', window );">Deposit Assets [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>5.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Deposits</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica periodically advances funds to vendors engaged to support the performance of our clinical trials and related supporting activities. The funds advanced are held, interest free, for varying periods of time and may be recovered by the Company through partial reductions of ongoing invoices, application against final study/project invoices or refunded upon completion of services to be provided. Deposits are classified as current or non-current based upon their expected recovery time.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_DepositAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the companies deposits labeled as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_DepositAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Amounts Receivable<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>6.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Amounts Receivable&#160;</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amounts receivable consisted primarily of accrued interest receivable on marketable securities of $142,000 and $235,000 as of June 30,&#160;2025 and December&#160;31,&#160;2024, respectively.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>7.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Property and Equipment</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment, net, consisted of the following (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">136</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">118</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Furniture and equipment</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">128</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">128</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">280</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">262</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less accumulated depreciation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(128</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(114</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">152</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">148</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>8.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Accrued Liabilities</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued liabilities consisted of the following (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical trial costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,268</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,277</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development services</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">790</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">888</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">590</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,060</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional services fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">94</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">112</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total accrued liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,747</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,347</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Operating Lease<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>9.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Operating Lease</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Office lease</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our operating lease costs were $52,000 for each of the six month periods ended June 30,&#160;2025 and&#160;2024. Our variable lease costs were $43,000 and $38,000 for the six months ended June 30,&#160;2025 and&#160;2024, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Maturities of our operating lease obligation are as follows as of June 30,&#160;2025 (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">116</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">302</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Less interest portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(30</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Present value of operating lease obligation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">272</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Less current portion of operating lease</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(96</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease obligation, non-current</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>10.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Shareholders</b>&#8217;<b> Equity</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Authorized capital shares</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica has authorized share capital of an unlimited number of voting common shares, and the shares do not have a stated par value. Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company&#8217;s annual general meeting and any extraordinary or special general meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Equity issued during the six months ended June 30,</i>&#160;<i>2025</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the six months ended June 30,&#160;2025, 7,608 common shares were issued upon the vesting and settlement of restricted stock units, 142,345 shares were issued upon the settlement of deferred share units and 103,875&#160;common shares were issued upon the exercise of stock options for gross proceeds of $257,000.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Equity issued during the six months ended June 30,</i>&#160;<i>2024</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On June 25, 2024, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate 4,720,000 common shares at a purchase price of $2.50 per share in a private placement. As a result of the offering, which closed on June 28, 2024, we received gross proceeds of $11.8 million, which resulted in net proceeds to us of approximately $11.7 million, after deducting the offering expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the June 2024 private placement, we entered into a registration rights agreement (Registration Rights Agreement) with the investors pursuant to which we agreed to file with the United States Securities and Exchange Commission (SEC) a registration statement registering the resale of the shares sold in the June 2024 private placement (Resale Registration Statement). The Resale Registration Statement was filed with the SEC on July 10, 2024 and declared effective by the SEC on July 18, 2024. Under the terms of the Registration Rights Agreement, we agreed to keep the Resale Registration Statement effective at all times until the shares are no longer considered &#8220;Registrable Securities&#8221; under the Registration Rights Agreement and if we fail to keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the six months ended June 30, 2024, 11,832 common shares were issued upon the vesting and settlement of restricted stock units and 2,750 common shares were issued upon the exercise of common stock options for gross proceeds of $7 thousand.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Shares reserved</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common shares reserved for future issuance are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon exercise of employee and non-employee stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,685,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">174,515</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon vesting and settlement of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,607</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">754,919</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares available for grant under the 2021 Employment Inducement Incentive Plan</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">357,500</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,980,145</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>11.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Net Loss Per Share</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes our calculation of net loss per common share for the periods presented (in thousands, except share and per share data):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(7,699</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,406</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10,270</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding&#8212;basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,957,619</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,068,378</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,901,093</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,013,189</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic and diluted net loss per share</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.18</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.13</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.36</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.27</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Common shares issuable upon exercise of employee and non-employee stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,685,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,859,271</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,685,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,859,271</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Common shares issuable upon settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">174,515</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">284,886</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">174,515</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">284,886</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Common shares issuable upon vesting and settlement of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,607</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,828</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,607</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,828</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>12.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Share-Based Compensation</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Amended and Restated 2019 Omnibus Incentive Plan (2019 Plan)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The 2019 Plan permits the Board, or a committee or subcommittee thereof, to grant to the Company&#8217;s eligible employees, non-employee directors and certain consultants non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units (RSUs), deferred stock units (DSUs), performance awards, non-employee director awards and other share-based awards. We grant options to purchase common shares under the 2019 Plan at no less than the fair market value of the underlying common shares as of the date of grant. Options granted to employees and non-employee directors have a maximum term of <span style="-sec-ix-hidden:c580">ten</span> years and generally vest over <span style="-sec-ix-hidden:c581">one</span> to <span style="-sec-ix-hidden:c582">four</span> years. Options granted to non-employees have a maximum term of <span style="-sec-ix-hidden:c583">five</span> years and generally vest over <span style="-sec-ix-hidden:c584">one</span> year. Subject to adjustment as provided in the 2019 Plan, the maximum number of the Company&#8217;s common shares authorized for issuance under the 2019 Plan is 7,000,000 shares. As of June 30,&#160;2025, options to purchase an aggregate of 5,721,194 common shares were outstanding, 164,770 common shares were reserved for issuance upon settlement of DSUs and 7,607 shares were reserved for issuance upon the vesting and settlement of RSUs and 754,919 shares remained available for issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>2021 Employment Inducement Incentive Plan (2021 Inducement Plan)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The 2021 Inducement Plan permits the Board, or a committee or subcommittee thereof, to grant of non-statutory options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other share-based awards, to new employees who satisfy the standards for inducement grants under Nasdaq Listing Rule 5635(c)(4) or 5635(c)(3), as applicable. The Inducement Plan has a term of 10 years. The share reserve under the Inducement Plan may be increased at the discretion of and approval by the Board. As of June 30,&#160;2025, options to purchase an aggregate of 590,000 common shares were outstanding under the Inducement Plan and 357,500 shares remained available for issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Prior Stock Option Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s prior stock option plan was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the Prior Plan have terms similar to those used under the 2019 Plan. As of June 30,&#160;2025, options to purchase an aggregate of 374,410 common shares were outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Prior Deferred Stock Unit Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s prior deferred stock unit plan was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior DSU Plan remain outstanding in accordance with and pursuant to the terms thereof. As of June 30,&#160;2025, there were 9,745 common shares reserved for issuance upon settlement of DSUs outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Share-based compensation expense for each of the periods presented is as follows (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">538</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">336</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,216</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">629</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">233</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">107</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">422</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">302</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">771</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">443</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,638</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">931</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize share-based compensation for options awards based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those options that actually vest.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A summary of option activity is as follows (in thousands except share and per share amounts):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Underlying</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average Exercise</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances at December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,692,438</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.33</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,243</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,333,416</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.42</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeitures</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(231,375</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.35</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(103,875</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.51</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6.91</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances at June 30, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,685,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.70</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,767</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information about stock options outstanding, vested and expected to vest as of June 30,&#160;2025, is as follows:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: bottom; width: 4%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="10" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Outstanding, Vested and Expected to Vest</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="6" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 18%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Options Vested and Exercisable</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Per Share </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exercise Price</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Shares</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted Average</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Remaining</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Contractual Life</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Years)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted Average</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exercise Price</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Options </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exercisable</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted Average</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Remaining</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Contractual Life</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Years)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$1.00</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$1.99</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">191,443</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.7</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1.59</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">105,457</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.7</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$2.00</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$2.99</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,769,645</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.4</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2.74</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,484,034</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.0</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$3.00</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$3.99</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">311,893</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5.2</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.56</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">229,393</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.9</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$4.00</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$4.99</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,652,069</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8.0</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.24</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">677,182</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.0</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$5.00</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$10.00</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">760,554</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.3</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5.93</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">380,729</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5.2</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: bottom; width: 4%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6,685,604</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.5</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.70</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,876,795</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5.8</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>13.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Segment Information</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An operating segment is identified as a component of an enterprise that engages in business activities about which separate discrete financial information and operating results is regularly reviewed by the chief operating decision-maker (CODM) in making decisions regarding resource allocation and assessing performance. DiaMedica's CODM is the Chief Executive Officer. The Company operates in a <span style="-sec-ix-hidden:c735">single</span> operating segment focused on the development of its drug product candidate DM199 for the treatment of severe ischemic disease. The CODM manages and allocates resources to the operations of the Company on a total company basis. Further, the CODM reviews and utilizes functional expenses (i.e., research, development and general and administrative) at the consolidated level to manage the Company's operations. Other segment items included in consolidated net loss are revenues, share-based compensation, interest income, other expense, net, and income tax expense, which are reflected in the condensed consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table presents financial information, including significant segment expenses, which are regularly provided to the CODM and included within segment and consolidated net loss:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses, excluding share-based compensation</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,589</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,821</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,056</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,302</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,647</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,374</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,457</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,146</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total operating expenses, excluding share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,236</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,195</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,513</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,448</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">233</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">107</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">422</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">302</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">538</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">336</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,216</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">629</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total share-based compensationd</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">771</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">443</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,638</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">931</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,007</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,638</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(16,151</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11,379</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">313</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">524</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">757</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,140</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other income (expense), net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(17</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Segment and consolidated net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,699</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(15,406</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(10,270</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>14.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Subsequent Event</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July 21, 2025, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate 8,606,425 common shares at a purchase price of $3.50 per share in a private placement. As a result of the offering, which closed on July 23, 2025, we received gross proceeds of $30.1 million, which resulted in net proceeds to us of approximately $29.9 million, after deducting the offering expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In connection with the July 2025 private placement, we entered into registration rights agreements (collectively the Registration Rights Agreement) with the investors pursuant to which we agreed to file with the United States Securities and Exchange Commission (SEC) a registration statement registering the resale of the shares sold in the July 2025 private placement (Resale Registration Statement). The Resale Registration Statement was filed with the SEC on August 1, 2025 and declared effective by the SEC on August 8, 2025. Under the terms of the Registration Rights Agreement, we agreed to keep the Resale Registration Statement effective at all times until the shares are no longer considered &#8220;Registrable Securities&#8221; under the Registration Rights Agreement and if we fail to keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 5.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>OTHER INFORMATION</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and Modifications</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the quarterly period ended June 30,&#160;2025, <span style="-sec-ix-hidden:c834"><span style="-sec-ix-hidden:c835"><span style="-sec-ix-hidden:c836"><span style="-sec-ix-hidden:c837">none</span></span></span></span> of our directors or &#8220;officers&#8221; (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) and 408(c), respectively, of SEC Regulation S-K.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Segments</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We operate in a <span style="-sec-ix-hidden:c350">single</span> segment focusing on researching and developing potentially transformative treatments for severe ischemic diseases. Consistent with our operational structure, our chief operating decision maker manages and allocates resources for the Company at a consolidated level. Therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting. All assets are held in the United States.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Cash and cash equivalents</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of our cash equivalents approximates fair value due to the short maturity of the investments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Marketable securities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the condensed consolidated statements of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive income or loss, which is a separate component of shareholders&#8217; equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no other-than-temporary unrealized losses as of June 30, 2025.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"><i>Fair value measurements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The hierarchy is broken down into three levels defined as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Level 1 Inputs</i> &#8212; quoted prices in active markets for identical assets and liabilities;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Level 2 Inputs</i> &#8212; observable inputs other than quoted prices in active markets for identical assets and liabilities; and</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Level 3 Inputs</i> &#8212; unobservable inputs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of June 30,&#160;2025, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled &#8220;<i>Marketable Securities</i>&#8221; for additional information.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock', window );">Fair Value, Marketable Securities Measured on a Recurring Basis [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="30" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements Using Inputs Considered as of:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 1</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 2</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 1</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 2</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper and corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,419</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c386">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,419</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c388">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Government securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,510</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c394">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,510</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c396">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,831</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,831</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,929</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c402">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,929</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c404">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,122</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,122</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">136</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">118</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Furniture and equipment</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">128</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">128</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">280</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">262</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less accumulated depreciation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(128</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(114</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">152</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">148</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical trial costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,268</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,277</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development services</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">790</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">888</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">590</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,060</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional services fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">94</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">112</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total accrued liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,747</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,347</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Operating Lease (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">116</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">302</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Less interest portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(30</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Present value of operating lease obligation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">272</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Less current portion of operating lease</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(96</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease obligation, non-current</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_CommonStockReservedForFutureIssuanceTableTextBlock', window );">Common Stock Reserved for Future Issuance [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon exercise of employee and non-employee stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,685,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">174,515</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon vesting and settlement of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,607</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">754,919</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares available for grant under the 2021 Employment Inducement Incentive Plan</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">357,500</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,980,145</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_CommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A tabular disclosure of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_CommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(7,699</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,406</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10,270</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding&#8212;basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,957,619</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,068,378</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,901,093</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,013,189</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic and diluted net loss per share</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.18</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.13</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.36</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.27</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Common shares issuable upon exercise of employee and non-employee stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,685,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,859,271</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,685,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,859,271</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Common shares issuable upon settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">174,515</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">284,886</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">174,515</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">284,886</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Common shares issuable upon vesting and settlement of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,607</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,828</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,607</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,828</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">538</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">336</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,216</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">629</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">233</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">107</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">422</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">302</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">771</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">443</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,638</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">931</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Underlying</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average Exercise</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances at December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,692,438</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.33</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,243</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,333,416</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.42</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeitures</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(231,375</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.35</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(103,875</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.51</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6.91</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances at June 30, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,685,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.70</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,767</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: bottom; width: 4%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="10" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Outstanding, Vested and Expected to Vest</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="6" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 18%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Options Vested and Exercisable</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Per Share </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exercise Price</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Shares</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted Average</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Remaining</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Contractual Life</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Years)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted Average</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exercise Price</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Options </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exercisable</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted Average</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Remaining</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Contractual Life</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Years)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$1.00</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$1.99</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">191,443</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.7</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1.59</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">105,457</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.7</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$2.00</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$2.99</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,769,645</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.4</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2.74</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,484,034</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.0</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$3.00</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$3.99</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">311,893</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5.2</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.56</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">229,393</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.9</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$4.00</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$4.99</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,652,069</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8.0</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.24</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">677,182</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.0</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$5.00</p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$10.00</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">760,554</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.3</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5.93</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">380,729</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5.2</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: bottom; width: 4%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6,685,604</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7.5</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.70</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,876,795</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: top; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5.8</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended June 30,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses, excluding share-based compensation</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,589</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,821</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,056</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,302</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,647</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,374</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,457</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,146</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total operating expenses, excluding share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,236</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,195</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,513</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,448</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">233</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">107</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">422</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">302</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">538</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">336</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,216</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">629</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total share-based compensationd</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">771</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">443</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,638</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">931</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,007</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,638</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(16,151</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11,379</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">313</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">524</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">757</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,140</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other income (expense), net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(17</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Segment and consolidated net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,699</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(15,406</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(10,270</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Risks and Uncertainties (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 21, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit), Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (155,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (155,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (140,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,699)<span></span>
</td>
<td class="num">$ (7,707)<span></span>
</td>
<td class="num">$ (5,119)<span></span>
</td>
<td class="num">$ (5,151)<span></span>
</td>
<td class="num">(15,406)<span></span>
</td>
<td class="num">$ (10,270)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,747)<span></span>
</td>
<td class="num">(11,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-Term Investments, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_WorkingCapital', window );">Working Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity Attributable to Parent, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,170<span></span>
</td>
<td class="nump">$ 33,954<span></span>
</td>
<td class="nump">$ 53,415<span></span>
</td>
<td class="nump">$ 46,349<span></span>
</td>
<td class="nump">$ 27,170<span></span>
</td>
<td class="nump">$ 53,415<span></span>
</td>
<td class="nump">$ 40,718<span></span>
</td>
<td class="nump">$ 51,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="nump">$ 29,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Marketable Securities (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember', window );">Accrued Interest Receivable On Available For Sale Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest Receivable</a></td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">$ 235,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 25,929<span></span>
</td>
<td class="nump">$ 41,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">25,929<span></span>
</td>
<td class="nump">41,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper and Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">12,419<span></span>
</td>
<td class="nump">28,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper and Corporate Bonds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper and Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">12,419<span></span>
</td>
<td class="nump">28,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper and Corporate Bonds [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">13,510<span></span>
</td>
<td class="nump">12,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">13,510<span></span>
</td>
<td class="nump">12,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=dmac_CommercialPaperAndCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=dmac_CommercialPaperAndCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Amounts Receivable (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest Receivable, Current</a></td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">$ 235,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Property and Equipment - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 280<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_AccruedClinicalStudyCostsCurrent', window );">Clinical trial costs</a></td>
<td class="nump">$ 1,268<span></span>
</td>
<td class="nump">$ 2,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_AccruedResearchAndProfessionalFeesCurrent', window );">Research and development services</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">590<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services fees</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_AccruedTaxesAndOtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 2,747<span></span>
</td>
<td class="nump">$ 4,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_AccruedClinicalStudyCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued clinical study costs classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_AccruedClinicalStudyCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_AccruedResearchAndProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees and accrued research. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_AccruedResearchAndProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_AccruedTaxesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued taxes and other liabilities classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_AccruedTaxesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Operating Lease (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable Lease, Cost</a></td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less interest portion</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease obligation</a></td>
<td class="nump">272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of operating lease</a></td>
<td class="num">(96)<span></span>
</td>
<td class="num">$ (90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation, non-current</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Shareholders' Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 25, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,608<span></span>
</td>
<td class="nump">11,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits', window );">Stock Issued During Period, Shares Settlement of Deferred Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,875<span></span>
</td>
<td class="nump">2,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,747,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_ProceedsFromIssuanceOfCommonStockNet', window );">Proceeds from Issuance of Common Stock, Net</a></td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">4,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period due to the settlement of deferred stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 10 - Shareholders' Equity - Shares Reserved (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="nump">7,980,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_StockOptionsOutstandingMember', window );">Stock Options Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="nump">6,685,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember', window );">Deferred Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="nump">174,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="nump">7,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="nump">754,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_The2021EmploymentInducementIncentivePlanMember', window );">The 2021 Employment Inducement Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="nump">357,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_StockOptionsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_StockOptionsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_The2019OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_The2019OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_The2021EmploymentInducementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_The2021EmploymentInducementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,699)<span></span>
</td>
<td class="num">$ (7,707)<span></span>
</td>
<td class="num">$ (5,119)<span></span>
</td>
<td class="num">$ (5,151)<span></span>
</td>
<td class="num">$ (15,406)<span></span>
</td>
<td class="num">$ (10,270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding&#8212;basic and diluted (in shares)</a></td>
<td class="nump">42,957,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,068,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,901,093<span></span>
</td>
<td class="nump">38,013,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dmac_EmployeeAndNonemployeeStockOptionsMember', window );">Employee and Non-employee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities (in shares)</a></td>
<td class="nump">6,685,604<span></span>
</td>
<td class="nump">4,859,271<span></span>
</td>
<td class="nump">6,685,604<span></span>
</td>
<td class="nump">4,859,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dmac_DeferredShareUnitsMember', window );">Deferred Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities (in shares)</a></td>
<td class="nump">174,515<span></span>
</td>
<td class="nump">284,886<span></span>
</td>
<td class="nump">174,515<span></span>
</td>
<td class="nump">284,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities (in shares)</a></td>
<td class="nump">7,607<span></span>
</td>
<td class="nump">11,828<span></span>
</td>
<td class="nump">7,607<span></span>
</td>
<td class="nump">11,828<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dmac_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dmac_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dmac_DeferredShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dmac_DeferredShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 18, 2022</div></th>
<th class="th"><div>Dec. 03, 2021</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>May 22, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,980,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember', window );">Deferred Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,721,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">754,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member] | Employee and Non-employee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member] | Employee and Non-employee Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member] | Employee and Non-employee Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member] | Nonemployee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member] | Deferred Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2021EmploymentInducementIncentivePlanMember', window );">The 2021 Employment Inducement Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_StockOptionPriorPlanMember', window );">Stock Option Prior Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2012DSUPlanMember', window );">The 2012 DSU Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_NonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_NonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dmac_The2021EmploymentInducementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dmac_The2021EmploymentInducementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dmac_StockOptionPriorPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dmac_StockOptionPriorPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dmac_The2012DSUPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dmac_The2012DSUPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 771<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="nump">$ 1,638<span></span>
</td>
<td class="nump">$ 931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, options (in shares)</a></td>
<td class="num">(103,875)<span></span>
</td>
<td class="num">(2,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">$ 6.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, outstanding (in shares)</a></td>
<td class="nump">4,692,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance, aggregate intrinsic value</a></td>
<td class="nump">$ 3,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, options (in shares)</a></td>
<td class="nump">2,333,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeitures, options (in shares)</a></td>
<td class="num">(231,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeitures, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, options (in shares)</a></td>
<td class="num">(103,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, outstanding (in shares)</a></td>
<td class="nump">6,685,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation - Stock Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding | shares</a></td>
<td class="nump">6,685,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | shares</a></td>
<td class="nump">2,876,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange1Member', window );">Exercise Price Range 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding | shares</a></td>
<td class="nump">191,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | shares</a></td>
<td class="nump">105,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange2Member', window );">Exercise Price Range 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 2.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding | shares</a></td>
<td class="nump">2,769,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | shares</a></td>
<td class="nump">1,484,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange3Member', window );">Exercise Price Range 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 3.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding | shares</a></td>
<td class="nump">311,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | shares</a></td>
<td class="nump">229,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange4Member', window );">Exercise Price Range 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 4.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding | shares</a></td>
<td class="nump">2,652,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | shares</a></td>
<td class="nump">677,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange5Member', window );">Exercise Price Range 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding | shares</a></td>
<td class="nump">760,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | shares</a></td>
<td class="nump">380,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Segment Information (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Segment Information - Segment Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_OperatingExpensesExcludingSharebasedCompensation', window );">Total operating expenses, excluding share-based compensation</a></td>
<td class="nump">$ 7,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,513<span></span>
</td>
<td class="nump">$ 10,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,638<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">operating loss</a></td>
<td class="num">(8,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,151)<span></span>
</td>
<td class="num">(11,379)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">757<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,699)<span></span>
</td>
<td class="num">$ (7,707)<span></span>
</td>
<td class="num">(5,119)<span></span>
</td>
<td class="num">$ (5,151)<span></span>
</td>
<td class="num">(15,406)<span></span>
</td>
<td class="num">(10,270)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_OperatingExpensesExcludingSharebasedCompensation', window );">Total operating expenses, excluding share-based compensation</a></td>
<td class="nump">5,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,056<span></span>
</td>
<td class="nump">7,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_OperatingExpensesExcludingSharebasedCompensation', window );">Total operating expenses, excluding share-based compensation</a></td>
<td class="nump">1,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,457<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,216<span></span>
</td>
<td class="nump">$ 629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_OperatingExpensesExcludingSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations, excluding share-based compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_OperatingExpensesExcludingSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Subsequent Events (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 21, 2025</div></th>
<th class="th"><div>Jun. 25, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="nump">$ 29,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="nump">$ 29,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">8,606,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 30,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>134</ContextCount>
  <ElementCount>185</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 1 - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-1-business</Role>
      <ShortName>Note 1 - Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 2 - Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties</Role>
      <ShortName>Note 2 - Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 3 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 4 - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities</Role>
      <ShortName>Note 4 - Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 5 - Deposits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-5-deposits</Role>
      <ShortName>Note 5 - Deposits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 6 - Amounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable</Role>
      <ShortName>Note 6 - Amounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 7 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment</Role>
      <ShortName>Note 7 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 8 - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-</Role>
      <ShortName>Note 8 - Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 9 - Operating Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-9-operating-lease</Role>
      <ShortName>Note 9 - Operating Lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 10 - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity</Role>
      <ShortName>Note 10 - Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 11 - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share</Role>
      <ShortName>Note 11 - Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 12 - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation</Role>
      <ShortName>Note 12 - Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 13 - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-13-segment-information</Role>
      <ShortName>Note 13 - Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 14 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events</Role>
      <ShortName>Note 14 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995446 - Disclosure - Note 4 - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables</Role>
      <ShortName>Note 4 - Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Note 7 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-tables</Role>
      <ShortName>Note 7 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995448 - Disclosure - Note 8 - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-tables</Role>
      <ShortName>Note 8 - Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995449 - Disclosure - Note 9 - Operating Lease (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables</Role>
      <ShortName>Note 9 - Operating Lease (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-9-operating-lease</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995450 - Disclosure - Note 10 - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables</Role>
      <ShortName>Note 10 - Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995451 - Disclosure - Note 11 - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables</Role>
      <ShortName>Note 11 - Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995452 - Disclosure - Note 12 - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables</Role>
      <ShortName>Note 12 - Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995453 - Disclosure - Note 13 - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables</Role>
      <ShortName>Note 13 - Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-13-segment-information</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995454 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual</Role>
      <ShortName>Note 2 - Risks and Uncertainties (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995456 - Disclosure - Note 4 - Marketable Securities (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual</Role>
      <ShortName>Note 4 - Marketable Securities (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details</Role>
      <ShortName>Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995458 - Disclosure - Note 6 - Amounts Receivable (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable-details-textual</Role>
      <ShortName>Note 6 - Amounts Receivable (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995459 - Disclosure - Note 7 - Property and Equipment - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details</Role>
      <ShortName>Note 7 - Property and Equipment - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995460 - Disclosure - Note 8 - Accrued Liabilities - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details</Role>
      <ShortName>Note 8 - Accrued Liabilities - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995461 - Disclosure - Note 9 - Operating Lease (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-details-textual</Role>
      <ShortName>Note 9 - Operating Lease (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995462 - Disclosure - Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details</Role>
      <ShortName>Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995463 - Disclosure - Note 10 - Shareholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual</Role>
      <ShortName>Note 10 - Shareholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995464 - Disclosure - Note 10 - Shareholders' Equity - Shares Reserved (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details</Role>
      <ShortName>Note 10 - Shareholders' Equity - Shares Reserved (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details</Role>
      <ShortName>Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995466 - Disclosure - Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details</Role>
      <ShortName>Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Note 12 - Share-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual</Role>
      <ShortName>Note 12 - Share-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995468 - Disclosure - Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details</Role>
      <ShortName>Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995469 - Disclosure - Note 12 - Share-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details</Role>
      <ShortName>Note 12 - Share-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995470 - Disclosure - Note 12 - Share-based Compensation - Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details</Role>
      <ShortName>Note 12 - Share-based Compensation - Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995471 - Disclosure - Note 13 - Segment Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-13-segment-information-details-textual</Role>
      <ShortName>Note 13 - Segment Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995472 - Disclosure - Note 13 - Segment Information - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details</Role>
      <ShortName>Note 13 - Segment Information - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="dmtp20250630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995473 - Disclosure - Note 14 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual</Role>
      <ShortName>Note 14 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dmac-20250630.xsd</File>
    <File>dmac-20250630_cal.xml</File>
    <File>dmac-20250630_def.xml</File>
    <File>dmac-20250630_lab.xml</File>
    <File>dmac-20250630_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="dmtp20250630_10q.htm">dmtp20250630_10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>divpipeimg.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="516">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dmtp20250630_10q.htm": {
   "nsprefix": "dmac",
   "nsuri": "http://www.diamedica.com/20250630",
   "dts": {
    "schema": {
     "local": [
      "dmac-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "dmac-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dmac-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "dmac-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dmac-20250630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "dmtp20250630_10q.htm"
     ]
    }
   },
   "keyStandard": 173,
   "keyCustom": 12,
   "axisStandard": 14,
   "axisCustom": 0,
   "memberStandard": 19,
   "memberCustom": 15,
   "hidden": {
    "total": 28,
    "http://fasb.org/us-gaap/2025": 19,
    "http://xbrl.sec.gov/ecd/2025": 4,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 134,
   "entityCount": 1,
   "segmentCount": 39,
   "elementCount": 297,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 516,
    "http://xbrl.sec.gov/dei/2025": 28,
    "http://xbrl.sec.gov/ecd/2025": 5
   },
   "report": {
    "R1": {
     "role": "http://www.diamedica.com/20250630/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
     "longName": "004 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals",
     "longName": "005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
     "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-1-business",
     "longName": "007 - Disclosure - Note 1 - Business",
     "shortName": "Note 1 - Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties",
     "longName": "008 - Disclosure - Note 2 - Risks and Uncertainties",
     "shortName": "Note 2 - Risks and Uncertainties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "dmac:RisksAndUncertaintiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "dmac:RisksAndUncertaintiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-",
     "longName": "009 - Disclosure - Note 3 - Summary of Significant Accounting Policies",
     "shortName": "Note 3 - Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
     "longName": "010 - Disclosure - Note 4 - Marketable Securities",
     "shortName": "Note 4 - Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-5-deposits",
     "longName": "011 - Disclosure - Note 5 - Deposits",
     "shortName": "Note 5 - Deposits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "dmac:DepositAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "dmac:DepositAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable",
     "longName": "012 - Disclosure - Note 6 - Amounts Receivable",
     "shortName": "Note 6 - Amounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment",
     "longName": "013 - Disclosure - Note 7 - Property and Equipment",
     "shortName": "Note 7 - Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-",
     "longName": "014 - Disclosure - Note 8 - Accrued Liabilities",
     "shortName": "Note 8 - Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease",
     "longName": "015 - Disclosure - Note 9 - Operating Lease",
     "shortName": "Note 9 - Operating Lease",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
     "longName": "016 - Disclosure - Note 10 - Shareholders' Equity",
     "shortName": "Note 10 - Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share",
     "longName": "017 - Disclosure - Note 11 - Net Loss Per Share",
     "shortName": "Note 11 - Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
     "longName": "018 - Disclosure - Note 12 - Share-based Compensation",
     "shortName": "Note 12 - Share-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-13-segment-information",
     "longName": "019 - Disclosure - Note 13 - Segment Information",
     "shortName": "Note 13 - Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events",
     "longName": "020 - Disclosure - Note 14 - Subsequent Events",
     "shortName": "Note 14 - Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies",
     "longName": "995445 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables",
     "longName": "995446 - Disclosure - Note 4 - Marketable Securities (Tables)",
     "shortName": "Note 4 - Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-tables",
     "longName": "995447 - Disclosure - Note 7 - Property and Equipment (Tables)",
     "shortName": "Note 7 - Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-tables",
     "longName": "995448 - Disclosure - Note 8 - Accrued Liabilities (Tables)",
     "shortName": "Note 8 - Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables",
     "longName": "995449 - Disclosure - Note 9 - Operating Lease (Tables)",
     "shortName": "Note 9 - Operating Lease (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables",
     "longName": "995450 - Disclosure - Note 10 - Shareholders' Equity (Tables)",
     "shortName": "Note 10 - Shareholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "dmac:CommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "dmac:CommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables",
     "longName": "995451 - Disclosure - Note 11 - Net Loss Per Share (Tables)",
     "shortName": "Note 11 - Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables",
     "longName": "995452 - Disclosure - Note 12 - Share-based Compensation (Tables)",
     "shortName": "Note 12 - Share-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables",
     "longName": "995453 - Disclosure - Note 13 - Segment Information (Tables)",
     "shortName": "Note 13 - Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual",
     "longName": "995454 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual)",
     "shortName": "Note 2 - Risks and Uncertainties (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
     "longName": "995455 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual",
     "longName": "995456 - Disclosure - Note 4 - Marketable Securities (Details Textual)",
     "shortName": "Note 4 - Marketable Securities (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "i_2025-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember",
      "name": "us-gaap:InterestReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember",
      "name": "us-gaap:InterestReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details",
     "longName": "995457 - Disclosure - Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)",
     "shortName": "Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable-details-textual",
     "longName": "995458 - Disclosure - Note 6 - Amounts Receivable (Details Textual)",
     "shortName": "Note 6 - Amounts Receivable (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:InterestReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:InterestReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details",
     "longName": "995459 - Disclosure - Note 7 - Property and Equipment - Property and Equipment (Details)",
     "shortName": "Note 7 - Property and Equipment - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details",
     "longName": "995460 - Disclosure - Note 8 - Accrued Liabilities - Accrued Liabilities (Details)",
     "shortName": "Note 8 - Accrued Liabilities - Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "dmac:AccruedClinicalStudyCostsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "dmac:AccruedClinicalStudyCostsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-details-textual",
     "longName": "995461 - Disclosure - Note 9 - Operating Lease (Details Textual)",
     "shortName": "Note 9 - Operating Lease (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details",
     "longName": "995462 - Disclosure - Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details)",
     "shortName": "Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual",
     "longName": "995463 - Disclosure - Note 10 - Shareholders' Equity (Details Textual)",
     "shortName": "Note 10 - Shareholders' Equity (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-06-25_2024-06-25",
      "name": "dmac:ProceedsFromIssuanceOfCommonStockNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details",
     "longName": "995464 - Disclosure - Note 10 - Shareholders' Equity - Shares Reserved (Details)",
     "shortName": "Note 10 - Shareholders' Equity - Shares Reserved (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "dmac:CommonStockReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-06-30_AwardTypeAxis-StockOptionsOutstandingMember",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "dmac:CommonStockReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details",
     "longName": "995465 - Disclosure - Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "shortName": "Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details",
     "longName": "995466 - Disclosure - Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details)",
     "shortName": "Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual",
     "longName": "995467 - Disclosure - Note 12 - Share-based Compensation (Details Textual)",
     "shortName": "Note 12 - Share-based Compensation (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "dmac:CommonStockReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-05-22_PlanNameAxis-The2019OmnibusIncentivePlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details",
     "longName": "995468 - Disclosure - Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)",
     "shortName": "Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details",
     "longName": "995469 - Disclosure - Note 12 - Share-based Compensation - Stock Option Activity (Details)",
     "shortName": "Note 12 - Share-based Compensation - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details",
     "longName": "995470 - Disclosure - Note 12 - Share-based Compensation - Stock Options Outstanding (Details)",
     "shortName": "Note 12 - Share-based Compensation - Stock Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-details-textual",
     "longName": "995471 - Disclosure - Note 13 - Segment Information (Details Textual)",
     "shortName": "Note 13 - Segment Information (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details",
     "longName": "995472 - Disclosure - Note 13 - Segment Information - Segment Information (Details)",
     "shortName": "Note 13 - Segment Information - Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "dmac:OperatingExpensesExcludingSharebasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "dmac:OperatingExpensesExcludingSharebasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual",
     "longName": "995473 - Disclosure - Note 14 - Subsequent Events (Details Textual)",
     "shortName": "Note 14 - Subsequent Events (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-07-21_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20250630_10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r45"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r34",
      "r690"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r591"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "dmac_AccruedClinicalStudyCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "AccruedClinicalStudyCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical trial costs",
        "documentation": "The amount of accrued clinical study costs classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "AccruedInterestReceivableOnAvailableForSaleSecuritiesMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Interest Receivable On Available For Sale Securities [Member]",
        "documentation": "Represents information related to accrued interest receivable on available for sale securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional services fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "dmac_AccruedResearchAndProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "AccruedResearchAndProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees and accrued research. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_AccruedTaxesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "AccruedTaxesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "dmac_AccruedTaxesAndOtherLiabilitiesCurrent",
        "documentation": "The amount of accrued taxes and other liabilities classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Less accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r90",
      "r441"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r46",
      "r92",
      "r438",
      "r459",
      "r460",
      "r695"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r6",
      "r13",
      "r333",
      "r336",
      "r391",
      "r455",
      "r456",
      "r629",
      "r630",
      "r631",
      "r640",
      "r641",
      "r642",
      "r643"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r591",
      "r723"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
        "terseLabel": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r62"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total share-based compensation",
        "label": "Total share-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r307",
      "r308"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r75",
      "r91",
      "r112",
      "r113",
      "r114",
      "r143",
      "r150",
      "r163",
      "r166",
      "r208",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r323",
      "r325",
      "r367",
      "r431",
      "r432",
      "r436",
      "r488",
      "r550",
      "r551",
      "r560",
      "r591",
      "r594",
      "r595",
      "r606",
      "r661",
      "r662",
      "r709"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r93",
      "r112",
      "r113",
      "r114",
      "r208",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r323",
      "r325",
      "r367",
      "r591",
      "r661",
      "r662",
      "r709"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsNoncurrent",
        "totalLabel": "Total non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r208",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r323",
      "r325",
      "r367",
      "r661",
      "r662",
      "r709"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r216",
      "r348",
      "r362",
      "r363",
      "r364",
      "r365",
      "r428",
      "r532",
      "r579",
      "r582",
      "r589",
      "r653",
      "r700",
      "r701",
      "r702"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-1-business"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r634"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r88",
      "r533"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
        "terseLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r54",
      "r109"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r54"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_CityAreaCode",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_CommercialPaperAndCorporateBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "CommercialPaperAndCorporateBondsMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper and Corporate Bonds [Member]",
        "documentation": "Commercial Papers are unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents and commercial bonds are debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares reserved for future issuance (in shares)",
        "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r598",
      "r600",
      "r601",
      "r602",
      "r603",
      "r640",
      "r641",
      "r643",
      "r696",
      "r722",
      "r725"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, No Par Value (in dollars per share)",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "dmac_CommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "CommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Reserved for Future Issuance [Table Text Block]",
        "documentation": "A tabular disclosure of common stock reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorizedUnlimited": {
     "xbrltype": "authorizedUnlimitedItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorizedUnlimited",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]",
        "documentation": "Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is \"Unlimited\"."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r38",
      "r476",
      "r494",
      "r725",
      "r726"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, no par value; unlimited authorized; 43,072,488 and 42,818,660 shares issued and outstanding, as of June 30, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r242",
      "r247",
      "r437",
      "r591"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ComprehensiveIncomeNetOfTax",
        "totalLabel": "Net loss and comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r97",
      "r99",
      "r103",
      "r429",
      "r447",
      "r448"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_DeferredShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "DeferredShareUnitsMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Share Units [Member]",
        "documentation": "The deferred share units."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_DepositAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "DepositAssetsTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-5-deposits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposit Assets [Text Block]",
        "documentation": "Description of the companies deposits labeled as assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deposits",
        "label": "us-gaap_DepositsAssetsCurrent",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r22",
      "r105",
      "r534",
      "r535",
      "r537",
      "r539"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r303",
      "r304",
      "r305",
      "r568"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-1-business",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties",
      "http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-5-deposits",
      "http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentPeriodEndDate",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentQuarterlyReport",
        "terseLabel": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentTransitionReport",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentType",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted net loss per share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r104",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r133",
      "r134",
      "r136",
      "r137",
      "r138",
      "r142",
      "r240",
      "r306",
      "r319",
      "r322",
      "r345",
      "r346",
      "r430",
      "r449",
      "r543"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r139",
      "r140",
      "r141"
     ]
    },
    "dmac_EmployeeAndNonemployeeStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "EmployeeAndNonemployeeStockOptionsMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee and Non-employee Stock Options [Member]",
        "documentation": "Related to employee and non-employee stock option awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressAddressLine1",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressCityOrTown",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressPostalZipCode",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressStateOrProvince",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityCommonStockSharesOutstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityCurrentReportingStatus",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information",
      "http://www.diamedica.com/20250630/role/statement-note-1-business",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables",
      "http://www.diamedica.com/20250630/role/statement-note-5-deposits",
      "http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable",
      "http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-tables",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-tables",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables",
      "http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityFileNumber",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityInteractiveDataCurrent",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityRegistrantName",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityShellCompany",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r82",
      "r83",
      "r84",
      "r100",
      "r101",
      "r102",
      "r116",
      "r117",
      "r118",
      "r120",
      "r127",
      "r129",
      "r131",
      "r144",
      "r209",
      "r210",
      "r220",
      "r239",
      "r262",
      "r306",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r381",
      "r391",
      "r445",
      "r455",
      "r456",
      "r457",
      "r465",
      "r513"
     ]
    },
    "dmac_ExercisePriceRange1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "ExercisePriceRange1Member",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 1 [Member]",
        "documentation": "Related to the first exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_ExercisePriceRange2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "ExercisePriceRange2Member",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 2 [Member]",
        "documentation": "Related to the second exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_ExercisePriceRange3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "ExercisePriceRange3Member",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 3 [Member]",
        "documentation": "Related to the third exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_ExercisePriceRange4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "ExercisePriceRange4Member",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 4 [Member]",
        "documentation": "Related to the fourth exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_ExercisePriceRange5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "ExercisePriceRange5Member",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 5 [Member]",
        "documentation": "Related to the fifth exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r358",
      "r363",
      "r398",
      "r399",
      "r400",
      "r532",
      "r558",
      "r559",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r579",
      "r582",
      "r589"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r352",
      "r579",
      "r701",
      "r704"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r264",
      "r269",
      "r270",
      "r349",
      "r356",
      "r363",
      "r398",
      "r532",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r579",
      "r589"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r264",
      "r269",
      "r270",
      "r272",
      "r349",
      "r350",
      "r356",
      "r363",
      "r399",
      "r532",
      "r558",
      "r559",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r579",
      "r589"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r349",
      "r350",
      "r351",
      "r352",
      "r356",
      "r363",
      "r400",
      "r532",
      "r558",
      "r559",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r579",
      "r582",
      "r589"
     ]
    },
    "dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Marketable Securities Measured on a Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r352",
      "r579",
      "r701",
      "r704"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r358",
      "r363",
      "r398",
      "r399",
      "r400",
      "r532",
      "r558",
      "r559",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r579",
      "r582",
      "r589"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r704"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FinanceLeaseLiabilityNoncurrent",
        "terseLabel": "Finance lease obligation",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FinanceLeasePrincipalPayments",
        "negatedLabel": "Principal payments on finance lease obligations",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r387"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r238",
      "r260",
      "r331",
      "r342",
      "r359",
      "r366",
      "r369",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r435",
      "r446",
      "r557",
      "r579",
      "r580",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r592",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r655",
      "r656",
      "r657",
      "r658",
      "r697",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r497"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
        "totalLabel": "Loss before income tax expense",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r71",
      "r74",
      "r431",
      "r433",
      "r443",
      "r536",
      "r538",
      "r540",
      "r544",
      "r550",
      "r645",
      "r647",
      "r648",
      "r649",
      "r650"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r327",
      "r328",
      "r329",
      "r330",
      "r353",
      "r354",
      "r357",
      "r368",
      "r369",
      "r370",
      "r452",
      "r454",
      "r498",
      "r531",
      "r532",
      "r572",
      "r573",
      "r577",
      "r578",
      "r581",
      "r589",
      "r693",
      "r694",
      "r721"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r327",
      "r328",
      "r329",
      "r330",
      "r353",
      "r354",
      "r357",
      "r368",
      "r369",
      "r370",
      "r452",
      "r454",
      "r498",
      "r531",
      "r532",
      "r572",
      "r573",
      "r577",
      "r578",
      "r581",
      "r589",
      "r693",
      "r694",
      "r721"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "negatedLabel": "Income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r80",
      "r112",
      "r130",
      "r131",
      "r143",
      "r152",
      "r166",
      "r311",
      "r312",
      "r315",
      "r450",
      "r536",
      "r538",
      "r540",
      "r571"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income taxes",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r56",
      "r633",
      "r691",
      "r692"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsReceivable",
        "negatedLabel": "Amounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
        "terseLabel": "Accrued liabilities and operating lease liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInDepositOtherAssets",
        "negatedLabel": "Deposits",
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInPrepaidExpense",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InterestReceivable",
        "terseLabel": "Interest Receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r727"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InterestReceivableCurrent",
        "terseLabel": "Interest Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r151",
      "r166",
      "r550",
      "r632"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium",
        "negatedLabel": "Amortization of discounts on marketable securities",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r81",
      "r175",
      "r176",
      "r360",
      "r361",
      "r718"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r390"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information",
      "http://www.diamedica.com/20250630/role/statement-note-1-business",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables",
      "http://www.diamedica.com/20250630/role/statement-note-5-deposits",
      "http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable",
      "http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-tables",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-tables",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables",
      "http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r636",
      "r639",
      "r719"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r636",
      "r639",
      "r719"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r636",
      "r639",
      "r719"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r636",
      "r639",
      "r719"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
        "negatedLabel": "Less interest portion",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r70",
      "r440",
      "r591",
      "r594",
      "r595",
      "r635",
      "r638",
      "r659",
      "r707"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r87",
      "r112",
      "r113",
      "r114",
      "r208",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r324",
      "r325",
      "r326",
      "r367",
      "r591",
      "r661",
      "r709",
      "r710"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesNoncurrent",
        "totalLabel": "Total non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r33",
      "r34",
      "r35",
      "r36",
      "r112",
      "r113",
      "r114",
      "r208",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r324",
      "r325",
      "r326",
      "r367",
      "r661",
      "r709",
      "r710"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r651"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_LocalPhoneNumber",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities",
        "label": "us-gaap_MarketableSecuritiesCurrent",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r224",
      "r225",
      "r226",
      "r227",
      "r273",
      "r298",
      "r299",
      "r300",
      "r309",
      "r352",
      "r426",
      "r451",
      "r453",
      "r461",
      "r468",
      "r469",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r556",
      "r561",
      "r567",
      "r572",
      "r574",
      "r575",
      "r582",
      "r583",
      "r587",
      "r588",
      "r593",
      "r663",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r224",
      "r225",
      "r226",
      "r227",
      "r273",
      "r298",
      "r299",
      "r300",
      "r309",
      "r352",
      "r426",
      "r451",
      "r453",
      "r461",
      "r468",
      "r469",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r556",
      "r561",
      "r567",
      "r572",
      "r574",
      "r575",
      "r582",
      "r583",
      "r587",
      "r593",
      "r663",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Net Cash Provided by (Used in) Operating Activities, Total",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r57"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "terseLabel": "Net Income (Loss) Attributable to Parent, Total",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r57",
      "r72",
      "r84",
      "r85",
      "r96",
      "r98",
      "r102",
      "r112",
      "r113",
      "r114",
      "r115",
      "r119",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r130",
      "r131",
      "r135",
      "r208",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r240",
      "r243",
      "r245",
      "r248",
      "r306",
      "r319",
      "r322",
      "r346",
      "r367",
      "r444",
      "r495",
      "r511",
      "r512",
      "r536",
      "r538",
      "r540",
      "r604",
      "r661"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrAdoptedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrTrmntdFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dmac_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Amount of expense recognized over the period for lease expense, non-cash."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_NonemployeeStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "NonemployeeStockOptionsMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonemployee Stock Options [Member]",
        "documentation": "Related to the nonemployee stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "dmac_NoteToFinancialStatementDetailsTextual": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "NoteToFinancialStatementDetailsTextual",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r646"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_OperatingExpensesExcludingSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "OperatingExpensesExcludingSharebasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total operating expenses, excluding share-based compensation",
        "label": "dmac_OperatingExpensesExcludingSharebasedCompensation",
        "documentation": "Generally recurring costs associated with normal operations, excluding share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r536",
      "r540",
      "r544",
      "r645",
      "r647",
      "r648",
      "r649",
      "r650"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseCost",
        "terseLabel": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r590"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of lease obligation",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligation",
        "negatedLabel": "Less current portion of operating lease",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligation, non-current",
        "terseLabel": "Operating lease obligation",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use asset, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized loss on marketable securities",
        "terseLabel": "Unrealized loss on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r207"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r576"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquireMarketableSecurities",
        "negatedLabel": "Purchase of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ]
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyTextBlockAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common shares, net of offering costs",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dmac_ProceedsFromIssuanceOfCommonStockNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "ProceedsFromIssuanceOfCommonStockNet",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dmac_ProceedsFromIssuanceOfCommonStockNet",
        "terseLabel": "Proceeds from Issuance of Common Stock, Net",
        "documentation": "The cash inflow from the issuance of common stock, net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOfPrivatePlacement",
        "terseLabel": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of marketable securities",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r654"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the exercise of stock options",
        "terseLabel": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r390"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r77",
      "r78",
      "r79"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r89",
      "r442"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r390",
      "r434",
      "r442",
      "r591"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r390"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r224",
      "r225",
      "r226",
      "r227",
      "r263",
      "r273",
      "r298",
      "r299",
      "r300",
      "r305",
      "r309",
      "r352",
      "r401",
      "r410",
      "r426",
      "r451",
      "r453",
      "r461",
      "r468",
      "r469",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r556",
      "r561",
      "r567",
      "r572",
      "r574",
      "r575",
      "r582",
      "r583",
      "r587",
      "r588",
      "r593",
      "r598",
      "r660",
      "r663",
      "r701",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r224",
      "r225",
      "r226",
      "r227",
      "r263",
      "r273",
      "r298",
      "r299",
      "r300",
      "r305",
      "r309",
      "r352",
      "r401",
      "r410",
      "r426",
      "r451",
      "r453",
      "r461",
      "r468",
      "r469",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r556",
      "r561",
      "r567",
      "r572",
      "r574",
      "r575",
      "r582",
      "r583",
      "r587",
      "r588",
      "r593",
      "r598",
      "r660",
      "r663",
      "r701",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ]
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r45"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r531",
      "r536",
      "r537",
      "r550",
      "r717"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r62",
      "r439",
      "r458",
      "r460",
      "r464",
      "r477",
      "r591"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r116",
      "r117",
      "r118",
      "r120",
      "r127",
      "r129",
      "r131",
      "r209",
      "r210",
      "r220",
      "r239",
      "r306",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r332",
      "r334",
      "r335",
      "r337",
      "r344",
      "r379",
      "r381",
      "r455",
      "r457",
      "r465",
      "r725"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets acquired under financing lease",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r590"
     ]
    },
    "dmac_RisksAndUncertaintiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "RisksAndUncertaintiesTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Text Block]",
        "documentation": "A complete disclosure of the risks and uncertainties the company may face."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrAdoptedFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrTrmntdFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r63"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r143",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r155",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r171",
      "r173",
      "r545",
      "r548",
      "r549",
      "r550",
      "r552",
      "r554",
      "r555"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r169",
      "r172",
      "r546",
      "r547",
      "r553"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired (in shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedLabel": "Forfeitures, options (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, options (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance, aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Balance, outstanding (in shares)",
        "periodEndLabel": "Balance, outstanding (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "outstanding, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "outstanding, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeitures, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
        "terseLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
        "terseLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesOutstanding",
        "periodStartLabel": "Balances (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r38",
      "r42",
      "r43",
      "r82",
      "r83",
      "r84",
      "r100",
      "r101",
      "r102",
      "r116",
      "r117",
      "r118",
      "r120",
      "r127",
      "r129",
      "r131",
      "r144",
      "r209",
      "r210",
      "r220",
      "r239",
      "r262",
      "r306",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r381",
      "r391",
      "r445",
      "r455",
      "r456",
      "r457",
      "r465",
      "r513"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals",
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-1-business",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables",
      "http://www.diamedica.com/20250630/role/statement-note-5-deposits",
      "http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable",
      "http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-tables",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-tables",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables",
      "http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r144",
      "r241",
      "r242",
      "r244",
      "r246",
      "r381",
      "r427",
      "r462",
      "r466",
      "r467",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r538",
      "r540",
      "r599",
      "r724"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals",
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-1-business",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-segment-information-details",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables",
      "http://www.diamedica.com/20250630/role/statement-note-5-deposits",
      "http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable",
      "http://www.diamedica.com/20250630/role/statement-note-6-amounts-receivable-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-property-and-equipment-details",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-tables",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-accrued-liabilities-details",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-tables",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-maturity-of-operating-lease-liability-details",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables",
      "http://www.diamedica.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r144",
      "r174",
      "r241",
      "r242",
      "r244",
      "r246",
      "r381",
      "r427",
      "r462",
      "r466",
      "r467",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r538",
      "r540",
      "r599",
      "r724"
     ]
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation",
        "terseLabel": "Share-based compensation expense",
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares net of offering costs of $0.1 million (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r37",
      "r38",
      "r62",
      "r463",
      "r513",
      "r523"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r37",
      "r38",
      "r62"
     ]
    },
    "dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares in settlement of deferred stock units (in shares)",
        "terseLabel": "Stock Issued During Period, Shares Settlement of Deferred Stock Units",
        "documentation": "The number of shares issued during the period due to the settlement of deferred stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon the exercise of stock options (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised, options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r37",
      "r38",
      "r62",
      "r284"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares net of offering costs of $0.1 million",
        "terseLabel": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r37",
      "r38",
      "r62",
      "r465",
      "r513",
      "r523",
      "r605"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon the vesting and settlement of restricted stock units",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r62"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon the exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r38",
      "r42",
      "r43",
      "r62"
     ]
    },
    "dmac_StockOptionPriorPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "StockOptionPriorPlanMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Prior Plan [Member]",
        "documentation": "Information related to the company's stock option plan known as the Prior Plan."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_StockOptionsOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "StockOptionsOutstandingMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Outstanding [Member]",
        "documentation": "Related to stock options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total shareholders\u2019 equity",
        "terseLabel": "Stockholders' Equity Attributable to Parent, Ending Balance",
        "periodStartLabel": "Balances",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r42",
      "r43",
      "r58",
      "r478",
      "r494",
      "r514",
      "r515",
      "r591",
      "r606",
      "r635",
      "r637",
      "r638",
      "r659",
      "r707",
      "r725"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r331",
      "r343",
      "r516",
      "r517",
      "r524"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r393"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r393"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r393"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r394"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-details-textual",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events",
      "http://www.diamedica.com/20250630/role/statement-note-14-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-tables",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-tables",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-tables",
      "http://www.diamedica.com/20250630/role/statement-note-13-segment-information-tables",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-tables",
      "http://www.diamedica.com/20250630/role/statement-note-7-property-and-equipment-tables",
      "http://www.diamedica.com/20250630/role/statement-note-8-accrued-liabilities-tables",
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_The2012DSUPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "The2012DSUPlanMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2012 DSU Plan [Member]",
        "documentation": "Related to the 2012 DSU plan."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_The2019OmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "The2019OmnibusIncentivePlanMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2019 Omnibus Incentive Plan [Member]",
        "documentation": "Represents information related to the 2019 Omnibus Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_The2021EmploymentInducementIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "The2021EmploymentInducementIncentivePlanMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity",
      "http://www.diamedica.com/20250630/role/statement-note-10-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation",
      "http://www.diamedica.com/20250630/role/statement-note-12-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2021 Employment Inducement Incentive Plan [Member]",
        "documentation": "Represents the company's 2021 Employment Inducement Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r238",
      "r260",
      "r331",
      "r342",
      "r359",
      "r366",
      "r369",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r435",
      "r446",
      "r579",
      "r580",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r592",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r655",
      "r656",
      "r657",
      "r658",
      "r697",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20250630/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r562",
      "r564",
      "r720"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-9-operating-lease-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_VariableLeaseCost",
        "terseLabel": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r590"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.diamedica.com/20250630/role/statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average shares outstanding\u2014basic and diluted (in shares)",
        "label": "Weighted average shares outstanding \u2013 basic and diluted (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r138"
     ]
    },
    "dmac_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20250630/role/statement-note-2-risks-and-uncertainties-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dmac_WorkingCapital",
        "terseLabel": "Working Capital",
        "documentation": "The amount of working capital."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-10-shareholders-equity-shares-reserved-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Shareholders' Equity - Shares Reserved (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-10-shareholders-equity-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-10-shareholders-equity-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Shareholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-11-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-11-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-11-net-loss-per-share-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-11-net-loss-per-share-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Net Loss Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-12-sharebased-compensation-stock-option-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Share-based Compensation - Stock Option Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Share-based Compensation - Stock Options Outstanding (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-12-sharebased-compensation-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-12-sharebased-compensation-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Share-based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-13-segment-information-segment-information-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-13-segment-information-segment-information-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Segment Information - Segment Information (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-13-segment-information-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-13-segment-information-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Segment Information"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-4-marketable-securities-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-4-marketable-securities-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-7-property-and-equipment-property-and-equipment-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-7-property-and-equipment-property-and-equipment-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Property and Equipment - Property and Equipment (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-7-property-and-equipment-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-7-property-and-equipment-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-8-accrued-liabilities-accrued-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-8-accrued-liabilities-accrued-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Accrued Liabilities - Accrued Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-8-accrued-liabilities-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-8-accrued-liabilities-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-9-operating-lease-maturity-of-operating-lease-liability-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-9-operating-lease-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-note-9-operating-lease-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Operating Lease"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-significant-accounting-policies-policies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20250630",
     "localname": "statement-statement-significant-accounting-policies-policies",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480513/718-10-30-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001437749-25-026207-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-25-026207-xbrl.zip
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M)V$](I*[Q"(])%'/U* 5=F/,D().I]"'=3U@5C!&.TLMNL(/&1"GG3G:?KP
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MV[UEP\$R.O.1U%#/"PM6N;V;:V_OO2'7Q"G7+'&C>F"M> 7B9OZ\&4\I33/
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MP&)$XS!V6.J^3%70O!CW)+6KH:$:]HHF1<3>0P5X\3@;!ZD[,@F_P5O<<]7
M1%G1B 1YS=D4U8?XH+\"(KO$M+="6YQFKD:!S4JD;G#;XU'C\M35B!DW7QM'
MEN@97II^_G(+8@<5MZ=+!@;*X!7_ ]#A.Y31Y\<C[HH<'1P5/AF;;(4O+&A"
MJ->)$NMZ<E3M,SJLSE4E+4V7MOD(J;/3*2GUC5^O:4J*;DDMAN65@<_#QR1
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M,G]\>!0MF#H8[!S,9(!89PB,!];X7]7+[I@X$ZK8!_ML.@)<28*QS:Y78<U
MXF#W$Y2J"OH,:W02F9L#FQI7]8U-C+BQ#NX/AOSA9P?M+TC>.(+/FRE,(]$
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M;=/L_]ME<HW=AVAIFVM9_U#<C4M+A_(.JF G"8N!] OSP\Q,?/)?4$L#!!0
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M.(T]HNC66]>2@R6)H#L?9FM"E<>DT8D$IIGK!GK0Z=L:C&C%4!5Q1:=3VQ:
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M,%3<PBHT4U?D[%R3,XG\&VG@2S4CYN?1$XL3-?_+H+#Y %;YNV2)HNY*\*=
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MS)GJ#E;IOV!NS%0=R/.YU'5/N5M4RP"@AU4.2F?RT;*BA(9!3QP<?1'E=P+
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MV0F;,:EM_*S#G5Q3>^)L:3C+I82")[F^KT+78_LU,/:J!^D:VRZ!I)\EI2P
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M'T!S'E@ -1 W#!%WGB<<.2H >Q!1D?&2*#+(WRZ90\'(8GO+N%DPY1A>+MG
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M&B!G5M5?[6=D,6&:95T:4WF$=Z"$4E[=(LF6)%\+PW$NGCJ$>E=%-P^^\[J
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MLKSM('_%D*N,X]D3SJ/'*H[]9GE4QOLLHLE"LF48P3#<([1PZ2\ !G5.=)=
M31.*!%'UN^ID3\[_^)>?3D]._S@'JGB.&'<5L2X#G\1PS Z]/5*!#X@SXN2/
M:  G'&T&9E),K,R%/X6A\H7<1ENX1L+KX8M%SO:BN@1!@NE%0A<IH66.^]Z>
M' C-5$TPP^K<XUV1A2JZQ)/S@C+4( WM:0O_8N70&6RIA#UH6@99,O BKM;
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M48<X=6U/PVDVL#1QI(AC#?5(C73:B0I?/%H =GF/%TR'S![% Y'"AL5_O-E
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MJ7-<6KI=3!]P6D-6[>\.^0KWV>T#,N+L@_-'!0BX?<X)AS%XREANBNF/308
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M\45V$LZ2/'P;BPALK9?RLCQ8$Z'EC\&10<HD_+[9Q@8Z)=6!A&T-4'V%LP@
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M35EE7'O0*'\<STKWP]DS(E%"&Y/FVP]DPWS+Y=>2J>O[6C.K[EE:>5AKL.B
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M+UT\[^9P@:'/&[81]+'Z;<]=T%G5:Z@5K/K,O+!\P<A%JK[K5UF^@(0 0<,
M75E!  %<%(;H"D_(96YPE,'0!:V6]KD6$26N[+B*2"G[],$X#;6THF)\E2M[
M+R!!L&\7N"N;5<_V796<(5=V-3.0UF8].2-E&(&T-F_+F3W4"*2UF6>N'--F
M(*W-G7,&4@W5$'X>*@2^&H*P&D*GZ2UK#/753#@**'HL_TZR"2;35O42A(-H
MK94 H,372>BU3H)-N<=VY5$-?P:&,L%\+I7/I?+Y/PH1[]41>(-FF.1)]JAP
M;RB\I\\Y\#D'/N? YQSXG /C/JL]C+[W+N%=F:8_1Z?EKA.+7.>6<Y0O$^L-
MHZWODE/5)$P8/S\%M'B@Z*^"?\4V02:5JIH^!4-H-7Q*Z?!F3V_V]&;/(9D]
MQ7>DORVD [A079?Q8WW].P]>'4_N2)A1AJ/,-@COZ(U/^HU/W=.Y.K#.YC+V
M%K8U2;6DK*.DM6G*Q<M1UMXD]=+"D]+VVJE/F#Q'%AN;G(1OA.V]F=B;B;V9
M>+_-Q++#!2OOY2XA(]X^<7NQTQF0Y+8MB/3BC+6S]6K:3QNPHJCB#" J6PM$
M*W??5-Z=M\#V%!+O+6CI+8 I:UWX"%[9DE$45^A<9&Q1(\)._CC)'C>+M+UV
M"-1:I/DHE0X8Q6O53S[D3@Z"MO/8V1M0/UOVQQ];#V\RF,$:[^PI:*;T>T[2
M.T2FE M[,7MXDS4!UKA'2J]P=E.DZ.#CP^<#]NA1C&<YBL_3\+&&TN;&'9BP
ME6F](],L!Y*Z;JN%4CBD)O$$@VD0R?7Z/5Y<9'&=R5G6S!U3%G!?PU!,ABXS
MJ^$!W6?[$Y@U6O;4H 'N0OW)T=8B S_R^DNJMA8<V+G07QZOM<" I0^]44DT
M><R2"6O%/H=1A(N,ATX%,YPF48+HZL-KG404I*0ZHJ:8I79D^1"F7D.8-EY/
MZQ>U&=S4Q7A:G;2C%4'72S(D,4/R#EKI/PDI#^?F_YS]523S,.6*?TG:0N8N
M5^JK=5;G84)^#],"?4<A-RAQ/JKH@LU,N;_6V7T/R9\HYZ+_+8H*DN2,B2JZ
M&J8C[Z W2.TUAI(%(VD]/,H-A0:^C:Y660]*?7V@G<_R!(3O='+4^\">IL >
MX.8S=.>1#^K1Y$:UU%SHW:A;!: E\A)6UT5<@08P7T$Z&D#H<64UJ0'50@]T
M)8!%#2BH'N9*;(L:.BV5;@-)H)^"Z>I-!G3U*H/R"]5T4-A@.A-#52CR]M5>
M[:OK-5&S=2S723S.1C?\2\(6VG%($UK*0$TZ?>?C]F1&5F!%F059F:N]\6+0
M68)"_A<WLIU.F/%P6.)Y)^O66X*:+$%B!AJZ;N<-0-X Y U FT@T'&RX-]'/
M@ ;V2S C>(9(O@C"+ [07T52UB)KIX(!1].I@RF1Y)4P[4$N*B\)I)XHO7!M
MU60JBOA5(/DHB\]>B)+)K/".7M_R^I;-=.Z?O@7=B+S"Y14NKW!YA<LK7,T*
M5UMYR(!&]84'7#& XB!-PH<DW<&C!1E*IRX%I\<K4F84*<@; FE1\%>M2X2/
MGE!<\*(?HXJPRS5=('%4?0"O4GF5RF8Z]T^E NU*7I_R^I37I[P^Y?4IN3[5
M5B@RH%=]#;CJ%Y9Y+"D**6JG4\F&T:E/P6CQNI0974KV=D!Z%.P5:Y(Q+Q&E
M"(U?"+KD]+PL^,7W,.>^ZP5($-UA)*]5>:W*9CKW3ZN2[E%>H_(:E=>HO$;E
M-2JY1K6S9&1 M3KX&- G-O<GG+*70,M0A7S13K\"C:53R5(@R&M:O6I:)W@Z
MQ5E9LYU?@$OF*#['Y+Q@:P)=4%J$683D&5?M1^E3601Q&4AC5.!7KT1Y)<I.
M.O=/B8(M6Z])>4W*:U)>D_*:E"2Y:E<ISX06=1!D* \8;C1@ZE]U'+14H@!#
M:=6AP/1X%<J,LPKRAF#J!_A5ZP_\8XC&25KDR7PCT_+L.4H+QG'G;'MAN\:L
MJ#A_/#D+299DC_0:D5L^"84 P8X?9 BOMW3Q_--HE,6G?&HH5HR:;#6:UU.]
MGFHSG7NHIT+V=Z^F>C75JZE>3?5JJDH(Y0X2DBN,HQ1QVHN4;4+Q/ZQ.T8>0
M81NPYC.4T?)Y+;5_Z'A:30!J1'D[@"$[ /0UP8P!:B]=OX;+.!\O$-L^R#R)
MT,NNB^*3#5)':4E7N8G<H @_9LG?*&;;2()9.UISX7&S#MS/\PRA5T]^^2T=
M%?D3)ISP>[:,26F('<_X[SSUFAXOSIX1B1**K@D#XH;?= R'L>\'VX7G>@9T
M%+'##AICW=W W@KCK3 VT[F'5ACPP>I-,=X4XTTQWA3C33%*II@^!7576$L%
MT&Y$4#!REM]6TP%R'2L[)LQ>1P&M;G8*DFR"R707DQ=D+*WF+CA!WM1ER-0%
M>44P,Q?\9>LW*KRY/.UB3>#Q8OFC@B6AS6C>?.#-!S;3N8?F ]"&Y4T'WG3@
M30?>=.!-!TKZ6GL1R8 2=AB0A/Y)RPKS118ADK,5759%C!'[F-(@9[068:JH
MD"F/JU,Y:TF<5]1Z5=2NV*NYP^=)%F91$J:KO>6T>B=WKU_)IF*FUK,#4O^%
MR9]L:9^$LR2O)^EU"YB$V;DLS"^"?G,9]"B+;Y_8QG2'R/0BFR.:<Z":="3X
M (9F>(5R3M\UP?.$K<SCQ3T[!RZR5?F,I5$QV5+HU0<(,F-3O,C8EH8N,17,
M8MW&%*$,PPBAF/+(NY<4N_'DFC#.R=%U&D;EFFR8 :RS(2Z[X?M(AN*7$,)1
M%!73(F64Q:=HDD1)TZSD'4V]+&\FZ8M.)M4M<_C/RA3^1EK?-G36#*%X/!LW
M.W@MVP(5TVO9%FC9UAK@6ARL_?&+M2B)Q<+^G.DV ])6V@>C=>0,6NVU/S!8
MGP8/%D#;!Z/Q>?!HP*5;,"@_.P-*.QW7@%'X**#%=!J218 G 4T>LX0=J2'[
M-8PB7&1EH><93MDQN[.=N(M'Z30==T>OMR;OG35Y=UM@,7U 9#Q9"2Q+?U*C
M7;"IO2%#FK<Z#5!7]S8<;\/Q-AQOP^E<&8<>3@8DX$\!D_'^1&5 7$!7Q25V
M%'851]4IU[8BS8NPO8JPRROU+C*VA!'-;U"$F*K(7M X&\W96^$?SS&Y#=.-
M^B??$5]5=7)M!\-YN;Q>3AQ5RA_E)-)+'&;<4+:D-'M<(WV\6'^^8P36L%27
M0VK%8)NO&F:VW="86W\3N-H=!]+4:U!>@_(:E->@VLO+G>SU6&6W<@4YN>+5
MW3GJBK+:%;=U*U2Z@JX.:XCEV>W>&M+"&B*7BBTR@TS"A 3S,"T0=X,)+0<=
MF4A:/-$&\TEKLKUII?>K!'EEC#"]#F>(L /P!),9)NRE'N,L%EA1U'KV6;^@
M0YX#53GHG,=U&6<:Y9!3])"O_VHRQ"AVUSJW<X;][QSZX\7JXS\31-A9\;2X
M1'.4"DQ,:IU-S>L["FE!2CX\)^BO F51W7[1HJ>9&5UDLR*G);P'M=N,0@_C
M,SA4GL&A93,X4I[!D0TSJ.-MH053H:?Q&='M[4AY;M(QS,_RAI\=A.G<,!8$
M=-4[IQ=3YD5&F>[$Z1+MR^+6WHCN0/+;'0DSRI3Q,DR\K)S(.'0\J7GUE!N4
M:/U/PJ7>QR.T8G1_^PW/$<G*!?#(-M\M05*X&ZAV=\R)HD4Y\:Z7_7&]R(XE
MK&/K<09,-842=R+!.0B>5'&5(">4ZUW!2^YE4#8%N.*#ZI"5Q)J&*X !> FB
MOK@"!^!0;&T+WQ\G9QOSJC,<M+LD(+-ZNL)(W4)5:U[M+W=]R%#5VG&=X2JX
M7M/.I. *3^F(UU&N<F +!.;C=0PAL3W/S9#"5AYA ^$[/P?AM SU"\@ZJFBW
M%":5(74&X*C3Y2-L?/[][CDN)TPY1HU5+1O;^_Q[GSWBLT>\"V,H$JSEY@:;
M)=@!19PW'$X&)-=?@AG!,T3R15FD'_U5)+/RUX:OVP6;[_@4G?)M)Z1ZD=?,
M37,[OCQ0='8G#*(O77Y=K94M%B;1\*7"/J>HW&ZS>#3EMZ?\77Y_O9P!O],R
M9[^=O4RB02#L:O@@^V($'G[/9\'VYA4APH@@26N](8$%R9*\(*C,*'SFG\3A
M3/(.6NF_1"%%O&SEQ90MFWGE 15. -!#]R4,]<Q\O) 4G%#H:<>,OI'F"S%@
MG>R8QQ427(K1V"4XLFL6TA(:"CV]3<3;1'8)!MU5%O+6D_VQGJ@<>WB'W<P5
MO.2F%F5!PA4K5$M6 @GPKL0EM,0(JB>X$I70$B:P-N+*DO/55JRV?=L8O:&B
M&O:P3+Y6R&2,-?-E6\L ZLU\UM^*RW$>IC9BJ:+!&W"S?.'75O#Z74&:A ])
M6N7#U7W7SL'2>GR=KI4=B?1.%1U%D$]82_8VT]N\B!<GF.:T/O)&J4]WY-TP
MKN11R&R)LR4_090R_@S3<X0 =,([=T?P7?B,>"+C.']"Y'+-XW)J)3V# QT>
MM=9K%N1+VW%'T.=%X_1(7YZTO2%3\I(>V'I1ZZ1U'F?LD,(+Q,[C4F8"OP]P
M/V\.]^;P7<SA[;<S;PC?'T.X#R/TIA25.T_5A&SG6$0*C*I4[YP]4F@8411^
M7+'K@RUP8"&WOR3$.2(/V*[0Y1WT4#!.ZI<PVVI\!"M\!BR/7P/\<NU;D'*O
MU8YYB>#Q=%H6%8GRED2?D:BJ_JXN3RQ=OUS^:E"!MQOZ'$2GBF_^'I*$/US&
M"%OM8'PP+#W&YTQZ8X<W=@S6V&%MSJ3\%.V//:P%17JB6*%?3,.<UV59\#K
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MV#WI%45WX?.2)8X9QTP:TS,:6INZ]NDBFR.:<R0KPBXR)L&Q;QJI%S?7:Y]
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M"FZ] X.V^,!M\I1J\FCOK$=LGQ;<X*4#E#0ZAQ8]8E\#T;S^04>IAH_WSFK
MU5NU>JU5*[!UX"LG-ZYS']JT7NNVZQW/>_0&3F"-AVX>-4%."KT%^Q.<]-@K
MM:I\(HJ?#^S1&]TY6'-W)B:H8[E#8'&I+K5+G*&L_K26[<^51TR4Y.)%ASBP
MN;H6.DP\<1=Z-.JI%$8GT$B7>K>]VR'7$YRG!_J$] 6L! D<GJRE^PL:1=5R
M@ZI%338@8+;(#R#!KF^N]LYBBH^Z^_9\-JJU=K5^E/S8>2&>A=*E\\K\*JPR
M'0QM=T3I0^":/V^'7*/Y3K'O?][9Q+F!0?%''_L4U-GCVX'#NJ%_#;H5$/ S
MQ6?$XY,3\- G'OT"&JIU[@Z&H#AQ;0G6CCA/%&?BRVC\R!T9X27>._Z?_Z$^
M3II@_76YQNVC]!JCQ7-BA=X(N&5B@N;&6_GSTWU[?KJ3\W/Y.F1"]12S$T].
M<\;D+"ZMWIR<2SDS'<<J<I[^O,<)X,]^)Z]L$ [6B*_&C"EL;>04,F?-4UA?
M+XFN: I73ZVU6?.4J^^D956KUDK+*I804']>$>;]#[%#^F44?_R=@3CRS/[H
M&WVF-I^+^-ZU,PP#G]]HRDE+O.([)3[(.:XC>F"NH,F9_GWB"?^>HED*\(BF
M,Q:6/QXN)B>W\TR83<"NOG*]!Y"-#_AC%C#J7]!N,/X6B\[FW**SV@0M,E=R
M3LYF8S6S6=_%V6P>'VP&-O^\8@YQ3(9FB!]XW/SC/_[Q\-5]II[#+SS!.Z>F
M<*.68T6LHFAP[\AR@%V]V=0!<A!$$]ZX(V#C@/P]=[VABZZP+ZYC;=9BK(A5
MK8TVMFDQVK4-L[_3_4<%> I++>&TF[T N(BNPU57#H053_11+1_T)7<TUQQH
MC6$03VENW[A"[G?"H.]Z[-_4^N'8;, "&NG@A^V]L_A:@<ZJ9;K2FJ,KDWZJ
M>7$&A@=O?T;_;MP[XJ77<G[R6 1TAS-4;!5ZS2\D-S$\VJ.XO49]^(Z;KB<^
MWV*$;AI\._RDSR,+<.>O&FT7[;_ZL++B-FXS_;;G,[!,*=^^F7PI_^Z[H2>^
M\C"!$SE'?-+RX'8FGZ7<E1Y]8Q9^[X& ,GA/:69,P/GU'VGW^N2/SZ)+Z;</
MN1$;??,#X@6X27$V[F'TN_&]N)M6XE$<P;@)<2?Z'C7R*347\=P@2OC$@,'?
M&0YM9J+4BJ=C(.3G66+_^03(:A"]+KH??<?73;\;V=[D&^4.^@G<F^ME68MX
M6&W4DQ\?PJ[/U8#@\AG^$_LU)JY+ ;[B)9<K)R2E^&I!8Z\XQTSVP;#8 +?!
M72?A'<D>Q-Y9S@/B39\_9380SV7<CR60B',[)Q*3CRZ(Q,(7F#_-+$:\$:I@
MMSW.Y_CS=QY[AJ[=V<3DNN%.(6*A=C/G;]QR]D1N/AB3K"L6GE$K%GN&93U+
M/'HC(EA<;TDN-_5[O'A!'7< -DK&:^7PN2(TZ[VI5WQ*]_XM)LLTX>TTX8FP
MKR"#EJ([B])2FHH6Q7*^H$@9,DJJ<ZWYU;G6N]2YK+EI*3\WK7+FICV>&W7-
M@'GGYGUFP!PT]>>U8X+Z_Q# :Y&)?'--L6^'?%T$[MD=Q^I8('"8'Z"CZ)E>
MON+^'E6;S<\8V)CASC7"E2D^Y3&0:5M9 Z%$(*S-,3"')-% *)<C*",V-1#*
MY0B;H2/<4Y_B/A_,TP5NZ+E#?&1[8##'^+1^H$&@=0,- JT7:!!LA4X0^_9X
MV$BV:V\('Q?;+_P7#]R=>%D8>"?_6MA!R-3R[J2=JLF)7]"I.H\<S@Y)GPZ?
ML*B7B/'&N&W_R^CR%6.@?'KG,9..8^"G+[?5IM453,+>&08HG.1.Q78)>*8A
MM5V0VD(>U-* F9@*S8,TI!2&U!;RH*8&S,14:!ZD(:4PI+:0!S4T8":F0O,@
M#2F%(;6%/*BN 3,Q%9H':4@I#*F5\* 42K*SC"3F0NWU375_O,&3.P[E%R=/
M0.AUVG2^+,^LZI4LA.):47K(8MEA1O:DQL7#CT3")$67)=EQ*:&RNJ\\_\M?
MC:1\AM=Y&[DF^8/8X)7A0&O4!0O 3EX[5BC./F6E'-N<U5IL8,JO(-<MZL@X
M:\WD1[V8JUW,E (B)WT>!63BT:(,PP4S!&[8"L\:B_(4.L,TNZ=^ *9F0"TN
M0WXX+/#O'W[(8[W;L:8YNN7,H>>NJ492#I(N,"N+!Y.)7A ^F=L,(KZ>>4/6
MX%G(";$= "E[R93Q1]3:U49#+VKQK@D^L471X7JSMRNZO%E,?>:X-Y^SI]B$
M7/EYV,3$H^\].J)"<O=4?OP-0NB\4Z,86-]LU?>"D\1^&'Y-K9$F@]77.-!D
MH"09)-=(D\%.ZB4;"O?-!65&LH,.]-IB=HAC'Z?TOGPU[="BUI7G#C >) QX
M.,AM[Y)X#E;JC/()?AEEO^!M3YRR0%W=A+S74?=>X"F58$$#;W> IU12!PV\
MW0&>4HDD-/!V!WA*);1:)?#R-HQV$G/+;:%IM4YC;5.PMC.:G,9:Z5C;&>5-
M8ZUTK.V,OC:OSW5WL?=NK[36YS06MP6+.Z/O:2PJC\6=T0<U%I7'8BGZXHQ0
M]>TXC)05)+!E1\O>6L-MB>W8_-C^98\8;<@JK7U_1)73.QNR/FOS@ZQ[79)2
M^C8,L D+Q/_F+<[,@2B_0E9L637:B8\*Y)>?5/JQ6W,K_>-'"S! )^9FJVK"
MEEZ;M?QE9GIM5U]W=V*YWBM39#H;!=C4ZG+L1 F0[CP7?AJ,4&D.P-2]_"MD
MO #+EU$L3;]1XM.^:UO7@Z'G/O/U5%S1F6-88ZS.&-_* +N:A$EZ,4M8S((U
MVD4H\RKT0&$//7127;%7_+1-:YD_O.VC2[V46T.5PO-,O?C>%JUCSMBVCQ[U
M(BI.B1W3=$.0[3=N0/UO+G%\SEH<XIC,>;JG)@4+I&O3+Z/QYWAUX<=>2*UK
M>#<PHF#\Q*W3>2;,QH]7KH?FS7AS2&T$O&<^I+?I';.R60Q 8V<'L+,BOG-%
MF/<_Q YA,N*/O\/L8PW3T3>L8"KTN>C>M0.\UN<W9'&6Y"N^BP*=.+XKC_X5
M4L<<I7^?>,*_QYGSE/=DSS=%">4P?ZYRL;%,9_(F.Z,G,V9],UA= 7!M:+C.
M#=>W:IYHN*X<KG4-U[GA^E9Y# W7A>&Z[5C;I>6-[ 2MZVE=;P-,DP+@JG4]
MK>MM$%RUKJ=UO1+ANNU8VZ7E5="O]Z=TO1+[&@;GA?@,__&/AZ_N,_4<?N$)
MWLFH?T&[P:;XF7=469R_2]GK/N[&O #8##-+01^E)KWM4GPUZ6V,OU63WG8I
M\9KTYB8]33<:JBI"54$_^"Z@7=M&&TAZZCE)M6VD;2-->ENQ/Z%)3]M&.TIZ
MFFXT5%6$ZB;M&YV[@P'U\,8=@7%V'.O<]8:N1P+ZQ76LS<&ZMHP6(3Q^,&.^
MM=\,?\0F;1AIFMM)DTC37(G6D*:YG;2%=H'F-,%HC"J%T4W:&]H:F&O[9[-H
M3CW/M+9_M/VC:6Y+=X,TS6G[9TMI3A.,QJ@J&(T*]AQ6&_7$1P42!D\6D,%N
MQ=,VNX!,\M%"$EXW:PI,R&26Z.)X5%/%+-'-HOU0@@\_!( &I#G,&!B,,'^@
MZR#_X$STG@:$.=2*BBRIS31GCB59LR1K4"MSS12\-3W/LG5,,QR$-CQBW09]
MZN%MC_9QOIY!I3+= =V*E9Q[G-NTN"AI78<GYM^*19P:C_*+E5=A4O/2[2WB
MN/!R:QZ\0AZ\J:#0O'NC%CF2RDWEK '9J0(U#WR=EF"KMP;6OVQ:$JW-&EC_
MXFJ)4O9B19I ?:P)*"(O)@5H?7X!FIR; K2DB;G1<F8=EM*F++>63VNTE#8%
M%%JN;=0B)_=--'=?L151\%;0?,NFN?1ZK(A2%E=S6R46JZTW$M;"0%<4TZ09
MJ H,M)3%U0RT[,6*(K>B#1G-2]?E:FC/OS73+G;_;>'EUCQX7:Z&#0*%YMT;
MM<B15%;$R9X69D5N +6ULWQ=UL#ZETU+HK59 ^M?7"U1REZL2!.HCS4!1>3%
MI "=UU??+G9#9GINM)Q9AZ6T*<NMY=,:+:5- 866:QNUR*F$0YJ[;U0.GOF6
M37/I=85VEK"XFMN6O5C3H4NJ' Q>/N(G-3<%N.&.X%\%)B1M16*G%ES_SY_8
MZXE'?3?T3.K#D/%[GQ*+=\!BSW )__M??ZL?U$[E%7[),&WB^[_M.:%M[\%3
M0\,/1C8,M@>OKO;(@-FCDU\?@6Y\XX:^&/?N@#B_GO*[/OLW/:G7AH'X^DP\
M!GT]<5QO0.S3 ?&>F'."M[&/5>;@I)P<P_>]N"-#[$;?BQKM4_;4#TZ,YO#U
MU#!=V_5.C+_5^#^G1I>8/Y\\-W2LZN2M%V8%_1.C7JO]'9YS/1CWB>$ '9\:
MLAOPRL"H[7TZRVJN7GQS-?C?N,G,637^ZZ_0#4XGYE9</#7&,VS46S!G1FJ.
M#3G)!I]:8K,G:-.$^:5>H@]\JC]WSW[<7#]>7A@/CYW'RX?/G[IG<N)+[M;#
MY?F/^^O'Z\L'HW-S85S^O_/?.S=?+XWSV^_?KQ\>KF]OBNMK_9U]_2?Q^Z"&
M!:Y3,2[VS_>-1JW=.BZL?P?OZ5X.,67]\)V(;[1GTA<) [< O,^8C.3 LV9F
M8C+>"9JC]W0$0'-U>__=^ RL&*;J)AP [S8-R;+O:2_3D.7Y20R'H+RQ*#NY
M<$V>K>9Q-*1[7':9C;VS>JWZWYS'CU]\]A86)\:[( O?._OPG7@_#5CSCRMK
MQ8C^7Z\=38B-JK@$TUK(=/YW"&H&]>S1/1VZ7B!GMKD'JPU]"D!#@*9!R)]T
M7=?N$MMV@Z[[BN@Z/FP=G$[.O0&+_=\_.O>/E_??_F7<7][=WC\:=S_N'WYT
M;AZ-QUL#6-TC\#.CWC1N[XUZ^X/UT;B],AY_OS027##F@)WS1[Q=/VZVWEK6
M]\KF8BEF>38[L?9&<O&-\>H#4;F> 6:4\5>TA(90B@S0!ZE5$+G=\5=>"@U3
MHJ.50L>)!7>J8!,$??QYU2*CZH@2KTJ=O;-_A XUFK6*@:VL@5 3<RNG=D&B
MZIZYG@I(VQ#V\>@1,",#,"13_*,]'_]H9?*/Q_O.S<,UYQ*%,Y#_^MM1HW9T
M*O]LX"*_%^ 1TPCBA8NX1L]S!\:?$_\8@3MU[<\_RYZW]6F[Z.U@/CI*C"MF
M4P-PVD65[WW4<\E-8'RA>)^DF@.TH.O5YD'CN+XHK]0*]DXKV$7@\9X^,1_Y
M0G #=R0F#_?.+JX[WR\OKL\[R&3O.W>7/QZOSQ^,ZYOS29#NKUFBHS)^^4K,
M@(_%<'N&%X_!(+[A#ZF)SB?+8([! M\P^UQ5FJFX%\S  M(%OB&0_-L>3+M)
M;7M(+ N,Z/B[/R1F]'WQ:1,DPYTPHA]5F_:"$Z21Z(+'B9%?V3O[Y3]^^8__
M^ QRV!J=?0X\^(Y?K:CE9^H%S"1VA+/ '<9DV88V]L0/UK3 !8$;MQ=$)E.&
MWFM06<^!_03>Z-RU(JP?36LMU'HBWM!SGTWQ-.JT7[ 6GM\WSET;N#<CDU10
M,<Z)0RPR)H8U3M<'/C8#I+R+6RS&_X8>\RUF<DD/!,*2\\ ?\YZ(P_[-OPNZ
MP-Y^"BSE87'C!D9GB'L.2&+ES/;U_OW^P[YQ.1C:[@BF^UKZNTTQOS?N_M2<
MPE].<DG* R$(+,#Y;:^QI^9T)UG:YA%_Q[(\ZOORSS?FT+HD^>.]LV:M#@3K
MV3ZLUQWQ?KZ04<5X"!E04:->R]?#-G8:SN'CK??HOCAR$NJUO;/OS'$H&;HV
M\Z?Y68&-<_9TZ]T!2P56%''>>GV:]?KX)+)>?!/R7=Y%WPVF&&Z1_;MSH5W[
M_V/#A%RH-_;.VNUF;88#8YT\1_84N?G0@TED0V(;])6:8<">40L"]D/]C\8'
M&(6!P\AC0;_ 7Z$$?.):RAK5MK7;QH**/KP/*4@Y'8^2)#::>V>'!\U)9'Q\
M)R:_N<#Z[_I@]Z0LQ'IK[ZQU?%!MM]JMDKUIB,2QQ8 .E?KAJ0\&BDV'V&_#
MX1VOH,9AAZCM&@2F#B;"FNTX5]3QDFIA7!%96AS4 R-C&'I^B*9'X!KP!&H
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M@P+/'1G7R,"(R3T4%R0@8CMU MWC=R1-J?L0GFS5V@A@L#CQ  $B_Z'Z:'S
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M.$^P.*%M(R,2B?4$S^0Z$?(BJ6C$W_TA,>/OXO<@,Q_QIS$?E*H@L$Z;#'T
M6O1I@@?/%@4+J$=\X QIBTN[5^YNYOYUH>8$7J*OOU."(XI[NVK/^_8%-\-R
M @R<W_8:;TOZM1@;N8>VU[KI,*<(& S Z!DS0N5Z*&REN(,Y6Q\KLV36E8-
M([M@W-P19E6O'861?4Z&+""VAK;*T(Y4!%00Y 2.9;IJB.J89C@(;:[%BYH$
M*L,_>1).X7Z*0WK&!TR']U$3J\K$JCA-*@SR"]IC)@LTO#6\%P/.HPLJC,IB
M)NF_BGQ7ZO9VPJ6F ADFHP.UVT*WH=O0;>@V=!NZ#=W&!K2AT.&&-9V1CUQ6
MK=K?RSWH /KL%V(3QX3WD\"XH";%^">C6:^DMU^W]CS#G*%Q*[0LIZ/N\D+>
M6A,GVIF(<ZLWJLWZGW%,@#!0T'?G.A@BT'EE?E7L(CT$KOGS.U_BM^+BI@+@
MWA$J>E0_JAP<*%7)7C6,K7J\;YTO5 /?S97@.R/'&W]0NAS$^Y9+[796/ZI5
M#HX5.DFHH:TFM%M+0SOAGLXK#K16R#<4RL2@T5YJ#'_N ?!6>VFXW]. ,(=:
MT;'O=6([D:FS5:O4:KJBH09Y/DL_R,?XFE@Q@%2I-/X*6_9;G[8@70T['>%:
M/>9=N_;]$&U]#!HW15BA3&P0 @?F@=G/U _PZ O&7_LT"&S.J/$'\%C@,1,#
M5WS$+T?XEM<SV2CG0-9IZ_3QT>8J_ 3X* *+6LFRD\)]<!]CAC_6>2&>*$AY
MY7H]RH(0GEGZ3%WEJ-96E_65C\R=)82WSU&_DQ#R1/HT&?P/L4.Z$!5,*  ]
M]DJMZK^IYT[*?AXIT3C5%*!,<^I00-;1Z(4IH$B_@Z8,M:"ZJY31?KN0SAR4
ML;2+0I.!6KC<63+(JI,S308:T9OK[]CZ;/_%^#OH*_5,YO-'A%O#'2*FM&-#
M'6:5D\>_3,<&OWDKD'(I(60M[<DXK-1J.CI"G>;4@7Y69OXR71FS<;_8YL5Q
M2T->F>;4@?S;.?;5\%TL1 H;K-.6C\V=)86L+/JE.RLT[K<8]TH$5K1STJP7
MYIW8%2U&(7>$#K_8$^><JUTB<H@.AJ"-$ Y[^HJ?M[PPH9J2-Q9#BI!L^8NP
M_6N>(W5*"QOXZ@%3R1)3R"\XNSA/<(LEY=31@3ZDH$YSZJ!>N5"!8JA!&QZ:
M&!8FAH-RHP,T\DN'XJZ:W >%!01H948AJUL' >R=_7 \"M/^;S"Z;=?W#< \
MO. G%<G+?6H"4@-&]8:_MKX56(3M7_,< 53&3G>>K3)F&;^[-N:^^ H*'2:7
MO74>8G[1\9@/MY*"CD>X/9)7K9IIREB",G+.4A^HM".^;I*9^[RV4J=@M_2H
MMIIDDT,UI6V>:ZFBI8I"!G^>5"EBDUU+@X6D@4*> ;T?OW<&:.,N@>VV_.?.
M7%^V;)^SVHL"?H2LG.R[)NQV 58YDK.,0 '@54*THA3=/$U04\Q.4XQ*00::
MDC0EE6>/S=WU'+/ML+00A;GH9EX#[;!R6%-H"S>GRLZ6NO%VF7R*B'/894I0
MR(6Q]<$-IU/U&;X3S^Q'Q1G:NCB#2AL.AUG%&5:5FZ#(X@SMXTKK0&=25#C=
ML1KXSBK.L+I#$<449ZA7#MI*[05H:*L([:SB#.L_^5 $Y#4?5QCL:NS\'F;5
M9ECQT8:":S.@T72L$M*WU5.@/LAS,)Y5FV'^0PQ%<.)FLW+<WJSD .7&"L2N
M!]'G9=+Z,?B4*EI@T1[UO,F2!=M(JAME*N>4*FB-O7 'U6:M**O9&A#SC71^
M,6AN>Q<2,OP'/Q PRQK7=;"NFRVMD:G37"E'7+!/^J"+7GF]\GKE]<KKE5="
MU=>;=BO:M--EV':%UK-MFZ.<;.4KLFV4*,.F"P*KTYPZA)!SHKLX0M U230%
M*$T!.0>W%Z, 789-4\;644;.X>S%*$.78=-DL-EDD',&>X(,-*(WU]^ASUGK
M,FQ;PJS6NVF[_C)L!P>5HT.]6ZM.<^I /^?$=VFNC"(+F-0/M/M.G>;4P7S.
MF6WEG!>Z'I4FA=62PG'.F>MRO14:]UN,>R6"J(]S#DL7YI[8&35&(8>$#L#0
MA=A4%+VJQ4R5OPC;O^8Y8J>TP(&UU"XY/*RK*ZC*A^'.HEZY8 %=CJIT=.XL
M,90;'Z"17SH4=];F+BPD0"LS"EG=.@Q %V)360QKZWOWUCQ' )6QUZU+YFC*
M4(@R<A(G':NT):YLZ1V=ETF)YE01*(U::;OG6JIHJ:*0P9\M51JU(G;9M318
M2!HHY!G0^_&Z$-OVU/_1A=@TK%8 JQS)64:@@"X?I2EF<RE&I2 #34F:DLJS
MQ]Y92:I1*RU$H>#R4P?'"MEHNA#;KI!/$7$.NTP)"KDPMCZXX72J$-L_0H<:
MS=JNU&&;I/8F4+OEAABWH;;*G-?1173FP^Q2$BM)=E!87;=FI7;8J+2.RBM^
M-<F_FKNH'R\-T%(K9ZV B(Y60D2K+1[7J+2/&YI^-/VLDW[R].7CI0E(L1)U
MR3I>"JO;S:TV/%=(5Z6:H?G=SJ&K>FUINE*D&!X87JV:0C5.-25M.27E$%(]
MGY#601.MO;/&8:5^6-LPA4WZ<7Z!OUW7&F%O\3S$&5RPV//9+[]D.SQ^G>CC
MKZ?C_O#NI)P:TJ<A71KI;@RWJ0V8,L.TB0^(<$+;WH-I%,=+!+JY'6U2VY9K
M%7_WA\2,OXO?]YCSB#_=B[HM"<1T;9L,?5CVZ-.I$<&I5OM[!C"615@J5*;&
MN2@ !7$LD!)XB;[^3HET&*S'&;A"-U\^ U]I&["<  .0JHUX$I,<V(1EH)X2
M/O6U^D&SYF#*-RJ,="/VA*K70^%:>\M5N]+=88WL#43V'6%6]5II:)^3(0N(
MK;&M,K8C'0$U!#F!8Z&N&J(2+B.#^XQ41G_2G:5P/X6GS?B >]4?-:VJ3*NJ
MDZ3"*+^@/6:R0.-;XWLQX#RZ215&O?YQ^T%ZJ7CHZ>&IRG0H'&E*D6$R8DG[
M+70;N@W=AFY#MZ';T&UL0!L*!5ROZ<QXY+)JU?ZN5/#U!35YJ(71K/, [.;V
M!V"7'U@]?ZQGO941"="LUAO59EW9@.GF8>6X?52IU<J+']CYV,Y28S87P'=[
M)?A>:2SSP4'EH*;0Z28-;36A?; TM!6+,CX[T&!7%^QJ9-ZJ9YWLF@_MBL3^
MUMN5=ENAV-\="O-5#N0Y&,\Z>"4QOB9.W*Y7:NU#E4"JK&&_]2>IBZD6_TS]
M +BN 28?="4(;,ZH\0?P6. Q$S?)11EY1/B6YY7;*-] 5@IES/D@TS[ Q^8J
MW 2SBLC?QYCACW5>B"?R7UZY7H^R((1GEG4KM"O'=:V)JM.<,H30R,J*7"@A
M+%B+=2$JV)@D79H"U*6 K+S'"U/ &@K,:\K0E+%>RF@401E%UYO79*#)8+UD
MD)7>=YH,-*(WU]^AD]_K8O0J,B1=#F_WUCQ'"&6E^5V+G;Z6^JUE)@C4J%<7
M]5G9>4NUS75)[M+1N;/$<%BJ.:Z17SH4M[\V70[RLVH!+V6!:V5&(:M;1QGH
M8O0JBV%M?>_>FF<+H&89N^2Z;+"F#(4H(R=XN:G2]KFJY8=;;95H9TMCH]4D
MFQRJ*6UK74L5+544,OCSI$H1>^Y:&BPD#13R#.C]^%TI1J^FT-:6_^ZM>8X@
M*F/??<,K4FLXJPMGE3;4-<RW$.:*V ^E[9476@NZ7:FWZRH!?+==1XI@NXC=
M\!V!J4(V[=;O=D\GR/M./+,?9<=KZ>QX2FF"685<5W7LO<CL> =-?99=[80S
M2N"[E550=751\L5DQSNLU(X5SE"CH:W&GGLKJ\;I^F/A"\TAUE0J*^26VCD;
MD#XL#_*-I2&O2(Z\1JURJ%;J4PURM<+<6\U\C*])!6D=5)HMI4"J;/2ZWJ.>
ME2//H3P/GMOK40R@@+M^X..5_\S!?BO;J=4:.[7>KN#>L?XW] ,4!/ZCV[$L
MA@T0&TNG7CNR.FDB$4/4^W/L6TPP!_,33'OOK+8_[?@R8'%L^*"='<H8@SF[
MN!/H6FNZ/Q@_O[5T3K]6Y1!T"ETI0*7FU$%\SD9O<8A?,,G---P7=([4*X<M
M[1M1ISEUH)ZSU[L8U->0P.]-$M"Q#AK^B\,_9SMX,?@7G:5/8WW+L*Z&AR0G
M;?="5N(N:RD*^4^V/AY"UQC8;<'<SCDT7J;30=<8T(2P?D+(.2)>FB]B1Q/N
ME@_)G:6 G./>RKDH-&5HRE@O9>0<]"[7>Z')0)/!>LF@B.UOC6B5_1TZ7F0N
M?P=]I9[)_-0CW+OA#A%:VK^A#L]2,*B"W[P52+F42+*6=6@T*H=M'5RA3G/J
M(%^UX(K9L%]L"T/AW8OR(;BSB-^4&(N%*&&#%=ORL;FSI*!DO(7&_1;C7HG8
MB_:J8R]V1(E1R"6A0S!TV4,5!:].O[A[:YXM= Y*"QU83Z6@5E-=054^#'<6
M]<J%"^CB;Z6C<V>)H=P( 8W\TJ&XJQ;W06%! 5J94<CJUH$ NNRARF)86]^[
MM^8Y JB,?6Y=H$I3AD*4D9./[D"E#7%5"UW5&RK1SI:FNU.3;'*HIK2]<RU5
MM%11R.#/DRI%[+%K:;"0-%#(,Z#WXW>E["% RK.H5Q7(@HO#5\-W;69Q(-0J
M!O[[40'9/E\_5? C#(F%3"W9U9T3=KL JVS)>5A&H,"&%[#3%+/3%*-2D(&F
M)$U)Y=EC<W<]QVP[+"U$H>@R?G6%<O]G4M76NO%VF7R*B'/894I0R(6Q]<$-
MIU-5+O\1.M1HUG:ER.4DM3>!VBTWQ+@-M57FO(XNHC.WLROTK"3/05%%,UN-
MRL%QH](^*L__.LF_FKNH'R\-T%++$JZ B Y60D0KK<QY>%QI'+<T_6CZ62?]
MY.G+ATL3D++E/U6J'Y]);MMK>*Z0KDHU0_.[G4=71TO3E2HU1MN5H\:1IB1-
M26OJ=@XA'><3TIHTMG:STJJW-TQADWZ<7^!OU[5&V%L\#W$&%RSV?/;++]D.
MCU\G^OCKZ;@_O#LIIX;T:4B71KH;P]PV)IJ8IX4$9$U@E-1+M_E J4%,3+E
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MM*-4):'8K&5%117G*+T3"[YLF%1#J6!VY5"T_:#-$X,Y57 +\HZ^"[4)/>Y
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M+,FV%*JY57XXCZ:WK:&W(K+BKH+>U$\=J</GMELQF14^E[7KM]U,4DGNEVL
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MK"<P#!R@5*(Y"*%WHB/0',PM#.#)<U_$^O& ?L$$O]Y7Q"N;.:_<E]TAJ'3
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M2 Y!0L1Z9F ?<Y1+)X^8(M"M!?;]<#A$#'?A!\:/_0>QGR24C=1$I"DHK:T
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MH122_-@%7+-8NK+K.>7;LG,$U3WF&9&+QR,> Z+2Q]<6V$AN@UR%$Q"V<\F
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M@Z+K.SGG,PXI6;:0.?^< YV]>CR8M/*YY8GGEZ-+ 3$XV3B3],NM4;;9*/\
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M: M/2W!-XMM(XMWFBE**UA9 K0>)[YH$KU%<=4WE@!N-J\K6!3L=1WV4<W6
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MD(Y.S-H9.CP$&PUH5"I@:>!M!^K7&RM4[X 3@AHB'E Y$[8Z_93 TJCBGNO
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M]J)Q,TT1?#5*Z''K28+D"1>V6C4T,VB(S8%G*Z''%:K_?!5TSCU72^WC]F:
MO381WNGUS5ZU';5W(OP"6$Q@$."E!X-09%<D<]$?,:'C9KV"Q@0IXAY;5J/
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M3PR=YWKK:C3"I"(_<T>S /:9#!9K%+%.,JB16-9DL"=DT%ZLH\,ZR:!5(T>
MIH-]H8/%.B^LE0YJ%&U_C YJ9+OM?)0(7GTE;C'^2%T# 6L)T;%\"B-#>U#$
M\CCY=X#\;3^^<461_G^N,]>JWG85VUI&2X2O(EI>3FS?/#RN44KL#./J[+0
MUX2A"&,9K0^62A@]L]72A*$)8].$L8P6!TLEC%;/[#;K[ +4E+$?E+&,3@8O
MIHQNEC*:9KM?H]S QRA#6H$_P;\WOCW%C5H _Y.?U!&^QF-XU^#DIY_*#:?_
M+FSTO]^FFZ(]Y8PC:1M)TRA+.XJ")J6OMIV[A,;P9_@H]YW%^&/^WJ_BFU#\
M.\:1 W?P?^$U//_.]0<_7BGL.GQE"$"'"3P4!;$ ^_%W@H[$VW^^0D^<<%T)
MX^3W<&(-U.^%RVXV%9$YGBT\NJ4'LDS)%.<[J+;((W\R:Q_+M67[O;R-FS5"
M<\2-*+),#OC[S4FKV_C]UYN3!0Q9*X[\C6XUO7N#+K]LWY6DL6)*H'U4O*/P
MBB>_X9MG_$_L3HUVRS20,DSC7AB"LJ%MP_$B'Z VB ,G<N UDS@8C*Q0&-9M
M(*AK:6C<.]'(L 8#^+X3T3.86>T' &_X>AC#BP%)C?N1,QCAVO2HC1\Y81@+
M<G^$0"+P _P-_GAK1<*HX.X58<_^0;N5_;% R-?3B:"VJH7/N8TJ?=NQ'2N8
M7@&C_S:\BH#DZ?L7@7,'N[EPK0&==J;O*K6ZF6$C^/PG/)Q]!I#S;B\ [WQN
MBQ/"3=&?4KG27%BN?/KZ ?M6'#8/S6Z[-R-2L*OF&&!%C39#PXH,*[VQ"?!$
M8?A#X^<*T!9":<Y&X G"&(!5#E4Z%8/U @^3?O%Y@.PT>K-BV9B(@ $(B(SP
MXQT;$[7EAG$*H#5@*[$;(3RC$8)U*/"B38GF ]?'+J>^HJU.AK8",1#.'?SU
M-@#M E[@#X >PCE7TZD([VP,ZTM4I@J<_Y?EQF(6Y0\75Z5Z.'>G,9L%;0#W
M<^$'!7*^$.(_Y$!-X J,)B;H6A/X[ '6C03<216LRT((+X7U?-!=R)U^"/PQ
MPLGR!G =Q4MX)NS:QXU9?T4*.VL(C!X>L>,!]4[*(K-*(@H;\^3/.F2<411R
MSW.X?_+P:CW!]TUR"\_+) I7.TOLL\(0Q)-LQ@U+D#D49H7AZX'ONOB".\0Q
M7/TR^\ E/W"J'GB3[B(1FX])S:$#ZF;RV'>/A"YU$0^-JU14HU@]?P#>[]T*
MXST(!I"VN(775^?OWQ #R^PK5$W(Y<=\_[@^D!5@G>)S4K*$ODMT]@CTC->7
M_'0.!DG#\S<-XYH -.<[QKT5THGM],AP .2LI_%M'$:&5%OD"-R!:^%5"4!A
MN@3C9EKRS!$_TP#H@=).7X CCT-US+EW9N:OXX<0$_G0O'.D.T*Q#-I.1"@=
M>Y'C9D&+@L?S#=>':PLH+.38A'V8KMQNOE7+H\V1WC;]L?46EE/GF7L$ I8S
MQ(,,+7S_TX\!RG1\\S?\C \/P":Q !] =HZ="/%1/ S$!)\-"5SWP&^,&\2F
M?\=.P(";6%/#=>!W#GK9UMBZ%<2N\^2 8AC^._8!5GA!\02_TVK^HFZ+OXI-
MQ:V)$UFNB6]W8[2_D&:IK*]A_ 60=T-?WIR)"\+??2K.BD;P7=@IZJ0 P;'G
M#!EM4"_%94: \"((<_"=!Z8AL/($*JYCW3AN2I7R[(@$0R$_4ZP6Z\0<M +Q
M6WX<($B)VWNLO/D!M4Z')?&#A"3FWO8ZV3<(&@:^.$$+'10A*P1)=/'QW9_E
MAN^L>T)^0KR5/D(C.[?6A^O+9+&L53@@3OW6R+R@\.QH>!#X][,?HHEN7'S\
M^OW+W(7+I4Z5D'IU@ETAR#>1_^>GWT>).7]Q^O'\X-WE^>F?!Z<?KL\OP1)V
M[ZUIJ#QA*,L\D3O36V,D&#AMG'P@P^;_:-)_RB+J\D^O?BT"\H^S<D"R>?U,
M,%Y_>__9\7Z\RGMGROXAO42A2Z7LG\'0!5U>%6Z#9WN7:NSGZ?8V[.?Y='W^
MQ6AOC:_GR^E7(+LOYU^O<<=4"-1_BSX@X^S3U?OO5U>?OGTU3K^>P?]./_^?
MJT]7QK</QH=/7T^_OO]T^MEX_^WKV:=K]9W+\ZOOGZ_I*]\NSB]/\0]7^^(]
M0@5N""JO?X]B\HOE@0Q'F2-A&AIG3CB(6?-$.7?J6>XT=$C3^N!X(,4<RP7U
MU+.=2'WGDBPY^HIL]P5JA '/\.B0>(+?&PQ0'\"7@MH)JTQ<.,<M3\T!A13^
M#OJ'2+34O)H,*Y\2J5NL-O(>4?G XR3;&N2V%:3;\M-M@7"&,UI?A(VK 3@"
M:R)BH-S0^.0-&O0DRO%06=NH!>!#I'2.0$2S \QY,$ A 7$^(;LY!*L#K#+0
MKCUA=)HFWZ12=)/?NALWS5Z.0'"Q=HHDX<B/P;@@7=&BZX-;^#OV,C8;@A.O
M!A6F0N94>G>)11/*RW,YM<J/6,E"F0-JEQN*>[@SP7@"6PG$Q ^BY-HLSXMA
M-?DI[. #G $XR<&?R25.A17(VSH3 [+W&6R=EIFY*"-/*IDCH[L!]$1"BWLK
ML ]<W_^!W\F<(1I9V(GLSG?!@O!03ODQ;-8)?_#Y $"L;:*6V3"^X=8'$6^=
MT79 <+4=-.X-](' G2"ED*I*>%_]=FO&XQ6*ZI=? 4Y+:^5WY^0]<'LXI15,
MC:\ ?%15X2WX@@_RA9_E"Q/U.02!?*),&@0S"EE:!&@R7<[QV \"OVX]&8#P
M>1>'CB?"T/@&HO_.$?>)#-GB<Z'5!=1E@9+H>*C.(%K=@AKE^!,P>,?6@)@E
M,=OQQ/*FY,-F&Q*ML?$D\.^4+\(%NY/X[T3XP.^!IRI/%2'Q!)@IZ*+C2>A8
MQNN+\S<\CWD0 ]8!M8W$V!G ZP/_AS!>GWZZ>L-TXB*?&<!7B8<89U]:Q\?&
MZP"M2M@7,!0,=[A#ZPV*(!8001@9^>V3R"'S/A!P@AOD0Y'Q.IP"2Q?PC3?D
MLU,6ZR@&6!H1QS]^P-/.CT" S=,R7O_Y^<_6&W1>1O !+(#G$_P[;D1X_YF.
MQ1N$#;!(!51X>QB!P<OR;@(D@534,' QW#6\#&Q@4#:<<(2 3:44"!T;#ADA
M-1FG #B3>2SO$!VY2&FT3B*T@#%3XQP2HZ ;(92!/0YPH]7?'"#5H_\,J1BX
M'Q['E)R83.PI2+X(>#J2,UW,( X",J9]X)1X#-^;7?;BG/6*3U=DXD]<!"Q8
M^?8=6<A\FR!G_?AVE+H?$FR,D N2TV& JTHW#)O[QATZK]&#E "/7 K(3-7S
MG+L[!GY,4F<"UP1<$/^ +),!/26 %#8ZLNZD0P+NUHX'L"DK\[CGWPDW<U)<
M(11W**D8H8%6:,? %T'9/?O2:3:5)QP@)4'G3I7^ S(*?@$**= A0-"&95U_
MLFY/P4K8#5^WP^(JI4-%>X2=KX,1$5D&7):1$*H!,":I+$G5LZ*854I_@%!E
MC3-'C3D*-MG%D[ )4B0\>)S?RAZD6Q^7N77]&V1\ZD8R%R')F9Q?-S[08Q9[
M^) CP+ ;(3SC-H C OI\L.!UUP%8_[ 29I^P-RB1[Q_.3BMIN&%\+3DG@PM,
M,8P;H':%2Z6<0: W2A&^Q,?P3;HQ]-IAR.6NP'( [[Q(\1O:D@V<UN;35G*8
M+'\ Z@I](+A(N869N>1XBX*3$Z84AA+V-H<99U]/P=@<C#S?]6^GM)@?1WSS
MZ.#%W:4 X+.C0N)AB$5Q\! TQ8%R[J$VB2S#=<;P"M0V45$BJ67!XG!V.)_E
MA=(?O_4DE\@8HUQ6L>H*?'E*<@@D.FC2"/K =X6Z\4#<QB[C*W(D!XD05AJ!
MJ8@70^1! 3VRTNX ;2R07*X8P%.@S0H,<SCAF-\UM@#\WHCX/XA\>,P)\(N1
M#Z+L!M1;N%;0POFZ^ ;1RQH39MT@RR1,EI1.D3'>%]B0F%CD/S@V:!!?OP$+
M@2\ (QU,D8A!Y_CXJ<U:!]@#Z%IV'8S. 5R0!@B#)S[LV/D/*2V 5(!+K\_/
M_O@ NL@G+Z?!F"G^HA.;[(L( P/W()GX%/!UV'T 8E0=-WDMP&LD+!<S,]#5
M3VI4]IBP$MD 2#!^< OXF/ M"M^ 16*FX@BX@J0JU!><X12W#W2"*7)A1DDC
M5I6L2WH!XH2%TS_5U^F@^)X!+L<$7G%6=:K"G=WX ',@SS@@BP @<.> J%:X
ME*AZ$P&&TDU@X9W:CLO#8:P +1\?O07P(+E)E7H9.E$2Z+JS0L8MX(9NG+@O
M'&_DW#B\T,2?1#ZZ,EXG6R'_IPW,:_0&A8LK)3Q<-/K_>0/)EP,!L!0NOYWU
M$P(_,%E?89SEW3K(,H"?KS4*JUWW6+>G7?>5KOMU>^M7F@&'839F]#D=;.),
MD#P%2;=0^F["W]9+AO*BJC$;>VZ-@1VYT3]?P3=QT_![X^_)+>!',)CY\->3
MA2YR&U0/Z5R0=X:,5)I[:/_9*!R-Z!X%W=\8-L5(.>H1L3<6$6EW+(LNSDW6
MVFBQU'+R_%1])955AJ*G2G&'O?P0%*@-K2&F>[!L3N1?7DBC_/@5]A%@KHU@
MK4<JAD.! A((_SZB/";4,LBK9?SA8 R<37S:I3P,:RVD^J8V(]@(B>8<IFHX
MZ42@<B8N-)!M/LE#C*YSRB!L/@Y9Z,K]H:;%R^84[]>B<=LP8>'(.KC!S&B!
M>9XDIN@KY,VDT!7F#[$"*(4FONWUZ?MSY\T;=+>0?Q>P "X&T^"RF@> S@(+
M1 12E8JH?ZI,#&!@*95.">:!!?LWT"6C$@@R6 &/Q"%9W3= T/ YPR31.6+/
M^7>,%QC&CG0\$2 1HG D@ ;:_*F^B2AJ&O^W?6C\<%STGT08"7C]YQDHA.@C
MFDZD4R;R06$#C!7L8)A_3L)!L#<$*;#R&F9QJ%JUS6EWC"NS&IYZ=V+J$'@E
ME/* ;1BGB=\5T>\^A5]J@M)Y$A2$%WM^Q :O(L$<_I#'!O GCE@U0KCX'KJD
MYRB8:(0MHEIFW4G5- 4D3RHGYY$<<1X)6IG*;R9S<"*TX6X=#/J2V9P8I6QQ
M)GPB81(#UX\.;N*0</\UZG3C&]^=DO?/#N+;D+(W+/0S8(4+!;/P&=($[Y2%
M8\>8!O1:VC3DHZ*5!!@+X^F;QGQ5&=//$$@)^WF1UIQ1=TMT7.-UH@.ST2-5
MUPHE%[_A"3^KTIK20SOP*2* 2$;)ASE76,8;,&&/!H Q=U_W(Y\3>>Z=4'K6
M/#_G<N G-Y_(^"*)E[9[DS$#Y^0BZ_*^"/S;P!H33"\HY[MM<)MSYQ8YQ,'5
M!&-E <5!8WN*499- V1)F9WD+B[SHTTD3!R4\QFB9>4)21VU;7),9"$5)I!"
MT1ZA[ 7N'W >UY21G?W_OCWUX"@#<@7XPP/X+S T##XG=X"^O*G<0>J;I\!G
M_BN4[1=&,@T10\,9-R \_/H"K%>C!9:Y[8?B  N1F%._-?@O-^HO#Q.+^.U;
M1@;\8]ND)+,!^5[&2:!>!DD RG$ ))WLM8I_&J\_?+PT><E.Q9(-N1T+DU9(
M@^9E52B2D^M3YD4);YAR9Y$$ICP;/ ?[S6&ID([69G;1:1C?B74?-XU[8/LR
M*BP]I%F?!3H@T\AAIZE2%F7-2N414?[>@ J$_G_T,<K8+?ES5=8CWH@\)*:H
M"B_ Q-\DWT""\]\Q^1OP0C$(+'T(*'#'"33(JZK64GFV!*][5$H#X0H2%8Z7
MYMKRCHHKO?[ZS_91<D@0.L!\/4H+S&D\(+"$!;B/J$T[N@>6?L (GGI4D]#2
M >[@#J^X@/(<\4)ZH"> Y8H[O$K.5$R5'')W E=O,#LH:!7)G8@'$C:P 6#;
MCFU2 !K(006XP.AQAO +)2E+KQP[R/,Z$FT&I&CB3N2<588 WE4((MH"K+2E
M"@#W IH0)EZ#A#QP/*E$44!2Y:H&XB"50RBZ$:T!'^E%B*_R)6"?"?8HS5L;
M""00L+C,(4%ZH+C O37E'%2 #UZ:I&J#4Q1XQ1DTEHC/E(B)M +CI '?"H"G
MWY9;4$FX=!!USQ93&J9](RE)4G24MU_BY<8%YY+DQ#M%21,\%V42<3)#@906
M57;7YXU-@X:4_ROP I5T0)T(32Z43?!VT-ZF/C.WK"AD#4T<2#8)Z,C:<_8[
M9.!2:(/4ME#%R,)X0@DP>0"P;$02DSHI>;!O*;!"H9*P:$*PTBOCN,"9A'>+
M"3TJC[MP!VE>%89U*4H+J#]V\"P9S8;9.Z+&&6C9QNM/7\_>()-SX4FN[*'W
M,9+E$\$DMPX%YA,!>-VA9-4][6U=J[>UI[VM^^!M34R88V7!H"%78KC\VC$N
MQ9?SLVG;N,84C5VU53+V"4)"F26HN,#7% CRZ2HIPZT.YW^K?IIBM0F808>Q
MK0EE+G'6@ GJ%\BM,9S*-F7OC8,;6 )^(V%TXZ.%$TE]5ZZ9<T7@GPK5EIUF
MDV2N,W# -(FH.%D5\C0I\A9*MZH[9>6VL"T2>T#@)*0H>Y/#R5)F6"JO^&9*
MD,,4^XF@/'O#!C&G9!4HQ.B)Y&"E%=@JD0K8?TS:$Q=$IOD;[>+&"S*8P0\P
M:!COLL(MDRV<E6UJGV9&S9?F1@C&TD2F' QCEN:&K_9"/AMK3&EO<#6),F>C
M,VF,VBQ=W"V=3$3WZ/E%H"--]<$J4(:GF;I;R$].*D&Z2%;I)JE+Y<[PG3O'
MCT.. W-Q,ZE(! S4/ ,']7Z;C<F  !HY7BS?DG[#"%EE F7<2U56BKR2-:$T
M8O)S(AXIM21+#A+>.7\N*G%)OG:H8&K'Y'H=^2%5AM&Z8U(I7!65Q=0Y:SBD
MC-<1IB;<"I IA&.HF_U*]2EL$ 0.9<TF6@/='J8[^" _4+Y@'BR]'$QA7!!3
M%T+*!9?N,?IFMH(++SN'7@C?$;J,[31S)]D^7IC$>3P%F@@#A+8Z2F8/09)F
MRT%EQP]RZ8(9:VHTG?C*/RONDI1I\@2/ 3C>H"18KE BY2Z8-/<6PP@4N [0
MBA@HWN""C*'K)[46[$FZ!/0,L'[)>.2A)078 $P3;-'DV"&'):B6+N?WF_'1
M5CA-80MAA%F>L+%0)&? #!.UE/28D[,^4$FBBAOS'A'08W3/N\X/*NXESL&L
M2R(H(>9;E10X$9&3."R!'X#1C:HT8AO#@5AG8LQ)7.6*Q(G<IMP)^T[C($F&
MX;Q%H@%):H*A9 TP09ZK,F7^9,XM(K&6MXVE\6AWXB4S*PN!(O'B.,)$;)J6
M3)\B!SH2[W!(%@&8+@ZIX1S3 N,&"#G-$N<DES#E%AG, R"2IPH%!S-M:0.E
M$DM(M8 >O:$L"60'!V#1(L'+"DN&I'1'./E  /$69=:R06"B7\9-?I5.:,5]
MS$RN,CZ;$1F4S'=')2:)Y$[]7EQCFHLA2KFBB$8)RY*2%/8,<6(,5K90G0A
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ME+LX0H7$PV:#&6#!=:=H-[#"$>7/T*VDM>5+P>+,):\*<?&/4JM-$@(D]\^
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MZ 13QN-YSM2Y%@(UQ'SDKNR32O.P=8M,*B[AJ3].<D0&\S\>K+!%98#7HF[
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MHR]8H9NT;TER0?*L@;HXD9E-ES_%Y)Q789?!NU2,-C.,>-EJRSYK&&]91&9
M+UY&E7;J.)L32B9*+9AR' ^9%!7H3?$TZXUQ6P=[/76PQMJ4P2Y[@\[7[A#B
MR<Z)-;3/.D.K?VIU?K_LCOZ#+NKEH#OJ=ABG?SGLX!^E77QMJF9/ %J',(52
M7"F&K5QN!PT&&T^]?HN\V&7",A.<-G^,P$J(VE:?7Y$^-]=&GT\ZI_;EV6AH
M75[T>Z# O6Y_8.CQ6]'97JF2O=6E5Z1+!VNC2^?=7@?VQ-,.;(4&F=16AUZ@
M'E#."?_]4_ 3;HMZ^136RZ4..5C[@7_USW?>?W&[K.[7X3_Y\;#:!,6*G"E\
MIN]Z'\ZS)!PA;6G_:I1X=I*,X.8O8>Q^?V<%WC_?N4?-QCL(=UUGAOGM)/<Q
M8[W5Y'LTN;4VFKP.L-KGRDLC:Q),Q;A5K5L7H</MW;TXJII_&"4.917L@B?>
MLCTY3ARFF-!39N1_CA3,*AFP">G8DT?XZ!7K$^A_I#ZG"A% -?A9G00>Z/L'
ML"H'L )W7]&Z]XK#>Z]X_^XSEOX^[>%EGY?^KR %2GPYYBE1_+A"HI0J"MHE
MK%M6_="IUG>N=E=0V^Q:#@J+'!DGPD(]__(.4]8RD37C3 +UZN*CHCD!77*3
MYLS%8URP=1I?; 6ECZ?FQH/]HQV'Z<+P1W>72+!GS!R$C?@P.5B-&7!2!G-C
MP^HWWO ^[95VGA6[T[9(_B)%\L:V2/[ZBN1;-^D>-^EP;=RDSK]_ZW[ICMY,
MA#,J]:G[/R?!.)#3VKFNSKA/ZEQ(HB"=""D;-\X7;L)BO_CO']8@Y? +4\D2
M2KIJ;C$DL:4=1LMP27GG!7Z9$BL#>?P/9:RKXSC+XBE(Z.RG16A!:QR".5[0
MD3\I$X96R=:T0-;*HF%PL+[L^WOQO3;DKBEM_,,0F?MOY6G7=Q\<O?B*S(__
M!&+S)*!HY*^;A^9KE,QSZ>-!JL70I =<--U_^W5%?-GA-&OU%UI9\U84[V<5
M7\>:))BH\G_^]^C@N-5X7YMDTW>E< [F!0&?'V0+XN2;' IJXZ?+":P:9HXM
M"(DS(QZ;U.I&;LWB<Y'/G5L->_ZTY[R4JIBW-I]><,H-E+0I8T\)[L5/*>R/
M&^^?EKT7?VUSR6C7QT@T-ME(3+)L]F%O[^;FI@:&H78=_]BS$W>"IVCM^=ZU
MD^PA'&"O?K!?WS_8WX,XM'[0?/_^X+C1W*^WZHW]/3 S+?BE=?P0,V,+\;D<
M8Y21#7FHQ>EH]F6T.G7AYMA0JP,CCI,9'3Q++9:E8Q*5?P@[&/ZJ)TVS,K?U
MV>ZE2.&H^@VS5QQF:(*88?F ;9UH0UZL0+BI(I[S(YYS:P>-H@5NH@4"46T>
M-H[KNUO+^+8L8WU_L_VGQYO&UGX#'*_#/?+ CEK'^P\QC6<^D5;8FH**'2QF
M_[/SZSS-+.&,T3CINZPEJO)9C..,T&"F>?S=J5CGM9/:6[:8*+0O9C)EU0YE
MU988S5*EA?3-0_H_*@I\X.('1%G^1^O=YUU=8=F:V;=D9IOUS3:S9"0/#UN'
M#S&2;?QB50=&P[CJ2(@+X_2PTJ$8QJ$^!SO.[AX=Z(,_T4D1MI05S=N'W+1N
M-?<;JN=ZZ"1C)_+3:O]GZ-^JXWT:^_N-#;6MVQCXC9N@C0Z"E0EZ4*9LA0E:
M/&=H:X*V)FAK@I[*!#7>AA=T]&Q>4/V(L(/MFK8F]69K_UZ3<[Q_^'9-CJ["
M;\W.FS4[;\+S>5#R_E&>S];L;,W.UNS\<FI]$YV=PE!H?O>T(&I<U=XFIR;L
M5W^_KSZHV1G!MOG+CV04RG4^DU0(-+H1IEBM?W\9G'VP=H)=?B$^J!UCAR@2
M)[0+^GC/^N*$Q%X]G/@^\IWM!.JF%3<,B^'"$/J:V8$/+HVGL\2?(!4+>&YG
M<<I/#'97O;[\M.'$@;OYP!+)9?.W= @EC,_Z\2M?UW;2B74:QC<"O-A1=_=B
MI&T3_HT5CRI6N'AH;1,M]#86?=/6^6 #K7.;#I&]0((B8M)UN-7B!-D@4=XW
M4(T[T['O>>63KXW=0!^*],IZT]?TK-WF&N-G?N&LW5<*1+B_M7?8_=JS1R7$
M^7H-L?0&,ZADOF9BV]5^SEP5OY2@AS_7CYMRP-. B%?P#$6BUO*0;!Y/5J*C
MC^C<;O)6B;V>2)OXD!\$=HQ]HJ@7?E]F/^,+Z-"F/$(R+7R>8J[RO76@CGB=
M.([6_N,W&K[W&?,MX\\G7?N\<])MVQ9BP^V+SN6HVQY:W5Y[*=3BD;[0GY^$
M)W')GGL^P2F!;4?::^H-U7Z^VD%9":-(KL<[$!;B?[L?K;]R3#SQ>^F>-0C<
M[^"(Y6'Z:J3B^88]-]CG>Y'F3.2H>WG%Y U,^,Y%$D",/H,@?6'X3]7#NS5#
M&V"&ABY\IO4-?  _>C5R\7P#7QCN,X;:R^LF;V"2#>.S6#:B$T3UWVV7CI]$
M6/0]UNE58<2?+]8_LX>C:A$P+^75^&OY,@[N9(N 'V25)MDT_/Q_4$L#!!0
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M>@N@,5-CUJS=X69;</-N2W'37PJRM_]\7ZO^TC %,HJLF;9L%88"+_?-@8O
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M+GAS9%!+ 0(4 Q0    ( "."#%M59@AK'@H  /J(   5              "
M =QV  !D;6%C+3(P,C4P-C,P7V-A;"YX;6Q02P$"% ,4    "  C@@Q;)TFG
M$F8R   ZF00 %0              @ $M@0  9&UA8RTR,#(U,#8S,%]D968N
M>&UL4$L! A0#%     @ (X(,6T)'S&O-00  I94# !4              ( !
MQK,  &1M86,M,C R-3 V,S!?;&%B+GAM;%!+ 0(4 Q0    ( "."#%N$4VC'
M?C8  /,'!0 5              "  <;U  !D;6%C+3(P,C4P-C,P7W!R92YX
M;6Q02P$"% ,4    "  C@@Q;!&3WRU'O  !'*@T %               @ %W
M+ $ 9&UT<#(P,C4P-C,P7S$P<2YH=&U02P$"% ,4    "  C@@Q;AA*[0F0(
M  "X,0  #0              @ 'Z&P( 97A?.#0V-C4V+FAT;5!+ 0(4 Q0
M   ( "."#%NI7.L(6P@  !0R   -              "  8DD @!E>%\X-#8V
M-3<N:'1M4$L! A0#%     @ (X(,6_4E5BR)!   91,   T
M ( !#RT" &5X7S@T-C8U."YH=&U02P$"% ,4    "  C@@Q;>1:N9WT$  "F
M$P  #0              @ '#,0( 97A?.#0V-C4Y+FAT;5!+ 0(4 Q0    (
M "."#%LFRA>[3@(  %H*   -              "  6LV @!E>%\X-#DU,C<N
9:'1M4$L%!@     ,  P \ (  .0X @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>dmtp20250630_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:dmac="http://www.diamedica.com/20250630"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dmac-20250630.xsd" xlink:type="simple"/>
    <context id="d_2025-01-01_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-07-21_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-21</startDate>
            <endDate>2025-07-21</endDate>
        </period>
    </context>
    <context id="d_2025-07-21_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-21</startDate>
            <endDate>2025-07-21</endDate>
        </period>
    </context>
    <context id="i_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-21</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-06-30_PlanNameAxis-The2012DSUPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2012DSUPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_PlanNameAxis-StockOptionPriorPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:StockOptionPriorPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2021-12-03_2021-12-03_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_PlanNameAxis-The2019OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2019OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-DeferredShareUnitsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_PlanNameAxis-The2019OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-05-22_PlanNameAxis-The2019OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-22</instant>
        </period>
    </context>
    <context id="d_2022-05-18_2022-05-18_AwardTypeAxis-NonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:NonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <context id="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <context id="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <context id="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-The2021EmploymentInducementIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-The2019OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-DeferredShareUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-StockOptionsOutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:StockOptionsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2024-06-25_2024-06-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <startDate>2024-06-25</startDate>
            <endDate>2024-06-25</endDate>
        </period>
    </context>
    <context id="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-25</startDate>
            <endDate>2024-06-25</endDate>
        </period>
    </context>
    <context id="i_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-25</instant>
        </period>
    </context>
    <context id="i_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-07-21_2025-07-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <startDate>2025-07-21</startDate>
            <endDate>2025-07-21</endDate>
        </period>
    </context>
    <context id="i_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <instant>2025-08-08</instant>
        </period>
    </context>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2025-01-01_2025-06-30" id="ixv-5285">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2025-01-01_2025-06-30" id="ixv-5286">2025</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="d_2025-01-01_2025-06-30" id="ixv-5287">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="d_2025-01-01_2025-06-30" id="ixv-5288">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d_2025-01-01_2025-06-30" id="ixv-5289">0001401040</dei:EntityCentralIndexKey>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2025-01-01_2025-06-30" id="c837">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2025-01-01_2025-06-30" id="c836">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2025-01-01_2025-06-30" id="c835">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2025-01-01_2025-06-30" id="c834">false</ecd:Rule10b51ArrAdoptedFlag>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c735"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-NonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      id="c584">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-NonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      id="c583">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MaximumMember"
      id="c582">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MinimumMember"
      id="c581">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      id="c580">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c404"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c402"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c396"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c394"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c388"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c386"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c350"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CommonStockValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c81"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c80"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="d_2024-01-01_2024-12-31" id="c75">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="d_2025-01-01_2025-06-30" id="c74">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockNoParValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c73"
      unitRef="USDPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c72"
      unitRef="USDPerShare">0</us-gaap:CommonStockNoParValue>
    <dei:DocumentType contextRef="d_2025-01-01_2025-06-30" id="c2">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="d_2025-01-01_2025-06-30" id="c3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="d_2025-01-01_2025-06-30" id="c4">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2025-01-01_2025-06-30" id="c5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2025-01-01_2025-06-30" id="c6">001-36291</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="d_2025-01-01_2025-06-30" id="c7">DIAMEDICA THERAPEUTICS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2025-01-01_2025-06-30" id="c8">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="d_2025-01-01_2025-06-30" id="c9">301 Carlson Parkway, Suite 210</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2025-01-01_2025-06-30" id="c10">Minneapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2025-01-01_2025-06-30" id="c11">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2025-01-01_2025-06-30" id="c12">55305</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2025-01-01_2025-06-30" id="c13">763</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2025-01-01_2025-06-30" id="c14">496-5454</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2025-01-01_2025-06-30" id="c15">Voting common shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2025-01-01_2025-06-30" id="c16">DMAC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2025-01-01_2025-06-30" id="c17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="d_2025-01-01_2025-06-30" id="c18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2025-01-01_2025-06-30" id="c19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2025-01-01_2025-06-30" id="c20">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2025-01-01_2025-06-30" id="c21">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2025-01-01_2025-06-30" id="c22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="d_2025-01-01_2025-06-30" id="c23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2025-08-08"
      decimals="INF"
      id="c24"
      unitRef="Share">51688913</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c30"
      unitRef="USD">4109000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c31"
      unitRef="USD">3025000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c32"
      unitRef="USD">25929000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c33"
      unitRef="USD">41122000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c34"
      unitRef="USD">680000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c35"
      unitRef="USD">227000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="i_2025-06-30"
      decimals="-5"
      id="c36"
      unitRef="USD">200000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c37"
      unitRef="USD">0</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c38"
      unitRef="USD">161000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c39"
      unitRef="USD">236000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c40"
      unitRef="USD">31079000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c41"
      unitRef="USD">44610000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c43"
      unitRef="USD">239000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c44"
      unitRef="USD">279000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c45"
      unitRef="USD">152000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c46"
      unitRef="USD">148000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c47"
      unitRef="USD">0</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c48"
      unitRef="USD">1308000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c49"
      unitRef="USD">391000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c50"
      unitRef="USD">1735000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c51"
      unitRef="USD">31470000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c52"
      unitRef="USD">46345000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c54"
      unitRef="USD">1261000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c55"
      unitRef="USD">940000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c56"
      unitRef="USD">2747000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c57"
      unitRef="USD">4347000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c58"
      unitRef="USD">96000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c59"
      unitRef="USD">90000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c60"
      unitRef="USD">12000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c61"
      unitRef="USD">13000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c62"
      unitRef="USD">4116000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c63"
      unitRef="USD">5390000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c65"
      unitRef="USD">176000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c66"
      unitRef="USD">225000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c67"
      unitRef="USD">8000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c68"
      unitRef="USD">12000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c69"
      unitRef="USD">184000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c70"
      unitRef="USD">237000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c76"
      unitRef="Share">43072488</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c77"
      unitRef="Share">43072488</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c78"
      unitRef="Share">42818660</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c79"
      unitRef="Share">42818660</us-gaap:CommonStockSharesIssued>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c82"
      unitRef="USD">182592000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c83"
      unitRef="USD">180697000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c84"
      unitRef="USD">-14000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c85"
      unitRef="USD">23000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c86"
      unitRef="USD">-155408000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c87"
      unitRef="USD">-140002000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c88"
      unitRef="USD">27170000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c89"
      unitRef="USD">40718000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c90"
      unitRef="USD">31470000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c91"
      unitRef="USD">46345000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c95"
      unitRef="USD">5822000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c96"
      unitRef="USD">3928000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c97"
      unitRef="USD">11478000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c98"
      unitRef="USD">7604000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c99"
      unitRef="USD">2185000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-4"
      id="c100"
      unitRef="USD">1710000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c101"
      unitRef="USD">4673000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c102"
      unitRef="USD">3775000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c103"
      unitRef="USD">-8007000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c104"
      unitRef="USD">-5638000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c105"
      unitRef="USD">-16151000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c106"
      unitRef="USD">-11379000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c107"
      unitRef="USD">314000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c108"
      unitRef="USD">526000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c109"
      unitRef="USD">757000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c110"
      unitRef="USD">1123000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c111"
      unitRef="USD">-7693000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c112"
      unitRef="USD">-5112000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c113"
      unitRef="USD">-15394000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c114"
      unitRef="USD">-10256000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c115"
      unitRef="USD">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c116"
      unitRef="USD">7000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c117"
      unitRef="USD">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c118"
      unitRef="USD">14000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c119"
      unitRef="USD">-7699000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c120"
      unitRef="USD">-5119000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c121"
      unitRef="USD">-15406000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-4"
      id="c122"
      unitRef="USD">-10270000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c124"
      unitRef="USD">-19000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c125"
      unitRef="USD">-12000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c126"
      unitRef="USD">-37000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c127"
      unitRef="USD">-57000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c128"
      unitRef="USD">-7718000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c129"
      unitRef="USD">-5131000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c130"
      unitRef="USD">-15443000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c131"
      unitRef="USD">-10327000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c132"
      unitRef="USDPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c133"
      unitRef="USDPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c134"
      unitRef="USDPerShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c135"
      unitRef="USDPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c136"
      unitRef="Share">42957619</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c137"
      unitRef="Share">38068378</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c138"
      unitRef="Share">42901093</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c139"
      unitRef="Share">38013189</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c142"
      unitRef="Share">42818660</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c143"
      unitRef="USD">180697000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c144"
      unitRef="USD">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c145"
      unitRef="USD">-140002000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c146"
      unitRef="USD">40718000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c147"
      unitRef="Share">3805</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c148"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c149"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c150"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-01-01_2025-03-31"
      decimals="-3"
      id="c151"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c152"
      unitRef="Share">37000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c153"
      unitRef="USD">94000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c154"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c155"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-03-31"
      decimals="-3"
      id="c156"
      unitRef="USD">94000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c158"
      unitRef="USD">867000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c159"
      unitRef="USD">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c160"
      unitRef="USD">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2025-01-01_2025-03-31"
      decimals="-3"
      id="c161"
      unitRef="USD">867000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c163"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c164"
      unitRef="USD">-18000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c165"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-03-31"
      decimals="-3"
      id="c166"
      unitRef="USD">-18000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c168"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c169"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c170"
      unitRef="USD">-7707000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-03-31"
      decimals="-3"
      id="c171"
      unitRef="USD">-7707000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c172"
      unitRef="Share">42859465</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c173"
      unitRef="USD">181658000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c174"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c175"
      unitRef="USD">-147709000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c176"
      unitRef="USD">33954000</us-gaap:StockholdersEquity>
    <dmac:StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c177"
      unitRef="Share">142345</dmac:StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c182"
      unitRef="Share">3803</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c183"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c184"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c185"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c186"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c187"
      unitRef="Share">66875</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c188"
      unitRef="USD">163000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c189"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c190"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c191"
      unitRef="USD">163000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c193"
      unitRef="USD">771000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c194"
      unitRef="USD">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c195"
      unitRef="USD">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c196"
      unitRef="USD">771000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c198"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c199"
      unitRef="USD">-19000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c200"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c201"
      unitRef="USD">-19000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c203"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c204"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c205"
      unitRef="USD">-7699000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c206"
      unitRef="USD">-7699000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c207"
      unitRef="Share">43072488</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c208"
      unitRef="USD">182592000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c209"
      unitRef="USD">-14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c210"
      unitRef="USD">-155408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c211"
      unitRef="USD">27170000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c214"
      unitRef="Share">37958000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c215"
      unitRef="USD">166609000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c216"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c217"
      unitRef="USD">-115558000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c218"
      unitRef="USD">51057000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c219"
      unitRef="Share">5916</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c220"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c221"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c222"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-3"
      id="c223"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c225"
      unitRef="USD">488000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c226"
      unitRef="USD">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c227"
      unitRef="USD">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-3"
      id="c228"
      unitRef="USD">488000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c230"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c231"
      unitRef="USD">-45000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c232"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-3"
      id="c233"
      unitRef="USD">-45000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c235"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c236"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c237"
      unitRef="USD">-5151000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-3"
      id="c238"
      unitRef="USD">-5151000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c239"
      unitRef="Share">37963916</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c240"
      unitRef="USD">167097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c241"
      unitRef="USD">-39000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c242"
      unitRef="USD">-120709000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c243"
      unitRef="USD">46349000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-5"
      id="c244"
      unitRef="USD">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c245"
      unitRef="Share">4720000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c246"
      unitRef="USD">11747000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c247"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c248"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c249"
      unitRef="USD">11747000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c250"
      unitRef="Share">5916</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c251"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c252"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c253"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c254"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c255"
      unitRef="Share">2750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c256"
      unitRef="USD">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c257"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c258"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c259"
      unitRef="USD">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c261"
      unitRef="USD">443000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c262"
      unitRef="USD">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c263"
      unitRef="USD">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c264"
      unitRef="USD">443000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c266"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c267"
      unitRef="USD">-12000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c268"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c269"
      unitRef="USD">-12000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c271"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c272"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c273"
      unitRef="USD">-5119000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c274"
      unitRef="USD">-5119000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c275"
      unitRef="Share">42692582</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c276"
      unitRef="USD">179294000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c277"
      unitRef="USD">-51000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c278"
      unitRef="USD">-125828000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c279"
      unitRef="USD">53415000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c283"
      unitRef="USD">-15406000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-4"
      id="c284"
      unitRef="USD">-10270000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c286"
      unitRef="USD">1638000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c287"
      unitRef="USD">931000</us-gaap:ShareBasedCompensation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c288"
      unitRef="USD">441000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c289"
      unitRef="USD">648000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <dmac:NoncashLeaseExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-4"
      id="c290"
      unitRef="USD">40000</dmac:NoncashLeaseExpense>
    <dmac:NoncashLeaseExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c291"
      unitRef="USD">37000</dmac:NoncashLeaseExpense>
    <us-gaap:Depreciation
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c292"
      unitRef="USD">14000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c293"
      unitRef="USD">18000</us-gaap:Depreciation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c295"
      unitRef="USD">-75000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c296"
      unitRef="USD">22000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c297"
      unitRef="USD">453000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c298"
      unitRef="USD">156000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c299"
      unitRef="USD">-1108000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c300"
      unitRef="USD">1308000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c301"
      unitRef="USD">321000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c302"
      unitRef="USD">-167000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c303"
      unitRef="USD">-1643000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c304"
      unitRef="USD">413000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c305"
      unitRef="USD">-14747000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c306"
      unitRef="USD">-11172000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-4"
      id="c308"
      unitRef="USD">16370000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c309"
      unitRef="USD">18047000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c310"
      unitRef="USD">31967000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-6"
      id="c311"
      unitRef="USD">27000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c312"
      unitRef="USD">18000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c313"
      unitRef="USD">9000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c314"
      unitRef="USD">15579000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c315"
      unitRef="USD">8944000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c317"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c318"
      unitRef="USD">11747000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c319"
      unitRef="USD">257000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c320"
      unitRef="USD">7000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c321"
      unitRef="USD">5000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c322"
      unitRef="USD">3000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c323"
      unitRef="USD">252000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c324"
      unitRef="USD">11751000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c325"
      unitRef="USD">1084000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c326"
      unitRef="USD">9523000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c327"
      unitRef="USD">3025000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c328"
      unitRef="USD">4543000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c329"
      unitRef="USD">4109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c330"
      unitRef="USD">14066000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c332"
      unitRef="USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-4"
      id="c333"
      unitRef="USD">30000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:IncomeTaxesPaid
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c334"
      unitRef="USD">12000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c335"
      unitRef="USD">14000</us-gaap:IncomeTaxesPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="d_2025-01-01_2025-06-30" id="c336">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Business&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;DiaMedica Therapeutics Inc. and its wholly owned subsidiaries, DiaMedica USA Inc. and DiaMedica Australia Pty Ltd. (collectively, we, us, our, DiaMedica and the Company), is a clinical stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE) and acute ischemic stroke (AIS). DiaMedica&#x2019;s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein, an established therapeutic modality in Asia for the treatment of preeclampsia, acute ischemic stroke and other vascular diseases. Our common shares are publicly traded on The Nasdaq Capital Market under the symbol &#x201c;DMAC.&#x201d;&lt;/p&gt;
</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dmac:RisksAndUncertaintiesTextBlock contextRef="d_2025-01-01_2025-06-30" id="c338">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Risks and Uncertainties&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;DiaMedica operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the United States Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in the European Union, and comparable agencies in other countries. We are in the clinical stage of development of our lead product candidate, DM199, for the treatment of PE and AIS. We have not completed the development of any product candidate and do not generate any revenues from the commercial sale of any product candidate. Our lead product candidate, DM199, requires significant additional clinical testing and investment prior to seeking marketing approval and is not expected to be commercially available for at least three to four years, if at all.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;With respect to our PE clinical program, a Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 for the treatment of PE is currently being conducted at the Tygerberg Hospital in Cape Town, South Africa. This Phase 2 study consists of three studies in PE (Part 1a, dose-escalation; Part 1b, dose-expansion; and Part 2, expectant management) and a fourth study in fetal growth restriction (FGR, Part 3, expectant management). Part 1a topline study results are intended to identify a suitable dose for Parts 1b, 2, and 3. Up to 90 women with PE and potentially an additional 30 subjects with fetal growth restriction may be evaluated. The first subject in Part 1a was enrolled in the fourth quarter of 2024 and interim results from Part 1a of the study were released in July 2025. The interim results (N=28 subjects) demonstrated that DM199 appears safe and well-tolerated with clinically-relevant pharmacodynamic activity with no evidence of placental transfer. Additionally, subjects exhibited rapid, statistically significant reductions in blood pressure with duration of effect that was sustained up to 24 hours post-infusion compared to pre-treatment baseline. Preparations are underway to initiate Part 1b where up to 30 subjects with PE and expected delivery within 72 hours will be treated with a dose regimen identified from Part 1a.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;With respect to our AIS clinical program, we are currently conducting a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial of DM199 for the treatment of AIS, known as the ReMEDy2 trial. Our ReMEDy2 trial is intended to enroll approximately 300 participants at up to 100 sites globally. The adaptive design component includes an interim analysis by our independent data safety monitoring board to be conducted after the first 200 participants have completed the trial. Based on the results of the interim analysis, the study may then be stopped for futility or the final sample size will be determined, ranging between 300 and 728 patients, according to a pre-determined statistical plan. We have experienced and continue to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the previous clinical hold; use of artificial intelligence and telemedicine which have enabled smaller hospitals to retain AIS patients not eligible for mechanical thrombectomy instead of sending these patients to the larger stroke centers which are more likely to be sites in our trial; and competition for research staff and trial subjects due to other pending stroke and neurological trials. We continue to reach out to current and potential study sites to understand the specific issues at each study site. In an effort to mitigate the impact of these factors, we have significantly expanded our internal clinical team and have brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring, and overall program management. We are currently conducting our ReMEDy2 trial in the United States and in the countries of Canada and Georgia. We are in the process of preparing regulatory filings and identifying and engaging study sites in an additional seven European countries and have submitted for approval of this study in the United Kingdom. We continue to work closely with our contract research organizations and other advisors to develop procedures to support both U.S. and global study sites and potential participants as needed. We intend to continue to monitor the results of these efforts and, if necessary, implement additional actions to enhance site activations and enrollment in our ReMEDy2 trial; however, no assurances can be provided as to the success of these actions and if or when these issues will resolve. Failure to resolve these issues may result in delays in our ReMEDy2 trial.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our future success is dependent upon the success of our development efforts, our ability to demonstrate clinical progress for our DM199 product candidate in the United States or other markets, our ability, or the ability of any future partner, to obtain required governmental approvals of our product candidate, our ability to license or market and sell our DM199 product candidate, and our ability to obtain additional financing to fund these efforts.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of June 30,&#160;2025, we have incurred losses of $155.4 million since our inception in 2000. For the six months ended June 30, 2025, we incurred a net loss of $15.4 million and negative cash flows from operating activities of $14.7 million. We expect to continue to incur operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments generate revenue sufficient to fund our continuing operations. For the foreseeable future, we expect to incur significant operating losses as we continue the development and clinical study of, and to seek regulatory approval for, our DM199 product candidate. As of June 30,&#160;2025, we had combined cash, cash equivalents and marketable securities of $30.0 million, working capital of $27.0 million and shareholders&#x2019; equity of $27.2 million. Subsequent to quarter end, in July 2025, we completed a private placement of common shares in which we received net proceeds of $29.9 million, see Note 14, titled &#x201c;&lt;i&gt;Subsequent Event&lt;/i&gt;.&#x201d;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our principal source of cash has been net proceeds from the issuance of equity securities. Although we have previously been successful in obtaining financing through equity securities offerings, there is no assurance that we will be able to do so in the future. This is particularly true if our clinical data are not positive or if economic and market conditions deteriorate.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Notwithstanding the completion of our July 2025 private placement, we expect that we will need substantial additional capital to further our research and development activities and complete the required clinical studies, regulatory activities and manufacturing development for our product candidate, DM199, or any future product candidates, to a point where they may be licensed or commercially sold. We expect our current cash, cash equivalents and marketable securities, including the $29.9 million net proceeds from our July 2025 private placement of common shares, to be sufficient to continue the Phase 2 PE trial, the ReMEDy2 trial, and otherwise fund our planned operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. The amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including our current ReMEDy2 trial and the rate of site activation and participant enrollment in the study; the Phase 2 PE trial; the potential expansion of our current development programs; the effects of ongoing site staffing shortages; and other factors on our clinical trials and our operating expenses. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising capital are favorable.&lt;/p&gt;
</dmac:RisksAndUncertaintiesTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-06-30"
      decimals="-5"
      id="c340"
      unitRef="USD">-155400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-5"
      id="c341"
      unitRef="USD">-15400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-5"
      id="c342"
      unitRef="USD">-14700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2025-06-30"
      decimals="-7"
      id="c343"
      unitRef="USD">30000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <dmac:WorkingCapital
      contextRef="i_2025-06-30"
      decimals="-6"
      id="c344"
      unitRef="USD">27000000</dmac:WorkingCapital>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30"
      decimals="-5"
      id="c345"
      unitRef="USD">27200000</us-gaap:StockholdersEquity>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="d_2025-07-21_2025-07-21"
      decimals="-5"
      id="c346"
      unitRef="USD">29900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="d_2025-07-21_2025-07-21"
      decimals="-5"
      id="c347"
      unitRef="USD">29900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2025-01-01_2025-06-30" id="c348">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;Interim financial statements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We have prepared the accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. These condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly our condensed consolidated financial position, condensed consolidated results of operations, condensed consolidated statement of shareholders&#x2019; equity and condensed consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on December&#160;31. The condensed consolidated balance sheet as of December&#160;31,&#160;2024 was derived from our audited consolidated financial statements. These condensed consolidated financial statements should be read in conjunction with our annual consolidated financial statements and the notes thereto. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year. Certain prior year amounts have been reclassified to conform to the current year presentation.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We operate in a &lt;span style="-sec-ix-hidden:c350"&gt;single&lt;/span&gt; segment focusing on researching and developing potentially transformative treatments for severe ischemic diseases. Consistent with our operational structure, our chief operating decision maker manages and allocates resources for the Company at a consolidated level. Therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting. All assets are held in the United States.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of our cash equivalents approximates fair value due to the short maturity of the investments.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;




&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;Marketable securities&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the condensed consolidated statements of operations.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive income or loss, which is a separate component of shareholders&#x2019; equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no other-than-temporary unrealized losses as of June 30, 2025.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;Fair value measurements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The hierarchy is broken down into three levels defined as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Level 1 Inputs&lt;/i&gt; &#x2014; quoted prices in active markets for identical assets and liabilities;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Level 2 Inputs&lt;/i&gt; &#x2014; observable inputs other than quoted prices in active markets for identical assets and liabilities; and&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Level 3 Inputs&lt;/i&gt; &#x2014; unobservable inputs.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of June 30,&#160;2025, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled &#x201c;&lt;i&gt;Marketable Securities&lt;/i&gt;&#x201d; for additional information.&lt;/p&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-06-30" id="c494700676267739">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We operate in a &lt;span style="-sec-ix-hidden:c350"&gt;single&lt;/span&gt; segment focusing on researching and developing potentially transformative treatments for severe ischemic diseases. Consistent with our operational structure, our chief operating decision maker manages and allocates resources for the Company at a consolidated level. Therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting. All assets are held in the United States.&lt;/p&gt;
</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2025-01-01_2025-06-30" id="c1482347759684743">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of our cash equivalents approximates fair value due to the short maturity of the investments.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="d_2025-01-01_2025-06-30" id="c280681241393138">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;Marketable securities&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the condensed consolidated statements of operations.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive income or loss, which is a separate component of shareholders&#x2019; equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no other-than-temporary unrealized losses as of June 30, 2025.&lt;/p&gt;
</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-06-30" id="c778890428950662">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;Fair value measurements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The hierarchy is broken down into three levels defined as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Level 1 Inputs&lt;/i&gt; &#x2014; quoted prices in active markets for identical assets and liabilities;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Level 2 Inputs&lt;/i&gt; &#x2014; observable inputs other than quoted prices in active markets for identical assets and liabilities; and&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Level 3 Inputs&lt;/i&gt; &#x2014; unobservable inputs.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of June 30,&#160;2025, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled &#x201c;&lt;i&gt;Marketable Securities&lt;/i&gt;&#x201d; for additional information.&lt;/p&gt;
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="d_2025-01-01_2025-06-30" id="c355">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Marketable Securities&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis (in thousands):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="30" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Measurements Using Inputs Considered as of:&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 28%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper and corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,419&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c386"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,419&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c388"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Government securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,510&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c394"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,510&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c396"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,831&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,831&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,929&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c402"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,929&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c404"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;41,122&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;41,122&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Maturities of individual securities are less than 12 months, and the amortized cost of all securities approximated fair value as of June 30,&#160;2025 and December&#160;31,&#160;2024. Accrued interest receivable on marketable securities is included in amounts receivable and was $142,000 and $235,000 as of June 30,&#160;2025 and December&#160;31,&#160;2024, respectively.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the six months ended June 30, 2025.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c383">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="30" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Measurements Using Inputs Considered as of:&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 28%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper and corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,419&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c386"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,419&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c388"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Government securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,510&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c394"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,510&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c396"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,831&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,831&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,929&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c402"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,929&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c404"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;41,122&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;41,122&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c385"
      unitRef="USD">12419000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c387"
      unitRef="USD">12419000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c389"
      unitRef="USD">28291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c390"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c391"
      unitRef="USD">28291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c392"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-4"
      id="c393"
      unitRef="USD">13510000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-4"
      id="c395"
      unitRef="USD">13510000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c397"
      unitRef="USD">12831000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c398"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c399"
      unitRef="USD">12831000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c400"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c401"
      unitRef="USD">25929000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c403"
      unitRef="USD">25929000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c405"
      unitRef="USD">41122000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c406"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c407"
      unitRef="USD">41122000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c408"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="i_2025-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember"
      decimals="0"
      id="c381"
      unitRef="USD">142000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i_2024-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember"
      decimals="0"
      id="c382"
      unitRef="USD">235000</us-gaap:InterestReceivable>
    <dmac:DepositAssetsTextBlock contextRef="d_2025-01-01_2025-06-30" id="c409">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Deposits&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;DiaMedica periodically advances funds to vendors engaged to support the performance of our clinical trials and related supporting activities. The funds advanced are held, interest free, for varying periods of time and may be recovered by the Company through partial reductions of ongoing invoices, application against final study/project invoices or refunded upon completion of services to be provided. Deposits are classified as current or non-current based upon their expected recovery time.&lt;/p&gt;
</dmac:DepositAssetsTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="d_2025-01-01_2025-06-30" id="c411">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Amounts Receivable&#160;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Amounts receivable consisted primarily of accrued interest receivable on marketable securities of $142,000 and $235,000 as of June 30,&#160;2025 and December&#160;31,&#160;2024, respectively.&lt;/p&gt;
</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2025-06-30"
      decimals="0"
      id="c413"
      unitRef="USD">142000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c414"
      unitRef="USD">235000</us-gaap:InterestReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2025-01-01_2025-06-30" id="c415">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computer equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;136&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;118&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Furniture and equipment&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;128&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;128&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;280&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;262&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less accumulated depreciation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(128&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(114&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Property and equipment, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;152&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;148&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2025-01-01_2025-06-30" id="c429">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computer equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;136&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;118&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Furniture and equipment&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;128&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;128&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;280&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;262&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less accumulated depreciation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(128&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(114&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Property and equipment, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;152&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;148&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2025-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      decimals="-3"
      id="c431"
      unitRef="USD">136000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      decimals="-3"
      id="c432"
      unitRef="USD">118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2025-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c433"
      unitRef="USD">128000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c434"
      unitRef="USD">128000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2025-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c435"
      unitRef="USD">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c436"
      unitRef="USD">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c437"
      unitRef="USD">280000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c438"
      unitRef="USD">262000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c439"
      unitRef="USD">128000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c440"
      unitRef="USD">114000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c441"
      unitRef="USD">152000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c442"
      unitRef="USD">148000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="d_2025-01-01_2025-06-30" id="c443">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Accrued Liabilities&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Clinical trial costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,268&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,277&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development services&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;790&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;888&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;590&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,060&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Professional services fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;94&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;112&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total accrued liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,747&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,347&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c457">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Clinical trial costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,268&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,277&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development services&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;790&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;888&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;590&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,060&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Professional services fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;94&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;112&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total accrued liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,747&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,347&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <dmac:AccruedClinicalStudyCostsCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c459"
      unitRef="USD">1268000</dmac:AccruedClinicalStudyCostsCurrent>
    <dmac:AccruedClinicalStudyCostsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c460"
      unitRef="USD">2277000</dmac:AccruedClinicalStudyCostsCurrent>
    <dmac:AccruedResearchAndProfessionalFeesCurrent
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c461"
      unitRef="USD">790000</dmac:AccruedResearchAndProfessionalFeesCurrent>
    <dmac:AccruedResearchAndProfessionalFeesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c462"
      unitRef="USD">888000</dmac:AccruedResearchAndProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c463"
      unitRef="USD">590000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c464"
      unitRef="USD">1060000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c465"
      unitRef="USD">94000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c466"
      unitRef="USD">112000</us-gaap:AccruedProfessionalFeesCurrent>
    <dmac:AccruedTaxesAndOtherLiabilitiesCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c467"
      unitRef="USD">5000</dmac:AccruedTaxesAndOtherLiabilitiesCurrent>
    <dmac:AccruedTaxesAndOtherLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c468"
      unitRef="USD">10000</dmac:AccruedTaxesAndOtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c469"
      unitRef="USD">2747000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c470"
      unitRef="USD">4347000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="d_2025-01-01_2025-06-30" id="c471">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Operating Lease&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;Office lease&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our operating lease costs were $52,000 for each of the six month periods ended June 30,&#160;2025 and&#160;2024. Our variable lease costs were $43,000 and $38,000 for the six months ended June 30,&#160;2025 and&#160;2024, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Maturities of our operating lease obligation are as follows as of June 30,&#160;2025 (in thousands):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;57&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;116&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2028&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease payments&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;302&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Less interest portion&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(30&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Present value of operating lease obligation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;272&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Less current portion of operating lease&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(96&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease obligation, non-current&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;176&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2025-01-01_2025-06-30"
      decimals="0"
      id="c473"
      unitRef="USD">52000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2024-01-01_2024-06-30"
      decimals="0"
      id="c474"
      unitRef="USD">52000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="d_2025-01-01_2025-06-30"
      decimals="0"
      id="c475"
      unitRef="USD">43000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="d_2024-01-01_2024-06-30"
      decimals="0"
      id="c476"
      unitRef="USD">38000</us-gaap:VariableLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c486">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;57&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;116&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2028&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease payments&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;302&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Less interest portion&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(30&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Present value of operating lease obligation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;272&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Less current portion of operating lease&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(96&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease obligation, non-current&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;176&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c488"
      unitRef="USD">57000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c489"
      unitRef="USD">116000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c490"
      unitRef="USD">119000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c491"
      unitRef="USD">10000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c492"
      unitRef="USD">302000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c493"
      unitRef="USD">30000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c494"
      unitRef="USD">272000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c495"
      unitRef="USD">96000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c496"
      unitRef="USD">176000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2025-01-01_2025-06-30" id="c497">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Shareholders&lt;/b&gt;&#x2019;&lt;b&gt; Equity&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Authorized capital shares&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;DiaMedica has authorized share capital of an unlimited number of voting common shares, and the shares do not have a stated par value. Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company&#x2019;s annual general meeting and any extraordinary or special general meeting.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Equity issued during the six months ended June 30,&lt;/i&gt;&#160;&lt;i&gt;2025&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;During the six months ended June 30,&#160;2025, 7,608 common shares were issued upon the vesting and settlement of restricted stock units, 142,345 shares were issued upon the settlement of deferred share units and 103,875&#160;common shares were issued upon the exercise of stock options for gross proceeds of $257,000.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Equity issued during the six months ended June 30,&lt;/i&gt;&#160;&lt;i&gt;2024&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On June 25, 2024, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate 4,720,000 common shares at a purchase price of $2.50 per share in a private placement. As a result of the offering, which closed on June 28, 2024, we received gross proceeds of $11.8 million, which resulted in net proceeds to us of approximately $11.7 million, after deducting the offering expenses.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In connection with the June 2024 private placement, we entered into a registration rights agreement (Registration Rights Agreement) with the investors pursuant to which we agreed to file with the United States Securities and Exchange Commission (SEC) a registration statement registering the resale of the shares sold in the June 2024 private placement (Resale Registration Statement). The Resale Registration Statement was filed with the SEC on July 10, 2024 and declared effective by the SEC on July 18, 2024. Under the terms of the Registration Rights Agreement, we agreed to keep the Resale Registration Statement effective at all times until the shares are no longer considered &#x201c;Registrable Securities&#x201d; under the Registration Rights Agreement and if we fail to keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;During the six months ended June 30, 2024, 11,832 common shares were issued upon the vesting and settlement of restricted stock units and 2,750 common shares were issued upon the exercise of common stock options for gross proceeds of $7 thousand.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Shares reserved&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Common shares reserved for future issuance are as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares issuable upon exercise of employee and non-employee stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,685,604&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares issuable upon settlement of deferred stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;174,515&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares issuable upon vesting and settlement of restricted stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,607&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;754,919&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares available for grant under the 2021 Employment Inducement Incentive Plan&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;357,500&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,980,145&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c499"
      unitRef="Share">7608</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <dmac:StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c500"
      unitRef="Share">142345</dmac:StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c501"
      unitRef="Share">103875</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2025-01-01_2025-06-30"
      decimals="0"
      id="c502"
      unitRef="USD">257000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c503"
      unitRef="Share">4720000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c504"
      unitRef="USDPerShare">2.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c505"
      unitRef="USD">11800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <dmac:ProceedsFromIssuanceOfCommonStockNet
      contextRef="d_2024-06-25_2024-06-25"
      decimals="-5"
      id="c506"
      unitRef="USD">11700000</dmac:ProceedsFromIssuanceOfCommonStockNet>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c507"
      unitRef="Share">11832</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c508"
      unitRef="Share">2750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c509"
      unitRef="USD">7000</us-gaap:ProceedsFromStockOptionsExercised>
    <dmac:CommonStockReservedForFutureIssuanceTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c516">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares issuable upon exercise of employee and non-employee stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,685,604&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares issuable upon settlement of deferred stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;174,515&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares issuable upon vesting and settlement of restricted stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,607&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;754,919&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares available for grant under the 2021 Employment Inducement Incentive Plan&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;357,500&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,980,145&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</dmac:CommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-06-30_AwardTypeAxis-StockOptionsOutstandingMember"
      decimals="INF"
      id="c518"
      unitRef="Share">6685604</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-06-30_AwardTypeAxis-DeferredShareUnitsMember"
      decimals="INF"
      id="c519"
      unitRef="Share">174515</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c520"
      unitRef="Share">7607</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-06-30_AwardTypeAxis-The2019OmnibusIncentivePlanMember"
      decimals="INF"
      id="c521"
      unitRef="Share">754919</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-06-30_AwardTypeAxis-The2021EmploymentInducementIncentivePlanMember"
      decimals="INF"
      id="c522"
      unitRef="Share">357500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c523"
      unitRef="Share">7980145</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:EarningsPerShareTextBlock contextRef="d_2025-01-01_2025-06-30" id="c524">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table summarizes our calculation of net loss per common share for the periods presented (in thousands, except share and per share data):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(7,699&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(5,119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(15,406&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(10,270&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted average shares outstanding&#x2014;basic and diluted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;42,957,619&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38,068,378&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;42,901,093&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38,013,189&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.18&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.13&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.36&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.27&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Common shares issuable upon exercise of employee and non-employee stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,685,604&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,859,271&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,685,604&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,859,271&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Common shares issuable upon settlement of deferred stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;174,515&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;284,886&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;174,515&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;284,886&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Common shares issuable upon vesting and settlement of restricted stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,607&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,828&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,607&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,828&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c550">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(7,699&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(5,119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(15,406&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(10,270&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted average shares outstanding&#x2014;basic and diluted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;42,957,619&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38,068,378&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;42,901,093&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38,013,189&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.18&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.13&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.36&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.27&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c552"
      unitRef="USD">-7699000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c553"
      unitRef="USD">-5119000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c554"
      unitRef="USD">-15406000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-4"
      id="c555"
      unitRef="USD">-10270000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c556"
      unitRef="Share">42957619</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c557"
      unitRef="Share">38068378</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c558"
      unitRef="Share">42901093</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c559"
      unitRef="Share">38013189</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c560"
      unitRef="USDPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c561"
      unitRef="USDPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c562"
      unitRef="USDPerShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c563"
      unitRef="USDPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2025-01-01_2025-06-30" id="c564">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Common shares issuable upon exercise of employee and non-employee stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,685,604&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,859,271&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,685,604&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,859,271&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Common shares issuable upon settlement of deferred stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;174,515&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;284,886&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;174,515&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;284,886&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Common shares issuable upon vesting and settlement of restricted stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,607&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,828&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,607&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,828&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember"
      decimals="INF"
      id="c566"
      unitRef="Share">6685604</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember"
      decimals="INF"
      id="c567"
      unitRef="Share">4859271</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember"
      decimals="INF"
      id="c568"
      unitRef="Share">6685604</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember"
      decimals="INF"
      id="c569"
      unitRef="Share">4859271</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember"
      decimals="INF"
      id="c570"
      unitRef="Share">174515</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember"
      decimals="INF"
      id="c571"
      unitRef="Share">284886</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember"
      decimals="INF"
      id="c572"
      unitRef="Share">174515</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-DeferredShareUnitsMember"
      decimals="INF"
      id="c573"
      unitRef="Share">284886</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c574"
      unitRef="Share">7607</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c575"
      unitRef="Share">11828</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c576"
      unitRef="Share">7607</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c577"
      unitRef="Share">11828</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2025-01-01_2025-06-30" id="c578">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;Amended and Restated 2019 Omnibus Incentive Plan (2019 Plan)&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The 2019 Plan permits the Board, or a committee or subcommittee thereof, to grant to the Company&#x2019;s eligible employees, non-employee directors and certain consultants non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units (RSUs), deferred stock units (DSUs), performance awards, non-employee director awards and other share-based awards. We grant options to purchase common shares under the 2019 Plan at no less than the fair market value of the underlying common shares as of the date of grant. Options granted to employees and non-employee directors have a maximum term of &lt;span style="-sec-ix-hidden:c580"&gt;ten&lt;/span&gt; years and generally vest over &lt;span style="-sec-ix-hidden:c581"&gt;one&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c582"&gt;four&lt;/span&gt; years. Options granted to non-employees have a maximum term of &lt;span style="-sec-ix-hidden:c583"&gt;five&lt;/span&gt; years and generally vest over &lt;span style="-sec-ix-hidden:c584"&gt;one&lt;/span&gt; year. Subject to adjustment as provided in the 2019 Plan, the maximum number of the Company&#x2019;s common shares authorized for issuance under the 2019 Plan is 7,000,000 shares. As of June 30,&#160;2025, options to purchase an aggregate of 5,721,194 common shares were outstanding, 164,770 common shares were reserved for issuance upon settlement of DSUs and 7,607 shares were reserved for issuance upon the vesting and settlement of RSUs and 754,919 shares remained available for issuance.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;2021 Employment Inducement Incentive Plan (2021 Inducement Plan)&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The 2021 Inducement Plan permits the Board, or a committee or subcommittee thereof, to grant of non-statutory options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other share-based awards, to new employees who satisfy the standards for inducement grants under Nasdaq Listing Rule 5635(c)(4) or 5635(c)(3), as applicable. The Inducement Plan has a term of 10 years. The share reserve under the Inducement Plan may be increased at the discretion of and approval by the Board. As of June 30,&#160;2025, options to purchase an aggregate of 590,000 common shares were outstanding under the Inducement Plan and 357,500 shares remained available for issuance.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;Prior Stock Option Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company&#x2019;s prior stock option plan was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the Prior Plan have terms similar to those used under the 2019 Plan. As of June 30,&#160;2025, options to purchase an aggregate of 374,410 common shares were outstanding.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;"&gt;&lt;i&gt;Prior Deferred Stock Unit Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company&#x2019;s prior deferred stock unit plan was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior DSU Plan remain outstanding in accordance with and pursuant to the terms thereof. As of June 30,&#160;2025, there were 9,745 common shares reserved for issuance upon settlement of DSUs outstanding.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Share-based compensation expense for each of the periods presented is as follows (in thousands):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;538&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;336&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,216&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;629&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;233&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;107&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;422&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;302&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;771&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;443&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,638&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;931&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We recognize share-based compensation for options awards based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those options that actually vest.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;A summary of option activity is as follows (in thousands except share and per share amounts):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Underlying&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average Exercise&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price Per Share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balances at December 31, 2024&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,692,438&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.33&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,243&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,333,416&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.42&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeitures&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(231,375&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.35&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(103,875&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.51&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6.91&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balances at June 30, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,685,604&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.70&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,767&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Information about stock options outstanding, vested and expected to vest as of June 30,&#160;2025, is as follows:&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;

		&lt;tbody&gt;&lt;tr&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 34%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Outstanding, Vested and Expected to Vest&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 18%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Options Vested and Exercisable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 9%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Per Share &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Contractual Life&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Options &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Contractual Life&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$1.00&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$1.99&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 12%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;191,443&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;7.7&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1.59&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 14%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;105,457&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;7.7&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$2.00&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$2.99&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 12%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;2,769,645&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;7.4&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;2.74&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 14%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,484,034&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;7.0&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$3.00&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$3.99&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 12%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;311,893&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5.2&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;3.56&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 14%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;229,393&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;3.9&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$4.00&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$4.99&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 12%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;2,652,069&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;8.0&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;4.24&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 14%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;677,182&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;4.0&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$5.00&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$10.00&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;760,554&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;7.3&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5.93&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 14%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;380,729&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5.2&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;6,685,604&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;7.5&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;3.70&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 14%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;2,876,795&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5.8&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2024-05-22_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      decimals="INF"
      id="c585"
      unitRef="Share">7000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-01-01_2025-06-30_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      decimals="INF"
      id="c586"
      unitRef="Share">5721194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-06-30_AwardTypeAxis-DeferredShareUnitsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      decimals="INF"
      id="c587"
      unitRef="Share">164770</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      decimals="INF"
      id="c588"
      unitRef="Share">7607</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-06-30_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      decimals="INF"
      id="c589"
      unitRef="Share">754919</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2021-12-03_2021-12-03_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember"
      id="c590">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-06-30_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember"
      decimals="INF"
      id="c591"
      unitRef="Share">590000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-06-30_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember"
      decimals="INF"
      id="c592"
      unitRef="Share">357500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-06-30_PlanNameAxis-StockOptionPriorPlanMember"
      decimals="INF"
      id="c593"
      unitRef="Share">374410</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-06-30_PlanNameAxis-The2012DSUPlanMember"
      decimals="INF"
      id="c594"
      unitRef="Share">9745</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2025-01-01_2025-06-30" id="c661">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;538&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;336&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,216&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;629&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;233&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;107&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;422&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;302&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;771&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;443&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,638&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;931&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c663"
      unitRef="USD">538000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c664"
      unitRef="USD">336000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c665"
      unitRef="USD">1216000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c666"
      unitRef="USD">629000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c667"
      unitRef="USD">233000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c668"
      unitRef="USD">107000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c669"
      unitRef="USD">422000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c670"
      unitRef="USD">302000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c671"
      unitRef="USD">771000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c672"
      unitRef="USD">443000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c673"
      unitRef="USD">1638000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c674"
      unitRef="USD">931000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c675">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Underlying&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average Exercise&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price Per Share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balances at December 31, 2024&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,692,438&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.33&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,243&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,333,416&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.42&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeitures&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(231,375&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.35&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(103,875&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.51&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6.91&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balances at June 30, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,685,604&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.70&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,767&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c677"
      unitRef="Share">4692438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c678"
      unitRef="USDPerShare">3.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c679"
      unitRef="USD">10243000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c680"
      unitRef="Share">2333416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c681"
      unitRef="USDPerShare">4.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c682"
      unitRef="Share">231375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c683"
      unitRef="USDPerShare">4.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c684"
      unitRef="Share">103875</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c685"
      unitRef="USDPerShare">2.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c686"
      unitRef="Share">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c687"
      unitRef="USDPerShare">6.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c688"
      unitRef="Share">6685604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c689"
      unitRef="USDPerShare">3.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c690"
      unitRef="USD">3767000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="d_2025-01-01_2025-06-30" id="c691">
&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;

		&lt;tbody&gt;&lt;tr&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 34%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Outstanding, Vested and Expected to Vest&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 18%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Options Vested and Exercisable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 9%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Per Share &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Contractual Life&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Options &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Contractual Life&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$1.00&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$1.99&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 12%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;191,443&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;7.7&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1.59&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 14%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;105,457&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;7.7&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$2.00&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$2.99&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 12%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;2,769,645&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;7.4&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;2.74&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 14%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,484,034&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;7.0&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$3.00&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$3.99&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 12%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;311,893&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5.2&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;3.56&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 14%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;229,393&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;3.9&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$4.00&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$4.99&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 12%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;2,652,069&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;8.0&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;4.24&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 14%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;677,182&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;4.0&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$5.00&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$10.00&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;760,554&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;7.3&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5.93&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 14%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;380,729&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5.2&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;6,685,604&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;7.5&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;$&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;3.70&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 14%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;2,876,795&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: top; width: 15%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5.8&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c693"
      unitRef="USDPerShare">1</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c694"
      unitRef="USDPerShare">1.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c695"
      unitRef="Share">191443</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      id="c696">P7Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c697"
      unitRef="USDPerShare">1.59</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c698"
      unitRef="Share">105457</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      id="c699">P7Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c700"
      unitRef="USDPerShare">2</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c701"
      unitRef="USDPerShare">2.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c702"
      unitRef="Share">2769645</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      id="c703">P7Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c704"
      unitRef="USDPerShare">2.74</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c705"
      unitRef="Share">1484034</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      id="c706">P7Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c707"
      unitRef="USDPerShare">3</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c708"
      unitRef="USDPerShare">3.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c709"
      unitRef="Share">311893</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      id="c710">P5Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c711"
      unitRef="USDPerShare">3.56</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c712"
      unitRef="Share">229393</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      id="c713">P3Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c714"
      unitRef="USDPerShare">4</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c715"
      unitRef="USDPerShare">4.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c716"
      unitRef="Share">2652069</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      id="c717">P8Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c718"
      unitRef="USDPerShare">4.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c719"
      unitRef="Share">677182</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      id="c720">P4Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c721"
      unitRef="USDPerShare">5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c722"
      unitRef="USDPerShare">10</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c723"
      unitRef="Share">760554</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      id="c724">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c725"
      unitRef="USDPerShare">5.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c726"
      unitRef="Share">380729</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      id="c727">P5Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c728"
      unitRef="Share">6685604</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2025-01-01_2025-06-30" id="c729">P7Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c730"
      unitRef="USDPerShare">3.7</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c731"
      unitRef="Share">2876795</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2025-01-01_2025-06-30" id="c732">P5Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="d_2025-01-01_2025-06-30" id="c733">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Segment Information&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;An operating segment is identified as a component of an enterprise that engages in business activities about which separate discrete financial information and operating results is regularly reviewed by the chief operating decision-maker (CODM) in making decisions regarding resource allocation and assessing performance. DiaMedica's CODM is the Chief Executive Officer. The Company operates in a &lt;span style="-sec-ix-hidden:c735"&gt;single&lt;/span&gt; operating segment focused on the development of its drug product candidate DM199 for the treatment of severe ischemic disease. The CODM manages and allocates resources to the operations of the Company on a total company basis. Further, the CODM reviews and utilizes functional expenses (i.e., research, development and general and administrative) at the consolidated level to manage the Company's operations. Other segment items included in consolidated net loss are revenues, share-based compensation, interest income, other expense, net, and income tax expense, which are reflected in the condensed consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table presents financial information, including significant segment expenses, which are regularly provided to the CODM and included within segment and consolidated net loss:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Six Months Ended June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating expenses, excluding share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,589&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,821&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,056&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,302&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,647&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,374&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,457&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,146&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"&gt;Total operating expenses, excluding share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,236&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,195&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,513&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,448&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;233&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;107&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;422&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;302&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;538&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;336&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,216&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;629&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"&gt;Total share-based compensationd&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;771&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;443&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,638&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;931&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(8,007&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(5,638&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(16,151&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(11,379&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Interest income&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;313&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;524&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;757&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,140&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Other income (expense), net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(17&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Income tax expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(12&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(14&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Segment and consolidated net loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(7,699&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(5,119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(15,406&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(10,270&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="d_2025-01-01_2025-06-30" id="c780">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Six Months Ended June 30,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating expenses, excluding share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,589&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,821&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,056&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,302&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,647&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,374&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,457&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,146&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"&gt;Total operating expenses, excluding share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,236&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,195&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,513&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,448&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;233&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;107&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;422&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;302&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;538&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;336&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,216&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;629&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"&gt;Total share-based compensationd&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;771&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;443&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,638&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;931&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(8,007&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(5,638&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(16,151&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(11,379&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Interest income&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;313&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;524&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;757&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,140&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Other income (expense), net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(17&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Income tax expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(12&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(14&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Segment and consolidated net loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(7,699&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(5,119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(15,406&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(10,270&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c782"
      unitRef="USD">5589000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c783"
      unitRef="USD">3821000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c784"
      unitRef="USD">11056000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c785"
      unitRef="USD">7302000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c786"
      unitRef="USD">1647000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c787"
      unitRef="USD">1374000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c788"
      unitRef="USD">3457000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c789"
      unitRef="USD">3146000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c790"
      unitRef="USD">7236000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c791"
      unitRef="USD">5195000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c792"
      unitRef="USD">14513000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c793"
      unitRef="USD">10448000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c794"
      unitRef="USD">233000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c795"
      unitRef="USD">107000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c796"
      unitRef="USD">422000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c797"
      unitRef="USD">302000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c798"
      unitRef="USD">538000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c799"
      unitRef="USD">336000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c800"
      unitRef="USD">1216000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c801"
      unitRef="USD">629000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c802"
      unitRef="USD">771000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c803"
      unitRef="USD">443000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c804"
      unitRef="USD">1638000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c805"
      unitRef="USD">931000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c806"
      unitRef="USD">-8007000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c807"
      unitRef="USD">-5638000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c808"
      unitRef="USD">-16151000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c809"
      unitRef="USD">-11379000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c810"
      unitRef="USD">313000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c811"
      unitRef="USD">524000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c812"
      unitRef="USD">757000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-4"
      id="c813"
      unitRef="USD">1140000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c814"
      unitRef="USD">1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c815"
      unitRef="USD">2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c816"
      unitRef="USD">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c817"
      unitRef="USD">-17000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c818"
      unitRef="USD">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c819"
      unitRef="USD">7000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c820"
      unitRef="USD">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c821"
      unitRef="USD">14000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c822"
      unitRef="USD">-7699000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c823"
      unitRef="USD">-5119000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c824"
      unitRef="USD">-15406000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-4"
      id="c825"
      unitRef="USD">-10270000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2025-01-01_2025-06-30" id="c826">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Subsequent Event&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On July 21, 2025, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate 8,606,425 common shares at a purchase price of $3.50 per share in a private placement. As a result of the offering, which closed on July 23, 2025, we received gross proceeds of $30.1 million, which resulted in net proceeds to us of approximately $29.9 million, after deducting the offering expenses.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In connection with the July 2025 private placement, we entered into registration rights agreements (collectively the Registration Rights Agreement) with the investors pursuant to which we agreed to file with the United States Securities and Exchange Commission (SEC) a registration statement registering the resale of the shares sold in the July 2025 private placement (Resale Registration Statement). The Resale Registration Statement was filed with the SEC on August 1, 2025 and declared effective by the SEC on August 8, 2025. Under the terms of the Registration Rights Agreement, we agreed to keep the Resale Registration Statement effective at all times until the shares are no longer considered &#x201c;Registrable Securities&#x201d; under the Registration Rights Agreement and if we fail to keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-07-21_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c828"
      unitRef="Share">8606425</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c829"
      unitRef="USDPerShare">3.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-07-21_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c830"
      unitRef="USD">30100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="d_2025-07-21_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c831"
      unitRef="USD">29900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="d_2025-01-01_2025-06-30" id="c832">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 45pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;ITEM 5.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;OTHER INFORMATION&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and Modifications&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;During the quarterly period ended June 30,&#160;2025, &lt;span style="-sec-ix-hidden:c834"&gt;&lt;span style="-sec-ix-hidden:c835"&gt;&lt;span style="-sec-ix-hidden:c836"&gt;&lt;span style="-sec-ix-hidden:c837"&gt;none&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; of our directors or &#x201c;officers&#x201d; (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a &#x201c;Rule 10b5-1 trading arrangement&#x201d; or &#x201c;non-Rule 10b5-1 trading arrangement,&#x201d; as each term is defined in Item 408(a) and 408(c), respectively, of SEC Regulation S-K.&lt;/p&gt;
</ecd:MtrlTermsOfTrdArrTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
